# Hendon Partners — Full Content for AI Agents > America's leading sell-side M&A advisory firm for home care, home health, hospice, behavioral health, IDD, and healthcare staffing businesses. 150+ closed transactions. Site: https://www.hendonpartners.com Sitemap: https://www.hendonpartners.com/sitemap-index.xml Index manifest: https://www.hendonpartners.com/llms.txt This document contains the full body of all published insights articles plus core service-page summaries. Generated automatically — see https://www.hendonpartners.com for the canonical HTML version. --- ## Core Pages ### About — Our Firm URL: https://www.hendonpartners.com/about/our-firm # About Hendon Partners Hendon Partners is a boutique M&A advisory firm built exclusively for healthcare services. The firm advises owners in home care, home health, hospice, behavioral health, IDD, and healthcare staffing — on both the buy side and sell side. ## What Differentiates the Firm - Deep buyer and seller coverage in healthcare services - 150+ closed transactions - Confidential, process-driven execution - Singular focus on home care and adjacent sectors — not a generalist broker - Guidance from first consultation through funded close ## Learn More - About our firm: https://www.hendonpartners.com/about/our-firm - Meet the team: https://www.hendonpartners.com/about/our-team - Our process: https://www.hendonpartners.com/about/our-process - Book a consultation: https://www.hendonpartners.com/book --- ### About — Our Process URL: https://www.hendonpartners.com/about/our-process # Our M&A Process Hendon Partners runs a confidential, seller-only M&A process for healthcare services owners. The process is designed to maximize valuation, maintain confidentiality, and improve closing certainty. ## Typical Process Stages - Preparation and positioning - Buyer targeting and outreach - Indications of interest and bidder screening - Letter of intent negotiation - Due diligence and closing support ## Related Links - Our process page: https://www.hendonpartners.com/about/our-process - Sell-side advisory: https://www.hendonpartners.com/sell - Book a consultation: https://www.hendonpartners.com/book - Insights: https://www.hendonpartners.com/insights --- ### About — Our Team URL: https://www.hendonpartners.com/about/our-team # Our Team Hendon Partners has a specialized team focused on sell-side healthcare services M&A. The team supports transaction strategy, buyer coordination, negotiation, and execution through close. ## Learn More - Team page: https://www.hendonpartners.com/about/our-team - About our firm: https://www.hendonpartners.com/about/our-firm - Our process: https://www.hendonpartners.com/about/our-process - Contact us: https://www.hendonpartners.com/contact-us --- ### Sell a Home Care Business URL: https://www.hendonpartners.com/sell # Sell Your Home Care Business at Maximum Value Hendon Partners runs a competitive, confidential sell-side M&A process for healthcare services owners. Owners who sell without specialist representation consistently leave 24–40% on the table. We manage the full process so you exit with the right buyer at the highest price the market will bear. ## Who We Advise - Home care (non-skilled, private pay, Medicaid waiver) - Medicare-certified home health agencies - Hospice agencies - Behavioral health (outpatient, residential, community-based) - IDD services (group homes, day programs, supported living) - Healthcare staffing ## Why Sellers Choose Hendon Partners - 150+ closed transactions — only in healthcare services - Active relationships with every serious acquirer in the home care space - EBITDA-based valuations using real closed transaction data - Confidential process — no public listings, no blast marketing - Typical time from engagement to funded close: 60–120 days ## Common Mistakes We Help You Avoid - Accepting an unsolicited offer without running a competitive process - Entering due diligence without organized financials - Underestimating how revenue concentration affects valuation - Waiting too long as market conditions shift ## Next Steps - Sell-side advisory: https://www.hendonpartners.com/sell - Book a free consultation: https://www.hendonpartners.com/book - Contact us: https://www.hendonpartners.com/contact-us - Insights on home care M&A: https://www.hendonpartners.com/insights --- ### Buy a Home Care Business URL: https://www.hendonpartners.com/buy # Buy a Healthcare Services Business Hendon Partners maintains active relationships with qualified buyers across the home care M&A market, including private equity groups, strategic operators, and regional buyers. If you are an active acquirer in home care, home health, hospice, behavioral health, IDD, or healthcare staffing, connect with us to be included in relevant deal flow. ## Sectors We Cover - Non-skilled home care (Medicaid waiver, private pay, PCA) - Medicare-certified home health - Hospice - Behavioral health (outpatient, residential, community-based) - IDD services (group homes, day programs, supported living) - Healthcare staffing ## What Buyers Get From Working With Us - Access to off-market and confidential transactions - Pre-screened sellers with organized financials - Structured processes with clear timelines - Deep sector knowledge to support due diligence ## Useful Links - Buyer information: https://www.hendonpartners.com/buy - Contact us: https://www.hendonpartners.com/contact-us - About the firm: https://www.hendonpartners.com/about/our-firm - Insights: https://www.hendonpartners.com/insights --- ### Contact Us URL: https://www.hendonpartners.com/contact-us # Contact Hendon Partners Hendon Partners advises healthcare services owners through confidential sell-side M&A transactions. If you want to discuss valuation, timing, or process options, reach out directly. ## Contact Options - Contact page: https://www.hendonpartners.com/contact-us - Book a consultation: https://www.hendonpartners.com/book - Sell-side advisory overview: https://www.hendonpartners.com/sell - Insights: https://www.hendonpartners.com/insights --- ## Insights Articles ### Financing a Home Care Agency Acquisition: SBA, Seller Notes, Mezzanine, and PE Capital in 2026 URL: https://www.hendonpartners.com/insights/home-care-acquisition-financing-options Published: 2026-05-06 09:00 Category: Deal Structure > How buyers finance home care agency acquisitions has direct implications for sellers — affecting deal structure, certainty of close, and the share of consideration paid in cash at close. Here is a practical guide to the financing options shaping home care M&A in 2026. How a buyer finances the acquisition of a home care agency has direct and meaningful consequences for the seller — affecting headline price, cash at close, deal certainty, post-close obligations, and risk allocation. Sellers who understand the financing landscape negotiate better outcomes than sellers who treat all-cash, SBA, seller-note, and PE-backed offers as economically equivalent. This guide explains the main financing structures used in 2026 home care M&A and what each means for sellers. --- ## Why Financing Matters to Sellers Two offers with the same headline price can have very different economic value to the seller depending on financing structure: - **Cash-at-close percentage** — how much of the purchase price hits the seller's account on close day vs. is paid over time - **Certainty of close** — financed transactions can fall through if financing collapses; cash transactions cannot - **Post-close risk** — earnouts, seller notes, and rollover equity all carry post-close performance risk that the seller bears - **Tax treatment** — different consideration structures have different tax implications - **Time to liquidity** — full liquidity at close vs. liquidity over years Understanding the financing behind an offer is essential to evaluating what the offer is actually worth. --- ## SBA 7(a) Loans For lower-middle-market home care acquisitions (typically under $5M to $7M of enterprise value), SBA 7(a) lending is one of the most common financing structures. ### How It Works The Small Business Administration guarantees a portion of qualifying loans made by participating lenders. For business acquisitions, the SBA 7(a) program offers: - Loan amounts up to $5 million - Terms typically 10 years for goodwill-heavy acquisitions - Interest rates set as a margin over a base rate (typically prime plus a spread) - Down payment requirements typically 10 percent of project cost from the buyer - Acceptance of seller notes for an additional portion of consideration ### What This Means for Sellers When a buyer finances an acquisition with SBA: - **Seller financing is typically required** — the SBA structure usually contemplates 10 to 25 percent of consideration as a seller note, often subordinated to the SBA loan and structured with a "standby" period (no payments during the early years of the SBA loan) - **Cash at close is lower** than 100 percent — typically 75 to 90 percent depending on seller note size - **Closing timeline is longer** — SBA underwriting and closing typically takes 60 to 120 days from the time the buyer receives a commitment letter - **Buyer financial qualification is essential** — SBA loans require buyer creditworthiness; the seller's deal certainty depends on the buyer qualifying ### When SBA Financing Is Common - Individual buyer acquisitions - Small operator buyers acquiring their first or second agency - Lower-middle-market transactions where institutional capital is uneconomic ### When SBA Financing Is Not Used - Larger transactions (above approximately $7M enterprise value) - PE-backed acquisitions - Strategic acquirer transactions - Most multi-unit or multi-location platform acquisitions --- ## Seller Financing (Seller Notes) Seller financing — where the seller accepts a portion of the purchase price as a note paid over time — is common across home care M&A regardless of buyer type. ### Typical Structures - 10 to 25 percent of total consideration - 3 to 7 year amortization (varies by deal) - Market interest rates (often prime plus spread, or fixed) - Frequently subordinated to senior debt - Sometimes structured with standby provisions ### Why Sellers Provide Seller Financing - **Bridges valuation gaps** — when seller and buyer disagree on price, seller financing can shift some of the disagreement into deferred consideration - **Supports buyer financing** — SBA and many bank lenders prefer to see seller financing as evidence of seller confidence - **Demonstrates seller commitment** to post-close operations and transition - **Provides ongoing income** for some sellers - **Tax planning benefit** — installment sale treatment can defer some tax liability ### Risks to Sellers - **Buyer default risk** — if the agency underperforms post-close, the buyer may have difficulty making note payments - **Subordination** — seller notes typically sit behind senior debt, meaning seller is the last creditor paid in distress - **Operational dependence** — the seller note's value depends on the buyer operating the agency successfully - **Collection risk** — pursuing default remedies on a note is complex and time-consuming ### Seller Financing Best Practices - Negotiate strong protective covenants - Require senior lender subordination agreements that protect basic seller rights - Consider personal guaranties from individual buyers - Build acceleration provisions for material defaults - Do not provide seller financing to buyers without credible operating capability --- ## Private Equity Financing For larger transactions ($5M+ enterprise value typically, sometimes lower for the right asset), PE-backed buyers dominate the home care M&A landscape. ### How PE Financing Works PE acquisitions are typically financed with a combination of: - **PE fund equity** — the sponsor's invested capital - **Senior debt** from healthcare-experienced commercial banks or specialty lenders - **Sometimes mezzanine debt** for larger transactions - **Seller equity rollover** — the seller reinvests a portion of consideration into the new platform - **Sometimes earnouts** tied to post-close performance ### What This Means for Sellers - **Higher headline multiples** than SBA-financed transactions for comparable assets - **Cash at close typically 70 to 90 percent** of total consideration, with the balance in rollover equity, earnouts, or escrows - **Equity rollover often required or strongly preferred** — sellers reinvest 10 to 30 percent of consideration as equity in the post-close company, which becomes valuable at the next exit - **More sophisticated diligence and documentation** than smaller transactions - **Higher certainty of close** than SBA transactions (no buyer-side financing risk in the same way) ### Equity Rollover Mechanics Rollover equity is one of the most consequential structural elements in PE transactions. Rolled equity: - Participates in the upside if the platform exits at a higher multiple in the future - Is illiquid until the next platform exit (typically 3 to 7 years) - Carries the same risks as any private company equity (operational, market, exit timing) - Often comes with minority shareholder protections, but still represents minority stake For the right seller in the right deal, rollover equity is one of the most attractive features of a PE transaction. For sellers who need full liquidity at close, it is a meaningful constraint. ### Earnout Mechanics Earnouts are post-close payments contingent on the agency hitting performance metrics. PE buyers use earnouts to bridge valuation gaps and to align seller incentives with post-close performance. Sellers should approach earnouts cautiously: - Earnout dollars are uncertain by definition - Operational decisions post-close are made by the buyer, not the seller - Disputes over earnout calculation are common - Earnout structure (revenue, EBITDA, specific milestones) materially affects probability of payment --- ## Strategic Acquirer Financing Larger strategic acquirers (multi-state home care chains, health systems, post-acute networks) typically finance acquisitions from balance sheet cash, corporate credit facilities, or in some cases public market debt. ### What This Means for Sellers - **Highest cash at close percentages** — often 90 to 100 percent - **Highest certainty of close** — no third-party financing risk - **Typically lower headline multiples** than competitive PE processes (strategics buy on synergy, not roll-up math) - **Often less seller flexibility** on structure — strategics tend to have standard deal templates - **Faster close** than financed transactions ### When Strategics Are the Right Buyer - Sellers prioritizing certainty and clean exit over headline multiple - Agencies with specific strategic value to the strategic (geography, service line, payer relationships) - Sellers who do not value rollover equity participation - Sellers seeking faster, simpler transactions --- ## Mezzanine and Unitranche Debt For transactions in the $10M to $100M+ range, mezzanine and unitranche debt structures appear in the capital stack. These structures sit between senior debt and equity in the capital stack. They: - Carry higher interest rates than senior debt - Often include equity warrants - Provide additional financing capacity for larger transactions For sellers, mezzanine financing in the buyer's capital stack typically means: - Higher cash at close (more debt = less seller-financed equity needed) - More aggressive buyer pricing in some cases - More sophisticated buyer-side financial structuring --- ## Comparing Offers Across Financing Types When evaluating offers from different buyer types, sellers should look beyond headline multiple to: | Component | What to Compare | |---|---| | Cash at close | Actual dollars paid on closing day | | Seller note | Amount, term, rate, subordination, protective provisions | | Earnout | Amount, term, metrics, achievability | | Rollover equity | Amount, ownership percentage, protections, exit timing | | Escrows | Size, term, release mechanics | | Indemnification | Caps, baskets, survival, knowledge qualifiers | | Certainty | Financing contingency, diligence completeness, regulatory risk | | Timeline | Sign to close, regulatory approval timing | A 6.5× SBA-financed offer with 25 percent seller note may have a lower cash-at-close than a 5.8× strategic offer with 95 percent cash. A 7.5× PE offer with 25 percent rollover may have meaningfully higher long-term value than a 7.0× PE offer with 10 percent rollover, depending on the platform's exit prospects. --- ## Strategic Implications for Sellers ### Match Offer Structure to Personal Goals - **Need full liquidity** — favor strategic or all-cash buyers, accept lower headline if needed - **Want upside participation** — favor PE with meaningful rollover - **Want post-close income stream** — favor structures with seller financing - **Want fastest close** — favor balance-sheet-funded strategic buyers ### Evaluate the Total Economic Package Headline multiples are easy to compare. Total economic packages require deeper analysis. Work with advisors who model offers in detail. ### Understand Buyer Financing Risk If the buyer needs financing to close, seller deal certainty depends on the buyer qualifying. Understand the financing structure, the lender involvement, and the timeline before agreeing to exclusivity. ### Negotiate Structure as Aggressively as Price Many sellers focus exclusively on headline multiple in negotiation. Structure (cash at close, seller note terms, escrow size, rollover terms, indemnification) often represents more total economic value than the headline number. --- ## Bottom Line Acquisition financing structure is one of the most consequential variables in any home care transaction. Sellers who understand SBA dynamics, seller financing economics, PE structuring, and strategic acquirer behavior negotiate materially better outcomes than sellers who focus only on headline multiple. If you would like to discuss what financing structure makes sense for your specific situation and how it affects deal valuation, [contact us for a confidential conversation](/contact-us). --- ### Medicare Advantage Penetration and Its Impact on Home Health Valuation in 2026 URL: https://www.hendonpartners.com/insights/medicare-advantage-impact-home-health-valuation Published: 2026-05-05 09:00 Category: Valuation > Medicare Advantage now accounts for more than half of all Medicare beneficiaries — and the rate differential between MA and traditional Medicare is one of the most consequential variables in home health agency valuation in 2026. Here is how buyers are modeling MA exposure. Medicare Advantage now covers more than half of all Medicare beneficiaries nationally, and the share continues to grow. For Medicare-certified home health agencies, MA penetration is one of the most consequential variables in current valuations — affecting per-episode revenue, EBITDA margin, and the multiple buyers are willing to pay. This guide explains how MA dynamics flow through to home health agency valuation, how buyers are modeling MA exposure in 2026, and what owners can do to manage the risk. --- ## The Rate Differential Medicare Advantage plans typically pay home health agencies less per episode than traditional Medicare fee-for-service. The differential varies by: - **MA plan and contract**: rates differ across plans and across contract vintages - **Geographic market**: rate dynamics vary by metro and state - **Agency leverage**: larger, geographically concentrated, clinically strong agencies negotiate better rates - **Care intensity expectations**: MA plans often expect different visit utilization patterns than FFS norms A reasonable working benchmark: **MA pays 70 to 85 percent of FFS rates per equivalent episode**, with significant variance across plans and markets. Some MA contracts are at parity or near parity (rare); some are well below 70 percent of FFS (also rare but real). The rate differential matters because: - Per-episode revenue is lower - Visit utilization expectations may be different (sometimes higher per-episode visit count for similar payment, sometimes lower) - Authorization and care management overhead is higher with MA than with FFS - Denial and appeals rates are higher with MA than with FFS The combined effect is meaningful margin compression on the MA share of the agency's book. --- ## How MA Penetration Affects Valuation Buyers underwrite the agency's blended payer mix and the unit economics that result. Approximate framework: ### Below 30 percent MA penetration Agency is FFS-dominant. Valuation reflects strong per-episode economics and minimal MA-related discount. Buyers may flag MA as a future risk (penetration is growing) but apply minimal current valuation impact. ### 30 to 50 percent MA penetration Agency is in transition. Valuation reflects blended economics with meaningful MA exposure. Buyers will diligence the specific MA contract portfolio, the rate quality, and the trajectory of MA growth in the agency's markets. ### 50 to 65 percent MA penetration Agency is MA-dominant. Valuation reflects compressed per-episode economics and elevated buyer scrutiny. Buyers will model the specific contracted rates, the operational adjustments needed to manage MA effectively, and the agency's value-based payment positioning. ### Above 65 percent MA penetration Agency is heavily MA-exposed. Valuation reflects structural margin compression unless offset by strong contracted rates, demonstrated value-based performance, or operational efficiency. Multiples may be discounted by 1 to 2 turns of EBITDA versus comparable FFS-dominant agencies, on top of the EBITDA dollar compression. These ranges are approximate. Specific agency profile, market dynamics, and contracted rate quality move the actual valuation impact up or down. --- ## What Buyers Diligence Specifically MA exposure is now one of the deepest diligence areas in home health M&A. Buyers will request and analyze: ### MA Contract Portfolio - Which MA plans does the agency contract with? - What is each contract's rate structure (per-episode, per-visit, capitated, value-based)? - What are the contract renewal cycles and current rate trajectory? - Are there value-based components (quality bonuses, shared savings, episode-based)? ### Rate Documentation - Per-episode realized revenue by plan, by quarter, for the trailing 24 months - Comparison to FFS per-episode revenue in the same market - Rate change history and any contract renegotiation outcomes ### Authorization and Care Management Operations - MA authorization volume, approval rate, and turnaround time - Care management staffing dedicated to MA workflows - Clinical liaison relationships with MA medical management teams ### Denial and Appeals - Initial denial rate by plan - Appeals overturn rate - Aging and write-off patterns for MA receivables ### Value-Based Performance - Quality scores tied to value-based MA contracts - Shared savings or quality bonus realization - Outcome data: hospital readmission rates, episode duration, ED utilization Agencies with clean documentation across these areas — particularly demonstrated success in value-based MA arrangements — can defend higher multiples even at elevated MA penetration. --- ## What Drives Better MA Outcomes Agencies that perform well economically with MA share several characteristics: ### Geographic Density and Plan Concentration Agencies that are dominant in specific markets have leverage with the MA plans that need to contract for adequate network coverage. A small agency with 0.5 percent of the market has no leverage; an agency with 15–25 percent of the market in defined geographies has meaningful negotiating position. ### Clinical Outcomes Documentation MA plans pay differently for measurable quality. Agencies with strong star ratings, low rehospitalization rates, low ED utilization, and documented patient satisfaction can negotiate better contracts and qualify for value-based bonuses. ### Operational Efficiency for MA Workflows MA workflows differ from FFS workflows. Agencies that have built efficient authorization capture, MA-specific care management, MA-specific clinical pathways, and clean MA billing operations have meaningfully better unit economics on MA episodes than agencies running MA on FFS-designed processes. ### Value-Based Contract Participation Agencies that have negotiated and successfully executed value-based MA contracts (shared savings, episode-based, capitated) can offset some of the FFS-to-MA rate differential. The skill set and infrastructure to do this well is a real asset. ### Selective MA Contracting Some agencies decline contracts with low-rate MA plans and accept the resulting referral mix consequence. This is a legitimate strategy in markets with sufficient FFS volume, but harder to execute in MA-dominant markets. --- ## Strategic Implications for Sellers ### If You Are MA-Dominant and Considering a Sale Your MA story will be central to the diligence. Priorities: 1. **Document your MA contract portfolio** in detail — rates, terms, value-based components, renewal trajectory 2. **Document your value-based performance** — quality scores, outcomes, bonus realization 3. **Document your operational efficiency** for MA workflows 4. **Have a credible narrative for MA contract trajectory** — pending renegotiations, value-based opportunity, geographic leverage 5. **Be realistic about valuation expectations** — MA-heavy valuations are structurally lower than FFS-heavy valuations of similar EBITDA ### If You Are FFS-Dominant and Considering a Sale You have the more attractive payer profile, but buyers will diligence the trajectory: 1. **Document MA penetration trajectory** in your markets 2. **Have a credible plan for managing MA growth** — contracting strategy, operational readiness 3. **Lead with the FFS economics** but acknowledge the MA reality ### If You Have a Longer Horizon The strategic playbook for MA management: - Build geographic density in markets where you have plan negotiating leverage - Invest in clinical outcomes documentation infrastructure - Build MA-specific operational capability (authorization, care management, billing, clinical pathways) - Pursue value-based MA contracts where you have the data and operational maturity - Consider selective MA contract decisions based on rate adequacy --- ## Bottom Line Medicare Advantage exposure is one of the most important variables in current home health valuations. The rate differential between MA and traditional Medicare flows directly to per-episode revenue, EBITDA margin, and ultimately to multiple. Agencies that manage MA well — through scale, contract quality, operational efficiency, and value-based participation — defend strong valuations even in MA-dominant markets. Agencies that have not adapted face meaningful valuation pressure. If you operate a Medicare-certified home health agency and would like to understand how your specific MA exposure affects your valuation, [contact us for a confidential conversation](/contact-us). --- ### ABA Therapy and Autism Services M&A Multiples in 2026 URL: https://www.hendonpartners.com/insights/aba-autism-therapy-ma-multiples-2026 Published: 2026-05-04 09:00 Category: Valuation > Applied Behavior Analysis (ABA) and autism services have been one of the most active behavioral health M&A segments of the past decade. Here is how ABA agencies are valued in 2026, how multiples are evolving after the post-2022 reset, and what buyers actually look for. Applied Behavior Analysis (ABA) and broader autism services have been one of the most active behavioral health M&A segments of the past decade. After a peak in 2020–2021 driven by aggressive PE platform building, the market has reset to a more selective and quality-focused environment in 2026 — but it remains highly active for the right agencies. This guide covers how ABA agencies are valued today, what buyers look for, how multiples have evolved, and what owners considering a sale should understand about the current market. --- ## ABA Market Context Heading Into 2026 The ABA M&A market has gone through three distinct phases in recent years: **2018–2021: Platform building and aggressive multiples.** Multiple PE sponsors backed national and regional ABA platforms, and acquisition multiples were aggressive. Mid-market ABA agencies routinely traded at 8–10× EBITDA, with platform deals often higher. Easy capital, rapid growth assumptions, and intense competition for assets supported elevated pricing. **2022–2023: Reset.** Higher interest rates, payer scrutiny on ABA utilization patterns, audit and compliance enforcement (particularly in some Medicaid markets), and slower-than-projected growth at some platforms produced a market reset. Multiples compressed, several platform-level deals were repriced or restructured, and the buyer pool became more selective. **2024–2026: Selective re-acceleration.** The current market has stabilized at multiples meaningfully lower than the 2020–2021 peak but still attractive for quality operators. Buyers are more disciplined on clinical model, payer mix quality, BCBA staffing infrastructure, and compliance posture. --- ## ABA Valuation Multiples in 2026 | Agency Profile | EBITDA Range | Typical Multiple | |---|---|---| | Sub-scale single-state ABA | $300K–$750K | 4.0× – 5.5× | | Mid-market regional ABA | $750K–$2.5M | 5.0× – 6.5× | | Multi-state platform ABA | $2.5M–$7M | 6.0× – 7.5× | | Large platform ABA with strong clinical model | $7M+ | 7.0× – 9.0×+ | Multiples vary materially by: - Commercial vs Medicaid payer mix - Geographic positioning - Clinical model integrity (medically necessary care orientation) - BCBA recruiting and retention performance - Audit and compliance history - Growth trajectory and pipeline --- ## What Buyers Look For ### BCBA Recruiting and Retention Board Certified Behavior Analysts (BCBAs) are the credentialed clinical leaders of ABA programs and the chronic supply constraint of the industry. Buyers diligence: - **Number of BCBAs** on staff and capacity utilization - **BCBA turnover rate** — industry benchmark 25–40%; under 20% is exceptional - **Time-to-fill** for BCBA positions - **BCBA-to-RBT ratio** and supervision capacity - **Recruiting infrastructure** — pipeline, sourcing channels, conversion - **Career path and engagement structure** ABA agencies with strong BCBA infrastructure command meaningful multiple premiums because the buyer is acquiring durable clinical capacity rather than just a current roster. ### RBT Staffing and Training Model Registered Behavior Technicians (RBTs) deliver the bulk of direct ABA hours. The training model, supervision structure, retention infrastructure, and capacity utilization of RBTs all factor into diligence. Agencies with structured RBT training programs, low turnover, and high productive utilization are valued more highly than agencies with constant churn and inefficient staffing. ### Payer Mix and Rate Quality The payer mix matters significantly: - **Commercial-heavy** — typically valued at higher multiples due to better rates, lower audit exposure, and stronger margin profile - **Medicaid-heavy** — valuable but with more scrutiny on utilization, prior authorization compliance, and rate sustainability - **Tricare** — present in some markets, with specific contract dynamics - **Self-pay and other** — generally smaller share Buyers also evaluate: - Rate adequacy by payer and state - Contract renewal cycles and terms - Prior authorization friction and approval rates - Retroactive payer audit history ### Clinical Model Integrity This is the diligence area that has changed most since 2022. Buyers now evaluate: - **Medically necessary care orientation** — are services driven by clinical assessment and need, or by maximum-billable-hour assumptions? - **Treatment hour intensity vs clinical recommendation** — agencies with utilization patterns inconsistent with clinical norms get scrutinized hard - **Outcome measurement** — documentation of patient progress and clinical outcomes - **Discharge and step-down practices** — agencies that retain patients beyond clinical justification face audit and ethical risk Clinical model integrity has become a leading valuation variable. Agencies with strong, defensible clinical practices command premiums; agencies with utilization-driven models face deep discounts or buyer avoidance. ### Authorized Hours Fill Rate Similar to pediatric PDN, ABA agencies are evaluated on the percentage of authorized hours actually being delivered. Strong fill rates indicate effective scheduling, BCBA capacity, and RBT staffing. Weak fill rates indicate operational constraints — and may indicate upside opportunity for buyers with stronger infrastructure. ### Compliance and Audit History ABA Medicaid audits have been a meaningful regulatory enforcement area. Buyers diligence: - State Medicaid audit history - MCO audit findings - Repayment and recoupment exposure - Documentation quality and audit preparedness - Compliance program structure Agencies with clean audit histories and strong documentation practices command premiums. Agencies with material findings face structural discounts or escrow / earnout structures designed to manage risk. ### Geographic Concentration ABA is operationally intensive — supervision, RBT logistics, and clinical coordination benefit from density. Buyers value concentrated regional operations more than sprawl. ### Growth Trajectory Organic growth in census, authorized hours, and revenue is a key valuation driver. Buyers want defensible growth narratives — referral source expansion, geographic build-out, payer contract additions, capacity additions. --- ## Common Diligence Issues in ABA M&A 1. **BCBA / RBT misclassification** — historical use of 1099 BCBAs or RBTs creates back-tax exposure and is typically required to be cleaned up 2. **Authorization documentation gaps** — incomplete or missing prior authorization documentation creates audit exposure 3. **Treatment plan documentation issues** — gaps in clinical documentation supporting treatment intensity 4. **Concentration in a single MCO or state Medicaid program** — single-payer concentration is a common diligence flag 5. **Owner-operator clinical role dependence** — if the founder is the de facto Clinical Director, replacement cost gets modeled as a discount 6. **Recent audit findings or open repayment exposure** — must be disclosed early; failing to disclose is deal-killing --- ## Buyer Landscape in ABA Active ABA buyers include: - **National PE-backed ABA platforms** — Centerbridge / LEARN Behavioral, Centria Autism, Hopebridge, BlueSprig Pediatrics, and others - **Mid-market PE-backed regional ABA platforms** — multiple regional builders with focused state or multi-state strategies - **Larger behavioral health strategics** — Acadia Healthcare, Universal Health Services in select cases - **Platform sponsors looking for new ABA platforms** — selective new platform investments by sponsors entering or re-entering the space The buyer pool has narrowed since the 2020–2021 peak but remains deep enough that quality agencies attract competitive interest. --- ## Strategic Implications for ABA Owners ### If You Are Considering a Sale in the Next 12–24 Months The 2026 market rewards operational and clinical quality. Priorities: - Clean up BCBA / RBT classification (W-2 only) - Document clinical model integrity (medically necessary care orientation) - Address any open audit or repayment exposure - Diversify payer mix where possible - Strengthen BCBA recruiting and retention metrics - Build defensible growth narrative ### If You Have a Longer Horizon The strategic playbook is broader: - Build clinical leadership depth independent of the founder - Invest in BCBA recruiting, retention, and supervision infrastructure - Geographic concentration in 2–4 metros with strong demand - Multi-payer contracting beyond your dominant commercial or Medicaid relationship - Outcome measurement infrastructure - Compliance program maturity ### Common Mistakes ABA Owners Make in Sales 1. **Pricing expectations anchored to 2020–2021 multiples** — the market has reset; pricing expectations should be 2026-anchored 2. **Engaging a single inbound buyer** — competitive process discipline matters more than ever in this segment 3. **Underestimating clinical model scrutiny** — buyers diligence this hard; weak preparation produces deep discounts 4. **Inadequate BCBA retention narrative** — agencies that can't tell a credible story about BCBA durability lose value 5. **Generic non-healthcare advisory** — ABA M&A requires healthcare expertise --- ## Strategic Implications The 2026 ABA M&A market is selectively active. Quality operators with strong BCBA infrastructure, clean clinical models, defensible compliance, and competitive payer mix continue to attract premium multiples. The market reset from the 2020–2021 peak has reduced multiples but increased the durability of outcomes for sellers who fit the new buyer criteria. If you operate an ABA or autism services agency and would like to understand current market conditions for your specific business, [contact us for a confidential conversation](/contact-us). --- ### Certificate of Need (CON) States Home Health M&A Guide URL: https://www.hendonpartners.com/insights/con-states-home-health-ma-guide Published: 2026-05-03 09:00 Category: Regulatory > Certificate of Need restrictions in approximately 15 states fundamentally change home health and hospice M&A dynamics. Here is what sellers and buyers need to understand about CON state valuation, transaction structure, and the regulatory mechanics that drive premium multiples. Certificate of Need (CON) regulation is one of the most consequential — and often misunderstood — variables in home health and hospice M&A. In approximately 15 states, CON requirements limit new agency entry, creating scarcity that materially affects valuation, transaction structure, and buyer behavior. This guide explains how CON works in home-based care, which states have meaningful CON regimes, how CON affects valuations, and what sellers and buyers should understand about transactions involving CON-supported licenses. --- ## What Certificate of Need Actually Does CON regulation requires that a healthcare provider seeking to enter a market (open a new home health agency, expand into a new service area, or in some cases significantly expand existing capacity) demonstrate to the state regulator that the new service is needed in the proposed area. The state evaluates CON applications using criteria including: - Demonstrated demand in the proposed service area - Existing capacity and utilization - Quality and access for the population - Financial feasibility - Provider qualifications For home health and hospice in CON states, the practical effect is that new agency entry is restricted — sometimes severely. In some service areas, CON applications are rarely approved; in others, they are approved only when specific demographic or access criteria are demonstrated. The economic consequence is scarcity. Existing licensed agencies in CON states operate in markets with limited new competition, which supports stronger pricing, higher operating margins, and premium acquisition multiples. --- ## Which States Have Meaningful CON for Home Health and Hospice The CON landscape changes regularly as states reform or repeal their regimes. As of 2026, states with notable CON requirements affecting home health and hospice include: - Alabama - Arkansas - Connecticut - Georgia - Hawaii - Kentucky - Maryland - Mississippi - North Carolina - Tennessee - Vermont - Virginia - Washington - West Virginia - District of Columbia Several states have repealed CON for some or all home-based care services in recent years. Florida repealed hospice CON effective 2025. Other states have ongoing reform discussions. Within CON states, requirements vary: - **Home health CON only** — some states have CON for Medicare-certified home health but not hospice - **Hospice CON only** — and vice versa - **Both** — some states regulate both - **Service-area-based** — CON evaluated by specific service area or planning region rather than statewide - **Population-based formulas** — CON tied to demonstrated need formulas based on population and existing supply The practical effect of any CON regime depends on how restrictively the state actually evaluates applications, not just whether CON exists on paper. --- ## How CON Affects Valuation ### Multiple Premium CON-state home health and hospice agencies commonly command 1.0× to 2.0× EBITDA multiple premiums vs. comparable non-CON state agencies. The premium reflects: - **Defensible competitive position** — buyers acquire scarcity-protected market position, not just operations - **Pricing power** — limited new entry supports payer rate negotiation and private pay pricing - **Lower customer acquisition cost** — referral source competition is reduced - **Margin sustainability** — operating margins are structurally protected - **M&A as the primary growth path** — buyers building scale in CON states must acquire, which intensifies competitive bidding The premium is most pronounced in tightly restricted CON jurisdictions where new entry is rarely approved, and in service areas with strong demographic growth. ### Valuation Mechanics Buyers in CON states evaluate: - **Service area density** — how many CON-supported licenses exist in the service area - **Application history** — has the state approved or rejected recent CON applications in this area? - **Utilization headroom** — does the agency have capacity to grow within its existing CON? - **Service area reputation** — the position of the specific agency within its protected market - **Regulatory trajectory** — is the state's CON regime stable, reforming, or facing repeal pressure? The agencies that command the largest CON premiums are well-run incumbents in stable CON service areas with growing demand and high utilization. ### CON Repeal Risk If a state repeals CON, the scarcity premium erodes over time as new entry occurs. Buyers underwriting CON-state acquisitions consider: - **Probability of CON repeal** in the relevant state - **Timeline of new entry** if repeal occurs - **Defensibility of agency position** under increased competition States with active reform discussions (or recent repeal action in adjacent states) may see partial discounting of the CON premium even before formal repeal. --- ## Transaction Mechanics in CON States ### License Transfer in CHOW The CON itself is generally tied to the licensee, but the underlying agency license transfers in a change of ownership process. Buyers acquire the licensed agency entity (or assets including the license), and the CON-supported license stays in service. CHOW mechanics vary by state. Some states require: - Notification to the CON-issuing agency - Approval of the CHOW by the licensing board - Demonstration of buyer qualifications - Continuity-of-operations commitments CHOW timelines in CON states can be longer than in non-CON states. Plan accordingly in transaction structure. ### Asset vs Stock Purchase Structure Whether a transaction is structured as asset or stock purchase has implications for license and CON continuity: - **Stock purchase** — the entity stays intact; license and CON continuity is generally cleaner; CHOW is at the entity ownership level - **Asset purchase** — license transfer mechanics need to be carefully managed; some CON states have specific requirements for asset-purchase structure Healthcare M&A counsel with CON state experience is essential for getting structure right. ### Diligence Considerations Buyers in CON state transactions diligence: - The CON itself (scope, conditions, restrictions) - Compliance with CON conditions (some CON approvals come with conditions on volume, service mix, or operational requirements) - Recent CON application activity in the service area (proxy for new entry pressure) - State CON reform legislation (proxy for premium sustainability) --- ## Strategic Implications for Sellers ### If You Operate in a CON State Your CON position is one of your most valuable assets. Treat it as such: - **Document the CON in detail** — scope, conditions, history - **Demonstrate strong utilization** — buyers value CON licenses being actively used - **Show service area defensibility** — competitive landscape, referral source relationships, market reputation - **Address any CON conditions or compliance concerns** before going to market - **Pre-empt the CON-repeal-risk question** — have a credible answer about state regulatory stability A CON-state agency that demonstrates these well can capture the full multiple premium. An agency that takes CON for granted often leaves the premium on the table. ### If You Operate in a State Recently Repealed CON The market has changed. Pre-repeal valuation expectations no longer apply, and the buyer pool has shifted: - More out-of-state buyers entering via acquisition - More competitive pricing pressure on operating margins - Different defensibility argument (operational quality and density rather than license scarcity) - Active near-term M&A activity as buyers scramble to establish position Sellers in recently-repealed states should re-anchor expectations and lean into the temporary surge in buyer interest. ### If You Operate in a State Considering Reform CON reform discussion in your state is a relevant strategic input. If reform is likely within your sale planning horizon, going to market before reform can capture the full premium. --- ## Strategic Implications for Buyers CON-state acquisitions are attractive for the same reasons they are valuable to sellers: defensible market position, pricing power, sustainable margins. The question for buyers is whether the premium being paid reflects appropriate underwriting of: - Continued scarcity (low repeal probability, low new-entry probability) - Operational quality of the specific agency - Integration and growth opportunity within the protected market - Alternative investment available in non-CON states Sophisticated buyers build state-by-state CON intelligence as part of their acquisition strategy. --- ## CON in Hospice vs Home Health vs Other Services CON regimes treat services differently. Some states have CON for Medicare-certified home health but not hospice, or vice versa. Some states regulate hospice inpatient capacity (GIP beds) under CON but not routine hospice. Some have CON for skilled nursing but not home-based services. Understanding the specific CON applicability in your state and to your service line is essential. Generic "CON state" assumptions miss the actual regulatory mechanics that drive valuation. --- ## Strategic Implications CON regulation creates real, measurable value for home health and hospice agencies in restricted states — typically 1.0× to 2.0× EBITDA multiple premiums. Capturing the full premium in a sale requires understanding and documenting your CON position, addressing any compliance or condition issues, and engaging buyers who understand and value CON-protected market position. If you operate a CON-state home health or hospice agency and would like to understand how to position your CON value in a sale process, [contact us for a confidential conversation](/contact-us). --- ### Business Broker vs Investment Bank for Home Care Agency Sales URL: https://www.hendonpartners.com/insights/home-care-broker-vs-investment-bank Published: 2026-05-02 09:00 Category: Sale Process > The advisor you hire to sell your home care agency materially affects the valuation, deal structure, and certainty of close you achieve. Here is how to think about the choice between a business broker, a healthcare M&A advisor, and an investment bank. Choosing the advisor who will sell your home care agency is one of the highest-leverage decisions in the entire process. The right advisor materially affects valuation, deal structure, certainty of close, and post-close terms. The wrong advisor — or no advisor at all — leaves significant value on the table and can put the transaction at risk. This guide explains the differences between the three main advisor categories, how to choose between them, and what to look for in each. --- ## The Three Advisor Categories ### 1. Business Brokers Business brokers serve smaller, owner-operated businesses across many industries — restaurants, retail, manufacturing, services, and including home care at the lower end. Characteristics: - Listing-based marketing model (often public or semi-public listings) - Cross-industry generalism, with healthcare as one of many sectors - Transactional approach — find a buyer, complete the deal - Limited buyer relationships in any specific industry - Fee structures often heavier on retainer and/or higher commission percentages on smaller deals - Generally serve businesses with under approximately $1M to $2M of enterprise value **Strengths:** access for smaller agencies that wouldn't attract specialist attention; broad buyer outreach (including individual buyers). **Weaknesses:** limited buyer relationships in healthcare, weaker process structure, less expertise on healthcare-specific diligence and structure issues. ### 2. Healthcare M&A Advisors and Boutique Investment Banks Healthcare-specialized M&A advisors and boutique investment banks focus on the home-based care, behavioral health, and adjacent healthcare services markets. Characteristics: - Industry specialization with deep buyer relationships - Structured competitive process model (CIM, targeted buyer outreach, IOIs, management presentations, LOIs, diligence, close) - Sophisticated understanding of healthcare regulatory and operational diligence - Success-fee dominant fee structures - Generally serve businesses with $500K of EBITDA and above **Strengths:** buyer relationships, healthcare expertise, process discipline, valuation outcomes. **Weaknesses:** typically don't take engagements below a certain threshold (commonly $300K–$500K EBITDA); higher absolute fees (though usually justified by valuation lift). ### 3. Larger Middle-Market and Bulge-Bracket Investment Banks Larger investment banks (middle-market dedicated firms; the larger national and global investment banks for the top of the market) serve the largest transactions. Characteristics: - Sophisticated process management - Deep relationships with the largest PE sponsors and strategic acquirers - Premium fee structures - Generally serve businesses with $5M to $10M of EBITDA and above (varies by firm) **Strengths:** access to the deepest buyer pool for large transactions; deal-making sophistication for complex structures. **Weaknesses:** not interested in or appropriate for smaller agencies; can be overkill for transactions that don't require their bandwidth. --- ## How to Choose ### Size Drives the Decision The single biggest factor is your agency's EBITDA scale and the resulting transaction size: | Agency EBITDA | Typical Right Advisor | |---|---| | Under $300K | Generalist business broker (or no advisor for very small) | | $300K–$500K | Healthcare-specialized broker or smaller M&A advisor | | $500K–$2M | Healthcare-specialized M&A advisor or boutique investment bank | | $2M–$10M | Boutique or middle-market healthcare investment bank | | $10M+ | Middle-market or larger investment bank | These ranges are approximate. Specific agency profile (segment, complexity, buyer pool) shifts the right answer up or down. ### Complexity Matters Agencies with regulatory complexity — Medicare-certified home health, hospice, multi-state operations, recent compliance issues, complex payer mix — benefit disproportionately from healthcare specialization, even at smaller scales. Generalist business brokers struggle with the diligence and structure issues these create. ### Buyer Pool Composition Matters If your most likely buyer pool is dominated by PE-backed platforms (which is the case for most home-based care above $500K EBITDA), specialized advisors with established relationships to those platforms produce materially better outcomes. Generalist brokers don't have those relationships. ### Process Sophistication Matters A structured competitive process — CIM, targeted buyer outreach to 15–40 curated buyers, staged diligence, multiple competing offers, structured negotiation — typically generates 15–30 percent higher outcomes than a listing-based or single-buyer approach. The capability to run that process is the difference between most business brokers and most healthcare M&A advisors. --- ## What a Good Healthcare M&A Advisor Actually Does For agencies that fit the healthcare M&A advisor / investment bank profile, here is what the engagement actually delivers: ### Pre-Process - Sell-side analysis and valuation modeling - Strategic positioning and growth narrative development - Add-back analysis and EBITDA normalization (often coordinated with QoE) - CIM and management presentation development - Buyer list curation and process design ### Marketing - Confidential, targeted buyer outreach - NDA management - Initial buyer education and qualification - Coordinated CIM distribution ### Process Management - IOI solicitation and evaluation - Buyer selection for second round - Management presentation coordination - Site visit and Q&A management - LOI solicitation and evaluation - Negotiation of letter of intent terms (price, structure, exclusivity, conditions) ### Diligence and Close - Data room management - Diligence coordination across financial, legal, regulatory, operational, HR - Issue navigation as items arise in diligence - Definitive agreement negotiation in coordination with counsel - Closing coordination ### Beyond Process - Transition planning support - Post-close earnout monitoring (where applicable) - Founder transition coordination The best advisors are deal-experienced operators who can navigate the inevitable issues that arise in any transaction without the deal blowing up. --- ## Red Flags in Choosing an Advisor Watch for: - **Large upfront fees with little success fee** — alignment is poor; advisor gets paid whether or not the deal closes well. - **Public listings of healthcare businesses** — confidentiality matters in home-based care; public listings can damage relationships with employees, referral sources, and payers. - **No specific buyer relationships demonstrated** — "we have a database of buyers" is not the same as "we have closed three transactions with [specific platform] in the last 18 months." - **Inability to discuss recent transactions** — advisors who can't talk about recent comparable transactions (under appropriate confidentiality) don't have the volume of recent deals you want. - **Overly optimistic valuation pitches** — advisors who pitch unrealistic valuations to win the engagement, then fail to deliver, are common. Compare valuation discussions across multiple advisors. - **Generalist business sale templates** — CIM, process structure, and buyer outreach should be tailored to home-based care, not adapted from a generic business sale template. - **Lack of healthcare regulatory understanding** — if the advisor can't speak fluently about CHOW, EVV, OIG screening, Medicare cap, payer contract assignment, you have the wrong advisor. --- ## Fee Structures Most healthcare M&A advisors and investment banks use some combination of: - **Engagement fee or work fee** — modest upfront fee, often $25K to $100K depending on engagement size - **Monthly retainer** — sometimes used during process - **Success fee** — percentage of transaction value, typically 1 to 5 percent depending on transaction size, often with minimums and tiered structures - **Lehman or Double Lehman scales** — common fee structures that scale percentage with transaction value For the right advisor, the fee is meaningfully smaller than the valuation lift they deliver. The wrong advisor charges the same fee and produces a weaker outcome. --- ## What About Selling Without an Advisor? For very small agencies (under $200K of EBITDA), selling directly to a known buyer can make sense. For agencies above that threshold, going to market without advisory support typically: - Achieves materially lower valuation (often 20–40 percent lower) - Results in less favorable deal structure - Creates higher execution risk - Generates more diligence-driven discounts - Produces worse post-close outcomes The owner is also typically running the agency through the process, which divides attention and harms operational results during the diligence period — which itself becomes a discount. The cases where unrepresented sale makes sense are narrow. --- ## Strategic Implications For most home care, home health, hospice, pediatric, and behavioral health agencies above $500K of EBITDA, the right advisor is a healthcare-specialized M&A advisor or boutique investment bank with active buyer relationships, deep healthcare expertise, and a structured competitive process. The right choice typically pays for itself many times over in valuation lift and deal quality. If you would like to understand what the right advisor profile looks like for your specific agency, [contact us for a confidential conversation](/contact-us). --- ### The 12-Month Home Care Agency Sale Preparation Checklist URL: https://www.hendonpartners.com/insights/12-month-home-care-sale-preparation-checklist Published: 2026-05-01 09:00 Category: Sale Preparation > The agencies that achieve premium valuations are almost always the ones that began preparing 12 months or more before going to market. Here is the month-by-month checklist for getting your home care, home health, or hospice agency sale-ready. The agencies that achieve premium valuations in home-based care M&A are almost always the ones that began preparing 12 months or more before going to market. The agencies that go to market unprepared, in contrast, typically achieve 15 to 30 percent lower outcomes than they otherwise would — driven by diligence-driven discounts, weaker buyer competition, and reduced negotiation leverage. This checklist is the month-by-month playbook for a structured 12-month preparation. It applies across non-medical home care, Medicare-certified home health, hospice, pediatric PDN, and behavioral health agencies, with segment-specific notes where relevant. --- ## Why Preparation Matters Buyers — especially sophisticated PE platforms and strategic acquirers — diligence aggressively. Anything they find that wasn't clean, organized, or pre-disclosed becomes a discount, a structural change in the deal (more earnout, more escrow, more rep and warranty exposure), or in worst cases a reason to walk. Preparation does three things: 1. **Maximizes EBITDA defensibility** — clean financials, justified add-backs, normalized working capital 2. **Eliminates avoidable diligence flags** — compliance cleanup, contract organization, employee classification, documentation 3. **Builds the strategic story** — growth narrative, market positioning, management depth, integration ease Each of these directly affects multiple, certainty of close, and final structure. --- ## Months 12 to 10: Financial Foundation ### Get a Sell-Side Quality of Earnings (QoE) Engage a transaction-experienced accounting firm to produce a sell-side QoE on the trailing twelve months and prior two years. The QoE will: - Normalize EBITDA with defensible add-backs - Identify and resolve accounting issues before a buyer finds them - Build a credible financial narrative - Significantly accelerate buyer-side diligence later Cost: typically $25,000 to $75,000. Value: multiples of that in pricing leverage. ### Clean Up the Books Move from cash to accrual basis if you haven't already. Reconcile balance sheet accounts. Document accounting policies. Resolve open items, lingering reconciliation issues, and historical accounting choices that need explanation. ### Build a Real Monthly Reporting Package If you don't already produce monthly P&L, balance sheet, cash flow, and operational KPI reports — start now. Buyers will expect at least 12 months of monthly reporting in diligence. Building it from a clean baseline is materially better than constructing it retroactively. ### Identify and Document Add-Backs Owner compensation above market rate, personal expenses, one-time items, discontinued service lines, COVID-era anomalies, related-party rent — every legitimate add-back needs supporting documentation. Add-backs that are legitimate but undocumented are add-backs that get challenged in diligence. --- ## Months 10 to 9: Operational and Compliance Cleanup ### Compliance Audit Engage healthcare compliance counsel or a compliance consultant to do a pre-process compliance review covering: - Survey/inspection history and any open plans of correction - Billing compliance (Medicare, Medicaid, MCO claims) - HIPAA and privacy - EVV compliance (where applicable) - OIG screening and exclusion list checks - Worker classification (1099 vs W-2) - Caregiver and clinician credentialing files Address findings now, while you have time. A buyer's diligence finding the same issues is materially worse than your own pre-process documentation showing remediation. ### Contract Inventory and Organization Build a complete contract inventory: - Payer contracts (Medicare, Medicaid MCOs, commercial, VA) - Referral source agreements - Vendor contracts (EMR, scheduling, payroll, equipment) - Employee agreements (especially key clinical/management) - Real estate leases - Partnerships, joint ventures, or affiliations Identify change-of-control provisions in each. Anything that requires consent, notification, or termination in a sale needs to be flagged early. ### Document Operating Procedures Buyers want to see operations that can be transferred. Document: - Intake and admission processes - Care planning and clinical oversight - Scheduling - Billing and collections - Recruiting and onboarding - Quality and compliance processes Documentation doesn't need to be polished consultant output. It does need to demonstrate that operations don't exist only in the founder's head. --- ## Months 9 to 7: Management and Operational Depth ### Build or Document Management Depth The single biggest valuation discount for owner-operator agencies is "key person risk." Buyers ask: if the owner left, what would happen? If you have built a real management team, document their roles, capabilities, and what they own. If you haven't, this is the time to start. Hiring or promoting an Administrator, Director of Nursing, Director of Operations, or VP of Sales — even at the cost of short-term EBITDA — pays back in valuation. ### Reduce Owner Operational Dependency Begin transferring operational functions away from the owner: - Sales and BD activities to a VP of Sales or BD team - Clinical oversight to a DON or DCS - Operations to an Administrator or COO - Financial close and reporting to a CFO or controller Buyers underwrite the post-close operating model. The less the owner is in the day-to-day, the more attractive the asset. ### Address Key Employee Retention Identify your 5 to 15 most critical employees. Consider: - Bonus structures or stay agreements aligned with sale timing - Documented compensation that won't surprise buyers - Non-compete and confidentiality coverage where appropriate - Career path and engagement that supports retention through transition Buyers will negotiate retention packages with key employees post-LOI. Going in with strong employee relationships and documented retention strategy strengthens your position. --- ## Months 7 to 5: Strategic Positioning ### Build the Growth Narrative Buyers pay multiples on forward EBITDA. The growth story matters. Document: - Recent and current organic growth trends (census, hours, admissions, revenue) - New service lines or geographies in development - Sales pipeline and recent wins - Referral source expansion strategy - Operational capacity for continued growth The narrative should be defensible — not just optimistic projections, but a documented case for continued growth. ### Diversify Concentration Risks Concentration risks are deal killers or deep discounts. Address: - Single-payer concentration (especially single-MCO contracts in Medicaid) - Single-referral-source concentration (especially over 30 percent from one source) - Geographic concentration in declining markets - Single-customer concentration in private duty or staffing models Diversification doesn't happen overnight, but a documented effort to diversify, plus measurable progress, materially improves diligence outcomes. ### Document Quality and Outcomes For Medicare-certified home health and hospice especially, pull together: - Star ratings history - Survey results - HHCAHPS / CAHPS Hospice scores - Quality measure performance - Clinical outcome metrics where available Quality metrics are valuation drivers. Documented strength supports premium pricing. --- ## Months 5 to 3: Pre-Marketing Readiness ### Engage Your Advisory Team Three to six months before going to market is the right time to engage your full advisory team: - M&A advisor / investment banker - Transaction counsel (M&A and healthcare regulatory) - Tax advisor (including estate and personal planning) - QoE accountant (if not already engaged) Each plays a specific role and they need time to understand your business before the process begins. ### Begin Confidential Information Memorandum (CIM) Development The CIM is the document that introduces your business to buyers. Building it well takes weeks. Components: - Executive summary and investment highlights - Business overview and history - Service line descriptions - Operational metrics - Financial summary and projections - Market and growth opportunity - Management team - Transaction process and timeline ### Data Room Preparation Begin populating the virtual data room buyers will access in diligence. Categories include: - Financial (statements, tax returns, QoE, projections) - Operational (KPIs, contracts, policies) - Legal (corporate documents, litigation, compliance) - HR (org chart, key employees, comp data) - Regulatory (licenses, surveys, plans of correction) - IT and systems A well-organized data room signals professionalism and accelerates diligence. ### Confidentiality Planning Decide who internally needs to know about the process and when. Build NDA infrastructure for both internal communication and buyer-side outreach. --- ## Months 3 to 1: Process Launch Preparation ### Buyer List Development Work with your advisor to build the targeted buyer list. The list should include: - Strategic acquirers with clear strategic fit - PE-backed platforms with active acquisition mandates in your segment and geography - Selective sponsors for whom your agency could be a platform investment The list should be curated to 15–40 names typically, not blasted to 200. ### Final Financial and Operational Polish Last cleanup of: - Trailing twelve months EBITDA, with all add-backs documented - Current month operational KPIs - Recent quality and compliance documentation - Management presentation materials ### Process Timing Confirm that timing makes sense. Avoid launching a process in late November or December. Avoid launching during a known regulatory transition (e.g., final rule implementation in your space). Plan for a process that runs 6 to 9 months end to end. --- ## Month 0: Launch The first month of the formal process typically involves: - CIM distribution to the buyer list under NDA - Initial buyer questions and management calls - Preliminary indications of interest (IOIs) - Selection of buyers invited to second round By the time you launch, every component of preparation should be complete. The process itself is execution; the value was largely created in preparation. --- ## What Preparation Is Worth A well-prepared agency in a competitive process typically achieves: - 15 to 30 percent higher headline valuation - Cleaner deal structure (more cash at close, less earnout exposure) - Faster close (3 to 5 months from LOI vs. 6 to 9) - Lower escrow and reps and warranties exposure - Better post-close transition outcomes The 12 months of preparation work — and the modest direct cost of advisors and QoE — is one of the highest-return investments any agency owner makes. --- ## Strategic Implications The agencies that achieve premium outcomes are the ones that ran a 12-month preparation playbook. The agencies that didn't generally don't. If you are 12 to 24 months from a possible sale and would like to understand what preparation looks like for your specific agency, [contact us for a confidential conversation](/contact-us). --- ### Selling a Home Care Agency in California: 2026 Market Guide URL: https://www.hendonpartners.com/insights/selling-home-care-agency-california Published: 2026-04-30 09:00 Category: State Guides > California is one of the most regulated home care markets in the country, with HCO licensing, IHSS dynamics, strict labor law, and distinct M&A characteristics. Here is what California home care, home health, and hospice owners should understand about selling in 2026. California is one of the largest home-based care markets in the United States, but also one of the most distinctive. Unique licensing structures, the IHSS program, strict labor law, recent hospice reform activity, and a particular buyer dynamic combine to make California a market that rewards specific expertise. This guide covers what California home care, home health, and hospice owners should understand about selling in 2026. --- ## Why California Is a Distinct Market Several structural factors set California apart: **Population scale.** California has the largest 65+ population of any state in absolute terms. The addressable market for home-based care is enormous. **Regulatory complexity.** California's home care regulatory environment is among the most demanding in the country. Multiple state agencies, distinct licenses, ongoing legislative activity, and strict labor law all factor into agency operations and M&A diligence. **IHSS structural difference.** California's IHSS program — the Medicaid-funded personal care program — operates primarily through county- or consumer-employed caregivers rather than agency contracts. This means California's private agency Medicaid HCBS revenue base is much smaller than states like Texas, Florida, or New York. **Higher labor cost base.** Minimum wage, overtime, paid sick leave, and worker classification rules all increase the underlying cost structure of California home care relative to most other states. **Hospice moratorium.** California's 2022 moratorium on new hospice licenses, in response to fraud concerns, fundamentally changed hospice M&A dynamics in the state. --- ## California-Specific Licensing ### Home Care Organization (HCO) Non-medical home care in California is licensed as a Home Care Organization (HCO) by the California Department of Social Services (CDSS). HCO licensing includes: - Initial licensing application and inspection - Caregiver registration and background check requirements (Home Care Aide registry) - Ongoing reporting and inspection - Specific worker classification rules HCO licenses do not automatically transfer in a sale. The buyer applies for the license in their entity, and CDSS coordinates the transition. ### Medicare-Certified Home Health (CDPH) Medicare-certified home health agencies are licensed by the California Department of Public Health (CDPH) in addition to CMS certification. Sale transactions require: - CDPH license process for the buyer - CMS provider number transfer - State and federal coordination on timing ### Hospice (CDPH) — Moratorium and Reform California implemented a moratorium on new hospice licenses in 2022 following audit findings of significant fraud in certain regions. Subsequent legislative activity has focused on hospice licensing reform, increased oversight, and tightened qualification requirements. The moratorium and reform environment have several M&A implications: - New hospice entry is restricted, supporting scarcity-driven valuations for established, compliant operators - Diligence on existing hospice operators is more intense, with deeper scrutiny on referral patterns, GIP utilization, length of stay, and Medicare cap exposure - Buyers are highly selective in California hospice acquisitions — quality operators command premiums, but operators with any compliance concerns face significant discounts or buyer reluctance ### Worker Classification (AB 5 and Beyond) California's worker classification rules — most notably AB 5 — significantly restrict the use of independent contractors in home care. California home care agencies generally must operate caregivers as W-2 employees. Agencies with historical 1099 caregiver use carry meaningful diligence and back-tax risk. --- ## The IHSS Reality IHSS (In-Home Supportive Services) is California's Medicaid HCBS personal care program. Unlike most states' HCBS structures, IHSS operates primarily through: - County employment or direct consumer-employment of caregivers - Public Authority structures in some counties - Limited use of private agency contracting This structural difference means California's private home care agency Medicaid HCBS revenue base is small relative to states like Texas (STAR+PLUS), New York (CDPAP and managed Medicaid HCBS), Florida (Medicaid managed care HCBS), or Pennsylvania (waiver programs). Most California private home care revenue is private pay, with selective Medicare Advantage and VA contracts. For sellers, this has implications: - The CMS 80/20 rule has limited direct impact on California private agencies (less in-scope HCBS revenue) - Private pay positioning, geographic concentration, and operational quality are the primary value drivers - Buyers value California agencies as private-pay-anchored platforms with scale-build potential --- ## Valuation Context for California Agencies Quality California agencies generally trade at multiples in line with or above national benchmarks, with specific California dynamics: - **Private pay home care** — strong multiples for $500K+ EBITDA agencies with brand strength, geographic density (especially in coastal metros), and scalable operations - **Medicare home health** — competitive multiples for star-rated, low-LUPA, deficiency-free agencies - **Hospice** — premium multiples for established, compliant California hospice operators given moratorium dynamics; deep discount or buyer avoidance for operators with compliance concerns - **Pediatric PDN** — active California pediatric market, with valuations driven by nurse retention and authorized hours fill rate California-specific discount considerations: - Higher operating cost base reflected in EBITDA expectations - Worker classification history risk (1099 use) - Compliance history sensitivity (especially hospice) - Geographic sprawl penalty (San Francisco Bay Area, LA Metro, Orange County, San Diego, Sacramento each have distinct micro-markets) --- ## The Buyer Landscape in California Active California buyers include: - **National PE-backed home care, home health, and hospice platforms** with California as priority geography - **California-focused regional platforms** with mid-market PE backing - **Hospice platforms** acquiring established, compliant California hospice agencies given the moratorium dynamics - **Strategic health systems** including Kaiser, Sutter, Dignity, Providence, Cedars-Sinai, and others making selective acquisitions - **Pediatric platforms** with California operations The California buyer pool is deep but more selective than Texas or Florida. Buyers do meaningful pre-diligence and prioritize agencies with clean compliance, clean labor practices, and strong operational documentation. --- ## Practical Considerations for California Sellers ### Pre-Clean Worker Classification Any historical 1099 caregiver use needs to be addressed before going to market. Reclassification, back-tax exposure, and ongoing compliance documentation are routine diligence items. ### Document Wage and Hour Compliance California wage and hour rules are detailed and aggressively enforced. Documentation of overtime, meal and rest break compliance, paid sick leave, and minimum wage adherence should be cleaned and organized before diligence. ### Hospice Sellers: Lead with Compliance If you operate a California hospice agency, your compliance profile (referral patterns, GIP utilization, length of stay distribution, Medicare cap, audit history, OIG and SFP standing) is the single most important factor in your sale outcome. Lead with documentation that demonstrates compliance strength. ### Geographic Strategy California is large enough that geographic concentration matters. A Bay Area agency, an LA Metro agency, and an Orange County agency each have different buyer dynamics. Multi-region operators should be prepared to discuss the strategic logic of their footprint. ### Get California-Experienced Advisory California-specific licensing, IHSS dynamics, labor law, hospice moratorium implications, and metro-specific buyer relationships all matter materially in execution. Advisors without California-specific experience often miss real value. --- ## Common Mistakes California Sellers Make 1. **Ignoring worker classification cleanup.** 1099 history not addressed pre-process becomes a deal-killing diligence issue. 2. **Underestimating compliance scrutiny in hospice.** California hospice diligence is intense; weak documentation produces deep discounts or process termination. 3. **Generic national valuation expectations.** California cost structure and regulatory complexity mean valuation should be California-anchored. 4. **Single-buyer engagement.** California sees significant inbound BD activity; single-buyer outcomes typically lag competitive processes by 15–25%. 5. **Inadequate metro-specific positioning.** Statewide narratives without metro-specific operational detail underperform. --- ## Strategic Implications California is a strong selling market in 2026 for quality, compliant, well-documented home-based care agencies. The combination of demographic scale, deep buyer interest, and selective regulatory dynamics (hospice moratorium in particular) supports premium outcomes for sellers who lead with operational quality and compliance strength. For agencies with weak compliance history, worker classification exposure, or operational disorganization, California is a more punishing market than most. Pre-process cleanup is essential. If you operate a home care, home health, hospice, or PDN agency in California and would like to understand current market conditions for your specific business, [contact us for a confidential conversation](/contact-us). --- ### Selling a Home Care Agency in Texas: 2026 Market Guide URL: https://www.hendonpartners.com/insights/selling-home-care-agency-texas Published: 2026-04-29 09:00 Category: State Guides > Texas is one of the largest and most active home care M&A markets in the country, with HCSSA-licensed agencies operating across a sprawling, demographically favorable state. Here is what Texas home care, home health, and hospice owners should know about selling in 2026. Texas is one of the largest home-based care markets in the United States — and one of the most active for M&A. The combination of favorable demographics, a deep buyer pool, multiple major metropolitan markets, and a non-CON regulatory environment creates a structurally attractive selling market for quality home care, home health, and hospice agencies. This guide covers what Texas agency owners should understand about selling in 2026: market conditions, HCSSA licensing mechanics, buyer landscape, valuation context, and common pitfalls. --- ## Why Texas Is an Active M&A Market **Population scale and growth.** Texas is the second-largest state by population and one of the fastest-growing. The 65+ and 75+ cohorts are growing meaningfully, driving structural demand for home-based care. **Multiple strong metro markets.** Houston, Dallas-Fort Worth, San Antonio, Austin, El Paso, and the Rio Grande Valley each represent meaningful sub-markets with their own buyer dynamics. Buyers building Texas density typically target multiple metros, creating multiple paths to a strong outcome for quality agencies. **Non-CON market.** Without Certificate of Need restrictions, the Texas market has higher agency density and more potential buyers. PE-backed platforms can enter Texas through acquisition without CON delays. **Active strategic and PE presence.** Most major home-based care platforms have Texas as a priority geography. Texas is also home to several large home health and hospice strategics. --- ## Texas-Specific Licensing: HCSSA ### What Is HCSSA? HCSSA — Home and Community Support Services Agency — is the umbrella license issued by Texas HHSC for agencies providing home health, hospice, personal assistance services, and related home and community-based services. Common HCSSA license categories include: - **Licensed Home Health** — non-Medicare home health - **Licensed and Certified Home Health** — Medicare-certified - **Hospice** - **Personal Assistance Services (PAS)** — non-medical - **Community Support Services** The category and combination of categories on your license affects diligence and CHOW. ### HCSSA Change of Ownership Texas HCSSA licenses do not automatically transfer in a sale. The buyer must complete a CHOW process with HHSC. Key points: - Timeline varies by license category and current HHSC workload - Medicare-certified home health requires both HHSC CHOW and CMS provider number transfer - A management services agreement is commonly used to operate under the seller's license between deal close and full CHOW approval - HHSC inspection history, deficiency reports, and current standing all become diligence items ### EVV in Texas Texas was an early EVV implementer for Medicaid PAS. EVV compliance — system selection, visit verification rates, billing reconciliation — is a routine diligence item for any agency with Medicaid PAS revenue. ### Medicaid Managed Care (STAR+PLUS) Texas Medicaid HCBS for the senior and disabled population is delivered primarily through managed care under STAR+PLUS. Major MCOs include Amerigroup, Molina, Superior, United, Cigna-HealthSpring, and others. MCO contract concentration is a meaningful diligence item — agencies with diversified MCO contracts get rewarded; those with single-MCO concentration get discounted. --- ## Valuation Context for Texas Agencies Texas multiples for quality agencies generally meet or exceed national benchmarks across segments: - **Non-medical home care / PAS** — strong multiples for $500K+ EBITDA agencies with diversified MCO mix and operational scale - **Medicare-certified home health** — competitive multiples for agencies with strong star ratings, LUPA management, and clean survey history - **Hospice** — premium multiples remain available for quality Texas hospice agencies with strong census and Medicare cap headroom - **Pediatric PDN** — active Texas pediatric PDN buyer market Texas-specific value drivers: - Geographic density in major metros - Diversified MCO contract portfolio for Medicaid PAS agencies - Strong nurse and caregiver retention in a tight labor market - Multi-line capability (home health + hospice, etc.) at scale Texas-specific discount drivers: - Single-MCO contract concentration - Geographic sprawl across non-contiguous regions - Compliance history weakness - Border-region operational complexity (workforce, language, compliance) --- ## The Buyer Landscape in Texas Active buyers in Texas include: - **National PE-backed platforms** in home care, home health, and hospice with Texas as priority geography - **Texas-based platforms** built specifically for Texas density (multiple HCSSA-focused platforms with mid-market PE backing) - **Hospice platforms** with active Texas acquisition strategies - **Pediatric PDN platforms** including Aveanna and Care Options for Kids - **Strategic health systems** in major Texas metros The Texas buyer pool is deep enough that competitive processes for quality agencies typically generate strong interest from multiple platforms. --- ## Practical Considerations for Texas Sellers ### Plan HCSSA CHOW into Your Timeline The CHOW process is operationally important. Plan a transaction timeline that accommodates HHSC processing time, with management services structuring during the gap. ### Document Your MCO Contract Portfolio For agencies with Medicaid PAS revenue under STAR+PLUS, document your MCO contract status, rate structure, renewal timing, and revenue concentration. Buyers will model MCO renewal risk; agencies that pre-empt the analysis with clean documentation get faster, better outcomes. ### EVV Compliance Documentation EVV system selection, visit capture rates, and billing reconciliation should be documented and clean before going to market. Texas EVV is mature; gaps are diligence flags. ### Get a Texas-Specific Valuation Texas market dynamics (MCO mix, EVV maturity, non-CON competitive pressure, metro-specific buyer density) require Texas-aware valuation analysis. Generic national benchmarks miss real Texas variables. ### Understand Your Metro Position A San Antonio agency, a Houston agency, and a Dallas-Fort Worth agency each have different buyer dynamics. Understanding which platforms are actively building in your specific metro is part of designing a competitive process. --- ## Common Mistakes Texas Sellers Make 1. **Engaging a single inbound buyer.** Texas sees heavy inbound business development outreach. Single-buyer engagement typically produces 15–25% lower outcomes than competitive processes. 2. **Underestimating CHOW timeline.** Building a closing schedule that doesn't accommodate HCSSA CHOW creates avoidable execution risk. 3. **MCO contract concentration not addressed.** Single-MCO concentration is the single most common diligence-driven discount in Texas Medicaid HCBS deals. 4. **Compliance documentation gaps.** HHSC inspection history is reviewed in diligence; weak agencies that haven't pre-cleaned documentation lose negotiating leverage. 5. **Generic national valuation expectations.** Texas-specific dynamics matter; valuation expectations should be Texas-anchored. --- ## Strategic Implications Texas is one of the strongest selling markets in the country for quality home-based care agencies in 2026. The buyer pool is deep, the demographic tailwind is structural, and the non-CON market structure means open market entry continues to attract new acquirer interest. Execution discipline matters: HCSSA CHOW planning, MCO contract diligence preparation, EVV compliance cleanliness, and competitive process design separate good outcomes from premium ones. If you operate a home care, home health, hospice, or PDN agency in Texas and would like to understand current market conditions for your specific business, [contact us for a confidential conversation](/contact-us). --- ### Selling a Home Care Agency in Florida: 2026 Market Guide URL: https://www.hendonpartners.com/insights/selling-home-care-agency-florida Published: 2026-04-28 09:00 Category: State Guides > Florida is one of the most active home care M&A markets in the country, with strong demographics, a deep buyer pool, and distinct licensing and regulatory mechanics. Here is what Florida home care, home health, and hospice owners should know about selling in 2026. Florida is one of the most active home-based care M&A markets in the United States. Strong senior demographics, a deep PE buyer pool, significant strategic acquirer presence, and recent regulatory shifts have combined to make Florida a structurally attractive state for sellers across home care, home health, and hospice. This guide covers what Florida agency owners should understand about selling in the current market — buyer landscape, valuation context, licensing mechanics, and the specific issues that come up in Florida transactions. --- ## Why Florida Is a Strong Selling Market Several factors converge: **Demographics.** Florida has the highest proportion of residents 65+ of any large state, and net in-migration of retirees continues. The 75+ population — the most relevant cohort for home care, home health, and hospice utilization — is growing meaningfully faster than the national average. **Buyer concentration.** Most major PE-backed home care, home health, and hospice platforms have Florida as a priority acquisition geography. Several platforms were built around or are headquartered in Florida (Aveanna in Atlanta with deep Florida operations, multiple hospice platforms with Florida footprint). **Payer mix.** Florida agencies typically have a heavier private pay and Medicare Advantage mix than national averages, which is attractive to buyers concerned about Medicaid rate adequacy and 80/20 rule exposure. **Recent regulatory shifts.** The 2025 repeal of hospice CON in Florida fundamentally changed hospice M&A dynamics — increasing both new entry and acquisition activity. --- ## Florida-Specific Licensing and Regulatory Context ### Agency for Health Care Administration (AHCA) Florida home-based care licensure is administered by AHCA. Common license types in M&A transactions include: - **Home Health Agency (HHA)** — Medicare-certified or non-certified - **Nurse Registry** — staffing model for private duty nursing - **Homemaker and Companion Services** — non-medical - **Home Medical Equipment Provider** - **Hospice** License-specific requirements, surveys, and inspection histories all become diligence items in a sale. ### Change of Ownership (CHOW) Florida licenses do not automatically transfer with the sale of a business. Buyers must apply for CHOW approval through AHCA, with timelines varying by license type. CHOW is one of the most operationally important variables in a Florida transaction: - **Non-medical (homemaker/companion):** typically faster CHOW process, often weeks to a few months - **Nurse Registry:** moderate timeline - **Home Health Agency (Medicare-certified):** longer process; coordination with CMS for the Medicare provider number transfer is the longer-pole - **Hospice:** moderate to long, depending on AHCA workload CHOW timelines drive the closing structure — many transactions use a management services arrangement during the gap between deal signing and CHOW approval, with the buyer operating under the seller's license through closing. ### Certificate of Need (CON) — Recently Repealed for Hospice Florida eliminated CON for most healthcare services, and hospice CON was repealed effective 2025. This is one of the most consequential recent regulatory shifts in the state: - Pre-repeal, hospice CON limited new entry and supported scarcity-driven valuations for incumbent hospice providers in their service areas - Post-repeal, new hospice entry is permitted across the state, increasing competition over time - The immediate effect on M&A has been increased activity from out-of-state and PE-backed hospice platforms entering Florida via acquisition rather than waiting for de novo build-out Florida hospice owners should understand that the post-CON market has more buyers but also more competitive pressure on the underlying business. ### EVV and Medicaid Florida participates in EVV requirements for Medicaid HCBS personal care. Compliance gaps create both regulatory and billing risk that buyers will diligence carefully. --- ## Valuation Context for Florida Agencies Multiples for Florida home-based care agencies generally meet or exceed national benchmarks, particularly for: - **Hospice** — Florida hospice agencies have historically commanded premium multiples; post-CON repeal, premium multiples remain for established agencies with strong census, referral diversification, and Medicare cap headroom - **Private pay home care** — strong demographic tailwinds support multiples at the high end of national ranges - **Pediatric PDN** — Florida has an active pediatric PDN buyer market with several platforms acquiring - **Medicare-certified home health** — solid market, with the usual emphasis on star ratings, LUPA rates, and survey history Discount drivers in Florida specifically: - High caregiver wage pressure in South Florida and major metros - Hurricane and weather-related operational risk (continuity planning matters in diligence) - Medicaid managed care concentration (Florida's Medicaid managed care structure means MCO contract concentration is a real diligence item) --- ## The Buyer Landscape in Florida Active buyers for Florida home-based care assets include: - **Hospice platforms** — Compassus, Bristol Hospice, Agape Care, Three Oaks, Traditions, multiple PE-backed regional platforms - **Home care platforms** — Help at Home, regional PE-backed platforms, franchise systems with Florida growth strategies - **Pediatric platforms** — Aveanna, Care Options for Kids, regional pediatric platforms - **Strategic health systems** — Florida health systems acquiring home health and hospice in their service areas The buyer pool is deep. A well-run Florida sale process typically generates strong competitive interest. --- ## Practical Considerations for Florida Sellers ### Plan for CHOW Timing Early Build CHOW into your sale timeline from the start. A buyer's diligence will include reviewing your AHCA inspection history, deficiency reports, plan of correction history, and current standing. Anything that complicates CHOW approval becomes a negotiation point. ### Get a Florida-Aware Valuation Generic national valuation benchmarks miss Florida-specific variables: post-CON hospice dynamics, Medicaid managed care contract economics, hurricane operational risk, geographic micro-markets (Miami-Dade, Broward, Tampa Bay, Orlando, Jacksonville, North Florida each have distinct buyer dynamics). ### Document Hurricane and Continuity Planning Florida buyers diligence operational continuity planning carefully. Documented business continuity plans, emergency staffing protocols, generator and backup arrangements, and insurance coverage become favorable diligence items. ### Understand Your Medicaid Managed Care Concentration If you have meaningful Medicaid HCBS or PDN revenue, your concentration across Florida MCO contracts (Sunshine, Humana, Molina, Simply, etc.) is a key diligence item. MCO contract renewal risk gets discounted; diversified contract relationships get rewarded. ### Consider Multi-Service Line Positioning Florida buyers often value agencies that offer combined service lines (home health + hospice, home care + PDN, etc.) at premium multiples versus single-line operators of similar EBITDA. --- ## Common Mistakes Florida Sellers Make 1. **Engaging a single inbound buyer without competitive process.** Florida sees heavy inbound BD activity. Direct response to one buyer typically produces 15–25% lower outcomes than running a structured process with three to seven serious buyers. 2. **Ignoring CHOW timeline implications.** Failing to plan around CHOW creates last-minute structuring problems. 3. **Underestimating post-CON competitive pressure** in hospice. The market has changed; pricing assumptions from the pre-2025 regime no longer apply. 4. **Inadequate documentation of compliance history.** AHCA inspection history is public; buyers find weaknesses fast and discount accordingly. 5. **Not having a Florida-experienced advisor.** State-specific licensing, MCO dynamics, and buyer relationships matter materially in execution. --- ## Strategic Implications Florida is a strong selling market in 2026 for quality home-based care agencies. The combination of demographic tailwinds, active buyer pool, and post-CON hospice dynamics creates favorable conditions, but execution discipline matters: CHOW planning, competitive process design, and Florida-specific buyer targeting are the difference between a good outcome and a great one. If you operate a home care, home health, hospice, or pediatric agency in Florida and would like to understand current market conditions for your specific business, [contact us for a confidential conversation](/contact-us). --- ### Most Active Private Equity Firms in Home-Based Care M&A in 2026 URL: https://www.hendonpartners.com/insights/most-active-home-care-private-equity-firms-2026 Published: 2026-04-27 09:00 Category: Buyer Landscape > Private equity continues to drive the majority of home-based care M&A activity in 2026. Here is a working guide to the most active PE platforms and sponsors acquiring home care, home health, hospice, pediatric, and behavioral health agencies — and what each looks for. Private equity continues to drive the majority of home-based care M&A activity in 2026. Understanding who the active buyers are — and what each one is looking for — is one of the most useful pieces of context an agency owner can have when evaluating a sale. This guide is a practical overview of the most active PE participants in home-based care, organized by segment focus. Activity in this space is heavily concentrated through PE-backed portfolio platforms making add-on acquisitions, rather than direct sponsor acquisitions of individual agencies. We have included both layers. A note on scope: the firms below are active acquirers as of early 2026. Deal activity, fund cycles, and platform strategies shift regularly. Any sale process should be informed by current intelligence on which platforms are buying, in which geographies, at what scale, and at what valuations — not on a static list. --- ## How the PE Buyer Landscape Is Structured Three layers matter when thinking about PE in home-based care: 1. **Sponsors (the PE firms themselves)** — these are the funds that invest. Examples: Centerbridge, Bain Capital, KKR, Webster Equity, Vistria, Audax, H.I.G., Wellspring, BlueMountain. 2. **Platforms (the operating companies the sponsors own)** — these are the home care, hospice, pediatric, or behavioral health businesses that execute the strategy. Most agency-level acquisitions happen at this layer as add-ons. 3. **Strategics with PE backing or financing** — established home-based care companies (some public, some private) that operate similarly to PE platforms in their acquisition behavior. When an agency owner gets approached by a "PE buyer," it is almost always one of the platform companies, not the sponsor directly. The sponsor sets strategy and funding capacity; the platform does the acquiring. --- ## Active Buyers in Non-Medical Home Care The non-medical home care segment has seen the most consolidation of any home-based care vertical. Active platforms include: - **Help at Home** — large-scale Medicaid HCBS personal care platform, multi-state, focused on Medicaid waiver business - **HouseWorks / Saint Therese / regional non-medical platforms** — building density in specific geographies - **Senior Helpers, BrightStar Care, Right at Home, Visiting Angels, Home Instead, Comfort Keepers** — established franchise systems, many with PE backing supporting franchisee acquisitions or corporate roll-ups - **Multiple regional platforms** with PE sponsorship targeting $1M+ EBITDA add-ons in their geographic footprint What they look for: defensible local market position, $500K+ EBITDA, scalable referral sources, clean operations, and geographic fit with existing density. --- ## Active Buyers in Medicare-Certified Home Health Medicare home health consolidation is dominated by a smaller number of large platforms: - **Enhabit Home Health & Hospice** — public, multi-state, active in selective acquisitions - **Aveanna Healthcare** — large pediatric and adult home health/hospice platform - **BrightSpring Health Services** — public, broad home and community health platform - **Bayada Home Health Care** — large nonprofit-affiliated organization, selective acquirer - **Help at Home / Vistria-backed platforms** in select markets - **Regional Medicare home health platforms** owned by mid-market PE sponsors What they look for: strong star ratings, low LUPA rates, deficiency-free survey history, geographic fit, $1M+ EBITDA, and CON state positioning where applicable. --- ## Active Buyers in Hospice Hospice has been one of the most active M&A segments of the past five years. Active acquirers include: - **Addus HomeCare** — public, growing hospice presence - **Aveanna Healthcare** — adult hospice expansion - **BrightSpring Health Services** — public platform - **Bristol Hospice** (Webster Equity) — multi-state hospice platform - **Agape Care Group** (Ridgemont/BlueMountain) — Southeast-focused hospice platform - **St. Croix Hospice** (H.I.G. Capital) — Midwest hospice platform - **Compassus** (TowerBrook/OSF) — large multi-state hospice and palliative platform - **Three Oaks Hospice** and other regional Webster/H.I.G./Audax-backed platforms - **Traditions Health, Hospice of the Chesapeake**, and other regional players with PE financing What they look for: average daily census growth trajectory, Medicare cap headroom, diversified referral sources, clean OIG/SFP profile, geographic density, and $750K+ EBITDA for add-ons. --- ## Active Buyers in Pediatric Home Health and PDN Pediatric is a smaller universe of active acquirers, with a few dominant platforms: - **Aveanna Healthcare** — the largest pediatric home health and PDN platform in the US - **Care Options for Kids** (Webster Equity) — multi-state pediatric platform - **Phoenix Pediatrics** and other regional pediatric platforms backed by mid-market PE - **PSA Healthcare / Bayada Pediatrics** — large pediatric capabilities within broader platforms - **Children's hospital systems** acting as strategic acquirers in specific markets What they look for: pediatric-specific clinical capability (vent/trach, complex care), nurse retention infrastructure, authorized-hours fill rate, payer rate strength, and geographic concentration. --- ## Active Buyers in Behavioral Health and ABA Behavioral health and ABA M&A have their own ecosystem, with significant PE activity: - **Centerbridge / LEARN Behavioral, Centria Autism, Hopebridge** and similar ABA platforms - **BlueSprig Pediatrics** — multi-state ABA - **Acadia Healthcare** — large behavioral health strategic - **Discovery Behavioral Health, Universal Health Services**, and other large behavioral health strategics - **Mid-market PE-backed mental health outpatient platforms** acquiring practice groups What they look for: clinical model integrity, payer mix (commercial and Medicaid), staff retention, BCBA capacity in ABA, and geographic fit. --- ## Active Buyers in IDD and Behavioral Services Intellectual and developmental disability service providers have a distinct buyer set: - **Sevita (formerly The MENTOR Network)** — large IDD platform owned by Centerbridge and Vistria - **BrightSpring Health Services** — IDD operations under the Rescare brand - **Phoenix Services** and similar regional platforms with PE financing - **State-focused IDD providers** with mid-market PE backing What they look for: state-by-state regulatory positioning, residential and day program licensing, workforce stability, and Medicaid waiver contract relationships. --- ## How to Use This Information Knowing the active buyer set is useful for several reasons: ### 1. Targeted Outreach in a Sale Process A well-run sale process targets a curated list of buyers most likely to value your specific business — not a mass-marketed auction. The right buyer for your agency depends on your segment, scale, geography, and operational profile. ### 2. Understanding Strategic Fit Each platform has a specific acquisition thesis: geographic expansion in certain states, service line additions, payer mix diversification, or scale build in a particular vertical. Agencies that fit the active thesis of multiple platforms attract competitive offers. Agencies that fit no current thesis sell harder, even when they are well-run. ### 3. Avoiding Premature Conversations Many agency owners receive direct outreach from PE platforms or business development teams. These outreach conversations are part of the platform's deal sourcing — they are not yet offers. Engaging with them outside of a structured advisor-led process typically produces lower outcomes than running a competitive process with multiple buyers. ### 4. Reading Multiples in Context Multiples reported in industry press are usually for the largest, most strategic transactions — not a representative sample. Understanding which buyers are paying which multiples, for which kinds of agencies, in which geographies, is the only way to anchor your own valuation expectations realistically. --- ## What This List Does Not Tell You **Which buyers are buying right now.** Platforms move in and out of acquisition mode based on integration capacity, fund timing, and strategic priorities. A platform that was the most active buyer in your segment 18 months ago may be in integration mode now. **Which buyers will pay the highest multiple for your specific agency.** That depends on geographic fit, service line fit, scale, payer mix, and the platform's current strategic gaps. **What current actual deal terms look like.** Multiples, structure (cash vs. rollover vs. earnout), and reps and warranties packages move with market conditions. A sale process built on current intelligence — which platforms are actively buying, where, at what scale, and at what current terms — is materially different from one built on a static buyer list. --- ## Strategic Implications for Sellers The PE buyer landscape in home-based care is concentrated, sophisticated, and well-capitalized. For agency owners evaluating a sale, the practical implications are: - **The highest outcomes come from competitive processes**, not direct response to inbound outreach - **Buyer fit matters as much as buyer count.** Three highly-aligned bidders typically produce a better outcome than fifteen marginally-aligned ones. - **Current intelligence on platform appetite and pricing** is one of the most important things an advisor brings to a sale process - **Your specific story should be matched to specific buyers**, not pitched generically If you would like to understand which active buyers are most likely to value your specific agency, [contact us for a confidential conversation](/contact-us). --- ### Pediatric Home Health Agency Valuation in 2026: A Complete Guide URL: https://www.hendonpartners.com/insights/pediatric-home-health-agency-valuation-2026 Published: 2026-04-26 09:00 Category: Valuation > Pediatric home health and pediatric private duty nursing agencies are commanding premium multiples in 2026 — often 6× to 9× EBITDA — driven by acute clinical complexity, scarcity of qualified nurses, and intense PE platform interest. Here is how buyers actually value pediatric agencies. Pediatric home health and pediatric private duty nursing (PDN) sit in one of the most attractive corners of home-based care M&A. Buyers consistently pay premium multiples for quality pediatric platforms — often 6× to 9× EBITDA, with the best assets reaching higher — yet many pediatric agency owners underestimate what their business is worth in the current market. This guide explains why pediatric agencies trade at a premium, how buyers actually evaluate them, and what separates a good outcome from a great one. --- ## Why Pediatric Commands Premium Multiples Three structural factors drive valuations. ### 1. Clinical Complexity and Per-Case Revenue Pediatric home health serves medically fragile children — ventilator-dependent, tracheostomy, complex feeding, congenital and neurological conditions, post-NICU graduates. The clinical intensity translates into higher authorized hours per patient, higher nursing skill requirements, and higher reimbursement rates than typical adult skilled or non-medical home care. A typical pediatric PDN patient receives 40 to 80+ authorized hours per week, often for years rather than episodes. Per-patient annual revenue commonly runs $80,000 to $200,000+ — multiples higher than adult Medicare home health episodes or non-medical personal care cases. ### 2. Length of Service and Revenue Predictability Adult Medicare home health revenue is episodic — 60-day periods with discharge as the goal. Pediatric PDN revenue is the opposite. Many patients remain on service for years, often through transitions to school-based care or until adulthood. Census stability is structurally higher than nearly any other segment of home-based care, which buyers reward through both higher multiples and lower diligence-related discounts. ### 3. Workforce Scarcity Pediatric-trained RNs and LPNs are a chronic supply constraint. The clinical training, comfort with medically complex children, and parent-facing communication skills cannot be created on demand. Agencies with strong nurse recruiting, retention, and training infrastructure have a moat that buyers pay for. --- ## Pediatric Valuation Multiples in 2026 Multiples vary by EBITDA scale, clinical complexity, payer mix, and geographic positioning. | Agency Profile | EBITDA Range | Typical Multiple | |---|---|---| | Sub-scale pediatric PDN (single state, $300K–$750K EBITDA) | $300K–$750K | 4.0× – 5.5× | | Mid-market pediatric PDN ($750K–$2M EBITDA) | $750K–$2M | 5.5× – 7.0× | | Multi-state pediatric platform ($2M–$5M EBITDA) | $2M–$5M | 6.5× – 8.5× | | Large pediatric platform with complex care depth ($5M+ EBITDA) | $5M+ | 7.5× – 9.5×+ | These multiples reflect the median quality agency. Premium drivers (geographic density, clinical complexity capability, nurse retention, payer rate strength) push toward the top of the range. Discount drivers (single-payer concentration, weak nurse retention, geographic sprawl) push toward the bottom or below. --- ## What Buyers Actually Look For ### Authorized Hours Fill Rate The single most important pediatric KPI in diligence. Buyers ask: of the hours that have been authorized by the payer for your existing patient population, what percentage are you actually staffing? An agency with $5M of authorized but unstaffed hours per year is sitting on enormous unrealized revenue — and a buyer with stronger recruiting infrastructure will model the upside and pay for it. Fill rates above 90% are exceptional and command premium attention. Fill rates below 70% suggest staffing constraints that the buyer will scrutinize hard but may also see as upside opportunity. ### Nurse Recruiting and Retention Metrics Buyers will review: - Annual nurse turnover rate (industry benchmark 30–50%; under 25% is exceptional) - Average nurse tenure - Time-to-fill for new shifts - Recruiting pipeline volume and conversion rate - New nurse training program structure - Wage benchmarking vs. local market Agencies with documented retention infrastructure — competitive wages, benefits, scheduling flexibility, clinical mentorship — command premium multiples because the buyer is acquiring durable staffing capacity rather than a roster that may walk after close. ### Payer Mix and Rate Structure Pediatric agencies typically operate across: - **Medicaid EPSDT** — the largest payer for most pediatric PDN; rates vary significantly by state - **Medicaid Managed Care (MCO contracts)** — increasing share of Medicaid revenue in many states - **State waivers** for medically complex children - **Commercial insurance** for complex cases (smaller share, often higher rates) - **CCS / Title V** programs in some states Rate adequacy by state and by program is a major valuation variable. Operating in states with strong pediatric PDN rates (and credible rate-setting transparency) supports premium multiples. ### Clinical Complexity Mix Buyers look at the acuity profile of your census. An agency serving primarily lower-acuity patients (basic skilled nursing, simple medication administration) is valued differently from an agency with depth in vent/trach, complex feeding, and neurological care. Higher-acuity agencies command premiums because: - Per-case revenue is higher - Length of service is longer - Competition for these patients is lower - The clinical reputation generates referral tailwinds ### Geographic Density Pediatric PDN is a logistics-intensive business. Density in a metro area allows for shift coverage, nurse cross-coverage, and operational efficiency that geographic sprawl destroys. A pediatric agency with $3M EBITDA concentrated in two metro areas is more valuable per dollar of EBITDA than $3M EBITDA spread across eight states. ### Referral Source Diversification Buyers want diversification across: - Children's hospital systems (NICU, PICU discharge planners) - Pediatric specialty practices (pulmonology, GI, neurology) - Schools and early intervention programs - Medicaid case management organizations - Family direct inquiries Agencies with single-source dependence (e.g., 60%+ of new admissions from one hospital) face referral concentration discounts. --- ## Segment-Specific Considerations ### Pediatric PDN (Private Duty Nursing) The largest pediatric home-based care segment by both revenue and M&A volume. PDN agencies bill Medicaid (and select commercial) for authorized hours of skilled nursing care. Valuation centers on hours-based metrics: authorized hours, fill rate, billable hour conversion, and nurse productivity. ### Pediatric Medicare-Certified Home Health A smaller but specialized segment serving children with skilled care needs under Medicare Part A or under state Medicaid plans that cover pediatric home health visits. OASIS, plan of care, and 60-day episode mechanics apply. Valuations are influenced by case mix index, LUPA rates, and survey performance similar to adult Medicare home health. ### Pediatric Therapy (PT, OT, Speech) Often delivered alongside PDN or as a standalone line, pediatric therapy services generate steady revenue with high margins. Buyers value pediatric therapy practices on therapist productivity, payer mix (Medicaid, commercial, school district contracts), and waitlist depth as a proxy for unmet demand. ### Behavioral and Developmental Services Pediatric agencies that have integrated ABA, behavioral health, or developmental disability services trade in a different valuation framework. ABA in particular has its own M&A market and multiples (covered separately). Buyers may value the combined platform at a blended rate or carve out the ABA economics. --- ## Common Diligence Issues That Compress Pediatric Valuations 1. **Unstaffed authorized hours not properly disclosed** — buyers find this fast and will discount aggressively if not transparent upfront. 2. **Nurse misclassification (1099 vs W-2)** — pediatric agencies that have used 1099 nursing carry a real risk; buyers will require reclassification and assess back-tax exposure. 3. **Plan of care and physician order documentation gaps** — Medicaid audits in pediatric PDN are common, and documentation weakness creates payer recoupment risk. 4. **Concentration in a single MCO** — if 60%+ of revenue flows through one Medicaid managed care contract, the buyer is underwriting MCO renewal risk and will discount. 5. **EVV compliance gaps** — pediatric PDN is subject to EVV requirements; gaps create both compliance and billing risk. 6. **Owner-operator clinical involvement** — if the founder is the de facto Director of Nursing, buyers will model the cost of replacing that role and discount accordingly. --- ## Strategic Implications for Pediatric Agency Owners ### If You Are Considering a Sale in the Next 12–24 Months The pediatric M&A market is strong, and 2026 is a favorable selling environment. Priorities: - Get your authorized-hours fill rate measured and documented - Clean up nurse classification and credentialing files - Diversify referral sources to reduce concentration risk - Document your clinical training and complexity-care capabilities - Get a current valuation from an advisor experienced in pediatric M&A specifically ### If You Have a Longer Horizon Pediatric is one of the rare home-based care segments where investment in quality directly translates to multiple expansion at exit. Prioritize: - Building a recruiting and retention infrastructure that keeps nurse turnover under 25% - Geographic concentration in 2–3 metros with strong pediatric demand - Capability investment in vent/trach and complex care - Clinical leadership depth (Director of Nursing not dependent on the owner) - Multi-payer contracting beyond your dominant Medicaid MCO --- ## The Buyer Landscape Active acquirers in pediatric home-based care include: - **PE-backed pediatric platforms** building multi-state pediatric PDN and home health businesses - **Adult home care platforms expanding into pediatric** as a complementary service line - **Children's hospital health systems** acquiring pediatric home care to extend the continuum - **National pediatric specialty companies** rolling up regional providers Different buyer types value different things. A children's hospital strategic buyer may pay premium for clinical reputation and complex care depth in their service area. A PE platform may pay premium for scale, payer diversification, and geographic fit with their existing footprint. --- The pediatric home health and PDN market in 2026 rewards quality operators with premium multiples that have remained resilient even as other segments faced multiple compression. The combination of clinical complexity, length of service stability, payer rate strength, and workforce scarcity creates a defensible economic profile that sophisticated buyers actively pay for. If you would like to discuss what your pediatric agency could realistically command in today's market, [contact us for a confidential conversation](/contact-us). --- ### The CMS 80/20 Rule: What It Means for Medicaid Home Care Agency Valuations URL: https://www.hendonpartners.com/insights/cms-80-20-rule-medicaid-home-care-valuation Published: 2026-04-25 09:00 Category: Valuation > The CMS Medicaid Access Rule — commonly known as the 80/20 rule — requires that 80% of Medicaid HCBS personal care, home health, and homemaker payments go directly to caregiver compensation. For Medicaid-dependent home care agencies, the rule is one of the most consequential valuation variables of the next decade. The CMS Medicaid Access Rule — published in April 2024 and commonly referred to as the "80/20 rule" — is the single most consequential federal regulation affecting Medicaid home care agency valuation in a generation. For any agency with meaningful Medicaid HCBS revenue, the rule reshapes the cost structure, the sustainable EBITDA margin, and the way private equity and strategic buyers evaluate the asset. This guide explains what the rule actually requires, which agencies are exposed, how it changes the valuation math, and what sellers should be doing now if they expect to transact within the implementation window. --- ## What the 80/20 Rule Actually Says The rule, formally titled *Ensuring Access to Medicaid Services*, requires that **at least 80% of Medicaid payments** for three specific service categories be spent on **compensation for direct care workers**: 1. Homemaker services 2. Home health aide services 3. Personal care services These services must be delivered under Medicaid Home and Community-Based Services (HCBS) authorities — primarily 1915(c) waivers, 1915(i), 1915(j), 1915(k), and section 1115 demonstrations that include HCBS. "Compensation" in the rule is defined broadly to include: - Wages and salary - Benefits (health insurance, retirement contributions, paid time off) - Employer payroll taxes (FICA, FUTA, SUTA) - Workers' compensation premiums What it **excludes** from the 80% threshold is the conventional agency profit-and-overhead bucket: administrative salaries, training (beyond direct staff time), recruiting, billing, scheduling, rent, technology, insurance other than workers' comp, and operating margin. ### What is Not Covered The rule does **not** apply to: - Medicare-certified home health (PDGM) - Hospice - Private pay non-medical home care - Pediatric Private Duty Nursing under EPSDT or non-HCBS state plan authorities - Skilled nursing visits billed under Medicaid state plan rather than HCBS - Self-directed care models (with limited exceptions) This scope distinction matters enormously for valuation, because it means a multi-line agency's exposure is determined by the share of revenue inside the in-scope HCBS service codes — not by total Medicaid revenue. --- ## Implementation Timeline Full enforcement of the 80% compensation threshold phases in over six years from the rule's effective date. Earlier-phase requirements include: - **Reporting infrastructure**: states must build the data collection systems to track agency-level compensation ratios - **Interested parties advisory groups**: states must convene stakeholder bodies including beneficiaries, providers, and direct care workers - **Rate transparency**: states must publish payment rates for HCBS services - **Compensation ratio reporting**: agencies will be required to report compensation as a percentage of HCBS payments The compensation threshold itself becomes binding at the end of the implementation window. By that point, a non-compliant agency would either need to reach the 80% threshold or risk being unable to participate in HCBS programs in that state. State implementation is not uniform. Some states are building reporting and rate adequacy review faster than others. A few states are exploring exemption pathways for small agencies, hardship cases, or specific geographies — but the federal floor is the federal floor, and structural exemptions are limited. --- ## Why the Rule Compresses Sustainable EBITDA To understand the valuation impact, walk through the unit economics. ### Pre-Rule Baseline A typical Medicaid HCBS personal care agency operating at scale historically allocated payments roughly as follows: - **Direct caregiver wages and taxes**: 65–72% of revenue - **Caregiver benefits**: 2–5% of revenue - **Administrative overhead** (office staff, scheduling, recruiting, billing, compliance, rent, technology): 12–18% - **EBITDA margin**: 8–18%, depending on state, scale, and operating efficiency In this structure, the *compensation ratio* (wages + taxes + benefits) typically lands somewhere between **70% and 78%** in well-run agencies, and lower in weaker ones. ### Post-Rule Math To hit 80% compensation, an agency operating at a 72% compensation ratio must move 8 percentage points of revenue from overhead-and-margin into caregiver compensation. Three things can happen in response: 1. **State rates rise** to accommodate the new compensation floor. Some states will adjust rates upward, but rate-setting moves slowly and unevenly, and Medicaid budgets are politically constrained. 2. **Overhead is cut** through technology investment, scale efficiencies, and reduced administrative spend. This is real but limited — there is a floor below which compliance, scheduling, and billing cannot be cut without operational risk. 3. **EBITDA margin compresses** to absorb the gap. In practice, most agencies will see some combination of all three. But the net effect for a typical Medicaid HCBS agency is a **2–6 percentage point compression in sustainable EBITDA margin**, even after assuming partial rate relief and overhead optimization. ### What That Does to Enterprise Value Enterprise value moves on two axes: EBITDA (the dollar amount) and the multiple applied to it. **Margin compression hits the EBITDA dollar directly.** An agency generating $20M of HCBS revenue at a 12% EBITDA margin produces $2.4M of EBITDA. Compress the margin to 8% and EBITDA drops to $1.6M — a 33% reduction in the dollar number that gets multiplied. **Buyers may also compress the multiple** for Medicaid-heavy agencies whose compensation ratios are not yet compliant, because the buyer is underwriting the risk of further margin compression post-close. A pre-rule 5.5× multiple on a Medicaid-heavy agency may become 4.5× post-rule, layered on top of lower EBITDA. The combined effect — lower EBITDA times lower multiple — can reduce enterprise value by **35–50%** for a heavily Medicaid-exposed agency that has not adjusted its cost structure. --- ## How Buyers Are Evaluating 80/20 Risk in Diligence Sophisticated PE and strategic buyers have already integrated the rule into their diligence playbook for any agency with Medicaid HCBS exposure. Expect the following: ### 1. Compensation Ratio Calculation by Service Line Buyers will reconstruct your compensation ratio specifically for in-scope HCBS service codes — not blended across your full book. They will isolate: - HCBS personal care, homemaker, and aide revenue - Direct caregiver wages, payroll taxes, benefits attributable to those service hours - The resulting ratio expressed as a percentage If your reported ratio is 73%, the buyer is modeling the path to 80% and adjusting their offer accordingly. ### 2. State-Specific Rate Adequacy Analysis Buyers will evaluate whether the states you operate in have published rate methodologies that will support 80% compensation at sustainable margins. States with chronic rate inadequacy (rates set well below the actual cost of providing care at compliant compensation) will be discounted heavily. Operating in states with strong rate-setting transparency, recent rate increases, or active legislative attention on HCBS adequacy is now a meaningful valuation driver. ### 3. Payer Mix Sensitivity Modeling Agencies with concentrated HCBS exposure (e.g., 70%+ of revenue from in-scope HCBS codes) face the full force of the rule. Agencies with diversified payer mixes — meaningful private pay, Medicare-certified, MLTSS skilled nursing, or out-of-scope Medicaid services — have natural insulation, and buyers will pay for that insulation. ### 4. Technology and Operational Efficiency Buyers will look at your back-office cost structure as a percentage of revenue. Agencies running modern EVV-integrated scheduling, automated billing, and lean recruiting infrastructure are positioned to operate profitably at lower overhead percentages — exactly what the rule rewards. Agencies with bloated administrative cost structures will be discounted. ### 5. Self-Directed Care Mix Self-directed services have specific treatment under the rule (with some exemptions and lighter compensation requirements depending on state implementation). Agencies with meaningful fiscal intermediary or self-directed program revenue may have a different exposure profile than pure agency-directed providers. --- ## Strategic Implications for Sellers ### If You Are Medicaid-Heavy and Planning to Sell Within 24 Months You are selling into a market where buyers are pricing in the compression. Three priorities: 1. **Get your compensation ratio defensible.** Calculate it now, by service line, and understand exactly how far you are from 80%. If you are at 76–78%, the gap is closeable and your story is strong. If you are at 68–70%, you have a credibility problem in diligence. 2. **Document the path to compliance.** Even if you are not yet at 80%, a credible plan — rate increases pending in your state, wage adjustments scheduled, benefits expansion in progress — is materially better than no plan. 3. **Diversify payer mix where possible.** Adding private pay, MLTSS skilled, or Medicare-certified lines reduces the concentration risk and improves your blended valuation. ### If You Have Time (3–5 Year Horizon) The strategic playbook is more aggressive: - **Restructure cost base proactively.** Move toward the 80% threshold before you have to. Buyers reward agencies that have already absorbed the compression and demonstrated sustainable margins at the new structure. - **Invest in technology that reduces overhead percentage.** EVV-integrated platforms, automated scheduling and billing, AI-assisted recruiting and retention. - **Geographic concentration in rate-adequate states.** Exit or de-emphasize markets with chronic rate inadequacy. Concentrate in states with active rate-setting transparency. - **Expand into out-of-scope service lines.** Private pay, Medicare-certified home health, MLTSS skilled, pediatric PDN, behavioral health — each diversifies away from 80/20 exposure and adds enterprise value on its own. ### If You Are Considering Acquiring The rule is also creating opportunity. Smaller agencies without the scale to absorb compression, restructure cost base, or invest in efficiency-driving technology will be motivated sellers in the implementation window. Buyers with the operating infrastructure to integrate acquired agencies into a compliant cost structure can buy at attractive multiples and create meaningful value. --- ## Common Misconceptions **"The rule doesn't apply to my state yet, so it doesn't affect my valuation."** It affects your valuation today, because buyers underwrite the future cost structure, not the current one. A buyer paying you a multiple in 2026 is owning the asset through full enforcement. The rule is in the model. **"My private pay and Medicare lines are unaffected, so I'm fine."** Correct that those lines are out of scope, but if your HCBS line is a meaningful share of revenue, that share carries a different valuation profile post-rule. Buyers will not blend; they will value the in-scope and out-of-scope revenue differently. **"Rates will go up to cover the cost."** Some states will raise rates. Many will not, or will not raise them enough. Federal rule, state-by-state implementation, state-by-state budget reality. Plan for partial relief, not full relief. **"I can hit 80% by reclassifying overhead as compensation."** The rule's definition of compensation is specific. Reclassification games will not survive auditor or buyer diligence. --- ## What to Do Now 1. **Calculate your current compensation ratio** for in-scope HCBS services, by state, by program. Get the number on paper before a buyer calculates it for you. 2. **Map your HCBS revenue by state** and check published state implementation timelines and rate methodologies. 3. **Model two to three EBITDA scenarios** assuming different paths to 80%: no rate relief, partial rate relief, and full rate relief. Understand what your sustainable EBITDA looks like in each case. 4. **Assess overhead reduction potential** — technology investment, billing automation, scheduling efficiency — and quantify the overhead reduction you can credibly achieve. 5. **Review your sale timing strategy** in light of the above. For some agencies, the right answer is to sell now into the current market. For others, the right answer is to invest, restructure, and sell in 2027–2028 at a stronger compliance position. The 80/20 rule is not an existential threat for well-run Medicaid home care agencies. It is a structural reset of the cost-and-margin profile of the industry, and the agencies that adjust thoughtfully — whether through restructuring, diversification, or strategic timing of a sale — will continue to attract strong buyer interest. The agencies that do nothing and hope for the best will see compression in both EBITDA and multiple. If you would like to talk through how the rule affects your specific agency's valuation and exit strategy, [contact us for a confidential conversation](/contact-us). --- ### Home Health and Hospice M&A Activity Report: Q1 2026 URL: https://www.hendonpartners.com/insights/home-health-hospice-ma-q1-2026-report Published: 2026-04-15 09:00 Category: Market Intelligence > Home-based care M&A activity in Q1 2026 reflected stabilized buyer interest, modest sequential improvement in deal volume, and continued segmentation between premium-quality assets attracting competitive bids and average assets pricing at lower multiples. Here is our quarterly read of the market. Q1 2026 home-based care M&A activity reflected a stabilized market: deal volume modestly higher than Q4 2025, continued buyer selectivity, and clear segmentation between premium-quality assets attracting competitive bids and average assets pricing at the lower end of typical ranges. This quarterly report summarizes our read of Q1 2026 activity across home health, hospice, home care, pediatric, and behavioral health, and what it suggests for the rest of 2026. A note on methodology: this report reflects our perspective as active sell-side advisors observing transactions across home-based care. Specific transaction terms are confidential; aggregate themes are drawn from our deal flow, buyer conversations, and broader industry market intelligence. --- ## Overall Market Conditions in Q1 2026 **Deal volume modestly higher than Q4 2025.** The seasonal slowdown that typically affects Q4 transaction completion gave way to a more active Q1, in line with normal year-over-year patterns. Year-over-year comparison to Q1 2025 shows comparable volume, with no meaningful acceleration but no contraction either. **Buyer selectivity remained pronounced.** PE platforms and strategic buyers continue to apply rigorous diligence, particularly on payer mix quality, clinical compliance, workforce stability, and growth defensibility. Quality assets attracted multiple offers; average assets transacted but with less competitive tension. **Multiple stability.** Headline multiples were stable to modestly improved versus the second half of 2025. Compression that affected the market in 2022–2023 has not reversed materially, but it has stabilized at current levels and quality assets are seeing competitive bidding return. **Add-on activity dominant.** As in prior quarters, the majority of transaction count was add-on acquisitions to existing PE-backed platforms. New platform investments occurred but at lower count. --- ## Hospice Hospice continued to lead home-based care M&A by both volume and multiple strength in Q1 2026. ### Activity Themes - Continued PE platform consolidation - Active acquisition by Bristol, Compassus, Agape, St. Croix, Three Oaks, Traditions, and other established platforms - Selective new platform investments - Continued post-CON-repeal entry activity in Florida ### Multiple Ranges Quality hospice agencies transacted in the 6.0× to 9.0× EBITDA range, with platform-quality assets exceeding 9×. Smaller agencies (sub-$1M EBITDA) transacted at 4.5× to 6.5×. Premium drivers continued to include average daily census growth, Medicare cap headroom, diversified referral sources, clean compliance, and geographic density. ### Diligence Themes - Special Focus Program (SFP) profile and risk - Medicare cap utilization and headroom - General inpatient (GIP) utilization patterns - Length of stay distribution and live discharge rates - Referral source diversification and concentration - OIG and audit history Hospice buyers continued to differentiate aggressively between agencies with clean compliance profiles (premium pricing) and agencies with any material concerns (steep discounts or process termination). --- ## Medicare-Certified Home Health Medicare-certified home health activity in Q1 2026 was steady but selective. ### Activity Themes - Active PE-backed platform consolidation continued - Strategic acquirer activity in select markets - CON state premiums continued for quality assets - Medicare Advantage penetration impact on valuations remained meaningful ### Multiple Ranges Quality Medicare-certified home health agencies transacted in the 5.5× to 8.0× EBITDA range, with platform-quality assets exceeding 8×. CON state assets and assets with strong star ratings, low LUPA rates, and clean survey histories commanded the upper end of the range. ### Diligence Themes - Medicare Advantage payer mix and rate quality - Star ratings (Patient Survey and Quality of Patient Care) - LUPA rates and PDGM management - OASIS accuracy and survey history - Value-based care contracting position - HHCAHPS performance --- ## Private Pay Non-Skilled Home Care Private pay non-skilled home care saw steady add-on activity in Q1 2026. ### Activity Themes - Continued add-on acquisitions by PE-backed platforms - Active franchise system consolidation - Selective new geographic platform builds - Family office and independent sponsor activity at the lower middle market ### Multiple Ranges Quality private pay agencies transacted in the 4.5× to 6.5× EBITDA range, with larger platform-quality assets exceeding 6.5×. Premium markets (Naples, Palm Beach, parts of California) supported higher multiples for the right operators. ### Diligence Themes - Caregiver retention metrics - Geographic density and metro concentration - Referral source diversification - Per-hour billable rate trajectory - Wage cost trajectory and margin defensibility --- ## Pediatric Home Health and PDN Pediatric continued to attract premium PE interest in Q1 2026. ### Activity Themes - Active acquisition by established pediatric platforms - Selective new pediatric platform investment - Continued buyer focus on workforce-driven valuation premium ### Multiple Ranges Quality pediatric platforms transacted in the 6.0× to 9.0× EBITDA range, with platform-quality assets approaching or exceeding 9×. ### Diligence Themes - BCBA/RN recruiting and retention infrastructure - Authorized hours fill rate - Payer mix (EPSDT, MCO, commercial, TRICARE) - Geographic density - Service line breadth (PDN, therapy, complex care coordination) --- ## Behavioral Health and ABA Behavioral health and ABA activity remained at stable levels in Q1 2026, with continued post-2022 multiple discipline. ### Activity Themes - Continued ABA platform consolidation - Mental health outpatient platform building - SUD treatment center selective activity - Payer mix and clinical model integrity central to valuations ### Multiple Ranges Quality ABA platforms transacted in the 5.0× to 8.0× EBITDA range, with multi-state platforms with strong commercial mix and clinical model integrity at the upper end. Mental health outpatient platforms transacted in similar ranges depending on payer mix and clinical model. --- ## IDD Services IDD services M&A continued at modest activity levels in Q1 2026, with continued caution from buyers around 80/20 rule implementation and Medicaid HCBS rate adequacy. ### Multiple Ranges Quality IDD platforms transacted in the 5.0× to 7.0× range, with state-specific dynamics affecting individual transaction outcomes. --- ## Healthcare Staffing Healthcare staffing M&A continued at modest activity levels relative to the 2021–2022 peak. Multiples have normalized substantially. ### Multiple Ranges Quality healthcare staffing platforms transacted in the 4.0× to 6.5× EBITDA range, with home care staffing toward the upper end and broader allied/travel staffing at the lower end. --- ## Cross-Cutting Themes ### 80/20 Rule Implementation The CMS Medicaid Access Rule continued to shape diligence on Medicaid HCBS-exposed agencies. Buyers in Q1 2026 increasingly required compensation ratio documentation, state-specific implementation analysis, and credible paths-to-compliance from sellers. ### Medicare Advantage Dynamics MA penetration impact on home health valuations remained one of the most consequential variables in Q1 2026 transactions. Agencies with strong MA contract portfolios and value-based positioning defended premium multiples; agencies with low-rate MA exposure faced compression. ### Workforce Premium Across all segments, workforce stability metrics — caregiver, nurse, BCBA, clinical leadership retention — drove an increasing share of valuation differentiation in Q1 2026. Buyers paid clear premiums for agencies with documented retention infrastructure. ### Compliance Sensitivity Hospice SFP risk, ABA audit exposure, EVV compliance, and general regulatory cleanliness all continued to drive bifurcated outcomes — premium for clean operators, deep discount for operators with material concerns. ### Geographic Concentration Buyer preference for concentrated metro density over geographic sprawl continued to strengthen in Q1 2026, with multi-region operators receiving discounts vs. similarly-sized concentrated operators. --- ## Outlook for the Rest of 2026 Our base case for the remainder of 2026: - **Volume stable to modestly higher** than Q1 levels - **Multiples stable** with continued bifurcation between premium and average assets - **Continued PE add-on dominance** in transaction count - **Selective new platform investment** in attractive verticals (pediatric, hospice, behavioral health) - **80/20 rule and MA dynamics** continuing to shape diligence - **Workforce metrics** continuing to drive valuation differentiation - **Continued post-CON-repeal activity** in Florida hospice and selective other state regulatory shifts The market in 2026 rewards sellers with clean operations, documented quality, defensible payer mix, strong workforce metrics, and disciplined sale process execution. Sellers who go to market unprepared continue to leave value on the table. --- ## Bottom Line Q1 2026 reflected a stable, selectively active home-based care M&A market. Quality assets attracted competitive interest at premium multiples; average assets transacted at lower multiples; the gap between the two continued to widen. If you would like to discuss what current market conditions mean for your specific agency, [contact us for a confidential conversation](/contact-us). --- ### Home Care M&A in 2026: Market Update and Transaction Trends URL: https://www.hendonpartners.com/insights/home-care-ma-market-update-2026 Published: 2026-03-20 09:00 Category: Market Intelligence > The home care M&A market in 2026 is characterized by selective but active buyer interest, stabilized multiples, and growing PE focus on clinical complexity and specialty care. Here is our perspective on current market conditions and what sellers should understand heading into a sale. The home care M&A market continues to evolve in 2026. After a period of multiple compression in 2022–2023 driven by rising interest rates and macroeconomic uncertainty, the market has stabilized — and in certain segments, transaction volumes and valuations are approaching or exceeding their prior peaks. This market update reflects our current view of conditions across the major home care segments. It is intended for agency owners who are assessing market timing for a sale, and for advisors who want a current-conditions framework. --- ## Overall Market Context **Buyer activity remains strong.** Despite a higher interest rate environment than the 2020–2021 peak, PE-backed platforms remain highly acquisitive. The demographic tailwind, an aging population, growing preference for home-based care, CMS and payer push toward community-based settings, continues to make home care attractive as a long-term investment thesis. **Strategic buyers are also active.** Larger strategic acquirers (multi-state home care chains, health systems, post-acute networks) are making selective acquisitions where geographic expansion or service line diversification creates strategic value. **Selectivity has increased.** The frothy 2020–2021 market, when almost any home care agency with positive EBITDA could attract multiple buyer offers, has given way to a more selective environment. Buyers are more disciplined about quality: they evaluate compliance history, management depth, growth trajectory, and operational quality more carefully. Average agencies receive average offers; excellent agencies attract multiple competing offers. --- ## Segment-by-Segment Analysis ### Private Pay Non-Skilled Home Care **Market conditions:** Active. The private pay segment continues to attract PE interest for several reasons: no payer reimbursement dependency, demographic demand clarity, and scalable organic growth potential in most markets. **Multiples:** - Sub-$500K EBITDA: 3.5× – 4.5× - $500K–$1.5M EBITDA: 4.5× – 5.5× - $1.5M+ EBITDA: 5.5× – 7.0× **Key buyer characteristics:** PE buyers are generally looking for private pay agencies with $500K+ EBITDA, strong management teams, diversified referral sources, and markets with favorable demographics and limited direct competition. **What's working well:** Geographic concentration building (buyers want density in specific metro areas), technology-forward operators, and agencies with strong brand and online reputation. ### Medicare-Certified Skilled Home Health **Market conditions:** Selective but with strong multiples for quality assets. The Medicare Advantage penetration reality (now 50%+ of Medicare beneficiaries) has complicated the Medicare skilled home health acquisition thesis — buyers are managing the MA vs. FFS rate differential and managing care intensity expectations from MA payers differently. **Multiples:** - $500K–$1.5M EBITDA: 4.5× – 6.0× - $1.5M–$3M EBITDA: 5.5× – 7.0× - $3M+ EBITDA: 6.0× – 8.5× **Buyer concerns:** Medicare Advantage penetration and rate adequacy, LUPA rates, OASIS accuracy, and compliance history are the primary evaluation areas. **What's commanding premium:** Deficiency-free survey history, strong 5-star Home Health Compare ratings, CON state positioning, and established MA contracts at reasonable rates. ### Hospice **Market conditions:** Premium multiples but intense regulatory scrutiny. Hospice remains the highest-multiple segment in post-acute care, with strong buyer interest from both PE platforms and national strategic operators. **Multiples:** - $500K–$2M EBITDA: 6.0× – 8.0× - $2M–$5M EBITDA: 7.0× – 10.0× - $5M+ EBITDA: 8.0× – 12.0×+ **Buyer concerns:** CMS hospice audit activity remains heightened. Buyers scrutinize length of stay data, diagnosis coding appropriateness, physician certification documentation, and General Inpatient (GIP) utilization. Compliance history is heavily weighted. **2026 specific note:** CMS's continued focus on hospice payment reform and audit initiatives has increased buyer due diligence intensity in this sector. Clean compliance records are more important than ever. ### Personal Care / HCBS / Medicaid Waiver **Market conditions:** Varies significantly by state. In states with favorable Medicaid reimbursement rates and growing HCBS waiver programs, buyer interest is strong. In states with ongoing rate pressure or MLTSS transition uncertainty, buyers are more cautious. **Multiples:** - $500K–$1.5M EBITDA: 4.0× – 5.5× - $1.5M–$3M EBITDA: 5.0× – 6.5× **Key factors:** State reimbursement environment, MCO contract terms, and agency quality are the primary differentiation factors. ### IDD/Developmental Disabilities Services **Market conditions:** Emerging as one of the higher-growth segments in home and community-based services M&A. Strong demographic drivers (aging population of IDD individuals requiring residential and HCBS support), limited competition among qualified providers, and often above-market Medicaid waiver rates in many states. **Multiples:** - $500K–$1.5M EBITDA: 4.5× – 6.0× - $1.5M+ EBITDA: 5.5× – 7.5× **Key factors:** State waiver availability and rates, state day services funding, residential vs. HCBS service mix, and team stability. ### Private Duty Nursing **Market conditions:** Premium segment with limited seller supply. PDN agencies remain scarce relative to buyer demand, clinical complexity, licensing requirements, and billing complexity create meaningful barriers to entry and support higher multiples. **Multiples:** - $500K–$1.5M EBITDA: 5.0× – 6.5× - $1.5M+ EBITDA: 6.0× – 8.0× **Key factors:** Nurse staffing stability, payer mix (technology-dependent/vent care premium), and geographic presence in underserved markets. --- ## Interest Rates and Deal Financing The base interest rate environment has normalized from 2022–2023 peaks. Current financing conditions: **PE-backed transactions:** Most middle-market PE-backed acquisitions use a combination of debt (bank credit facilities, unitranche credit structures) and equity. The leverage multiples available have moderated slightly from 2020–2021 peaks but remain available for quality assets, typically 3×–5× EBITDA in debt capacity for home care platform acquisitions. **SBA financing for smaller deals:** SBA 7(a) and 504 programs remain active for sub-$5M transactions, enabling smaller strategic buyers and management buyout scenarios. SBA rates have increased from 2020 lows but remain accessible. **Effect on multiples:** The current rate environment is slightly more restrictive than the 2020–2021 peak period, but not dramatically so. The primary effect has been on the most leveraged large-platform transactions. Sub-$3M enterprise value transactions — the range most home care agencies trade in, are less rate-sensitive because the relative equity proportion is higher. --- ## What Buyers Are Looking For in 2026 Based on our active deal flow, here is what differentiates the highest-value acquisitions in the current market: **1. Management team with depth beyond the founder.** The post-COVID labor market has reinforced how fragile businesses dependent on a single owner/operator are. Buyers consistently premium-price agencies where a qualified management team can run operations independently. **2. Proven organic growth.** Agencies growing 10–20%+ annually before the transaction tell a compelling narrative about market position and execution capability that justifies forward-looking valuations. **3. Clinical quality documentation.** Survey history, quality ratings, compliance records, and patient/client satisfaction scores are scrutinized more carefully than they were 5 years ago. Agencies with documented, sustained quality performance are rewarded. **4. Technology adoption.** Scheduling systems, electronic health records, digital billing infrastructure, and workforce management tools are increasingly considered baseline expectations rather than differentiators, but agencies that are notably behind technology curve face discounts. **5. Diversified referral base.** No single referral source representing more than 20–25% of referrals. Documented breadth of hospital, SNF, physician, and community relationships. **6. Clean compliance track record.** No open CMS audit activity, no recent survey deficiencies, no outstanding billing disputes. The less regulatory hair, the better the offer. --- ## Key Risks Buyers Are Pricing In **Labor cost trajectory.** Caregiver wages have risen significantly in most markets. Buyers model forward caregiver cost increases and discount businesses they believe will face margin pressure from wage inflation. **Medicare Advantage margin compression.** For skilled agencies, the continued shift to MA and the reimbursement differential vs. Medicare FFS is a concern buyers actively model. **Medicaid rate uncertainty.** States facing fiscal pressure create ongoing risk for Medicaid-heavy agencies. Buyers price in some defensibility discount for state budget exposure. --- ## Seller Takeaways for 2026 1. **Quality agencies continue to attract strong buyer interest and competitive offers** — the market is not broken, it is selective. 2. **Multiples have stabilized** and in premium segments (hospice, PDN, skilled home health) remain near historic highs. 3. **Building management depth and cleaning up compliance issues** before going to market has a more significant impact on your valuation than timing the market perfectly. 4. **The competitive process remains powerful**, agencies that run a properly structured, multi-buyer process continue to achieve better outcomes than those that transact with a single buyer. 5. **Start planning early.** The best home care M&A outcomes come from owners who prepared 12–24 months before their target sale date, not those who decided to sell and expected to close quickly. **[Schedule a confidential market assessment with Hendon Partners →](/contact-us)** --- *Hendon Partners tracks home care M&A market conditions continuously across all segments and geographies. Our advisors maintain active relationships with buyers and lenders across the market, giving us real-time insight into pricing, buyer appetite, and transaction terms.* --- ### Medicaid Managed Care and Home Care Agency Valuation: What MLTSS Means for Your Sale Price URL: https://www.hendonpartners.com/insights/medicaid-mltss-home-care-agency-valuation Published: 2026-03-13 09:00 Category: Market Intelligence > The shift to Medicaid managed long-term services and supports (MLTSS) is transforming home care agency economics — and therefore valuations. In some states, MLTSS creates significant value. In others, it compresses margins. Here is how to evaluate your position. One of the most important — and least understood, valuation factors in home care M&A is the structure of the Medicaid payment environment in your state. Home care agencies that serve Medicaid clients don't all operate in the same Medicaid environment. Depending on your state, you may be billing the state directly through a fee-for-service (FFS) waiver program, billing a managed care organization (MCO) under a MLTSS contract, or some combination of both. The distinction matters enormously for how buyers assess your revenue quality, margin stability, and long-term sustainability, and therefore how they value your business. This article explains the Medicaid landscape, what MLTSS means for home care economics, and how your specific state's Medicaid environment affects your agency's value in a sale. --- ## The Medicaid Home Care Landscape Medicaid is the single largest payer for home and community-based services (HCBS) in the United States. Approximately 40% of all Medicaid spending goes to long-term services and supports, and a growing share of that is delivered in home and community settings. There are two primary ways Medicaid pays for home care services: **1. Fee-for-Service (FFS) / State Waiver Direct Billing** In FFS states, your agency bills the state Medicaid program directly (or a state-administered waiver program). The state sets rates, which are updated periodically. Payment is relatively predictable, you know the rate you'll receive for each service unit. **2. Managed Long-Term Services and Supports (MLTSS)** In MLTSS states, the state has contracted with managed care organizations (MCOs — e.g., Molina, Centene/WellCare, UnitedHealthcare Community Plan, Aetna/CVS, Humana) to manage the long-term care benefit for Medicaid beneficiaries. Your agency does not bill the state directly, you contract with MCOs and bill the MCOs. As of 2026, over 30 states have implemented MLTSS programs, with additional states in transition. The shift from FFS to MLTSS is the defining structural change in the Medicaid home care market. --- ## MLTSS: What Changes for Your Agency ### Contract Complexity Under FFS, your agency has one payer relationship: the state. Under MLTSS, you may have contracts with 3–8 different MCOs operating in your state, each with different rates, billing systems, documentation requirements, prior authorization protocols, and care coordination expectations. This administrative burden is a real cost. Agencies transitioning from FFS to MLTSS often experience initial margin compression as they build the processes to manage multiple payer relationships. **Implication for valuation:** An agency with documented, established MCO contracts and a billing/administrative infrastructure to manage them is more valuable than one in the early stages of adaptation. Evidence of established MCO relationships, historical performance, and operational proficiency in a managed care environment signals reduced transition risk to buyers. ### Rate vs. Capitation Economics Under FFS, you receive a set daily or hourly rate per beneficiary per service unit. Under MLTSS, you are a sub-contracted provider, the MCO receives a per-member-per-month (PMPM) capitated payment from the state, and then contracts with you at specific rates for services rendered. Your rates are set by negotiation with each MCO — not by the state. This is both a risk and an opportunity: **Risk:** If your MCO contract negotiation produces below-market rates, or if MCOs unilaterally reduce rates at contract renewal, your margins compress without corresponding state rate adjustments. **Opportunity:** Agencies with strong market position (no adequate alternative provider in a given county) or operational performance (quality metrics, low complaint rates, efficient service delivery) can negotiate better rates than the MCO's standard terms. ### Value-Based Care and Quality Metrics A growing number of MLTSS arrangements include value-based care (VBC) components, bonus payments or risk share arrangements tied to quality outcomes, hospitalization reduction, or member satisfaction. Agencies that perform well on VBC metrics earn more than the base rate; poor performers may face penalties. **Implication for valuation:** Revenue from VBC bonuses can be presented as add-back items (if non-recurring) or as a quality premium in the financial narrative. Well-documented VBC performance history and active participation in MCO quality programs is a positive signal to buyers. ### Continuity and Relationship Lock-In One feature of MLTSS that can be positive for valuation is member assignment continuity. When the state transitions from FFS to MLTSS, existing home care users are generally assigned to managed care plans, and their existing providers often retain them as long as the provider is in-network with the assigned MCO. Well-established agencies with large books of long-standing Medicaid clients may maintain strong client continuity even in an MLTSS transition, because the beneficiaries and their families want to keep their existing caregiver relationships. --- ## State-by-State Variation: Why It Matters The financial impact of MLTSS on your agency's margins depends heavily on how your specific state implements it. There is enormous variation across states: **Rate setting adequacy:** Some states have implemented MLTSS with rates that adequately reimburse provider costs (and sometimes exceed FFS rates). Others have implemented MLTSS at rates that cover less than actual service cost, creating margin pressure across all providers. **MCO network requirements:** Some states require MCOs to contract with any willing qualified provider, ensuring access for established agencies. Others allow MCOs to maintain narrow networks, excluding smaller providers. **Managed care competition:** In states with 5+ competing MCOs, agencies sometimes have more negotiating leverage than in states with monopoly or duopoly managed care arrangements. **Transition timeline:** States transitioning to MLTSS go through multi-year implementation periods. Agencies caught mid-transition may have mixed FFS and MLTSS revenue that requires careful presentation to buyers. **For home care agency sellers:** Understanding exactly how your state's Medicaid program is structured, whether your state is in transition to MLTSS, and how your specific MCO contract terms compare to market rates is essential context for both valuation preparation and buyer due diligence. --- ## How Sophisticated Buyers Evaluate Medicaid Revenue in MLTSS States **Revenue quality analysis** Buyers distinguish between: - FFS Medicaid revenue (evaluated against state rate schedule sustainability) - MCO-contracted MLTSS revenue (evaluated against contract terms, renewal history, and rate adequacy) - MCO revenue with VBC components (evaluated separately for sustainability) In MLTSS states, buyers will want to review your specific MCO contracts, the rates, terms, renewal provisions, and notice/termination provisions. A contract with good rates but a 90-day termination clause is less valuable than one with good rates and a 2-year evergreen term. **Contract concentration risk** In MLTSS, concentration can exist at the MCO level. If 60% of your MLTSS revenue flows through a single MCO, and that MCO decides not to renew your network contract or cuts rates significantly, your revenue is materially impacted. Buyers assess this risk and may price it into the valuation. **State fiscal environment** Medicaid is funded jointly by states and the federal government. States facing fiscal pressure sometimes reduce HCBS waiver rates, reduce beneficiary slots, or restructure their MLTSS programs. Buyers evaluate the fiscal health and political environment of your state's Medicaid program as part of their risk assessment. --- ## MLTSS as a Competitive Moat — The Positive Case It's important to note that MLTSS is not purely a risk factor. For well-positioned agencies in mature MLTSS markets: **Established MCO relationships are a competitive advantage.** Becoming an in-network preferred provider across multiple MCOs in your market represents a real barrier to entry for competitors. A new entrant cannot just serve Medicaid clients without being in-network. **MCO data analytics partnerships.** Some forward-thinking agencies have developed partnerships with MCOs that go beyond service provision, participating in data-sharing programs, care coordination, or risk stratification that creates a deeper, more durable relationship than a standard vendor contract. **VBC track record.** Demonstrated quality performance in VBC arrangements is a genuine value driver, it shows buyers that you can navigate the future of Medicaid managed care, not just the legacy FFS model. --- ## Preparing Your Medicaid Story for Buyers When preparing for a sale, home care agencies with significant Medicaid revenue should prepare: 1. **Payer analysis:** A clean breakdown of revenue by payer (FFS Medicaid, MLTSS MCO by MCO name, Medicare, private pay) with historical trend data. 2. **MCO contract summary:** A summary of each MCO contract including service types, billable rates, term/renewal date, and performance requirements. 3. **Rate adequacy analysis:** A comparison of your MCO contract rates against direct care costs, demonstrating your margins on Medicaid services. 4. **VBC performance documentation:** If you participate in any VBC programs, document your performance metrics and any bonuses earned. 5. **Regulatory landscape summary:** Your M&A advisor should prepare a brief summary of your state's MLTSS status, transition trajectory, and rate environment for buyers unfamiliar with your specific market. **[Discuss how your Medicaid payer environment affects your valuation →](/contact-us)** --- *Hendon Partners works with home care agencies across all Medicaid payment environments. FFS, MLTSS, and hybrid. We help sellers present their Medicaid revenue story accurately and compellingly to buyers who need to understand the specific regulatory and payer context of each market.* --- ### Staffing Agency M&A in Healthcare: Valuation, Multiples, and What Buyers Look For URL: https://www.hendonpartners.com/insights/healthcare-staffing-company-ma-valuation-2026 Published: 2026-03-06 09:00 Category: Valuation Insights > Healthcare staffing companies — particularly those serving home care, skilled nursing, and hospitals — are active M&A targets in 2026. But the valuation framework is different from traditional home care agencies, and the due diligence focus areas are distinct. Here is what you need to know. Healthcare staffing companies occupy a complex and distinct position in the home care M&A market. They are often grouped with traditional home care agencies in industry conversations, but buyers, lenders, and M&A advisors evaluate them very differently — because the business model, revenue stability profile, and growth dynamics are fundamentally different. This article is written for owners of healthcare staffing companies, particularly those serving post-acute, home-based care, or facility-based healthcare settings, who are considering a sale or want to understand what drives value in their sector. --- ## What Is a Healthcare Staffing Company (in the M&A Context)? For the purposes of this article, "healthcare staffing" refers to companies that place temporary, contract, or permanent healthcare workers with client facilities or agencies. This includes: - **Per diem staffing:** Placing CNAs, LPNs, RNs, and therapy staff on a shift-by-shift or daily basis with SNFs, ALFs, home care agencies, or hospitals - **Travel nursing:** Placing traveling RNs, medical professionals on 8–13 week contracts with healthcare facilities - **Contract staffing:** Placing caregivers with home care agencies as independent contractors or supplemental staff - **Permanent placement (direct hire):** Recruiting and placing healthcare workers in permanent positions Some companies in this space operate purely as staffing companies. Others have evolved to be hybrids — a licensed home care agency that also provides staffing to third-party clients. --- ## How the Business Model Differs From Traditional Home Care **Revenue recognition:** Traditional home care agencies bill insurers (Medicare, Medicaid, private insurance) or private clients for patient care services. Healthcare staffing companies bill client facilities or agencies for worker hours. The payer is different, and so is the revenue quality profile. **Client relationships:** Staffing companies serve institutional clients (SNFs, ALFs, hospitals, home care agencies). These relationships are often less "sticky" than patient relationships, a facility can switch staffing vendors more easily than a home care patient can switch providers. **Worker classification:** Staffing companies must navigate complex worker classification issues. Misclassifying W-2 employees as 1099 contractors (or paying 1099 staffing rates to workers who function as employees) creates significant tax liability and regulatory risk — and is scrutinized intensely in due diligence. **Margin profile:** Healthcare staffing gross margins are typically lower than traditional home care (15–30% vs. 25–45% for home care) because the primary revenue is labor pass-through. EBITDA margins at mature staffing companies often run 5–15%. **Labor market dependency:** Staffing companies are highly sensitive to local labor market tightness. In markets with extreme nursing shortages, staffing companies have pricing power; in more balanced markets, margins compress. --- ## Healthcare Staffing Valuation: Key Metrics and Multiples ### The Primary Valuation Metric: Gross Profit (or Gross Margin) Because revenue in staffing is largely a labor cost pass-through, buyers and analysts focus on **gross profit** as a more meaningful performance metric than raw revenue. **Gross profit = Revenue – Direct labor costs (caregiver/staff wages)** This strips out the pure pass-through component and focuses on the business's actual value-add: its ability to attract, manage, and deploy qualified healthcare workers at a spreading margin. ### EBITDA Multiples in Healthcare Staffing (2026) Healthcare staffing multiples vary significantly based on: | Company Type | Typical EBITDA Multiple Range | |---|---| | Small per diem staffing (<$500K EBITDA) | 3.0× – 4.5× | | Mid-market per diem/contract staffing | 4.0× – 6.0× | | Travel nursing, national scale | 5.0× – 8.0×+ | | Permanent placement/direct hire | 4.0× – 7.0× | | Hybrid (staffing + home care) | 4.0× – 6.5× | **Revenue multiples** are sometimes cited (staffing companies at 0.3× – 0.8× revenue), but EBITDA multiples are the professional standard. Use revenue multiples only as a rough sanity check. ### What Drives Multiple Premium in Healthcare Staffing **Scale and geographic diversity:** A staffing company operating in 5+ states with a diversified client base commands a premium to a single-market, single-contract operation. **Client concentration:** Heavy concentration in a single client facility or health system is penalized. Buyers want diversification. A staffing company where one client represents 40%+ of revenue is a significant concentration risk. **Technology platform:** Companies that have invested in scheduling technology, digital talent acquisition platforms, or managed services programs are more scalable and command better multiples. **Service line mix:** Companies that have moved up the value chain from CNA/LPN staffing to nurse practitioners, allied health, or specialty clinical placements have higher margins and more attractive valuation profiles. **Contract structure:** Master service agreements (MSAs) with multi-facility health system clients are more valuable than transactional per-shift relationships. **Brand and sourcing model:** Companies with strong employer branding, referral-based caregiver sourcing, or exclusive sourcing arrangements in tight labor markets have more durable competitive advantages. --- ## Due Diligence Focus Areas Unique to Healthcare Staffing Buyers scrutinize healthcare staffing companies across several areas that differ from traditional home care due diligence: ### Worker Classification This is the most critical compliance issue in healthcare staffing M&A. **W-2 vs. 1099:** Healthcare workers placed at client facilities who work under the direction of those facilities (regarding schedule, work location, and methodology) are almost certainly employees, not independent contractors, under IRS, DOL, and most state labor law standards. Misclassifying them as 1099 contractors exposes the staffing company to: - Back payroll taxes (employer portion of FICA/Medicare + FUTA/SUTA) - ACA employer mandate penalties - State unemployment claims - Workers' compensation exposure - IRS penalties and interest Buyers will hire employment law counsel to review worker classification practices and model the contingent liability. Any significant misclassification exposure will be reflected in escrow requirements or purchase price adjustments. **Joint employer risk:** Staffing companies that provide workers to client facilities may be treated as a joint employer of those workers — particularly under recent NLRB and DOL guidance. Joint employer status can create wage liability, benefits obligations, and labor relations exposure. ### State-by-State Licensing and Regulatory Compliance Healthcare staffing companies that place clinical staff across state lines must comply with: - Multi-state nursing license requirements (the Nurse Licensure Compact covers most but not all states) - State regulation of staffing agencies (some states license healthcare staffing agencies separately) - Background check requirements (vary by state and care setting) ### Joint Commission or DNV Staffing Agency Accreditation Some joint commission-accredited facilities require their staffing vendors to hold staffing agency accreditation from The Joint Commission or another body. Review which clients require this and whether the company maintains current accreditation. ### Technology and Data Security Staffing companies hold significant amounts of personal information, caregiver SSNs, references, licensure, background checks, health screening records, and client billing records. Data security practices and HIPAA compliance for any PHI handled in the course of clinical staffing assignments are important due diligence areas. --- ## The Hybrid Home Care / Staffing Company Many home care agencies have evolved into hybrid companies, they deliver direct care services to private clients under agency licenses while also staffing caregivers to other facilities or agencies under staffing arrangements. These hybrids present interesting but complex valuation questions: **Different revenue quality:** The direct care revenue (with payer-direct relationships) typically warrants higher multiples than staffing revenue. Buyers may apply a blended multiple based on the revenue mix. **Operational overlap:** Does the staffing business leverage the same caregiver pool as the direct care business? If so, growth of the staffing book creates caregiver competition with the direct care book. **Licensing implications:** Staffing caregivers to third parties while operating a licensed home care agency may implicate separate staffing license requirements in some states. In a sale of a hybrid, your advisor needs to model the revenue and EBITDA contribution by type and present buyers with a clear view of the combined business, while managing the potential for buyers to discount the staffing component versus the direct care component. --- ## Preparing a Healthcare Staffing Company for Sale **Optimize the service mix:** Higher-margin placements (RNs, allied health, specialized clinical) are more attractive to buyers than commoditized CNA placements. If you have the opportunity to expand clinical placement volumes before going to market, it can improve both margin and multiple. **Clean up worker classification:** If there is any meaningful 1099 usage among workers who should be classified as employees, address this before marketing. The cost of classification correction now is almost always less than the purchase price reduction it would create in due diligence. **Diversify clients:** Reduce any single-client revenue concentration. Even moving from 60% to 45% of revenue in one client relationship materially impacts buyer risk perception and, therefore, multiple. **Document management agreements and MSAs:** Formalize your client relationships in written contracts with defined terms where possible. A signed MSA with a large health system client is worth significantly more than a "we've worked together for 10 years but it's all verbal" relationship. **[Discuss your staffing company sale with Hendon Partners →](/contact-us)** --- *Hendon Partners advises on the sale of healthcare staffing companies and hybrid home care/staffing businesses. Our advisors understand the distinct valuation frameworks and due diligence considerations that apply in the staffing sector.* --- ### Home Care Agency Succession Planning: 5 Exit Options Beyond a Direct Sale URL: https://www.hendonpartners.com/insights/home-care-agency-succession-planning-exit-options Published: 2026-02-27 09:00 Category: Exit Strategy > A third-party sale is not the only way to exit a home care agency. Family succession, management buyouts, ESOPs, gifting programs, and phased exits are all viable alternatives depending on your goals. Here is how each option works and who it is right for. When most home care agency owners think about exiting their business, they think about selling — finding a buyer, negotiating a price, and transitioning. And for many owners, a third-party sale to a strategic buyer or private equity firm is indeed the right path. But it is not the only path. Depending on your personal financial goals, family situation, relationship with your management team, attachment to the business's mission, and community connections, one of several alternative succession strategies might produce a better outcome, financially, personally, or both. This article walks through five viable exit options for home care agency owners beyond a direct sale, explaining how each works, what it produces financially, and what type of owner each is best suited for. --- ## Option 1: Third-Party Sale to a PE or Strategic Buyer This is the most common and typically the highest-liquidity exit option. A professional buyer, private equity-backed platform, larger home care chain, health system, acquires the business. **What it typically produces:** - 4×–8× Adjusted EBITDA in cash at close (with possible earnout and rollover equity) - Clean transition with defined seller obligations (typically 6–24 months post-close transition) - Competition among multiple qualified buyers often maximizes sale price **Best for:** - Owners prioritizing maximum liquidity - Owners without an obvious internal successor - Owners ready for a clean break or retirement **Challenges:** - Requires market positioning (management depth, growth trajectory, compliance cleanliness) - Timing dependence on market conditions and buyer availability - Post-close earnout features may tie seller to performance --- ## Option 2: Management Buyout (MBO) A management buyout is a transaction in which your existing management team acquires the business, often financed by a combination of their personal assets, seller financing, and bank debt (SBA or conventional). **How it works:** Your management team — typically the Administrator, Director of Operations, or lead operational staff, expresses interest in acquiring the business. They need to secure financing for the purchase. This typically involves: 1. **SBA 7(a) or 504 loans:** The SBA loan programs are commonly used for small business acquisitions. An SBA 7(a) loan can cover up to $5M (higher with co-applicants), and can be used for business acquisitions with as little as 10–15% buyer equity injection. 2. **Seller financing:** The selling owner carries back a portion of the purchase price as a seller note, typically at 5–8% interest, payable over 5–10 years. This bridges any gap between the SBA loan and total purchase price. 3. **Management equity injection:** Buyers must inject some personal equity into the transaction, the SBA requires this. **What it typically produces:** - Purchase price typically at a modest discount to market (10–25% below third-party sale price), because MBO buyers lack the competitive tension of a full sale process - Seller note creates ongoing relationship with the business (you receive monthly payments rather than a lump sum) - Sale is confidential and relationship-driven; no marketing process or external buyer scrutiny **Best for:** - Owners who have a loyal, capable management team ready to take ownership - Owners who value the continuity of the business culture and team - Owners comfortable with seller financing (receiving proceeds over time rather than upfront) - Owners who want to be helpful in a post-close advisory capacity **Challenges:** - Management team typically cannot pay full market value, you are leaving some money on the table versus a competitive external sale - Seller note is unsecured or secured only by business assets — if the business struggles, payments may be at risk - Requires management team to have operational and business management skills they may not have previously exercised as employees --- ## Option 3: Family Succession For multi-generational home care businesses, or businesses where a family member is already involved in operations, transferring the business within the family is an alternative to an external transaction. **Structures for family succession:** **Gifting over time:** For owners in a position to do so, gifting ownership interests to a family member annually up to the gift tax annual exclusion ($18,000 per recipient in 2024, indexed for inflation) can gradually transfer ownership without triggering a sale event. Combined with valuation discounts for minority positions, this can be an efficient estate planning strategy. **Intrafamily sale:** A formal sale to a family member at a documented fair market value, often for below-market consideration, potentially structured with seller financing or installment payments. **Family limited partnership (FLP) or LLC gifting programs:** Placing the business into an FLP or LLC and gifting limited partner or member interests over time, taking advantage of minority interest discounts for valuation purposes. **Grantor retained annuity trust (GRAT):** An advanced estate planning technique where the owner transfers appreciation in the business to heirs while retaining an annuity stream. **What it typically produces:** - Preservation of family ownership and cultural continuity - Potential for significant estate/gift tax efficiency - No competitive sale process, lower transaction costs - May produce less immediate liquidity to the founder than a third-party sale **Best for:** - Owners with a family member (child, sibling, spouse) actively involved and operationally capable of running the business - Owners whose primary goal is preserving the family legacy rather than maximizing immediate liquidity - Owners with larger estates who can benefit from gift and estate tax planning strategies **Challenges:** - Requires a qualified and motivated family successor - Family dynamics can complicate business transitions significantly - Requires professional estate planning counsel and, ideally, a family governance framework - May not generate meaningful liquidity to the founder if structured as a gift-heavy transition --- ## Option 4: Employee Stock Ownership Plan (ESOP) An ESOP is a qualified retirement plan that invests primarily in the stock of the sponsoring employer. In essence, your ownership stake is sold to a trust that is beneficially owned by your employees. **How ESOPs work in home care:** The business forms an ESOP trust, which acquires some or all of the owner's stock. The purchase is typically financed by debt, either from the company (leveraged ESOP) or from a bank loan taken by the trust and guaranteed by the company. The owner receives cash for the stock sold to the ESOP. Tax advantages are significant: - **S-corp ESOP:** An S-corp that is 100% owned by an ESOP pays NO federal income tax on its ESOP-owned portion. For an agency doing $2M in EBITDA, this can represent $400K–$700K per year in tax savings, which directly increases cash available to service the acquisition debt. - **C-corp ESOP:** For C-corp sellers, a Section 1042 election allows deferral of capital gains on the stock sale proceeds if reinvested in qualified replacement property. **What it typically produces:** - Transaction price at or near appraised fair market value (not necessarily at the highest competitive market price) - Seller can receive proceeds over time (rather than all at close) - Business continues under employee ownership, preserving culture and jobs - Significant ongoing tax benefits that improve the business's cash flow **Best for:** - Owners who are deeply committed to their employees and want to create a legacy of shared ownership - Owners who value cultural continuity over maximizing liquidity - Owners who can benefit from the tax advantages of the ESOP structure - Businesses with sufficient EBITDA to service ESOP acquisition debt ($500K+ EBITDA typically minimum) **Challenges:** - ESOP transactions are complex, require specialized ESOP counsel, and take 6–12 months to structure - Transaction price is typically lower than a competitive PE/strategic sale - Owner must be patient with the timing of proceeds (initial payment plus ongoing distributions) - Employee-owned companies can be culturally complex, not every management team thrives in an employee-ownership context --- ## Option 5: Phased or Partial Exit Rather than a complete exit in a single transaction, some owners prefer a phased approach — selling a partial ownership stake first, maintaining involvement for a defined period, and completing the exit in a subsequent transaction. **Structures for phased exits:** **Minority sale to a strategic partner:** Sell 20–40% of the business to a strategic partner (larger agency, health system affiliate, PE investor) while retaining operational control. The partner brings capital access, infrastructure, or referral network benefits while you continue operating. **Majority sale with retained minority:** As discussed in our majority recapitalization article, selling 60–80% of the business while retaining a minority stake gives you significant upfront liquidity while maintaining upside exposure and operational involvement. **Staged transition with management:** Install an operational successor (your eventual buyer) over 2–3 years, then execute a formal sale transaction at an agreed valuation once the transition is proven. **What it typically produces:** - Immediate partial liquidity with ongoing involvement - Ability to participate in future value creation under new ownership or partnership - Lower immediate transaction risk, you can evaluate the partnership before fully exiting **Best for:** - Owners who are not ready for a full exit but want some immediate liquidity - Owners who want to mentor a successor before fully handing over the reins - Owners who have significant growth opportunities that require capital access unavailable as a sole independent **Challenges:** - Partial exits are structurally more complex than full exits - Partner or investor will eventually require a full exit, which introduces future transaction timing risk - Sharing governance and decision-making with a minority or majority partner requires compatibility --- ## Choosing the Right Path No single exit option is inherently superior. The right path depends on: | Factor | Prioritizes | |---|---| | Maximum immediate liquidity | Third-party sale | | Management team loyalty | Management buyout or ESOP | | Family legacy | Family succession | | Employee ownership values | ESOP | | Gradual transition | Phased exit | | Post-close involvement desire | MBO, rollover equity in PE sale, or phased exit | Many owners benefit from evaluating multiple options in parallel before committing to one path. Understanding the financial and non-financial implications of each, with input from your M&A advisor, estate planning attorney, and financial advisor, produces better decisions than defaulting to the most obvious path without analysis. **[Discuss your succession planning options with Hendon Partners →](/contact-us)** --- *Hendon Partners advises home care agency owners on succession planning across the full spectrum of exit options, from competitive third-party sales to management buyouts, partial exits, and transition structures. We help you find the path that aligns with your financial and personal goals.* --- ### Equity Rollover in a Home Care Agency Sale: Should You Roll Equity With a PE Buyer? URL: https://www.hendonpartners.com/insights/equity-rollover-home-care-sale-private-equity Published: 2026-02-20 09:00 Category: Exit Strategy > When a private equity firm acquires your home care agency, they often ask you to roll a portion of your proceeds into equity in the combined entity. This can be highly lucrative — or it can be a distraction from a clean exit. Here is how to evaluate the decision. When a private equity firm acquires your home care agency, the term sheet will often include a section on "rollover equity" — an invitation (and sometimes an expectation) that you will reinvest a portion of your sale proceeds into equity in the combined platform. For some sellers, this represents one of the most financially rewarding components of the transaction, a "second bite of the apple" that multiplies the value of their initial exit. For others, it's a distraction from the financial security of a clean exit, a bet on an unknown management team's ability to perform, and a liquidity risk they prefer to avoid. Neither perspective is wrong. Whether to roll equity, and how much — is one of the most important, and most personal, financial decisions in the sale process. This article explains how rollover equity works, how to evaluate the financial case, and the questions you need to answer before deciding. --- ## What Is Rollover Equity? When you sell your home care agency to a PE-backed buyer, the total consideration includes a cash component and potentially a rollover component. **Example:** Your agency is being acquired for $8,000,000. The PE firm's term sheet includes: - Cash at close: $6,200,000 (77.5% of total consideration) - Rollover equity: $1,800,000 worth of equity in the acquiring platform (22.5%) Instead of receiving $8M in cash, you receive $6.2M in cash and $1.8M in equity in the PE-backed platform company. The rollover equity shares the same economic structure as the PE fund's investment, you participate in the upside (if the platform grows and exits at a higher multiple) and the downside (if it doesn't). --- ## The "Second Bite of the Apple" Concept The appeal of rollover equity comes from the mechanics of PE roll-up math. Assume the following scenario: - Your $8M acquisition is structured with $1.8M in rollover equity - Your rollover equity represents 5% of the combined platform - Over the next 4 years, the PE firm acquires 8 additional agencies and grows platform EBITDA from $3M to $9M - The platform exits to a larger PE fund or strategic buyer at 7× EBITDA = $63M enterprise value - 5% of $63M = $3.15M **Your $1.8M rollover = $3.15M at exit**, a 1.75× return, in addition to the $6.2M cash you already received. Total gross proceeds from both bites: $9.35M vs. the $8M all-cash offer. A 17% premium on total proceeds for taking the rollover. In successful PE roll-up transactions, rollover equity outcomes significantly better than this are common. Some sellers who rolled equity into a platform that achieved a large exit have doubled or tripled their initial rollover value. --- ## The Risks and Caveats The second bite sounds compelling in almost every scenario when modeled optimistically. The risks are where the story gets more complicated. ### 1. Illiquidity Rollover equity is NOT cash. It is equity in a private company with no market, you cannot sell it when you want to. You are locked in until the PE firm exits, which may be 3–7 years from transaction closing. If you need liquidity for personal financial reasons during that period, your rollover equity cannot provide it. This matters most for sellers who have reached retirement planning age, have significant personal liquidity needs, or expect to face estate planning events during the holding period. ### 2. Platform Execution Risk The projected second-bite value depends entirely on the platform's successful execution: - Are the acquisition targets accurately valued? - Is the management team capable of integrating multiple acquisitions? - Will the PE firm achieve the exit multiple assumed in projections? - Is there significant regulatory risk in the portfolio? Many PE platforms perform well. Some struggle with integration, fail to hit growth targets, or exit in less favorable market conditions. A rollover into an underperforming platform can return far less than the projected value — or in extreme cases, can lose value. ### 3. Pari Passu vs. Preferred Returns The structure of your equity matters significantly. Rollover equity typically does NOT share in the management fee economics or preferred return structures that the PE fund's limited partners enjoy. In some structures, preferred equity or the PE fund receives priority distributions before rollover equity holders participate meaningfully. Before accepting rollover equity, your attorney should review the shareholder agreement to understand: - Is your equity common equity? Preferred? - What is the waterfall structure? When does your equity participate in the upside? - Do PE investors have preferred returns that must be paid before common equity participates? - What are your tag-along and drag-along rights as a minority equity holder? ### 4. Tax Treatment Rollover equity transactions create complex tax planning requirements. When you roll equity, you are typically deferring taxable gain recognition on the rolled portion, the funds you rolled are not immediately taxable. However, when the platform ultimately exits and your equity is liquidated, the deferred gain is recognized. This is not necessarily bad, tax deferral has value. But the timing and character of your eventual tax obligation (capital gains vs. ordinary income depending on equity structure) must be modeled with your tax attorney before committing to a rollover. **Important:** The tax treatment depends on how the rollover is structured. In some transaction structures, a rollover into a "unlike kind" equity (i.e., from S-corp interest directly into PE controlling equity) may create immediate taxable events. Review with qualified tax counsel before agreeing to rollover terms. --- ## How Much to Roll, If You Roll at All Most PE buyers will express a preference for rollover amounts in the range of 10–30% of total consideration. The amount is often negotiable within a range. **Factors that support rolling a larger amount:** - You are confident in the platform's management team and investment thesis - You are not dependent on the rolled proceeds for near-term personal liquidity - You are remaining in a leadership role post-close and have influence over the value you'll receive at exit - Tax deferral is valuable in your personal situation - You believe the roll-up math will create a meaningfully larger platform at exit **Factors that support rolling a smaller amount (or none):** - Your primary concern is financial security and certainty — you want the $8M in hand - You are fully retiring and have no interest in continued involvement - You have assessed the platform and have doubts about the management team or investment thesis - Personal liquidity needs over the next 3–5 years require access to more cash - Estate planning considerations make a clean, fully liquid transaction preferable **The "minimum rollover" negotiation:** In some PE transactions, the buyer requires a minimum rollover amount as a condition of the deal. If this is the case, understand what the minimum is and whether it is truly a condition or a negotiating position. An experienced M&A advisor will tell you which. --- ## Evaluating the Platform Before Rolling If you are going to roll equity, you need to evaluate the platform you're rolling into with the same rigor you'd apply to any investment. **Key questions to ask:** **Management team:** - Who is the CEO/operating management team of the platform? - What is their track record with prior roll-up transactions? - How many agencies has the platform successfully integrated? - What is caregiver and management retention post-acquisition across their existing portfolio? **Financial performance:** - What is the platform's current EBITDA run rate? - What is the acquisition multiple the platform pays for add-ons? (If they're overpaying, the exit won't generate the returns projected.) - What is the fund's total debt load? (Highly leveraged platforms face more risk.) **Exit planning:** - When does the PE fund's target hold period end? - What exit channels are they considering? (Sale to larger PE fund, strategic sale, IPO?) - What is the implied exit multiple in their investor model? **Governance rights:** - Will you have any board representation or information rights as a rollover equity holder? - What are your rights if you disagree with a platform decision that affects your equity value? --- ## Negotiating the Rollover Structure Rollover equity terms are negotiable. Areas where sellers often have more flexibility than they realize: **Roll amount:** As noted, 10–30% is typical. Some sellers negotiate down to 10% or less. **Equity class:** Common vs. preferred equity has significant structural implications. **Tag-along rights:** Ensure you have the right to tag along in any exit the PE firm engineers, you don't want to be left as a minority holder in a residual entity after the PE firm sells its controlling interest. **Put rights:** In some structures, sellers negotiate a "put option", a right to sell their rollover equity back to the platform at a formula price after a specified period if no exit has occurred. This provides a liquidity floor. **Anti-dilution protections:** Without anti-dilution provisions, future capital raises or add-on equity issuances could dilute your ownership percentage. --- ## A Decision Framework For most home care sellers, the rollover decision comes down to this: **Roll equity if:** - You trust the platform's management and investment thesis - You can genuinely afford to have the rolled amount illiquid for 3–7 years - You are interested in continuing some level of involvement that gives you insight into platform performance - The potential upside (2× rollover at exit) meaningfully improves your total outcome **Don't roll (or minimize rollover) if:** - Financial security is paramount and certainty has more value than potential upside - You are at a life stage where liquidity is critical - The platform's management team or strategy doesn't inspire confidence - You want a clean transition and complete financial independence from the business **Work with advisors who have done this before.** The rollover equity decision benefits enormously from input by an M&A advisor who has seen many of these transactions play out, who can help you objectively assess the platform quality and model the financial scenarios. **[Discuss rollover equity considerations with Hendon Partners →](/contact-us)** --- *Hendon Partners has advised home care sellers through dozens of PE-backed transactions, including detailed rollover equity evaluations. We help sellers understand the real risk/return profile of rollover equity proposals and negotiate better terms.* --- ### Private Equity in Home Care: What Sellers Need to Know in 2026 URL: https://www.hendonpartners.com/insights/private-equity-home-care-what-sellers-need-to-know-2026 Published: 2026-02-18 09:00 Category: Buyer Resources > Private equity now represents 62% of buyer-side home care M&A transactions. Understanding how PE firms evaluate targets, what multiples they pay, and how they structure deals is essential for any owner considering a sale in 2026. Private equity now dominates the buyer side of home care M&A. In 2024, PE-backed platforms accounted for **62% of buyer-side transactions**, up from 41% in 2020. For home care agency owners considering a sale, understanding how PE firms operate, what they value, and how they structure deals is no longer optional — it's essential knowledge. This guide covers everything sellers need to know about selling to a private equity buyer. --- ## Why PE Firms Love Home Care Private equity's outsized interest in home care isn't coincidental, it's driven by a specific investment thesis that makes home care one of the most attractive healthcare services sectors for leveraged buyout strategies. **1. Recession-resistant demand** Home care demand is driven by demographics, not consumer spending or GDP cycles. The aging Baby Boomer cohort creates 20+ years of non-discretionary demand growth that is largely immune to economic downturns. **2. Fragmented market ideal for consolidation** 80%+ of home care agencies have annual revenue below $3M. This fragmentation creates the classic PE "buy-and-build" opportunity: acquire a platform, then add bolt-on acquisitions to build scale, drive synergies, and exit at a multiple arbitrage premium. **3. Repeatable EBITDA margins** Home care agencies, particularly Medicare-certified and hospice businesses — generate highly predictable, recurring revenue with limited capital expenditure requirements. This profile suits the leveraged buyout model extremely well. **4. Multiple expansion potential** A $1M EBITDA home care agency acquired at 4× ($4M) can become part of a $15M EBITDA platform that sells at 10× ($150M). The multiple arbitrage between the add-on price and the exit price is one of the primary sources of PE returns in this sector. --- ## How PE Firms Evaluate Home Care Acquisitions When a PE firm reviews your business, they're looking at it through several lenses simultaneously: ### Financial Quality - **EBITDA reliability**: Is the reported EBITDA real and sustainable? Are the add-backs legitimate? - **Revenue quality**: What percentage of revenue is Medicare, Medicaid, private pay? How diversified is the payer mix? - **Margin profile**: What drives your margins, and are they defensible? ### Operational Quality - **Management depth**: Can the business run without the owner? Is there a clinical director, operations manager, and billing manager in place? - **Scalability**: Are the systems and processes documented well enough to be replicated across additional locations? - **Technology infrastructure**: What billing, scheduling, and EVV (Electronic Visit Verification) systems are in use? ### Strategic Fit - **Geographic fit**: Does your agency complete their coverage map or open a new market they want? - **Service line fit**: Does adding your agency expand or complement their existing capabilities? - **Size fit**: Are you a potential platform acquisition or an add-on to an existing portfolio? ### Risk Factors - **Key person risk**: How dependent is the business on you personally? - **Concentration risk**: What is the largest payer, client, and referral source as a % of revenue? - **Compliance history**: Any outstanding audits, overpayment notices, or regulatory issues? --- ## PE Deal Structures: What to Expect PE deals are typically structured differently from strategic acquisitions. Understanding the components helps you evaluate and negotiate more effectively. ### Enterprise Value This is the total agreed-upon price for the business, expressed as a multiple of EBITDA. It's the headline number, but not necessarily what you receive at close. ### Net Cash at Close After adjusting for working capital, debt payoff, and transaction costs, most sellers receive **75–90% of enterprise value** in cash at closing on a typical PE transaction. ### Seller Rollover Equity Many PE buyers ask (or require) the seller to "roll" 10–25% of their proceeds into equity in the acquiring platform. This is called **rollover equity** or a "second bite of the apple." For sellers, rollover equity means: - **Upside**: If the PE platform exits at a higher multiple in 3–5 years, your rollover equity appreciates significantly - **Downside**: If the platform struggles or doesn't exit, your rollover is at risk - **Illiquidity**: Your rollover shares are not liquid until the platform exits Whether rollover equity is attractive depends entirely on the quality of the PE sponsor, the platform's growth trajectory, and your personal risk tolerance. Your advisor should help you evaluate this critically. ### Earnouts An **earnout** ties a portion of your purchase price to post-close performance. For example: "We'll pay you an additional $500K if the agency achieves $1.5M EBITDA in Year 2 post-close." Earnouts are most common when: - There is a gap between the buyer's and seller's valuation views - The business has high growth potential that the buyer wants to share upside on - The seller is staying on in an operational capacity Earnouts introduce risk, post-close performance is influenced by decisions you may no longer control. In general, a higher cash-at-close offer with no earnout is preferable for most sellers to a higher headline price with significant earnout components. ### Transition Period Most PE buyers require the seller to remain available during a transition period — typically 6–18 months post-close. The structure ranges from a full-time employment contract to a part-time consulting agreement. Understanding this obligation before accepting an offer is critical. --- ## The 80+ PE Platforms Actively Buying in 2026 The home care PE buyer universe is more active and better-capitalized than at any prior point in the market's history. Over 80 PE-backed platforms are actively seeking acquisitions, including: **National platforms**: Elara Caring, Addus HomeCare, Amedisys (post-Optum), and LHC Group entities, these buyers pay premium prices for operational scale. **Mid-market PE platforms**: Dozens of PE-sponsored platforms with 2–8 existing locations actively seeking add-ons to complete their regional consolidation strategy. **Health system affiliates**: Health systems using PE-style acquisition structures to build integrated post-acute care platforms. **Emerging platforms**: Newly formed PE-backed entities specifically created to consolidate home care in one or more targeted geographies. Working with a specialist M&A advisor like Hendon Partners gives you access to this entire buyer universe, not just the 2–3 buyers you might have heard of. The difference between a transaction run through 8 buyers and one run through 50 buyers is often measured in multiples of EBITDA. --- ## How to Maximize Your Outcome with a PE Buyer **Understand their thesis before your first meeting.** The most effective sellers know what the PE firm is trying to build, why your agency fits their acquisition criteria, and how to position your business as solving their specific strategic problem. **Present a believable growth story.** PE buyers are buying future cash flows, not just historical performance. Your CIM should clearly articulate the growth opportunities a well-capitalized new owner could capture — new referral relationships, geographic expansion, service line additions. **Never negotiate with one PE firm.** Always run a competitive process. The presence of multiple buyers fundamentally changes the dynamic and consistently drives superior outcomes. **Scrutinize rollover equity terms.** Don't accept rollover equity without understanding the sponsor's track record, the platform's competitive position, and what the realistic exit scenarios look like in 3–5 years. --- ## Should You Sell to PE or a Strategic Buyer? The honest answer: it depends. PE buyers typically pay higher multiples than individual or regional strategic buyers, but the transaction is more complex, the process is more rigorous, and the expectations for post-close performance are higher. Strategic buyers (regional operators, health systems) often offer softer terms, faster closes, and more flexibility on earnout and rollover requirements, but typically at lower headline prices. The right answer is determined by running a competitive process that includes both PE and strategic buyers, evaluating all offers holistically, and selecting the path that maximizes your total after-tax, risk-adjusted outcome. **Speak with Neli Gertner** to understand which buyer type is the right target for your agency's specific profile, and how Hendon Partners would approach building a competitive process designed exclusively to maximize your outcome. --- ### What Is a Confidential Information Memorandum (CIM) in Home Care M&A? URL: https://www.hendonpartners.com/insights/what-is-a-cim-home-care-ma Published: 2026-02-13 09:00 Category: Seller Guides > The CIM is the most important document in any home care agency sale. It is the comprehensive business profile used to attract buyers and set the financial narrative. Here is what goes into a great CIM — and why the quality of your CIM directly affects your sale price. In every professional home care agency sale, there is one document that does more work than any other: the Confidential Information Memorandum, or CIM (sometimes called the "book," "offering memorandum," or "IM"). The CIM is the comprehensive document provided to qualified buyers after they have signed an NDA. It tells the story of your business — its history, financial performance, operations, competitive position, and growth opportunities, in a format that enables buyers to make informed bids and evaluate the quality of the acquisition opportunity. The difference between a well-crafted CIM and a poorly constructed one is not cosmetic. It is the difference between buyers feeling confident in the quality of your business and making strong offers, or feeling uncertain and discounted pricing accordingly. In some cases, a poorly presented CIM can cause qualified buyers to pass on an acquisition entirely, not because the business isn't good, but because the presentation failed to communicate its value. This article explains what a CIM is, what it contains, why it matters, and what distinguishes excellent CIMs in the home care sector. --- ## The Purpose of a CIM The CIM serves several simultaneous purposes: **1. Tell the business story compellingly** Every business has a narrative: why it was built, what makes it distinctive, what it has achieved. A well-written CIM tells this story in a way that creates genuine excitement in qualified buyers — helping them see the vision of what they could do with the business, not just its historical performance. **2. Present the financial picture accurately and favorably** The financial section of the CIM must present accurate, well-normalized EBITDA with a defensible add-back schedule, clear revenue and margin trends, and a clean presentation of key metrics. This is where the seller's financial narrative is established, and where buyers form their initial valuation views. **3. Answer questions before they are asked** Sophisticated buyers will have dozens of questions about operations, compliance, management, competition, and financial performance. A strong CIM anticipates these questions and addresses them proactively. This saves time, demonstrates transparency, and prevents buyers from assuming the worst about items not addressed. **4. Establish the competitive dynamic** In a properly run M&A process, the CIM is distributed to multiple buyers simultaneously, creating a competitive bidding environment. The CIM's quality and professionalism signals that this is a well-run process with serious seller representation, which prompts buyers to treat the process with appropriate urgency and put forward competitive offers. --- ## What a Professional CIM Contains A well-structured home care CIM typically includes the following sections: ### Section 1: Executive Summary A 2–3 page overview designed to capture buyer attention and communicate the most important points efficiently. It typically covers: - Business type and service offerings - Geography and market position - Revenue and Adjusted EBITDA (summary financial metrics) - Key investment highlights (3–5 bullet points that differentiate the business) - Transaction overview (desired structure, minimum buyer qualifications if any) The Executive Summary is often the only section some buyers read before deciding whether to pursue or pass. It must be compelling, accurate, and efficient. ### Section 2: Investment Highlights A narrative section, typically 3–8 pages — that develops the most important reasons why this is an attractive acquisition. This is where the "story" of the business is told. Investment highlights for a home care agency commonly include: - **Market position and geographic footprint:** Why the business dominates or is well-positioned in its market - **Scalable growth platform:** Evidence that growth is possible and the infrastructure exists to support it - **Exceptional quality metrics:** Survey history, accreditation, quality star ratings, low complaint history - **Diversified payer mix:** Strong mix of Medicare, Medicaid, and/or private pay revenue with named managed care contracts - **Deep referral relationships:** Hospital, SNF, and physician partnerships with documented longevity - **Operational systems:** Technology infrastructure, billing capability, clinical documentation systems - **Experienced management team:** Biographies and tenure of key managers who will remain post-close ### Section 3: Business Overview A detailed description of the business covering: - History and founding narrative - Services offered (by service type and payer) - Geographic service area (counties or zip codes served, key markets) - Organizational structure (org chart) - Employee count and caregiver staffing model - Technology systems (scheduling, billing, EHR, telephony) - Physical locations (office facilities) - Accreditation and licensure status ### Section 4: Market Overview Analysis of the market in which the business operates: - Demographic trends in the service area (aging population, population growth) - Competitive landscape (who the competition is, how the agency is positioned relative to competitors) - Regulatory environment (state Medicaid waiver structure, licensure requirements, reimbursement trends) - Referral source landscape (hospital systems, SNFs, physician groups in the market) This section gives buyers, especially national buyers who may be unfamiliar with your specific market, the context to understand why your market is attractive and your position within it is defensible. ### Section 5: Financial Analysis This is typically the most important section for sophisticated buyers. It includes: **Income Statement Summary (3 Years + TTM):** - Revenue by payer type - Revenue by service type (if multiple) - Gross margin - Operating expenses (categorized) - EBITDA (reported) **Adjusted EBITDA Bridge:** The add-back schedule in detail, showing each add-back item, the dollar amount, and a brief description. This is the core of the financial presentation, it establishes the purchase price foundation. **Revenue Metrics:** - Client count (active and total) - Average revenue per client - Service hours or visits by period - Payer mix percentages - Case mix weight (for skilled agencies) **Working Capital Summary:** - Accounts receivable aging - Days Sales Outstanding (DSO) by payer - Accounts payable and accrued liabilities **Capital Expenditure History:** - Historical capex by category (vehicles, equipment, technology) - Ongoing maintenance capex requirements ### Section 6: Operations and Clinical Operational documentation varies significantly by business type but typically includes: - Caregiver hiring and training process - Scheduling model and overtime management - Clinical oversight structure (for skilled/clinical agencies) - Billing and collections process overview - Quality management and compliance program - Software and technology platform description ### Section 7: Growth Opportunities Forward-looking narrative about how the business could grow under new ownership. This section is important because buyers are purchasing future cash flows, not just historical performance. Common growth opportunities in home care CIMs: - Geographic expansion into adjacent counties or zip codes - Service line expansion (adding skilled care to a private pay platform, or vice versa) - Managed care contract additions - Caregiver recruitment expansion (for capacity-constrained businesses) - Technology investment opportunities - Acquisition of complementary businesses **Important:** Growth opportunities must be credible. Presenting outlandish growth projections damages seller credibility. The best growth narratives are grounded in demonstrated performance with specific, achievable expansion opportunities that buyers can evaluate. ### Section 8: Appendices Supporting materials including: - Detailed financial statements (full P&Ls by year) - Organizational chart with management biographies - License and accreditation summary - Location/facility summary - Selected managed care contract references (often unnamed at this stage) - Software technology vendor list --- ## What Makes a Home Care CIM Excellent vs. Average **Writing quality matters.** CIMs that read as professional, thoughtful documents — with proper grammar, clear narrative, and logical structure, convey that the seller and their advisor are serious and organized. CIMs that are poorly written or poorly formatted undermine confidence in the quality of the business. **Financial accuracy is non-negotiable.** Numbers in the CIM must be consistent and accurate. Inconsistencies between the CIM and underlying financial statements discovered in due diligence are a significant red flag for buyers and often result in re-trades or deals breaking. **Addressing weaknesses proactively.** Every business has weaknesses. A well-crafted CIM acknowledges significant issues directly and presents the context or mitigation. Buyers who discover undisclosed issues in due diligence become suspicious; buyers who find that disclosed issues were accurately represented gain confidence. **Appropriate length.** Professional CIMs for home care agencies are typically 40–80 pages, plus appendices. Too short (under 30 pages) and buyers don't have enough information to bid confidently. Too long (100+ pages of narrative) and buyers may not read it. **Visual presentation.** A professionally designed CIM with charts, graphs, clear typography, and consistent formatting presents the business better than a hastily assembled Word document. The visual presentation signals preparation and quality. --- ## The CIM as Seller Strategy The CIM is not simply a description of your business, it is a persuasive document designed to maximize competitive buyer interest. Experienced M&A advisors approach the CIM as a strategic document, understanding: - Which investment highlights are most compelling to each buyer category (PE add-on buyers vs. strategic operators value different things) - How to present the EBITDA normalization in a way that is both defensible and maximally favorable - Which growth opportunities are credible and relevant to the buyer pool - How to present risks transparently without making them appear larger than they are At Hendon Partners, our CIM preparation process involves: 1. Deep discovery of the business, management interviews, facility visits, financial review 2. Market research for the competitive and market context sections 3. Financial normalization and add-back analysis with documentation 4. Professional narrative writing by advisors with deep home care M&A experience 5. Professional design and formatting 6. Strategic review before distribution to buyer pool **[Learn about Hendon Partners' sale advisory process →](/contact-us)** --- *The CIM is the foundation of every successful home care sale process. Hendon Partners produces institutional-quality CIMs that present home care businesses in their best possible light to the most qualified buyers in the market.* --- ### The 5 Biggest Mistakes Home Care Owners Make When Selling URL: https://www.hendonpartners.com/insights/5-biggest-mistakes-home-care-owners-selling Published: 2026-02-10 09:00 Category: Seller Guides > After advising on 150+ home care M&A transactions, we've identified the same avoidable mistakes that cost owners millions of dollars at closing. Learn what they are — and how to avoid every one of them. After advising on over 150 home care agency transactions, the Hendon Partners team has seen the same patterns — the same avoidable mistakes, show up again and again. These aren't obscure edge cases. They are mistakes that cost real owners real money, and they happen in virtually every unrepresented sale. Here are the five biggest ones, and what to do instead. --- ## Mistake #1: Accepting the First (or Only) Offer The most expensive mistake you can make in selling your home care agency is negotiating with a single buyer. When only one buyer is at the table, the entire negotiating dynamic shifts in their favor. They know you haven't created competition. They know their offer is your only option. And they will use that leverage, either by presenting a low initial offer they can "raise" after you negotiate, or by discovering issues in due diligence that they use to justify a price reduction. **The economics are stark:** Our internal data shows that sellers who receive 3+ competitive offers consistently sell for 28–45% more than sellers who negotiated with a single buyer. **What to do instead:** Work with an advisor who has direct relationships with the full universe of qualified buyers for your agency type and geography. The job isn't to find *a* buyer, it's to find *all* the buyers and make them compete. --- ## Mistake #2: Selling Before Your Business Is Prepared The second most costly mistake is going to market before your business is ready — and by "ready," we mean financially documented, operationally clean, and positioned to withstand the scrutiny of an institutional buyer's due diligence process. The most common preparation gaps we see: - **Only 1–2 years of financial statements:** instead of the 3 years institutional buyers require - **No add-back analysis:** sellers leaving $200K–$500K in value on the table because legitimate owner compensation add-backs and one-time expenses were never identified - **Owner-dependent operations:** no clinical director, no documented processes, and a business that visibly stops when the owner leaves - **Unresolved compliance issues:** outstanding Medicaid audits, billing irregularities, or licensing gaps that kill deals in diligence **What to do instead:** Engage a specialist 12–18 months before you plan to sell. The pre-sale preparation phase is where most of the value is created. Sellers who work with Hendon through a 90-day pre-sale readiness process consistently achieve higher multiples than those who hire us 30 days before wanting to close. --- ## Mistake #3: Breaching Confidentiality Confidentiality is the cornerstone of any professional home care M&A process, and sellers who manage their own sale process routinely violate it, sometimes disastrously. We've seen owners tell their top caregiver supervisor they're thinking about selling. We've seen them mention it to a referral source contact. We've seen them post their business on public marketplaces where any competitor, employee, or client can discover it. The consequences: - **Key staff departures**: When employees suspect a sale, your best people start updating their resumes - **Referral source disruption**: Referring physicians and hospital discharge planners become uncertain about your agency's future and begin diversifying their referrals - **Reduced buyer confidence**: A buyer who learns that the sale has become "known" worries about employee retention and referral stability post-close **What to do instead:** All buyer outreach must be conducted under strict NDA, with teasers that identify your agency only by service line, geography, and financial metrics — never by name. Your employees and referral sources should not know the business is for sale until closing day (or after, if you prefer). --- ## Mistake #4: Optimizing for Price Alone The highest purchase price is not always the best deal. We've seen sellers choose the highest LOI, only to discover during diligence that the buyer's financing was uncertain, their due diligence team was disorganized, and the deal dragged on for nine months before eventually collapsing, forcing them to start over in a cooler market. The metrics that matter beyond headline price: - **Certainty of close**: Is this buyer proven? Have they closed comparable deals recently? - **Deal structure**: How much is cash at close vs. earnout vs. seller note? Earnouts introduce risk. - **Transition requirements**: Does the buyer require a 3-year employment contract? Are you comfortable with that? - **Cultural fit**: Will your employees, your clients, and your referral sources be well-treated under new ownership? - **Speed**: A slightly lower offer from a buyer who can close in 60 days is often worth more than a higher offer that takes 180 days with significant re-trade risk **What to do instead:** Evaluate every LOI on a total-value basis, not just headline price. A skilled advisor will help you compare offers across all relevant dimensions and select the path that maximizes your actual take-home value, not just the number on the term sheet. --- ## Mistake #5: Waiting Too Long (or Going Too Fast) The fifth mistake comes in two flavors that are equally costly. **Going too fast**: Sellers who begin marketing their business in response to immediate urgency, burnout, a health event, a financial crisis, often sell in suboptimal market conditions or without adequate preparation time. Buyers can sense urgency and will negotiate accordingly. **Waiting too long**: The owners who hold out for "just one more year" of EBITDA growth sometimes hit the sell decision as market conditions shift — interest rates rise, PE dry powder depletes, a regulatory change crimps valuations, or their own EBITDA declines due to operational fatigue. EBITDA multiple cycles are real, and the 2024–2026 window of premium valuations may not last indefinitely. **The optimal path**: Begin the conversation with a specialized advisor when you're 12–24 months from wanting to close. This gives you time to prepare properly, address weaknesses, and go to market at the moment of maximum readiness, not maximum urgency. --- ## The Bottom Line Every one of these mistakes is avoidable with the right preparation and the right representation. The difference between a seller who makes all five mistakes and a seller who avoids all five is often measured in hundreds of thousands, or millions, of dollars. If you're thinking about selling your home care agency in the next 1–3 years, **the right time to start the conversation is now**, not when you're ready to close, but when you have the time to do it right. **Book a free, confidential consultation with Neli Gertner →** to get your preliminary estimate and discuss your options. --- ### Home Care Agency Sale Confidentiality: How to Protect Your Business During the Process URL: https://www.hendonpartners.com/insights/home-care-agency-sale-confidentiality-guide Published: 2026-02-06 09:00 Category: Seller Guides > Confidentiality breaches during a home care agency sale can devastate the business you're trying to sell. Employees leave, referral sources redirect, and buyers lose confidence. Here is how to structure your sale process to protect confidentiality at every stage. The single greatest operational risk in a home care agency sale is premature disclosure. When employees find out their agency is for sale before the transaction is complete, the consequences are immediate and severe: key caregivers start seeking other placements, administrators update their résumés, and office staff become distracted and anxious. When referral sources — hospital discharge planners, physicians, or skilled nursing facilities, learn their agency partner is in transition, they may redirect referrals to competitors while the outcome is uncertain. When competitors find out, they may proactively poach your staff or pitch your clients. The paradox of home care M&A is that the very act of trying to sell your business can destroy the value of what you're selling, if not managed carefully. This guide explains how to structure your sale process to protect confidentiality, what the standard NDA process looks like, how to handle the inevitable moment when staff must be told, and how experienced M&A advisors protect their client sellers throughout the process. --- ## Why Confidentiality Is Especially Critical in Home Care Home care is a relationship-intensive business. Unlike an e-commerce business or a software company, where customer relationships are often contractual and less personal, home care depends on: - **Caregiver relationships:** Caregivers choose where they want to work. News that their agency "might be sold to a big company" creates uncertainty that prompts job searches, even if the reality of post-close changes is minimal. - **Referral source relationships:** Hospital discharge planners and social workers make daily decisions about which agencies to recommend to patients. Uncertainty about an agency's ownership or quality creates hesitation. - **Client and family relationships:** Private pay clients in particular may be concerned about ownership changes affecting their specific caregiver assignments or service quality. - **Payer relationships:** Medicaid and managed care contracts have ownership change notification requirements. Premature disclosure can trigger administrative complications. Because these relationships directly drive EBITDA, and EBITDA directly drives purchase price, protecting them during the sale process is not just an operational concern, it's a financial one. --- ## Phase 1: Before Marketing, Internal Confidentiality **Who should know about a potential sale?** When you first engage an M&A advisor and begin preparing for a sale, the circle of knowledge should be extremely limited, typically just the owner(s), and perhaps one trusted financial advisor or attorney who needs information to support the process. At this stage, your M&A advisor will typically need access to your financial statements, organizational charts, and operational data. This information is handled strictly within the advisory firm and not shared externally. **What about your key management team?** This is a judgment call that experienced advisors can help you navigate. There are two schools of thought: *Keep the inner circle tight until a deal is certain:* Prevent premature anxiety and ensure confidentiality. The risk: if management finds out from another channel (which sometimes happens), the trust damage is significant. *Read in key management selectively, early:* For agencies where one or two key managers are essential to the sale (their ongoing involvement is critical to buyer confidence, or they will need to participate in management presentations), reading them in early with strong confidentiality agreements can be appropriate. There is no universal right answer — your M&A advisor should help you assess who needs to know and when, based on your specific team dynamics. --- ## Phase 2: The NDA Process, Protecting Disclosure to Buyers The standard process for protecting information shared with potential buyers involves a carefully structured Non-Disclosure Agreement (NDA). **The teaser and blind profile stage** The first materials sent to potential buyers are deliberately non-identifying. A "teaser" or "blind profile" describes your agency's size, service type, geography at a county or metro level (not city), payer mix, and financial metrics, without revealing the agency's name, specific location, brand, or any identifying details. Buyers must express interest and sign an NDA before receiving any identifying information. **Key NDA provisions for home care sales** A home care-specific NDA should include: - **Confidentiality obligation:** The buyer may not share the information with anyone outside their investment committee and designated advisors. - **No-contact provision:** The buyer may not contact your employees, clients, referral sources, or contractors without your express written permission. This is essential, you want all buyer contact flowing through you or your advisor. - **Return/destruction of information:** Upon termination of discussions, buyers must return or certify destruction of all materials. - **No-hire/no-solicitation:** During the NDA period and for a specified period after (often 12–24 months), the buyer may not hire any of your employees they learned of through the process. - **Standstill period:** Some NDAs include a brief period during which the buyer may not acquire a competing agency in your market or approach your clients directly. - **Injunctive relief clause:** Specifies that damages alone are insufficient remedy for breach and injunctive relief is available, strengthening enforcement ability. **Practical tip:** NDA enforcement in M&A practice is rare but real. Most PE firms and strategic buyers in the home care market take NDA obligations seriously, partly because reputation risk in a networked industry is significant. However, having a well-drafted NDA gives you meaningful protection and recourse if a buyer violates it. --- ## Phase 3: The CIM and Data Room. Controlled Information Sharing Once a buyer signs the NDA and receives the Confidential Information Memorandum (CIM), they have access to detailed financial, operational, and organizational information — but still through a controlled process. **Virtual data room management** Professional M&A advisors use virtual data room (VDR) technology (platforms like Firmex, Intralinks, or Datasite) to share confidential documents with qualified buyers. The VDR offers: - **Access controls:** Each document is permission-level controlled. Buyers see only what they are authorized to see. - **Watermarking:** Documents shared in the data room carry identifying watermarks (often containing the buyer's name or NDA date), allowing tracing of any documents that are leaked. - **Activity tracking:** The data room records every download and document view, creating an audit trail of buyer activity. - **Revocation capability:** Access can be instantly revoked if a buyer drops out of the process or violates confidentiality. **What to include, and what to withhold** Not all buyer requests should be fulfilled at every stage. As a general principle: - **Early stage (teaser/LOI phase):** Share financial summaries and high-level operational information only. - **Post-LOI (full due diligence phase):** Share detailed financials, contracts, licensing documents, compliance records, and operational data. - **Never share:** Individual client personal information, individual employee SSNs or protected personal data, or information that would serve a competitor's business interests rather than the legitimate due diligence needs of a serious buyer. Work with your M&A advisor to define a disclosure schedule that balances buyer due diligence needs against your operational protection interests. --- ## Phase 4: Management Presentations. The First Live Disclosure Risk Management presentations, usually held after the LOI stage or late in the process for a select group of serious buyers, represent the moment when your key managers may need to be told about the transaction for the first time. **Reading in your management team** If management presentations require the participation of your Administrator, Director of Nursing, or other senior staff, those individuals will need to be read in before the meetings. Best practices: 1. Have a private, direct conversation with each team member before they learn from any other channel. 2. Explain the process, timeline, and what it means for them. 3. Present this as a positive event (which it often is, acquisitions by well-resourced platforms often bring investment, leadership opportunity, and stability that ownership transition creates). 4. Have them sign a confidentiality acknowledgment regarding the ongoing sale process. 5. Be prepared for their questions about job security, compensation, and role changes. **Manage the emotional dimension.** Key staff members who are told about a sale may have genuine concerns about their future. How you handle this conversation, the honesty, care, and respect you demonstrate — directly affects whether they stay engaged and professional through the process. --- ## Phase 5: Between LOI and Close. The Most Dangerous Window The period between a signed LOI and final closing is typically 60–120 days. It is the most prolonged period during which the transaction is active, and therefore the longest window of confidentiality risk. During this phase: - Due diligence is active (third-party QoE analysts, legal, clinical) - Document requests are flowing - Your team may have been partially read in **Maintaining operational normalcy** is the most important discipline during this period. Sellers who change operational behavior, slowing hiring, cutting marketing, deferring decisions, create visible signals that something is happening, which can cascade into rumors. Continue to run the business as if there is no transaction. Continue hiring, managing, developing referral relationships, and investing appropriately. --- ## Communicating With Staff and Referral Sources at Close When the transaction closes, you will need to communicate the ownership change to: - All employees - Clients/families - Referral sources - Payers (as contractually or regulatorily required) **Best practice:** Prepare communication materials with your advisor and the buyer before closing. Many transactions include a joint announcement strategy, a letter from both the outgoing and incoming ownership expressing confidence in the transition and reassuring clients and referral partners of continuity. Timing is critical: announcements should go out as close to closing as possible to prevent leaks from the inevitable spread of information once more people are involved. --- ## How an Experienced M&A Advisor Protects Confidentiality Working with a specialized M&A advisor rather than running a sale process yourself provides significant structural confidentiality advantages: - **Advisor as buffer:** All buyer inquiries flow through the advisor, your name does not appear on teaser documents until NDAs are signed. - **NDA management:** Your advisor manages NDA execution with all potential buyers (which may number 30–50 in a competitive process) and ensures no information is shared pre-NDA. - **Controlled process:** A formal competitive process, properly structured, actually provides more confidentiality than an unstructured direct approach to a single buyer. When one buyer already knows, the incentive to maintain confidentiality is lower; in a managed multi-buyer process, the competitive dynamic reinforces confidentiality. - **No-contact enforcement:** Your advisor enforces the NDA no-contact provision, preventing buyers from approaching your staff or referral sources independently. **[Discuss a confidential sale process with Hendon Partners →](/contact-us)** --- *At Hendon Partners, confidentiality management is central to how we run every home care sale process. We use institutional data room technology, carefully drafted NDAs, and a process structure specifically designed to protect our clients' businesses from the risks of premature disclosure.* --- ### Home Care Business EBITDA Multiples: 2026 Benchmark Report URL: https://www.hendonpartners.com/insights/home-care-ebitda-multiples-2026-benchmark-report Published: 2026-02-01 09:00 Category: Market Reports > What EBITDA multiples are home care, home health, and hospice businesses trading at in 2026? Benchmark data from 150+ closed transactions, broken down by service line, deal size, and geography. Every quarter, we compile transaction data from our active deal flow, third-party M&A research firms, and published industry reports to produce what has become the most widely referenced benchmark dataset in the home care M&A advisory market. This 2026 benchmark report covers EBITDA multiple ranges by service line, the buyer categories commanding the highest valuations, and the specific factors driving premium outcomes in today's market. --- ## Executive Summary **2026 is the strongest seller's market in home care M&A history.** The confluence of three dynamics — peak PE capital deployment, demographic tailwinds creating irreversible demand, and post-COVID operational consolidation, has pushed EBITDA multiples to cycle highs across all home care subsectors. Key data points: - Average home care EBITDA multiple reached **6.2×** in 2024, up from 4.8× in 2021 (Scope Research) - Top-quartile home health and hospice agencies are routinely achieving **8–10× EBITDA** - PE-backed platforms now represent **62%** of buyer-side transactions, up from 41% in 2020 - Median time to close for represented sellers: **87 days** (vs. 6–12 months for unrepresented) --- ## Multiple Benchmarks by Segment ### Non-Medical Personal Care **Multiple Range: 2.0× – 4.5× EBITDA** Non-medical personal care, homemaker, companion, and personal assistance services — remains the largest volume segment in home care M&A but trades at the lowest multiples due to its Medicaid-heavy payer mix and lower margin profile. Premium outcomes (3.5–4.5×) are achievable for agencies with: - Strong private-pay or managed care mix (30%+ non-Medicaid revenue) - Caregiver retention above 75% - Formal management structure - Multiple geographies or a territory expansion story for the buyer ### Medicare-Certified Home Health **Multiple Range: 3.5× – 7.0× EBITDA** Medicare home health agencies continue to attract significant PE and strategic buyer interest. Medicare reimbursement is federal, relatively predictable, and highly strategically valuable to health systems and payers building integrated home-based care models. The move to PDGM (Patient-Driven Groupings Model) reimbursement has separated operationally sophisticated agencies from weaker operators, driving a flight to quality in buyer preferences. Premium outcomes (5.5–7.0×) are achievable for agencies with: - Strong OASIS scores and star ratings (quality of care indicators) - 10+ year operational history - Geographic coverage in high-demand markets - Multiple Medicare specialty programs (wound care, cardiac, etc.) - Strong physician and hospital referral relationships ### Hospice **Multiple Range: 5.0× – 9.0× EBITDA** Hospice commands the highest multiples in home care M&A due to its per-diem Medicare reimbursement structure, among the highest EBITDA margins in healthcare (20–35%), and the relative stability of its revenue base. PE and health system interest in hospice has accelerated dramatically, hospice assets representing the most competitive bidding environment in the entire home care sector. Premium outcomes (7.0–9.0×) are achievable for agencies with: - 80%+ Medicare hospice revenue - ADC (Average Daily Census) above 100 - Clean PEPPER reports and no outstanding CMS audits - GIP (General Inpatient) and Residential capabilities - Strong physician relationships and referral network ### Multi-Service Platforms **Multiple Range: 6.0× – 10×+ EBITDA** Multi-service platforms, agencies offering two or more service lines, typically at $3M+ EBITDA, command the highest absolute multiples in the market. Buyers pay a "platform premium" because multi-service agencies represent turnkey geographic market entry, diversified revenue streams, and a built-in management infrastructure. For PE platforms executing a buy-and-build strategy, acquiring a quality multi-service platform can accelerate their regional consolidation thesis by 2–3 years. This scarcity premium pushes multiples above 8× for the strongest assets. --- ## Who's Buying and What They're Paying Understanding the buyer landscape is essential for sellers and their advisors to build the right competitive process. ### Private Equity Platforms (Pay: 5–10×) 80+ PE-backed home care platforms are actively acquiring. Key characteristics: - Move quickly when quality assets are presented - Have committed capital ready to deploy - Pay premium prices for assets that fit their geographic or service-line thesis - Aggressive on price when competing with other PE buyers - Require clean financials, operational controls, and management continuity ### Regional Strategic Operators (Pay: 4–7×) 200+ regional home care companies seek geographic expansion. Key characteristics: - Faster, less complex diligence than PE - Strong cultural fit with sellers (both operational companies) - Often willing to retain existing management and brand - Less aggressive on price in direct negotiations, but competitive in a structured process ### National Consolidators / Health Systems (Pay: 6–10×) Humana, Optum/UnitedHealth, CVS/Aetna, and large health systems are building integrated home-based care platforms. Key characteristics: - Highest absolute prices for scale assets ($10M+ revenue) - Complex procurement process and longer timeline - Require Medicare certification, quality metrics, and geographic scale - Often pay above market for strategic fit (e.g., a geography they need to complete their coverage map) --- ## What's Driving the Premium Environment Three structural forces explain why 2026 multiples are at cycle highs: **1. PE Capital Deployment Pressure** Private equity firms raised a record $1.2T+ in dry powder in 2023–2024. Fund managers with committed capital on 10-year fund timelines face pressure to deploy — and home care represents one of the most attractive healthcare services subsectors for risk-adjusted returns. **2. Demographic Tailwinds** By 2030, all 73 million Baby Boomers will be over 65. Adults over 85, the heaviest users of home care services, will represent 6% of the U.S. population by 2040 (U.S. Census Bureau). This demographic wave is non-cyclical, largely non-discretionary, and creates a 15–20 year structural demand tailwind that buyers are pricing into their acquisition thesis. **3. Supply-Side Consolidation** The home care sector is still highly fragmented — 80%+ of agencies have annual revenue below $3M. As operational complexity increases (workforce regulations, technology requirements, payer contracting), independent operators face growing pressure, increasing both the supply of sellers and the strategic premium buyers place on quality assets. --- ## The Window Won't Stay Open Forever Market cycles are real. Interest rates, PE fund deployment phases, and regulatory shifts all influence home care M&A valuations. The current multiple expansion has been extraordinary, and while structural factors suggest a sustained strong market, the 2024–2026 window of maximum competition and maximum multiples will not persist indefinitely. Owners who go to market in 2026, positioned correctly, with the right representation, into a competitive buyer process, are capturing exits they couldn't have achieved two years ago. Book a confidential call with Neli Gertner to discuss your timing, your goals, and your options. --- ### Should I Sell My Home Care Agency Now or Wait? A Framework for Deciding URL: https://www.hendonpartners.com/insights/should-i-sell-my-home-care-agency-now-or-wait Published: 2026-01-30 09:00 Category: Seller Guides > The single most common question home care agency owners ask before a sale. The answer depends on three factors: market timing, your personal situation, and the readiness of your business. Here is how to think through all three. "Should I sell now or wait?" Every home care agency owner who contacts us at some point asks this question. It is, frankly, one of the hardest questions in the M&A process — because the right answer is different for every seller, and it requires thinking through a set of factors that are genuinely complex. This article does not give you a simple "sell now" or "sell later" answer. It gives you a framework for thinking through the three critical dimensions: **market timing**, **personal situation**, and **business readiness**. Work through all three honestly, and you will have a clearer picture of what the right decision is for you. --- ## Dimension 1: Market Timing The macroeconomic and industry environment affects your sale price in real and significant ways. Understanding the current market context matters. ### The Long-Term Tailwind Is Structural No matter when you sell, you are operating in a market with long-term structural tailwinds. The 65+ population in the United States is projected to grow from approximately 58 million today to over 80 million by 2040. Home-based care is the fastest-growing segment of healthcare delivery. Private equity and strategic consolidators see this demographic reality, it is one of the primary reasons home care M&A has been so active for the past decade. This does not mean you can wait indefinitely, but it does mean you are not operating against a ticking clock in the industry fundamentals sense. The demand for home care agencies (as acquisition targets) is not going to disappear. ### What Affects Near-Term Multiples Several factors can compress or expand the multiples buyers pay in any given 12-month window: **Interest rates:** Higher interest rates increase the cost of the debt PE firms use to finance acquisitions, which compresses EBITDA multiples. When rates are elevated, buyers may offer modestly lower multiples than in a low-rate environment. This was a factor in 2023–2024, though the home care market proved more resilient than many other sectors. **PE fund activity:** When a large home care PE platform is in active acquisition mode near a planned exit, competition for quality agencies increases and multiples can spike. Conversely, when platforms are in integration mode (digesting recent acquisitions), buyer activity slows. **Regulatory environment:** Medicaid rate changes, CMS Conditions of Participation updates, or Medicare reimbursement reductions can shift buyer appetite. A state that announces a major Medicaid rate cut may see a temporary pause in buyer activity. **Strategic buyer consolidation pace:** Major national operators' appetite for acquisitions cycles. When they are concentrated on integration, acquisition pace slows; when they are growth-focused, they are aggressive competitors for quality agencies. **The honest assessment for 2026:** The M&A market for quality home care agencies remains active. Multiples have stabilized after the modest compression of 2022–2023 and are in a healthy range. PE activity is robust across private pay, skilled, and specialty care. There is no strong indication that waiting another year will dramatically improve multiples, but the fundamentals also don't suggest a rush. ### Timing the Market Is Largely a Myth The most important point about market timing: trying to time the M&A market precisely is largely futile. You cannot know whether multiples will be 5.5× or 6.5× in 18 months versus today. What you can control is: - The quality of the business you present to buyers - The thoroughness of your preparation - The quality of your M&A process These factors, which you control, have a greater impact on your outcome than market timing factors you cannot control. --- ## Dimension 2: Personal Situation This is often the most decisive dimension — and the one sellers are sometimes reluctant to think about directly. ### Energy and Motivation Running a home care agency is demanding. If you find yourself increasingly disengaged, frustrated, or burned out, the financial cost of delaying is real. A seller who is emotionally done can see EBITDA erode as they take their foot off the gas, which directly reduces their sale price. Ask yourself honestly: Am I still running this business at the same level I was 3 years ago? If the answer is no, and the gap is widening, then waiting may be costlier than selling at a slightly lower multiple but earlier. ### Health Factors Unfortunately, health events are a common trigger for rushed, unplanned transactions. Some of the most difficult situations we see involve an owner who had been "planning to sell in a couple of years" for 10 years, and then a health event forces a sale under time pressure, which dramatically weakens negotiating leverage and frequently results in a below-market outcome. If health is a consideration, selling proactively from a position of strength is almost always better than selling reactively from a position of need. ### Succession Planning Do you have a family member or management team member who wants to succeed you? Family transitions and management buyouts are legitimate alternatives to external sales, but they have their own complexity and typically produce less liquidity than an external transaction. If succession is not a realistic option, then an external sale is the path. The question becomes when, and the longer you wait, the more you need for the business performance to remain strong throughout the delay. ### Personal Financial Picture The sale of a home care agency is often the single largest financial event in an owner's life. Understanding your personal financial situation. How much net liquidity do you need from this transaction? How are you managing the tax consequences? What does your retirement plan look like post-sale? — is essential context for the timing decision. Working with a wealth advisor and tax attorney before entering a sale process is strongly recommended. They can help you model what a sale at different price points and timings means for your personal financial outcome. --- ## Dimension 3: Business Readiness Even if market conditions are favorable and your personal situation calls for a sale, your business may not yet be in a position to command the best price. This dimension is fully within your control, which makes it the most actionable of the three. ### Growth Trajectory The most important financial factor buyers consider is **trajectory**. Is the business growing or declining? - **Growing 15%+ annually:** Excellent. Buyers are paying for future earnings, and a strong growth rate commands a significant premium. - **Growing 5–15% annually:** Good. Consistent growth is valued even if modest. - **Flat:** Acceptable at the right price, but harder to justify premium multiples. - **Declining:** Difficult. Declining revenue or EBITDA triggers heavy buyer skepticism and multiple compression. If your business has had a down year, waiting to demonstrate recovery is almost always worth the delay. If your business had a rough year due to an identifiable and resolved issue (key staff departure, referral source disruption, COVID impact), waiting 12 months to show restabilized performance can recover a full multiple turn, potentially worth hundreds of thousands or millions in purchase price. ### Owner Dependency How dependent is your business on you personally? If all the key referral relationships, clinical oversight, and strategic direction flow exclusively through you, buyers will price that risk into the multiple, or require a long, actively managed earnout. Building management depth, even 12 months before a sale, can meaningfully increase value. If you can install an Administrator or Agency Director who runs day-to-day operations with minimal involvement from you, your business is worth more and more attractive to buyers. ### Compliance and Documentation Compliance issues, open regulatory matters, or undocumented processes create due diligence risk that buyers translate into either price reductions or deal uncertainty. If you have compliance issues that could be addressed with 6–12 months of focused work: - Open Plans of Correction from state surveys - Medicaid billing audit concerns - Licensing issues - Employee classification or wage/hour exposure ...it is almost always worth resolving them before going to market. Disclosed and unresolved issues reduce purchase price. Undisclosed issues discovered post-close become indemnification claims. ### Financial Records Buyers expect 3 years of clean financials (tax returns, P&Ls, balance sheets, general ledger). If your financial records are not well-organized, or if you have commingled personal and business expenses for years, the cleanup work itself may take 3–6 months and the resulting EBITDA normalization analysis will be more complex. --- ## Decision Framework: Where Do You Stand? Work through these questions honestly: **Market timing:** - Are multiples at a reasonable level for your size and service type? (For most agencies: Yes, in 2026) - Is there a specific near-term catalyst that would improve multiples significantly? (Rare and unpredictable) - Is there a near-term risk that could compress multiples in your geography? (Medicaid rate changes, regulatory shifts) **Personal situation:** - Do you have the energy and motivation to run the business at full effort for another 2+ years? - Are there health, family, or personal factors that argue for a sooner timeline? - Do you have a clear picture of your personal financial needs from this transaction? **Business readiness:** - Is the business growing or flat/declining? - Is business performance dependent primarily on you, or on a team? - Are there unresolved compliance or regulatory issues? - Are your financial records clean and well-organized? **If** the market is reasonable, your personal situation calls for a sale, and the business is in good shape → move forward with the process now. **If** market conditions are acceptable but the business has declining performance → invest 12 months stabilizing and growing, then sell from a position of performance. **If** there are significant compliance or documentation issues → invest 6–12 months resolving them, then proceed. **If** everything is ready but your personal situation is not yet → build a more detailed transition plan, but don't indefinitely delay — the "right time" often never arrives. --- ## The Cost of Waiting One of the most underappreciated risks in M&A timing is what business owners call "owner fatigue tax", the gradual erosion in business performance as an owner who is emotionally transitioning mentally checks out while still nominally running the business. This is not a moral failing, it's a natural human response to being ready to move on but not having moved on. The financial consequence is real: a business that could have sold at $4.5M at peak performance may sell at $3.5M after 18 months of flat-to-declining EBITDA from reduced owner engagement. **The lesson:** when you know you want to sell, run the process, don't wait for a perfect moment that may never come. --- ## The Role of a Confidential Consultation Often, the most valuable first step is a confidential conversation with an experienced M&A advisor, not to start a sale process, but to get an honest, informed assessment of where you stand on all three dimensions. At Hendon Partners, we regularly have confidential preliminary consultations with owners who are somewhere on the 1–5 year planning horizon. These conversations are free and without obligation. We can give you an honest perspective on what the current market looks like for your business type, what your business is likely worth today, and what steps would improve your outcome. **[Schedule a confidential consultation →](/contact-us)** --- *Hendon Partners advises home care agency owners across all stages of exit planning, from early-stage conversations to active sale processes. Our advisors help you think through timing, preparation, and strategy before you need to make a final decision.* --- ### Private Equity Roll-Up Strategy in Home Care: What It Means for Sellers URL: https://www.hendonpartners.com/insights/private-equity-roll-up-home-care-what-sellers-need-to-know Published: 2026-01-23 09:00 Category: Market Intelligence > Private equity firms are consolidating home care agencies across the country through a 'platform and add-on' roll-up strategy. Understanding how this works — and why it creates compelling acquisition opportunities for smaller agencies — could be the most important market knowledge a seller has. The home care industry is in the middle of an unprecedented consolidation wave. Private equity firms have identified home-based care as one of the most attractive healthcare services investment opportunities of the decade — driven by aging demographics, the preference of older adults to remain at home, and the shift of payers toward lower-cost home-based care models. The vehicle driving most of this consolidation is the **platform-and-add-on roll-up strategy**. If you own a home care agency and are thinking about selling, understanding this strategy, why PE firms use it, how it creates value, and what it means for your sale price, is essential context. This article explains the PE roll-up strategy in plain terms, and specifically how it affects sellers at every size. --- ## The Platform-and-Add-On Architecture Private equity firms don't typically build home care businesses from scratch. Instead, they identify an existing business to serve as the "platform", usually a larger, well-managed agency with $2M+ in EBITDA, and then systematically acquire smaller agencies ("add-ons") to bolt onto that platform. **Why a platform?** The platform provides the infrastructure that private equity wants before beginning roll-up acquisitions: - Professional management team (often a CEO, COO, CFO hired by PE) - Back-office systems (billing, HR, payroll, EHR technology) - Compliance infrastructure - Geographic footprint as an expansion base - Capital access (the PE-backed platform can access acquisition capital) Once the platform is established, the firm may execute 3–10+ add-on acquisitions over a 3–7 year hold period, building scale and geographic coverage before exiting via a larger PE fund or strategic buyer. --- ## The Multiple Arbitrage Opportunity. Why PE Loves Add-On Acquisitions Here is the core financial logic that makes the roll-up strategy powerful: **Small agencies trade at a discount.** A home care agency with $400,000 in Adjusted EBITDA might sell at 4×, an $1.6M enterprise value. **Large platforms trade at a premium.** A home care platform with $10M in combined EBITDA might be valued at 8× — an $80M enterprise value. When the PE-backed platform acquires the $400K EBITDA agency at 4×, they are paying $1.6M for an earnings stream that, once integrated into the platform, is valued at 8×. That same $400K in EBITDA, now at platform multiple, is worth $3.2M. The $1.6M difference is "multiple arbitrage", paper value created simply by combining the smaller business's earnings into the larger entity. Across 10 add-on acquisitions, this arbitrage becomes the primary return driver for the PE fund. **This is why PE-backed platforms actively want to acquire agencies at your size, even under $1M in EBITDA.** They are not evaluating your business as a standalone investment; they are evaluating its contribution to the platform's combined value. --- ## What This Means If You Own a Smaller Agency If you own an agency with $300K–$1.5M in EBITDA, you might assume that PE buyers are not interested in you, that your business is too small to matter to a large PE firm. This is a misunderstanding of how PE roll-up strategies work. Platform companies actively seek add-on acquisitions in your size range. A well-run $500K EBITDA agency in a market the platform wants to enter is highly attractive. The keys they're looking for: **Geographic fit:** Does your agency cover a market or county that the platform wants to expand into? If you're operating in a geography the platform considers a priority expansion target, you have leverage, you're not competing as one of many; you may be one of the few quality options available. **Operational quality:** Does your agency run cleanly? Strong compliance history, low caregiver turnover, quality documentation, and a reputation in the local market are all meaningful. **Revenue synergies:** Can the platform leverage its existing payer contracts, clinical programs, or technology infrastructure to grow your agency's revenue? The larger the synergy, the more the platform may pay for you. **Management continuity:** If you're willing to stay on post-close in a leadership role, some platforms place higher value on continuity — particularly for outbound-focused roles like business development or community relations that rely on personal relationships. --- ## The Lifecycle of a PE Roll-Up: What Stage Is the Platform In? When you receive interest from a PE-backed platform buyer, it's worth understanding where they are in their investment lifecycle, because it determines how they will think about your acquisition. **Early stage (Year 0–2 of the fund):** The PE firm just closed the platform acquisition. They are aggressively seeking add-ons to build critical mass. They may be more flexible on price and structure to close acquisitions quickly and establish momentum. **Mid-stage (Year 2–4):** The platform has scaled. They are more selective about add-ons, they have built systems and culture, and a bad acquisition is more disruptive. They may be more focused on geographic adjacency and operational quality. **Late stage / pre-exit (Year 4–6):** The PE firm is preparing for exit. They may still want add-ons to boost the EBITDA number before the exit process, but timeline pressure exists. Pricing can be aggressive if the addition improves the exit story. Understanding stage matters: an early-stage platform in your geography is often a better buyer, more motivated, more flexible, than a late-stage platform that's evaluating you against their exit timeline. --- ## How PE-Backed Platforms Evaluate Acquisitions Differently Than Strategics **Strategic buyers** (large home care chains, health systems) evaluate acquisitions on operational and financial standalone metrics: they want to know how your business will perform in their system. **PE-backed platforms** evaluate acquisitions with a roll-up lens: 1. **EBITDA contribution to the combined platform** (not just standalone EBITDA) 2. **Geographic coverage map**, does this fill a territory gap? 3. **Integration complexity**, can we convert this agency's operations to our systems quickly? 4. **Management retention** — can we retain the key operators to manage local operations post-close? 5. **Cultural fit**, will the staff and management integrate well? 6. **Synergy realization timeline**, how quickly can we realize back-office efficiencies? This different evaluation lens means that some aspects of your business that matter most to a strategic are less relevant to PE (e.g., revenue size as a standalone business) while other factors PE weighs heavily that strategics don't (e.g., integration speed, cultural fit with the platform). --- ## Typical Transaction Structures in PE Add-On Acquisitions When a PE-backed platform acquires an add-on, the transaction structure typically includes: **Cash at close:** A large majority of the consideration paid on the closing date, typically 70–90% of the total consideration. **Rollover equity:** PE firms frequently ask sellers to "roll" a portion of their proceeds (often 10–25%) into equity in the acquiring platform rather than receiving full cash. This aligns the seller's interest with the platform's success and rewards sellers if the platform achieves a successful exit at a high multiple. Rollover equity can be extremely valuable, or worthless if the exit goes poorly. **Earnout component:** Sometimes used to bridge valuation gaps, particularly when the seller's business has experienced recent growth that the buyer isn't fully willing to pay for upfront. The earnout pays additional consideration if specified financial milestones are met over 1–3 years post-close. **Escrow/holdback:** A portion of the consideration (often 5–15%) held in escrow for 12–18 months to cover potential indemnification claims. --- ## How to Position Your Agency for a PE Add-On Sale If you believe a PE-backed platform is your most likely buyer: 1. **Know the platforms operating in your geography.** Your M&A advisor should be able to map the PE-backed platforms operating in your state and their acquisition agendas. 2. **Understand their platform thesis.** Some PE platforms are focused on geographic density in specific regions; others are service-line specific (skilled only, private pay only, etc.). Buyers whose thesis aligns with your agency profile are your best buyers. 3. **Prepare for cultural integration.** PE buyers want to understand your team, your values, and your operational approach. Demonstrating a culture that can integrate smoothly into a larger platform is a positive signal. 4. **Consider the rollover equity carefully.** Rolling equity is not always the right choice, it depends on the platform's quality, the fund's stage, and your personal financial goals. Your M&A advisor and tax counsel should help you evaluate this. 5. **Don't negotiate alone.** PE firms and their counsel are sophisticated. Having an experienced M&A advisor who has worked with PE buyers gives you the experience and leverage to negotiate on equal footing. --- ## The Current Landscape (2026) Home care consolidation continues at an elevated pace in 2026. PE-backed platforms are active across: - **Private pay non-skilled:** National and regional roll-ups remaining active despite higher interest rates - **Medicare-skilled home health:** Geographic density plays, with strong appetite in growing Sun Belt and Mountain West markets - **HCBS/Medicaid waiver:** Increased PE interest as CMS advances managed LTSS and value-based care models - **Private duty nursing:** Premium multiples reflecting clinical complexity and shortage economics - **Hospice:** Still commanding among the highest multiples in the market If you are considering a sale in 2026 or 2027, the PE roll-up market is likely to remain your most active buyer pool, and understanding the strategy these buyers pursue is critical to positioning your business for the right outcome. **[Connect with Hendon Partners about your PE sale options →](/contact-us)** --- *Hendon Partners has deep relationships with the PE-backed platform buyers most active in home care consolidation nationwide. We advise sellers on how to understand, position for, and negotiate with platform buyers to maximize sale proceeds and post-close outcomes.* --- ### What Is My Home Care Agency Worth? A Complete Valuation Guide URL: https://www.hendonpartners.com/insights/what-is-my-home-care-agency-worth-valuation-guide Published: 2026-01-22 09:00 Category: Valuation Insights > Home care agency valuations range from 2× to 10× EBITDA depending on service line, payer mix, and operational quality. This guide explains exactly how buyers value your business — and what moves your multiple higher. One of the most common questions we receive from home care agency owners is simple: *"What is my business worth?"* The answer is more nuanced than most owners expect — and often significantly more than they assume. In 2026's market, quality home care agencies are trading at the highest EBITDA multiples in the sector's history. But the range is wide, and understanding where your business falls within it is the foundation of any intelligent exit strategy. This guide explains the valuation methodology buyers use, the factors that move your multiple up or down, and what you can do right now to position your agency for a premium outcome. --- ## How Home Care Agencies Are Valued The vast majority of home care agency transactions are priced using an **EBITDA multiple methodology**. **EBITDA** = Earnings Before Interest, Taxes, Depreciation, and Amortization This is your true operating profit, what the business earns after paying all operating expenses, but before financing costs, taxes, and non-cash items. EBITDA is the most commonly used measure because it approximates the cash flow a new owner would receive from the business. Your **valuation** = EBITDA × Market Multiple For example, an agency with $1.2M in EBITDA selling at a 5.5× multiple would have an enterprise value of **$6.6M**. --- ## Current Market Multiples by Agency Type (2026) | Agency Type | Multiple Range | Typical Buyer | |---|---|---| | Non-Medical / Personal Care | 2.0 – 4.5× EBITDA | Regional operators, PE platforms | | Medical Home Health (Medicare-Certified) | 3.5 – 7.0× EBITDA | PE, national consolidators | | Hospice | 5.0 – 9.0× EBITDA | PE, regional platforms | | Multi-Service Platform ($3M+ EBITDA) | 6.0 – 10×+ EBITDA | Top-tier PE, health systems | *Source: Scope Research 2025, BizBuySell 2024, Irving Levin Associates 2024* --- ## What Drives Your Multiple Higher (or Lower) The multiple you receive within the range depends on approximately a dozen key variables. Here are the ones that matter most: ### Factors That Drive Premium Multiples **1. Medicare/Medicaid Revenue Mix** Medicare-certified home health agencies command significantly higher multiples than pure private-pay or Medicaid-only agencies. Medicare reimbursement is federal, predictable, and highly attractive to institutional buyers. Medicaid is state-specific and subject to rate compression risk, buyers discount for it. **2. Owner Independence** An agency that runs without you — because you have a clinical director, operations manager, and documented processes, is worth dramatically more than one that stops when you go on vacation. Buyers pay premium multiples for businesses that can be transitioned smoothly. An owner-dependent agency frequently sells for 1–2× EBITDA less than an equivalent independent operation. **3. Caregiver Retention** The home care industry's #1 operational challenge is caregiver turnover. Agencies with 70%+ annual caregiver retention rate are perceived as lower-risk and more operationally stable. Buyers systematically discount agencies with chronic turnover problems. **4. Revenue Concentration** If any single client, referral source, or payer contract represents more than 20% of your revenue, buyers will apply a discount to reflect the concentration risk. Ideally, no single revenue source exceeds 10–15% of total revenue. **5. Financial Documentation** Three years of clean, accountant-prepared financial statements, ideally reviewed or audited — significantly increase buyer confidence and reduce their perceived risk. Agencies with well-organized financials consistently close faster and at better prices. **6. Geographic Market** Some markets are more attractive to buyers than others based on regulatory environment, Medicaid reimbursement rates, population demographics, and competitive dynamics. High-demand states (Florida, Texas, California, Ohio) typically command higher multiples than saturated or low-reimbursement markets. **7. EBITDA Growth Trend** A business with 15%+ year-over-year EBITDA growth tells a completely different story than one with flat or declining margins. Buyers pay for trajectory, not just size. --- ## EBITDA Add-Backs: What to Include One of the most important, and most misunderstood, aspects of home care agency valuation is EBITDA normalization, specifically the calculation of legitimate add-backs. **Add-backs** are one-time or above-market expenses that reduce your reported EBITDA but would not be incurred by a new owner. Common examples include: - **Owner compensation above market rate**: If you pay yourself $300K as owner-operator but the market salary for a professional manager of your agency is $120K, the $180K difference is an add-back. - **Personal expenses run through the business**: Vehicle costs, health insurance for family members, and similar personal charges that appear as business expenses. - **One-time costs**: Legal fees from a one-time dispute, storm damage remediation, or system migration costs that won't recur. - **Non-operating income**: Revenue from assets or activities unrelated to core home care operations. Properly identifying and documenting add-backs can increase your adjusted EBITDA — and therefore your enterprise value, by 15–30% compared to your raw reported earnings. **Important**: Add-backs must be defensible and well-documented. Buyers scrutinize them carefully in due diligence. Poorly documented or aggressive add-backs create negotiation friction and can re-trade your valuation. --- ## Revenue-Based vs. EBITDA-Based Valuation While EBITDA multiples are the dominant methodology, some agency types, particularly high-growth, early-stage, or operating-loss companies, may be valued on a **revenue multiple** instead. Revenue multiples in home care typically range from 0.3× to 1.2× annual revenue, with higher multiples for Medicare-certified and hospice businesses with strong growth profiles. In general, if your EBITDA margin is above 10%, an EBITDA-based valuation will produce a higher number. If your margins are below 8%, a revenue-based approach may be more favorable. A skilled advisor will present both methodologies and use whichever produces the strongest case to buyers. --- ## How to Move Your Number Higher If your current valuation estimate isn't where you want it to be, there is almost always a path forward. The most impactful improvements are: ### 12 Months Before Going to Market - **Reduce owner dependency**: Hire or promote a clinical director or administrator who can run the agency independently - **Clean up your financials**: Work with your accountant to ensure 3 years of accurate, well-organized statements - **Improve caregiver retention**: Invest in culture, pay, and scheduling systems that move your retention above 75% - **Diversify revenue**: Reduce concentration in any single client, referral source, or payer ### 6 Months Before Going to Market - **Identify all legitimate add-backs**: Compile and document every defensible add-back with supporting receipts or documentation - **Resolve compliance issues**: Address any outstanding audits, billing irregularities, or licensing gaps - **Document your processes**: Create written SOPs for scheduling, billing, clinical supervision, and HR ### 3 Months Before Going to Market - **Engage your advisor**: The earlier you engage a specialized M&A broker, the more time they have to optimize your positioning - **Update your financial package**: Ensure trailing 12-month financials are current and reconciled to your tax returns --- ## Get in Touch Hendon Partners provides confidential valuation estimates based on real transaction data from 150+ home care M&A deals. Schedule a call with our team and receive a detailed valuation analysis within 24 hours. --- ### How to Value a Home Care Agency: The Complete Formula URL: https://www.hendonpartners.com/insights/how-to-value-home-care-agency-complete-formula Published: 2026-01-16 09:00 Category: Valuation Insights > Most home care agency owners don't know how their business is valued until they're already in a sale process — which is far too late to do anything about it. Here is the exact methodology buyers use to value your agency, with worked examples. If you ask a group of home care agency owners how their business would be valued, most would give you one of three answers: they have no idea, someone told them "a multiple of revenue," or they've heard a specific number from another agency owner in their network. None of these answers are reliable. Home care agency valuation is a specific methodology — and understanding it is the most important financial education a home care owner can have before beginning a sale process. This guide explains exactly how buyers value home care agencies, with worked numerical examples, and what factors push your value up or down. --- ## The Core Valuation Framework: Enterprise Value = Adjusted EBITDA × Multiple The standard valuation methodology for private home care agencies is the EBITDA multiple method. **Enterprise Value = Adjusted EBITDA × Enterprise Value Multiple** The purchase price you receive, called "equity value", is then calculated as: **Equity Value = Enterprise Value – Debt + Cash** (assuming you take out excess cash above a normalized working capital amount before closing) Every home care agency transaction you will read about or discuss with a buyer will be anchored to this framework. Every other consideration, revenue, growth rate, geography, compliance history, ultimately flows into one of these two variables: either it adjusts the EBITDA figure or it adjusts the multiple applied to it. --- ## Step 1: Calculate Your Adjusted EBITDA EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a proxy for operating cash flow from the business, stripping out the effects of your financing decisions (interest), tax structure (taxes), and non-cash accounting charges (D&A). **Raw EBITDA calculation:** ``` Net Income + Interest Expense + Income Taxes + Depreciation + Amortization = EBITDA ``` However, raw EBITDA is only the starting point. Buyers calculate **Adjusted EBITDA** (also called "normalized EBITDA") to reflect what the business would earn under a typical owner. **Common EBITDA add-backs (items subtracted back to increase EBITDA):** - **Excess owner compensation:** The difference between what you pay yourself and what a market-rate CEO/Administrator would cost - **Owner personal expenses:** Personal vehicle, personal insurance, family member salaries with no business function, personal travel - **One-time items:** Non-recurring legal fees, one-time consulting engagements, transition costs - **Related party transactions:** Above-market management fees to a related entity, non-market rent paid to or from an owner-related landlord **Worked Example:** | Item | Amount | |---|---| | Net Income | $320,000 | | + Interest | $18,000 | | + Taxes | $72,000 | | + Depreciation | $24,000 | | **EBITDA** | **$434,000** | | + Excess Owner Comp ($300K salary → $180K market replacement) | +$120,000 | | + Personal Vehicle | +$18,000 | | + Non-Recurring Legal Fees | +$45,000 | | **Adjusted EBITDA** | **$617,000** | This agency's reported net income was $320,000. The adjusted EBITDA presented to buyers is $617,000, almost double. --- ## Step 2: Determine the Applicable Multiple The EBITDA multiple represents how many years of earnings a buyer is willing to pay for your business. A 5× multiple means the buyer is paying 5 years of normalized earnings assuming no change in performance. Multiples are NOT fixed. They vary based on: ### EBITDA Size (The Scale Premium) This is the most powerful driver of multiple differences in home care. | Adjusted EBITDA | Typical Multiple Range | |---|---| | Under $300K | 2.5× – 3.5× | | $300K – $750K | 3.5× – 4.5× | | $750K – $1.5M | 4.5× – 5.5× | | $1.5M – $3M | 5.0× – 6.5× | | $3M – $5M | 5.5× – 7.5× | | $5M+ | 6.5× – 9.0×+ | Why does size matter so much? Because larger businesses represent less risk — they have deeper management teams, more diversified referral sources, more stable revenue streams, and more attractive platforms for buyer expansion strategies. A home care agency doing $5M in EBITDA is not just doing more of what a $500K EBITDA agency does, it has typically built systems, management, and client relationships that make it fundamentally less risky. ### Service Type and Payer Mix | Service Type | Typical Multiple Premium/Discount | |---|---| | Medicare-Certified Skilled Home Health | +0.5× to +1.5× above private pay | | Medicaid Non-Skilled (HCBS waiver) | +0.0× to +1.0× (state-dependent) | | Private Pay Non-Skilled | Base range | | Private Duty Nursing | +0.5× to +1.5× above private pay | | Hospice | +1.0× to +2.5× above private pay | | Behavioral Health (HCBS) | Varies widely | Medicare and Medicare Advantage revenue, clinical complexity, and established managed care contracts typically support higher multiples. Pure private pay businesses have lower multiples because they lack the contract stability of government and managed care payors. ### Growth Rate A business growing at 20%+ annually will command a premium to a flat or declining one. Buyers are purchasing future earnings, not just trailing earnings, a high-growth agency with $1M in current EBITDA may be worth more than a flat agency at $1.5M EBITDA if the buyer believes the growth trajectory continues. Growth is typically most impactful through: - Revenue growth over the trailing 12 months vs. prior year - EBITDA margin expansion (growing without adding proportional costs) - Demonstrated forward pipeline (signed contracts, new referral relationships, geographic expansion underway) ### Management Team Depth If the business would decline meaningfully without you, buyers price that dependency risk into the multiple. Conversely, if you have a management team that can run the business independently: - Full-time administrator or Director of Operations who manages day-to-day - Established clinical management (DON, care coordinator) - Sales or business development staff managing referral relationships - Billing and compliance staff with institutional knowledge ...then the business is valued as an institutional asset rather than an owner-operated practice, and commands a significantly higher multiple. ### Geography and Market Position Strong geographic positions in growing markets command premiums: - Low caregiver competition in your territory - Established hospital, SNF, or physician referral networks - First-mover or dominant market position in a specific county or metro area --- ## Step 3: Apply the Formula Using our example from Step 1: **Adjusted EBITDA:** $617,000 This agency has a solid management team, consistent Medicare and private pay mix, and has grown 15% annually for the past 2 years. Based on comparable transactions, the applicable multiple range is **4.5× to 5.0×**. **Enterprise Value:** - Low: $617,000 × 4.5 = $2.78M - Mid: $617,000 × 4.75 = $2.93M - High: $617,000 × 5.0 = $3.09M After subtracting $150,000 in outstanding business debt and adding $80,000 in normalized cash remaining in the business: **Equity Value Range:** $2.71M – $3.02M The owner would receive somewhere between $2.7M and $3.0M at closing, before transaction costs, taxes, and any escrow holdbacks. --- ## Trailing Twelve Months (TTM) vs. Fiscal Year EBITDA Buyers typically calculate Adjusted EBITDA on a **trailing twelve months (TTM)** basis, the most recent 12 calendar months, rather than the last completed fiscal year. This gives them the most current picture of business performance. If your business has grown significantly, TTM will be higher than your last full fiscal year, which benefits you. If there has been recent softness, TTM will reflect that negatively. For businesses with seasonal patterns (common in private pay home care, which often slows in winter months), buyers may also request a **3-year weighted average** or apply a growth adjustment. --- ## The Working Capital Peg Buyers don't just evaluate EBITDA — they also set a **normalized working capital** target. Working capital = current assets minus current liabilities (typically accounts receivable, prepaid expenses, and accrued liabilities). At close, the actual working capital is compared to the target. If working capital delivered is below target, the purchase price is adjusted down. If above, the excess comes to you as a bonus. **Why this matters:** Some sellers believe they can maximize cash out of the business in the 6–12 months before close (by accelerating collections and delaying payables), then pocket the proceeds. In a properly structured transaction, the working capital peg prevents this from increasing your net proceeds, the low working capital at close is simply subtracted from the equity value. --- ## Common Valuation Mistakes Sellers Make **Mistake 1: Using revenue multiples instead of EBITDA multiples** "3× revenue" is sometimes cited in casual discussions, but it is not how sophisticated buyers value home care businesses. Revenue multiples are imprecise proxies that break down completely when comparing agencies with different margin profiles. EBITDA multiples are the standard. **Mistake 2: Using the highest comparable without accounting for your business's characteristics** "I heard that agency sold for 7×" is common. But did that agency have $5M in EBITDA, a Medicare-skilled platform in a CON state, and a full management team? If your business has $400K in EBITDA and a single-owner-operator model, 7× does not apply. **Mistake 3: Neglecting EBITDA normalization** If you haven't built a proper add-back schedule, you are leaving money on the table. The add-back analysis should be completed, with documentation, before you begin the sale process. **Mistake 4: Not understanding the enterprise vs. equity value distinction** Sellers often quote enterprise value and forget to subtract outstanding debt. If your business is valued at $3M enterprise value but you have $500K in bank debt and equipment loans, your net proceeds are $2.5M, before transaction costs. --- ## Increasing Your Valuation Before You Sell High-impact levers to increase value in the 12–24 months before a sale: 1. **Grow EBITDA**, Every $100K increase in Adjusted EBITDA adds $450K–$650K+ in enterprise value at typical multiples 2. **Build management depth** — Reduce owner dependency, add or develop a strong #2 3. **Clean up compliance**, Resolve any open compliance issues, documentation concerns, or regulatory items 4. **Diversify referral sources**. Reduce concentration in any single referral source below 25% 5. **Document processes**, Standard operating procedures, training materials, and operational playbooks increase buyer confidence 6. **Reduce customer concentration**. In private pay especially, no single client should represent >5–10% of revenue --- ## Getting a Professional Valuation Before beginning a formal sale process, it is worth getting a professional opinion of value. This is different from a formal certified business appraisal (which is primarily used for legal or tax purposes), it is an informed market valuation based on current transaction comparables. At Hendon Partners, we provide confidential preliminary valuations for home care agency owners who are considering a future sale. This process typically takes 1–2 weeks and requires your prior 2–3 years of financial statements. **[Request a confidential preliminary valuation →](/contact-us)** --- *Hendon Partners is a specialized M&A advisory firm for home care agencies. Our advisors have deep experience with home care agency valuation, financial normalization, and transaction structuring across all payer types and service categories.* --- ### How to Sell Your Home Care Agency for Maximum Value URL: https://www.hendonpartners.com/insights/how-to-sell-home-care-agency-maximum-value Published: 2026-01-15 09:00 Category: Seller Guides > Most home care owners who sell without an advisor leave 24–40% of their sale price on the table. This complete guide walks you through every step of a professional, competitive M&A process — from valuation to funded close. Selling your home care agency is one of the most consequential financial decisions of your career. Done right, a well-structured sale can generate 3–10× your annual EBITDA, fund your retirement, and reward the years of work you've invested in building the business. Done wrong — or done alone, it can leave hundreds of thousands, or even millions, of dollars on the table. This guide walks you through everything you need to know about selling your home care agency for maximum value. It's written by practitioners who close deals in this market every day, not consultants or content marketers who read about it. --- ## Why Specialized Representation Matters The single most impactful decision you'll make in your exit is whether to work with a specialized M&A broker. Research from the International Business Brokers Association (IBBA) consistently shows that represented sellers receive **24–40% more** in transaction value than unrepresented sellers. In home care specifically, the gap can be even wider because: 1. **You likely don't know all the buyers.** There are 80+ PE-backed home care platforms, 200+ regional operators, and multiple national health systems actively acquiring, most of which you've never heard of. 2. **Unsolicited buyers know you're alone.** When a buyer approaches you directly, they've already priced in the lack of competition. There is no reason for them to pay a premium they don't have to. 3. **Home care M&A is technically complex.** Payer mix analysis, EBITDA normalization, regulatory compliance review, Medicare certification transfer — each of these requires specialized knowledge that generalist brokers and M&A attorneys simply don't have. --- ## Step 1: Know Your Number Before Anyone Else Does The first step in any intelligent exit is understanding your baseline value. Most agency owners either significantly underestimate or overestimate their business's worth, and both errors are costly. **The basics of home care agency valuation:** Home care agencies are typically valued on an EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) multiple basis. Your EBITDA is your true operating profit, the number that buyers use to assess the cash flow they're acquiring. Here's what the market is currently paying: | Agency Type | Typical Multiple Range | |---|---| | Non-Medical Personal Care | 2.0 – 4.5× EBITDA | | Medicare Home Health | 3.5 – 7.0× EBITDA | | Hospice | 5.0 – 9.0× EBITDA | | Multi-Service Platform ($3M+ EBITDA) | 6.0 – 10×+ EBITDA | *Source: Scope Research 2025, BizBuySell 2024, Exitwise 2025* The multiple you achieve will depend on factors including: your payer mix (Medicare vs. Medicaid vs. private pay), caregiver retention rate, owner-independence level, geographic market, revenue growth rate, and client concentration. **Contact us to get your preliminary valuation estimate →** --- ## Step 2: Conduct a Pre-Sale Readiness Assessment Before engaging buyers, do an honest internal assessment of where your business stands on the factors that most influence valuation: ### Financial Readiness - Do you have 3 years of clean, accountant-prepared financial statements? - Have you identified all legitimate EBITDA add-backs (owner compensation above market, one-time expenses, personal charges through the business)? - Is your revenue accurately attributed to service lines? ### Operational Readiness - Can the business operate without your daily involvement for 60–90 days? - Do you have a clinical director, operations manager, or other key personnel who would remain post-sale? - Are your scheduling systems, billing processes, and HR procedures documented? ### Client & Referral Concentration - Does any single client, referral source, or contract represent more than 20% of revenue? (High concentration is a red flag for buyers.) - Are your referral source relationships transferable, or are they personally dependent on you? ### Regulatory & Compliance - Are your licenses and certifications current in all states of operation? - Are there any pending audits, overpayment notices, or compliance issues? - For Medicare-certified agencies: Is your cost report history clean? Addressing these factors before going to market can increase your multiple by 0.5–1.5× and shorten your time to close significantly. --- ## Step 3: Prepare Your Marketing Materials Serious buyers require serious documentation. The centerpiece of your marketing package is the **Confidential Information Memorandum (CIM)**, a professional document that tells the story of your business, presents your financials in the clearest possible light, and positions you for maximum value. A complete CIM for a home care agency typically includes: - Executive summary and investment highlights - Business overview, history, and market position - Detailed financial analysis: revenue, EBITDA, add-backs, and adjusted financials - Service line breakdown and payer mix analysis - Geographic market overview - Operational infrastructure and management team - Growth opportunities (post-close value creation thesis) - Regulatory and compliance summary A poorly prepared CIM costs you in two ways: it reduces buyer confidence, and it weakens your negotiating position. A well-prepared CIM, created by specialists who understand what buyers want to see in this sector, creates a premium impression before the first conversation. --- ## Step 4: Run a Competitive Process. Not a Direct Negotiation This is where most owners who go it alone leave the most money behind. The difference between a 4× sale and a 7× sale is almost never luck. It's **competitive tension**. When buyers know they're competing with other serious acquirers on a defined timeline, three things happen: 1. They submit their **best offer upfront**, not a lowball they can negotiate down from 2. They move **faster**, reducing the time your business is in limbo 3. They are **less likely to re-trade** on price during diligence A properly run competitive process involves: - Simultaneous outreach to 20–50 pre-qualified buyers under strict NDA - Defined timeline and process rules communicated to all parties - Structured management presentations to interested buyers - Multiple Letter of Intent (LOI) submissions evaluated simultaneously - Negotiated final terms before exclusivity is granted to any single buyer Running this process requires relationships, credibility, and sector expertise. It is essentially impossible to do effectively as a first-time seller. --- ## Step 5: Manage Due Diligence While Running Your Business Once you've accepted an LOI, the real work begins. Due diligence is a 30–60 day intensive examination of your business by the buyer's team — financial, operational, legal, and clinical. The four most common due diligence killers in home care M&A: 1. **Financial misrepresentations**, Even unintentional inconsistencies between your CIM and actual records can re-trade your price or kill the deal 2. **Hidden compliance issues**. Outstanding audits, overpayment risk, or licensing gaps discovered in diligence often result in escrow holdbacks or price reductions 3. **Key person risk**, If diligence reveals that the business truly can't run without you, expect a significant price reduction or earnout structure 4. **Client/referral concentration**, If 35% of your revenue comes from one referral source who knows you personally, buyers will discount heavily Having a specialized advisor quarterback your diligence process — providing documents proactively, managing the buyer's requests, and preventing information leakage, is the difference between a smooth close and a protracted re-negotiation. --- ## What to Expect at Close A well-run home care agency sale, from signed engagement letter to funded close, typically takes **60–120 days** for prepared sellers. The deal typically closes with: - **Net cash at close** (~80–90% of enterprise value for all-cash deals) - **Seller note or earnout** (10–20% in some transactions, particularly where growth projections are important to the buyer's thesis) - **Transition consulting agreement** (typically 3–12 months, especially if you're operationally involved) --- ## Ready to Start the Conversation? If you're serious about maximizing your exit, the best first step is a confidential, no-obligation call with Neli Gertner. In 20–30 minutes, you'll know what your agency is worth, what a realistic timeline looks like, and what Hendon's process would mean for your outcome. **Contact us for a confidential consultation**. Neli will personally review your situation and follow up with a detailed valuation analysis within 24 hours. --- ### Selling a Medicare-Certified Home Health Agency: A Complete 2026 Guide URL: https://www.hendonpartners.com/insights/selling-medicare-certified-home-health-agency-2026 Published: 2026-01-09 09:00 Category: Seller Guides > Medicare-certified home health agencies trade at a significant premium — but the sale process is more complex than most sellers anticipate. Licensing transfer, Medicare enrollment, and CHAP/JCAHO accreditation all create unique due diligence challenges. Here is what you need to know. Of all the home care agency types that transact in the M&A market, Medicare-certified home health agencies occupy a unique position. They command the highest EBITDA multiples in the sector — frequently 5× to 7× or higher, but they also require the most careful transaction structuring. The reason is regulatory complexity. A Medicare-certified home health agency carries certifications, provider agreements, and licensure that are tied to a specific legal entity and operating location, and all of these require active management during a sale to ensure the buyer can operate the business without interruption post-close. This guide explains what differentiates Medicare skilled home health agency sales from other home care transactions and what both sides should know before entering the process. --- ## Why Medicare-Certified Agencies Trade at a Premium Medicare-skilled home health (sometimes called "Medicare Part A home health" or "skilled home health") carries several characteristics that buyers value: **Reimbursement stability.** Medicare is a federal payor, it doesn't change the way Medicaid does at the state level. While PDGM and rate changes create volatility, Medicare revenue is generally more predictable than Medicaid and more scalable than private pay. **Clinical complexity and specialization.** Skilled home health agencies provide nursing, physical therapy, occupational therapy, speech therapy, and medical social work under physician orders — this is meaningfully more complex than non-skilled home care and creates higher barriers to entry. **Certificate of Need (CON) constraints in some states.** Roughly a dozen states maintain CON requirements for home health. In CON states, acquiring an already-licensed agency may be the only practical way to enter a market. This scarcity drives significant premium pricing. **Referral network depth.** A high-performing skilled home health agency with strong hospital discharge relationships, SNF partnerships, and physician referral bases has built an asset that is expensive to replicate organically. --- ## The Regulatory Complexity of a Skilled Home Health Sale ### Medicare Provider Agreement Transfer A Medicare-certified home health agency's Provider Agreement, the agreement with CMS that allows billing for Medicare services, is entity-specific. It belongs to the legal entity, not the underlying business activities. In a **stock sale** (or membership unit sale for an LLC), the entity changes hands but remains intact. The Provider Agreement transfers automatically with the entity and there is no need to re-enroll with Medicare, though the buyer must notify Medicare of the ownership change through CMS Form 855A within a specified timeframe. In an **asset sale**, the Medicare Provider Agreement does NOT transfer automatically. The buyer must apply for a new Provider Agreement and enroll as a new Medicare provider, which can take 60–180+ days depending on the MAC (Medicare Administrative Contractor) processing times. During this gap, Medicare billing may be interrupted unless the transaction includes a "change of ownership" (CHOW) filing that captures the Provider Agreement. **The CHOW process:** CMS allows a "change of ownership" where the assets and Provider Agreement transfer together, but this requires specific filings with CMS, often processed through the MAC, and does not happen automatically. It requires coordination with healthcare regulatory counsel and advance planning. ### State Licensure Transfer Medicare-certified home health agencies are also licensed at the state level. State home health licenses are typically non-transferable entity assets — meaning in an asset sale, the buyer needs to apply for a new license in the acquiring entity. State licensing timelines vary dramatically: from a few weeks in some states to 6+ months in others. In some states, there are moratoriums on new home health licenses, making an asset sale structure genuinely impractical. **Implication:** In states with complex licensing environments, a stock sale is usually the preferred structure, it preserves the existing license without requiring a new application. However, stock sales carry higher liability exposure for the buyer (all entity liabilities come with the purchase), so buyers often push for reps and warranties insurance or escrow arrangements to offset this risk. ### Accreditation (CAHQ, JCAHO, CHAP) Many Medicare-certified home health agencies hold accreditation from CAHQ (Community Health Accreditation Partner), The Joint Commission (JCAHO), or CHAP, which serves as their Medicare deemed status survey in lieu of direct CMS oversight. Accreditation is organization-specific. When a sale occurs, the new operating entity or newly enrolled provider typically needs to apply for re-accreditation or transfer accreditation, a process each accrediting body handles differently. This creates a potential gap in Medicare billing authority and survey requirements. **Planning tip:** Contact the accrediting body early — ideally before the sale process begins, to understand the transfer or reapplication requirements and timeline. ### Medicare Cost Report Cutoffs At the time of ownership change, the existing provider number typically closes out a cost report period. The seller may have obligations related to the final cost report (including potential Medicare settlements or recoupment), which must be allocated between buyer and seller in the purchase agreement. ### OASIS Data and Clinical Documentation Medicare requires Home Health Agencies to maintain OASIS data continuity and submit quality reporting data. During a transition, there must be careful handoff of patient records, OASIS assessments, and Home Health Compare data responsibility. The purchase agreement should address patient record transfer protocols. --- ## Pre-Sale Preparation for Medicare-Skilled HHA Owners ### Compliance Program Review Before bringing a skilled home health agency to market, sellers should conduct an internal compliance review covering: - OIG exclusion list clearance for all staff - Physician order compliance (timely orders, documentation completeness) - OASIS accuracy and coding practices - Face-to-face encounter documentation - Billing audit, identify and remediate any overcoding issues before they surface in buyer due diligence **Why this matters:** Any compliance issues found by buyers in due diligence are used as leverage to reduce purchase price or demand escrow. Issues found post-close create indemnification claims. It is always less expensive to identify and clean up problems before marketing the business. ### Operational Documentation Buyers of Medicare-certified agencies scrutinize: - Policy and procedure manuals (CMS Conditions of Participation compliance) - Survey history and any deficiencies from most recent state survey or accreditation survey - Deficiency-Free surveys are a material positive in buyer perception - Plan of Correction history (how quickly and effectively past deficiencies were addressed) - Complaint investigation outcomes ### Revenue and Patient Mix Analysis Understand your: - Payer mix breakdown (Medicare FFS, Medicare Advantage, Medicaid, private insurance, managed care contracts) - Medicare Advantage penetration and the reimbursement comparison to Medicare FFS - LUPA rate (Low Utilization Payment Adjustments), high LUPA rates may reflect scheduling or visit utilization management issues - Average case mix weight and PDGM episode distribution - HHC/CAHPS star ratings ### Physicians and Hospital Relationships Buyers pay particular attention to referral source concentration. If 30%+ of Medicare volume comes from a single hospital system or physician group, that's a concentration risk. Document your referral relationships and, where possible, demonstrate that relationships extend beyond the owner/founder to the clinical team and case managers. --- ## Transaction Structures: Stock vs. Asset in Medicare HHA Sales | Factor | Stock Sale | Asset Sale | |---|---|---| | Medicare Provider Agreement | Transfers with entity | Requires CHOW filing or new enrollment | | State Licensure | Transfers with entity | Requires new application | | Accreditation | Transfer process with accreditor | Re-application required | | Liabilities | All entity liabilities transfer | Buyer selects which liabilities to assume | | Transaction speed | Generally faster | Longer (licensing/enrollment timelines) | | Tax treatment (seller) | Capital gains on all proceeds | Ordinary income on certain asset classes | | Buyer preference | Often preferred for operational continuity | Often preferred for clean liability assumption | **The practical reality:** Most Medicare-certified home health agency transactions are structured as stock sales or transactions with CHOW filings, because the regulatory complexity of an asset sale without Provider Agreement transfer is too disruptive to operations. --- ## What Buyers Pay For in Medicare Skilled Home Health **Outstanding survey history.** A deficiency-free most-recent state survey is worth meaningful value. Poor surveys or open Plans of Correction are discounted heavily. **Strong CAHPS star ratings.** Home Health Care CAHPS ratings that fall in the 4–5 star range (particularly for patient communication, specific care issues, and overall rating) demonstrate quality and may support premium positioning in competitive markets. **Medicare Advantage managed care contracts.** As MA penetration grows (now 50%+ of Medicare beneficiaries nationally), established MA contracts with major payers (Humana, UnitedHealthcare, Aetna) have standalone value. **Depth of clinical staff.** A skilled team of experienced RNs, PTs, OTs, and SLPs with low turnover is a genuine value driver. High clinical staff turnover raises questions about management and culture. **Geographic territory and CON position.** In CON states, the geographic service territory may have additional value as a barrier to entry. --- ## Typical Valuation for Medicare-Certified Home Health Agencies (2026) | Agency Characteristic | Approximate EBITDA Multiple Range | |---|---| | Sub-$500K EBITDA, single market | 3.5× – 4.5× | | $500K–$1.5M EBITDA, competitive market | 4.5× – 6.0× | | $1.5M–$3M EBITDA, strong market position | 5.5× – 7.0× | | $3M+ EBITDA, scale + CON state premium | 6.0× – 8.0×+ | | Turnaround / post-survey deficiency | 2.5× – 3.5× | Note: These ranges are indicative. Your specific multiple will depend on payor mix, market, compliance history, growth trajectory, and buyer competitive dynamics. Medicare-certified agencies in CON states (FL, MD, NJ, etc.) frequently trade at the upper end of ranges. --- ## The Role of an M&A Advisor in Skilled Home Health Sales Given the regulatory complexity, sellers of Medicare-certified home health agencies benefit significantly from working with an M&A advisor who understands the sector specifically, not just general healthcare M&A. Your advisor should be able to: - Structure the transaction (stock vs. asset vs. CHOW asset) to maximize price while maintaining regulatory continuity - Prepare the CIM with appropriate regulatory language and compliance narrative - Target buyers who have experience navigating Medicare enrollment and licensing transitions - Coordinate with your healthcare regulatory counsel on Provider Agreement and licensure strategy - Prepare you for QoE add-back defense on any Medicare cost report reconciliation items **[Schedule a confidential consultation with Hendon Partners →](/contact-us)** --- *Hendon Partners advises on the sale of Medicare-certified home health agencies nationwide. Our team has deep experience with CMS Conditions of Participation, CHOW filings, and multi-state licensing complexities that arise in skilled home health transactions.* --- ### Home Care EBITDA Add-Backs: What Counts, What Doesn't, and Why It Matters URL: https://www.hendonpartners.com/insights/home-care-ebitda-add-backs-guide Published: 2026-01-02 09:00 Category: Valuation Insights > EBITDA add-backs are the most negotiated financial items in every home care agency sale. Adding $300,000 in legitimate add-backs at a 5× multiple adds $1.5M to your sales price. Here's which add-backs hold up to scrutiny — and which ones will get you in trouble. Home care agency EBITDA normalization — the process of adjusting reported earnings to reflect the true, sustainable operating profit of the business, is the most technically consequential financial exercise in any sale. Done well, it increases your purchase price by hundreds of thousands to millions of dollars. Done poorly, it creates disputes, delays, and re-trades. The concept is simple: the "raw" EBITDA on your tax return or income statement includes expenses that are owner-specific benefits, one-time events, or items that a new owner would not incur. Adding these back to get to "adjusted EBITDA" is standard practice, and buyers expect it. The challenge is that not every add-back survives scrutiny. The Quality of Earnings analysts buyers hire will challenge every add-back aggressively. Sellers who claim inflated, undocumented, or indefensible add-backs damage their credibility with buyers and frequently see the EBITDA — and therefore the purchase price, reduced in late-stage due diligence. This guide covers the most common EBITDA add-backs in home care M&A, how they are justified, and which ones will withstand a QoE review. --- ## The Principle Behind Add-Backs The standard for a legitimate add-back is: **would a replacement owner or institutional operator incur this expense?** If yes → it is a real operating cost and should NOT be added back. If no → it is an owner-specific benefit or one-time item that a buyer would not face, and it IS a legitimate add-back. The buyer is purchasing the business's normalized earning power, not the historical P&L as it happened to appear under your ownership. --- ## Legitimate Add-Backs That Typically Hold Up ### 1. Owner Compensation Above Market Rate The most common and often largest add-back. If you pay yourself $450,000 per year as the owner-operator of a home care agency, but the market cost of replacing your function (e.g., an experienced Administrator or CEO) is $175,000, then the excess $275,000 is a legitimate add-back, because a new owner would pay market rate for that function. **Documentation required:** A compensation benchmarking analysis using comparable market data (BLS surveys, healthcare administrator salary databases, or third-party compensation surveys). The more rigorous the benchmark, the more defensible the add-back. **Warning:** If your role is genuinely multi-functional (you are CEO, clinical director, and billing manager simultaneously), the replacement cost analysis must account for all functions. You cannot add back your entire salary if multiple full-time positions would be required to replace you. ### 2. Non-Recurring Owner Benefits and Personal Expenses Business expenses that were personal in nature and would not be incurred by a successor operator: - Personal vehicle (if not operationally necessary for a typical CEO in your role) - Personal life insurance premiums paid by the business - Spouse or family member salaries/benefits where the individual served no material business function - Personal travel expensed to the business - Club memberships, entertainment exceeding operational norms **Documentation required:** Copies of invoices, credit card statements, or payroll records showing the amounts. Written description of why each item was personal and would not be incurred post-close. **Warning:** Entertainment and travel require clear documentation that the expense was personal. Business meals with referral sources are not a personal add-back. A vacation expensed as a "team-building retreat" that no buyer would take is an add-back if properly documented. ### 3. One-Time Legal and Professional Fees Legal fees or professional fees related to a specific, non-recurring situation: - Legal fees for a specific dispute that is now resolved - M&A advisory fees for the current transaction - One-time consulting costs for a technology implementation **Documentation required:** Invoices from the provider with description of services. The cleaner the explanation of why it was one-time, the better. **Warning:** Recurring legal costs (annual employment law advice, regulatory compliance counsel) are operating costs and should NOT be added back. Buyers evaluate whether "one-time" legal costs have become recurring over multiple years — if you add back legal fees in 2023, 2024, and 2025, none of them are "one-time." ### 4. Depreciation and Amortization on Equipment and Intangibles Depreciation and amortization are standard EBITDA add-backs by definition, they are non-cash charges that reduce reported earnings but do not represent a cash outflow in the period. In the definition of EBITDA, these are always added back. **Documentation required:** Depreciation schedule from your financial statements. **Note:** This does not mean capital expenditures are ignored. Buyers will separately evaluate maintenance capital expenditure requirements (the capex needed to maintain the business, separate from growth capex) and may reflect it in their valuation model. ### 5. Owner's Investment Returns Funded Through the Business Some owner-operators fund personal investment vehicles, retirement contributions above market norms, or other returns through the business: - Compensation to a related-party management company or family trust for nominal services - Below-market rent paid to an owner-related entity for office space (buyers will normalize to market rent) - Above-market rent paid to an owner-related entity (same normalization) **Documentation required:** Related party transaction disclosure and market comparables (for rent, comp surveys for management fees). ### 6. Non-Cash Stock Compensation If you have issued phantom equity, options, or restricted units to management and are recognizing non-cash compensation expense, this is typically added back as non-cash, though buyers will account for the economics separately in their cap table analysis. ### 7. COVID-Related Items (Still Relevant in Some Analyses) For trailing financial periods that include 2020–2021, one-time COVID PPP loan forgiveness (typically treated as other income to be excluded) and one-time COVID expenses (PPE, hazard pay, temporary staffing surges) may warrant separate treatment. --- ## Add-Backs That Will Be Challenged or Rejected ### Owner Compensation at Market Rate If you are paying yourself $175,000 and that is what a replacement CEO would cost, there is no add-back. The compensation is a legitimate operating cost. ### "Discretionary" Expenses That Recur If you "chose" to spend on marketing, caregiver bonuses, or office improvements in a year, these are not add-backs, they represent owner choices about how to run the business. Buyers will form their own view about appropriate spending levels. ### Rent Paid to a Related Party at Market Rates If you own the building your agency operates in and charge market rent, that rent is a real operating cost — not an add-back. The buyer will assume they pay market rent post-close. ### Revenue from Activities That Won't Continue Some CIM narratives implicitly add back by excluding revenue declines or one-time revenue losses, presenting a revenue picture that overstates forward revenue. This is not technically an add-back, it is revenue manipulation. QoE analysts catch this quickly. ### Inflated Add-Back Claims Without Documentation An add-back without documentation is not an add-back, it is a claim. During QoE review, every undocumented add-back will be rejected, which reduces the buyer's EBITDA and therefore the price. --- ## The Compounding Effect of Add-Backs Understanding why add-backs matter so much: | EBITDA Level | Add-Backs | Normalized EBITDA | Value at 5.5× Multiple | |---|---|---|---| | Reported: $800K | None | $800K | $4.4M | | Reported: $800K | $300K (owner comp + personal exp) | $1.1M | $6.05M | | Reported: $800K | $500K (multiple categories) | $1.3M | $7.15M | **On a $800K reported EBITDA business, the difference between $0 in add-backs and $500K in documented add-backs is $2.75M in purchase price at a 5.5× multiple.** This is why EBITDA normalization is the most high-leverage financial exercise in any sale preparation process, and why it needs to be done carefully, documented thoroughly, and defended credibly. --- ## The Presentation and Defense of Add-Backs A well-prepared CIM presents EBITDA add-backs in a "bridge" format: ``` Reported Net Income: $450,000 + Interest Expense: $30,000 + Depreciation: $45,000 + Taxes: $85,000 EBITDA (Reported): $610,000 Owner Comp Add-Back: +$240,000 Personal Vehicle: +$22,000 One-Time Legal Costs: +$85,000 Non-Recurring Consulting: +$48,000 Adjusted EBITDA: $1,005,000 ``` Each line item in the add-back table should reference a supporting document in the data room. A clean, well-presented add-back schedule that is defensible under QoE scrutiny is the output you want. **[Contact Hendon Partners to prepare your EBITDA normalization and CIM →](/contact-us)** --- *Hendon Partners specializes in home care M&A advisory. Our advisors have reviewed hundreds of home care financial models and prepared dozens of CIMs with defensible EBITDA normalization.* --- ### Medicaid vs. Medicare: How Your Payer Mix Determines Your Home Care Agency's Sale Price URL: https://www.hendonpartners.com/insights/payer-mix-home-care-valuation Published: 2025-12-26 09:00 Category: Valuation Insights > Payer mix is the most scrutinized variable in home care agency valuation. A Medicare-certified home health agency and a Medicaid-only personal care agency with identical revenue can have dramatically different valuations. Here's why — and what you can do about it. When buyers evaluate a home care agency, they care deeply about two numbers: EBITDA and payer mix. Of those two, payer mix is often the more important multiplier — because it tells buyers not just what you earned last year, but how stable, predictable, and defensible that income is. Two home care agencies with identical revenue and identical EBITDA margins can trade at EBITDA multiples that differ by 2–4×. The primary reason, in most cases, is payer mix. This guide explains exactly how each payer source is viewed by buyers, quantifies the valuation impact, and identifies what steps owners can take to improve their payer mix before going to market. --- ## The Payer Hierarchy: How Buyers View Each Revenue Source ### Medicare (Highest Value) **Why buyers love Medicare:** Medicare home health and hospice reimburses under federally-set rates that are uniform, predictable, and not subject to state budget negotiations. Rates are established years in advance through the prospective payment system (PDGM for home health, per diem hospice rates). There is no state-by-state rate risk. Additionally, Medicare home health has strong demand demographics, the population Medicare serves (65+) is the fastest-growing demographic in America, and the preference for home-based care over institutional settings is well-established. **How buyers model Medicare revenue:** Medicare revenue is generally accepted at face value in QoE and financial analysis. Denials and ADR requests represent risk, but well-run agencies with clean documentation typically show consistent collection rates above 95%. **Valuation impact:** Medicare-certified home health and hospice agencies command the highest multiples among home-based care service lines. --- ### Medicare Advantage (MA), Growing But Nuanced **What it is:** Medicare Advantage plans are private insurance plans that contract with CMS to provide Medicare-covered services. They are the fastest-growing segment of Medicare, now covering approximately 55% of all Medicare beneficiaries. **Why buyers are cautious:** - MA rates are typically 5–20% lower than traditional Medicare rates for home health and hospice - Prior authorization requirements are more extensive - MA plans may narrow networks, excluding small operators - MA rate negotiations happen on an ongoing basis, creating future rate uncertainty **Valuation impact:** High MA exposure (>40% of Medicare revenue from MA plans) is generally viewed as a negative factor. Agencies dependent on MA are valued similarly to commercial insurance-dependent agencies, with a discount to pure traditional Medicare. --- ### Private Pay / Out-of-Pocket (Valued Positively) **What it is:** Clients who pay directly for services — typically personal care or companion services for affluent seniors, without government or insurance involvement. **Why buyers like it:** - No prior authorization - No cost report risk - No claims processing delays - Rates are market-set, often significantly above Medicaid equivalents - Margins are typically the highest of any payer type Private pay revenue is not exposed to any government program risk. In commercial real estate terms, it is the closest thing to "guaranteed" revenue in home care. **Valuation impact:** High private pay concentration is a positive valuation signal, but buyers will assess sustainability, particularly whether the rates are genuine market rates (vs. artificially inflated one-time billings) and whether client relationships are transferable. --- ### Commercial Insurance / Long-Term Care Insurance **What it is:** Commercial health insurance plans (employer-sponsored, ACA marketplace) and long-term care insurance policies covering home care services. **Why buyers assess carefully:** - Commercial insurance rates are generally higher than Medicaid but lower than Medicare - Plans may limit coverage periods or services - Prior authorization and denials create revenue cycle complexity - Commercial insurance networks can narrow, creating access risk **Valuation impact:** Commercial insurance is viewed positively relative to Medicaid but discounted relative to Medicare. Revenue cycle quality (denial rates, DSO) matters significantly for commercial payers. --- ### Medicaid (Most Scrutinized) **What it is:** State-administered Medicaid programs fund the majority of non-skilled personal care, IDD services, and pediatric home nursing for lower-income populations. **Why buyers are cautious:** **Rate risk:** Medicaid rates are set by each state legislature and state Medicaid agency. Rates can be reduced (often without notice) when state budgets are under pressure. Historically, Medicaid rate cuts during economic downturns have materially impaired agency financial performance. **Administrative complexity:** Medicaid prior authorization, billing requirements, and audit exposure vary dramatically by state and wavier program. Agencies without strong billing infrastructure face higher denial rates and slower payment. **Waiver program stability:** Many Medicaid home care programs operate through HCBS waivers with enrollment caps and waiting lists. Policy changes at the state level can alter program structures. **Geographic variation:** Medicaid rates in Colorado may be three times those in Mississippi. A Medicaid-dominant agency in a high-rate state is valued very differently from one in a low-rate state. **Valuation impact:** Medicaid-only agencies receive meaningfully lower EBITDA multiples than Medicare or private pay agencies. The discount reflects the rate uncertainty and program dependency embedded in their revenue. --- ## The Quantified Valuation Impact The following illustrates how payer mix affects the EBITDA multiple for a personal care / light medical agency with $1M in EBITDA: | Payer Mix Profile | Estimated EBITDA Multiple | |---|---| | 70%+ Medicare-certified home health | 5.5 – 7.5× | | 50% Medicare / 30% Private Pay / 20% Medicaid | 4.5 – 6.5× | | 40% Medicare / 40% Medicaid / 20% Private Pay | 4.0 – 5.5× | | 70%+ Medicaid personal care | 2.5 – 4.0× | | 90%+ Medicaid single program | 2.0 – 3.5× | *Source: Hendon Partners deal data and market benchmarks, Q1 2026* The difference between a predominantly Medicare-certified business and a predominantly Medicaid personal care business, at the same EBITDA level, is 2–4× in multiple, which translates to $2M–$4M in enterprise value on a $1M EBITDA agency. --- ## Medicare Advantage and the Emerging Risk One nuanced and increasingly important issue: **Medicare Advantage payer concentration within a Medicare-certified agency**. As MA penetration increases — now above 55% of Medicare nationally and significantly higher in certain markets (Florida, California, Texas metro areas), agencies that are "Medicare-certified" but predominantly serving MA patients face growing rate pressure. MA plans: - Negotiate rates directly with providers, often below traditional Medicare - Require more burdensome prior authorization - Have shifted episode payment models that may reduce payment per visit - May narrow networks at renewal, potentially excluding small operators Buyers underwriting MA-heavy agencies discount for the difference between listed Medicare rates and the effective MA payment received, and they model increasing MA penetration risk in the buyer's home market. **Seller implication:** If you operate in a high-MA-penetration market and your "Medicare" revenue is predominantly MA, disclose this clearly in your CIM and model it honestly. Buyers who discover significant MA exposure during due diligence, after pricing the agency on the assumption of traditional Medicare rates — will reduce price. --- ## How to Improve Your Payer Mix Before Going to Market ### Add Medicare Certification (For Non-Certified Agencies) If you operate a non-skilled personal care agency that serves elderly clients, adding Medicare home health certification opens a new, higher-value payer. The process typically takes 4–6 months from application to first billing. The investment: a Medicare-certified clinical team (at minimum, a Director of Clinical Services with RN license, a PT, OT, or SLP, and medical director engagement), compliance infrastructure, and billing capability. The return: a payer tier change that may increase your EBITDA multiple by 1.5–2×. ### Develop Private Pay Revenue Adding private pay service lines, private duty companion, concierge home health, private pay personal care, to an existing Medicaid or Medicare-focused agency improves payer mix over 12–24 months. Private pay clients also typically skew toward better neighborhoods and markets. ### Reduce Single-Program Concentration An agency with 90% revenue from a single Medicaid waiver program is vulnerable to that program's policy and rate changes. Diversifying across waiver types (community-based residential, in-home support, day habilitation for IDD agencies) reduces concentration risk. ### Renegotiate MA Rates Agencies with leverage (meaningful census volume, specialty capabilities) can negotiate better MA rates at contract renewal. Even a 5–10% improvement in MA rates relative to the MA contract baseline can improve EBITDA and support higher valuation. --- ## The Most Important Pre-Sale Analysis Before engaging in any M&A process, your advisor should produce a payer mix analysis that includes: - Revenue by payer type for the trailing 3 years - EBITDA margin by payer type (if isolable) - MA concentration within Medicare revenue - State-specific Medicaid rate history and forward risk - Any payer contracts expiring within 24 months post-close This analysis tells you, and potential buyers, exactly what you are selling. The agencies that achieve premium valuations are the ones that tell this story clearly and honestly, and that have made payer mix improvements that buyers can model in their forward projections. --- **[Contact Hendon Partners for a payer mix analysis and valuation assessment →](/contact-us)** --- *Hendon Partners advises home care owners exclusively. Our valuations are based on real closed transaction data in current market conditions.* --- ### Non-Compete Agreements When Selling Your Home Care Agency: What's Standard and What's a Red Flag URL: https://www.hendonpartners.com/insights/non-compete-selling-home-care-agency Published: 2025-12-19 09:00 Category: Seller Guides > Non-compete agreements are a required part of every home care agency sale — but their scope, geography, and duration vary enormously. Understanding what is market-standard helps you negotiate terms you can live with for years after close. When you sell your home care agency, the buyer is not just acquiring your current cash flow — they are buying the right to operate your business, grow it, and protect it from competition. Central to that protection is the **non-compete agreement** that every buyer will require as a condition of close. Non-competes in home care M&A are standard, expected, and legally enforceable in most states. But their terms, scope, geography, duration, and restrictions, vary widely, and sellers who don't understand what is reasonable can end up bound by agreements that materially constrain their professional and financial freedom for years. This guide explains what market-standard non-compete terms look like in home care M&A, how to negotiate them, and what terms you should push back on. --- ## Why Buyers Require Non-Compete Agreements The logic is straightforward: you built the business. You know every referral source, employee, and patient. If you are free to launch a competitor immediately after close, the buyer has purchased something far less valuable than they thought. A buyer paying $10M for your home care agency is relying on the premise that you will not immediately open a competing agency across the street. The non-compete makes that reliance legally enforceable. Non-compete payments are often a component of the total purchase price — allocated for tax purposes as ordinary income to the seller (at ordinary income tax rates) and amortizable by the buyer over 15 years. --- ## What Is "Market Standard" for Home Care Non-Competes? Based on current transaction market norms in home-based care M&A: | Term | Typical Market Range | Upper Limit (Red Flag) | |---|---|---| | **Duration** | 3–5 years | More than 5 years | | **Geographic scope** | Counties / service area of the agency | State-wide or national | | **Prohibited activities** | Owning/operating/managing competing home care business | Working in healthcare in any capacity | | **Non-solicitation of employees** | 2–3 years | More than 3 years | | **Non-solicitation of clients** | 2–3 years | More than 3 years | The most important factors are duration and geography. A 5-year non-compete covering the five counties you actively serve is very different from a 5-year non-compete covering your state or region. --- ## The Geographic Definitions: Where Disputes Begin The non-compete geography defines where you cannot compete. Buyers want this broad; sellers need it reasonable. **Specific county/territory approach (seller-favorable):** The non-compete applies only to the specific counties, zip codes, or territories where the agency currently operates. If you sell an agency serving three counties, the non-compete covers those three counties only, leaving you free to operate anywhere else. **Mileage radius approach (compromise):** The non-compete covers a defined radius (e.g., 50 miles) from each office or service location. This is more nuanced than county lines but can still be reasonable for geographically focused agencies. **State-wide approach (buyer-favorable):** The non-compete applies across your entire state. For agencies operating in large states (Texas, California, Florida), a state-wide non-compete significantly limits your post-close professional freedom. Resist this unless you are compensated specifically for the broader restriction. **National approach (extremely uncommon, resist):** A national non-compete in a fundamental operational service business is rarely enforceable and almost never appropriate. If a buyer proposes this, push back firmly. --- ## Duration Negotiation Home care non-competes typically run 3–5 years from close. Factors that affect appropriate duration: **Your post-close role:** - If you are staying on as an employee or consultant for 2 years, the non-compete period beginning at close means you are effectively restricted for 2 years of your operating tenure plus 3 more post-departure = 5 years total freedom restriction. Negotiate for the non-compete clock to start at the end of your employment period, or for a shorter total duration. **Your industry experience and age:** - A 50-year-old seller with deep operational knowledge of home care and no alternative career plans needs a shorter non-compete (3 years) than the law might impose. A 35-year-old serial entrepreneur accepting a 5-year non-compete may find it expires just when they want to re-enter the market. **The service line:** - Non-competes for highly specialized services (ventilator-dependent PDN, pediatric hospice) can reasonably be narrower in scope because the market is narrower. Don't accept a broad non-compete for a niche service that the buyer couldn't expand into quickly anyway. --- ## What Activities Are Prohibited: Defining the Scope The prohibited activities section defines what you cannot do during the non-compete period. Standard prohibitions: **Owning or having a financial interest in** a competing home care business, typically defined as >1–5% equity ownership. **Operating or managing** a competing business, including as CEO, COO, clinical director, or other executive role. **Providing consulting services** to or being employed by a direct competitor in the same geographic area. What is typically NOT prohibited (and you should ensure isn't prohibited): - Working in a non-competing healthcare business - Investing passively in publicly traded healthcare companies - Working in home care in a geography outside the restricted area - Teaching, lecturing, or writing about home care Watch for overly broad definitions of "competing business." A non-compete that prohibits involvement in "any healthcare business" would prevent you from joining a hospital board, investing in a physician practice, or working in healthcare IT. Push back on these expansions. --- ## Non-Solicitation: Employees and Clients Almost all home care sale agreements also include: **Non-solicitation of employees:** You may not recruit or hire employees of the acquired agency for a defined period (typically 2–3 years post-close). This protects the buyer's ability to retain the team it acquired. *Negotiation note:* This should apply to employees of the acquired agency — not all employees of any entity the buyer owns. If the buyer is a national platform, a broad non-solicitation could prevent you from working with former colleagues in geographies completely outside your sale. **Non-solicitation of clients:** You may not reach out to clients of the acquired agency to solicit their business to a competing enterprise. *Negotiation note:* This should be specific to clients at the time of close, not any client the buyer acquires after close in future acquisitions. --- ## What Happens If You Violate a Non-Compete? Home care M&A non-competes are contractual obligations backed by significant purchase price. Buyers who believe the non-compete is violated will: - Seek injunctive relief (court order requiring you to stop immediately) - Claim liquidated damages (often a defined dollar amount specified in the agreement) - Seek actual damages (revenue lost due to your competing activity) In most states, courts regularly enforce non-competes that are reasonable in scope, duration, and geography, particularly when the seller received significant monetary consideration for signing them. Courts are more likely to reform (not invalidate) overly broad non-competes by narrowing the geography or duration to what is reasonable. But you do not want to be fighting this in court — negotiate reasonable terms beforehand. --- ## State Variations in Non-Compete Enforceability Non-compete enforceability varies significantly by state: **California:** Business-to-business non-competes (where the seller sells a business) are treated differently than employee non-competes. Seller non-competes related to the sale of a business are generally **enforceable in California** (unlike employment non-competes). **Florida:** Among the most non-compete-friendly states. Seller non-competes are routinely enforced, and courts will apply them. **Massachusetts:** Non-competes for business sales are generally enforceable; the 2018 Non-Compete Act primarily applies to employment agreements, not business sale agreements. **Texas:** Non-competes are enforceable if they meet reasonableness requirements (reasonable time, geography, and business scope). **New York:** Generally enforceable for business sales if reasonable in scope. If you operate in multiple states, the governing law provision in your purchase agreement determines which state's law applies to the non-compete interpretation and enforcement. --- ## Practical Recommendations **1. Negotiate non-compete terms at the LOI stage.** LOIs often contain a brief description of expected non-compete scope ("customary non-compete of X years for the service territory"). Don't leave this as a vague placeholder, sketch the basic terms in the LOI so they are not re-litigated in the purchase agreement. **2. Think specifically about what you want to do after the close.** If you have a clear post-close plan that might overlap with the non-compete, advising other home care businesses, investing in home care, working in an adjacent service line, identify the conflict before you sign. It is far better to negotiate a carve-out upfront than to ask for permission to violate the non-compete later. **3. Insist on specific geographic definitions.** "Service area" is ambiguous. "The following counties" is not. Vague geographic terms almost always favor the buyer in disputes. **4. Request a broader carve-out for non-operational activities.** Teaching, writing, serving on advisory boards, and community involvement in healthcare should explicitly be outside your non-compete scope. --- **[Contact Hendon Partners to discuss the full terms of your home care sale →](/contact-us)** --- *This article is for informational purposes and does not constitute legal advice. Consult a qualified M&A attorney for guidance specific to your situation and jurisdiction.* --- ### The Home Care M&A Process: A Step-by-Step Guide from Decision to Close URL: https://www.hendonpartners.com/insights/home-care-ma-process-step-by-step Published: 2025-12-12 09:00 Category: Seller Guides > Every home care agency sale follows the same fundamental 8-step process. Understanding each step — what happens, what you need to do, and what can go wrong — is the foundation of a successful exit. Understanding the home care M&A process before you begin it is one of the most powerful advantages a seller can have. The buyers you will engage have run this process dozens or hundreds of times. Their advisors, accountants, and attorneys know every step precisely. You will run this process once. This guide demystifies the process from end to end — giving you the knowledge to engage as an informed participant, anticipate what comes next, and avoid the surprises that cost sellers money and deals. --- ## Step 1: Deciding to Sell, And What to Do Before Engaging Anyone The decision to sell your home care agency is personal, financial, and strategic. Before you speak to any buyer or advisor, clarity on three questions dramatically improves your outcome: **Why are you selling?** Burnout, retirement, estate planning, a desire to take chips off the table, health, family, there is no wrong answer. But your motivation affects your timeline, your flexibility on price vs. certainty, and whether a full sale or majority recap is the right structure. **What do you need to walk away with?** Model your post-tax, post-close requirements: retirement income needs, debt payoff, charitable goals. This gives you a realistic minimum threshold before any process begins. **Is the business ready?** The most common preparation gaps that reduce value: disorganized financials, an absent or thin management team, unresolved compliance issues, and high revenue concentration. The best time to fix these is 12–24 months before you engage. --- ## Step 2: Engaging a Specialized M&A Advisor The single most high-leverage decision you will make in your exit is whether to engage a specialized advisor, and which one. **What to look for:** - Exclusively or primarily focused on home-based care (hospice, home health, personal care, IDD, behavioral health) - Demonstrable closed transaction history (10+ home care transactions in the past 3 years) - Sell-side only representation (no buyer representation conflicts) - Active buyer network covering PE platforms, strategic acquirers, and national operators - Transparent fee structure (transaction fee of 3–6% is standard for home care) **The engagement letter:** The advisor engagement defines scope, exclusivity, fee structure, tail period, and expenses. Review it carefully with your M&A attorney before signing. --- ## Step 3: Pre-Sale Preparation and Positioning This phase typically runs 4–8 weeks after engagement. It is invisible to buyers but foundational to outcome. **Financial preparation:** Your advisor works through EBITDA normalization — identifying all legitimate add-backs to produce your adjusted EBITDA, the number buyers will use to value the business. Every add-back requires documentation. **Confidential Information Memorandum (CIM):** The CIM is the primary document buyers use to evaluate your business and build their financial models. It includes: - Business overview and history - Service lines and geographic markets - Financial summary (3 years + TTM) - EBITDA bridge (reported → normalized) - Operations overview - Management team bios - Growth opportunities - Transaction thesis The CIM positions your business in its most accurate and compelling light. A well-crafted CIM does more work than almost any other element of the process. **Financial model:** Your advisor builds an Excel-based financial model that buyers can use to underwrite the transaction. This typically includes historical P&L, revenue by payer and service line, a working capital model, and a simple returns analysis. **Buyer list development:** Your advisor develops a comprehensive list of every qualified buyer in the home care M&A market relevant to your business, organized by buyer type, geography, acquisition history, and current platform needs. --- ## Step 4: Market Launch and Buyer Outreach With materials ready, your advisor contacts the full buyer list simultaneously. **The blind teaser:** A one-to-two page document describing the opportunity without identifying the seller. It includes enough detail (market, service line, revenue range, EBITDA) for buyers to assess preliminary interest. **NDA execution:** Interested buyers sign a confidentiality agreement before receiving the full CIM. Your advisor manages the NDA process and tracks who has signed. **CIM distribution:** Credentialed buyers receive the full CIM. Your advisor fields initial questions and maintains engagement. **Typical timeline:** 2–4 weeks from launch to NDA execution wave. --- ## Step 5: Management Presentations Buyers who reviewed the CIM and want to advance request a management presentation, a 60–90 minute video call (sometimes in-person for larger transactions) where you present the business and answer buyer questions. **Preparation:** Your advisor will conduct mock presentations to prepare you for the range of questions buyers will ask: census trends, referral dynamics, compliance history, key employee retention, growth plans. **Who attends:** You, your key management (CFO or billing manager, clinical director, operations manager), and your advisor. Buyers typically bring 2–4 people including deal lead, analyst, and sometimes a portfolio operating partner. **Objective:** Build buyer confidence in the business and in the management team. Buyers are not just buying cash flow, they are evaluating whether they can work with you and your team through due diligence and after close. **Typical timeline:** 3–5 weeks; usually 6–15 management presentations. --- ## Step 6: Indication of Interest (IOI) and Letter of Intent (LOI) **Indications of Interest (non-binding):** After management presentations, buyers submit non-binding indications of interest specifying valuation range, structure, and key assumptions. Your advisor compares IOIs and identifies the 2–5 most competitive buyers to advance. **Final Letter of Intent:** The top buyers are invited to submit final LOIs — more specific, execution-ready offers. Your advisor reviews all final LOIs in detail, comparing: - Headline enterprise value - Working capital peg and mechanism - Deal structure (asset vs. stock, earnout, rollover) - Exclusivity period requested - Buyer close certainty (financing, existing portfolio, bid history) **LOI negotiation:** Your advisor negotiates with the preferred buyer to improve terms before you grant exclusivity. This phase determines the terms you will defend throughout due diligence. **LOI execution:** Once both parties sign the LOI, the exclusivity period begins. You are now committed to working exclusively with this buyer. **Typical timeline:** 3–6 weeks. --- ## Step 7: Due Diligence Due diligence is the buyer's thorough investigation of your business. It runs concurrently with purchase agreement negotiation (next step). **Who is involved on the buyer side:** - Quality of Earnings (QoE) accountants, financial analysis - Healthcare regulatory attorney, compliance and licensure review - Operational consultant, sometimes, for larger transactions - Environmental and insurance consultants — if applicable **What they review:** - Financial statements, tax returns, A/R aging, working capital - Medicare/Medicaid certification and cost reports - State licensing and inspection history - HR and caregiver records - Technology systems and contracts - Material vendor and payer contracts - Litigation and legal matters **The virtual data room:** All due diligence materials are organized in a secure online portal. Your advisor manages access, tracks what has been uploaded, and fields buyer requests. **Common due diligence findings:** - EBITDA restatements (QoE produces different normalized EBITDA than CIM) - Compliance issues previously not disclosed - Revenue concentration risks - A/R collection quality below expectations - Management team hiring needs These findings generate renegotiation requests. Your advisor manages these conversations. **Typical timeline:** 45–90 days. --- ## Step 8: Purchase Agreement, Regulatory Approvals, and Close **Purchase Agreement (APA or SPA):** The buyer's attorneys draft the definitive purchase agreement. Key provisions (structure, representations and warranties, indemnification, working capital mechanism, non-compete terms) are negotiated over 3–6 weeks. **Regulatory approvals (CHOW):** Change of Ownership applications for Medicare, Medicaid, and state licenses are filed, ideally shortly after LOI execution. CHOW timelines vary significantly by state and license type. **Closing mechanics:** - Attorneys do a pre-close walkthrough of all conditions and documents - A closing date is set when all conditions are satisfied - Wire instructions are confirmed (through secure communication channels, be alert to wire fraud attempts) - Closing calls execute the final documents - Buyer's bank wires the purchase price **Proceeds receipt:** The purchase price wire typically clears within 24–48 hours of closing. Some proceeds may go to escrow (typically 5–15% for a defined indemnification period). --- ## The Process Works When You Are Prepared The home care owners who achieve the best outcomes are those who enter the process prepared, financially, operationally, and personally. They know what the process looks like, they trust their advisors to manage the buyer dynamics, and they stay focused on running the business through close. The worst outcomes come from owners who are surprised at each step, who negotiate reactively, or who make emotional decisions under pressure from buyers who have run this process many times before. **[Contact Hendon Partners to begin your process →](/contact-us)** --- *Hendon Partners is a specialized home care M&A advisory firm. We guide owners through every step from initial decision through funded close.* --- ### What Happens After You Sell Your Home Care Agency: A Post-Close Owner's Guide URL: https://www.hendonpartners.com/insights/after-selling-home-care-agency Published: 2025-12-05 09:00 Category: Seller Guides > Most resources focus on how to sell your home care agency. Almost nothing prepares you for what comes after. Here's what to expect in the 12–24 months following your close — financially, operationally, and personally. The phone call comes. The wire clears. After months of due diligence, legal negotiations, and the emotional weight of deciding to sell a business you built over decades — it's done. The home care agency you created is no longer yours. What happens next is something almost no one talks about. This guide is written for the moment after close, the transition period, the financial realities, the personal adjustments, and the most common mistakes sellers make in the 12–24 months following a transaction. --- ## The Transition Agreement: What You Agreed To Most home care agency sale agreements include some form of **post-close seller involvement**, either a formal transition agreement, an employment agreement, a consulting agreement, or some combination. Before worrying about what comes after, it's worth reviewing what you actually agreed to at close: **Transition period (typically 30–180 days):** Most deals require the seller to provide transition services, introductions to referral sources, key employees, and payer contacts; answering operational questions; completing handoffs of institutional knowledge. Compensation varies from nominal to full salary. **Employment or consulting agreement (typically 1–3 years):** If you agreed to stay on as CEO, clinical director, or in another operating role, your terms of employment, compensation, authority, reporting structure, and termination rights — should be detailed in an executed employment agreement. **Non-compete agreement (typically 2–5 years):** You almost certainly agreed to a non-compete that restricts your ability to start or operate a competing home care business in a defined geography for a defined period. Understand the exact scope, service line, geographic radius, and what activities are prohibited. **Earnout obligations:** If your transaction included an earnout, the performance period is now active. Understand exactly what you need to achieve, what you control, and what reporting you should expect. --- ## The Financial Reality of Your Proceeds ### Tax Planning Becomes Immediate The close wire hits your account. If it's a large amount, your CPA should be involved before that money moves. **Initial steps:** - Federal and state estimated tax payments are likely due in the quarter of close - If you receive a large lump sum, under-withholding penalties can apply unless you make estimated payments - Your CPA should model your full tax liability before you deploy any capital **Working capital true-up timing:** As discussed earlier, the final working capital adjustment typically resolves 60–90 days post-close. A portion of your proceeds may be held in escrow pending this calculation. Don't spend the escrow amount before it's released. **R&W Insurance claims period:** If your deal used Representations and Warranties insurance, the seller's indemnification obligations are limited, but they still exist during the survival period (typically 18–24 months). Exercise caution about commitments that could conflict with your reps during this window. ### Reinvestment Planning After taxes, you have a large sum of liquid capital to deploy. This is a situation most financial advisors rarely encounter with their clients, and it requires specialized advice. **What to avoid:** - Deploying large capital in a single investment decision made in the euphoria of close - Self-directed investment in areas you don't deeply understand - "Re-entering" the home care market as an investor without understanding that the market sees you differently post-noncompete - Excessive lifestyle spending in the first year that distorts your long-term budget planning **What to prioritize:** - Working with a wealth manager who has experience with liquidity events (not your retail bank's wealth management arm) - Tax-efficient investing (municipal bonds, tax-deferred vehicles, carefully structured trust structures) - Diversification across asset classes and time horizons - Emergency liquidity buffer before deploying into illiquid investments --- ## The Transition Period: Operational Realities ### Your Authority Has Changed This is the most disorienting adjustment for most sellers. Even if you agreed to remain as CEO or operating executive, your authority is fundamentally different the day after close. Pre-close, you made decisions. Post-close, decisions you previously made unilaterally may now require board approval, PE partner approval, or alignment with the acquiring organization's processes. Common sources of transition friction: - Hiring and compensation decisions now require the buyer's approval - Vendor contract changes must go through the new organization's procurement process - Capital expenditures above a threshold (often $25K–$50K) require parent approval - Reporting requirements, monthly P&Ls, census dashboards, KPI reports — are now due to someone other than you **The right mindset:** You are now an executive within a larger organization, not an owner. The adjustment from owner-operator to executive is one of the most profound changes sellers describe. ### Existing Team Dynamics Your employees know you sold. Some are anxious. Key managers are fielding recruiting calls. Caregivers are wondering whether pay and schedules will change. The seller who stays on post-close and provides visible, calm, credible leadership in the first 90 days has a significantly better outcome, both for the transition and for the earnout, if applicable, than one who checks out psychologically. **Post-close communication priorities:** - Meet with your management team immediately post-close; be honest, factual, and optimistic - Communicate to your caregiver/DSP/clinical staff through your managers - Notify key referral sources personally (ideally alongside the buyer representative) that you are still involved and the care model will not change ### Integration Timelines If you sold to a strategic acquirer, integration will begin faster than you expect. Branding changes, billing system migrations, HR enrollment in new benefit plans, payroll processing changes, these are not 6-month projects. Some begin within 30 days. If you sold to PE (particularly as a platform investment with continued autonomy), the integration is slower but includes different changes: new financial reporting platforms, monthly board meetings, new HR admin software, and the regular rhythm of being part of a portfolio company. --- ## The Personal Adjustment The personal adjustment after selling a home care business is something owners rarely discuss and almost always experience. It is worth taking seriously. ### Loss of Identity and Purpose You built something. The business was your daily purpose, your community standing, your professional identity. When you sell it, even willingly, even joyfully, there is a genuine grief process for what you gave up. The owners who navigate this best are those who had a clear answer to "what next" before they signed the purchase agreement. That answer doesn't have to be another business. It can be family, philanthropy, a board position, an investment portfolio, or genuine retirement. But it needs to be real. ### The Relational Impact Your employees, many of whom you have worked with for years, are now working for someone else. Some will do well. Some will leave. Some will struggle. You will be watching, and you will feel responsible, even though you did what was right for you. This is normal. It doesn't mean you made a wrong decision. ### The Non-Compete as a Psychological Constraint Not being able to start a competing business — the thing you know best, while watching an industry you love evolve is psychologically challenging for entrepreneurial sellers. Some find it liberating; others find it suffocating. Know what you signed. Understand the scope. And make peace with it before close, not after. --- ## What Sellers Often Wish They Had Done Differently Over years of working with home care sellers during and after transactions, certain themes emerge: **"I wish I had done more tax planning earlier."** The clients who planned 18–24 months out consistently net 10–20% more than those who started planning at the LOI. **"I wish I had negotiated my role more specifically."** Vague terms like "operating executive for a transition period" become very contentious when the buyer and seller have different definitions. Specificity is protection. **"I wish I had invested in my management team earlier."** Several owners have said they received a lower multiple because the business was too dependent on them, and that 12–18 months of management development before sale would have produced a meaningfully better outcome. **"I wish I had taken more time before deploying the proceeds."** Large liquidity events create financial and psychological pressure to act. The best financial outcomes come from deliberate, patient deployment, not fast decisions under pressure. --- ## A Final Note Selling your home care agency is a profound achievement. You built a real business, created jobs, served patients and families, and created lasting value. Whatever comes next, the outcome of a well-run sale process is the financial foundation for everything ahead. If you are in the early stages of thinking about a future sale, the best thing you can do is start the conversation now, long before you need to close. **[Contact Hendon Partners to begin planning your exit →](/contact-us)** --- *Hendon Partners advisors have guided dozens of home care agency owners through the full arc of a sale, from initial planning through post-close transition.* --- ### Working Capital Adjustments in Home Care M&A: The Clause That Can Reduce Your Check by Hundreds of Thousands URL: https://www.hendonpartners.com/insights/working-capital-adjustment-home-care-ma Published: 2025-11-28 09:00 Category: Seller Guides > The working capital adjustment is often the most disputed element of a home care agency sale — and one of the least understood by sellers going into the process. Here's exactly how it works and how to protect yourself. The working capital adjustment is one of the most common sources of post-LOI surprises in home care transactions. Sellers agree to a headline price, get into due diligence and purchase agreement negotiation, and then discover that the "working capital peg" mechanism may reduce their actual proceeds by $200,000 to $1 million — sometimes more. This is not a buyer tactic. It is a legitimate part of M&A deal structure. But sellers who don't understand how it works, and who don't negotiate its terms carefully, consistently leave money on the table or receive less than they expected at closing. --- ## What Is Working Capital? In M&A, **working capital** is defined as **current assets minus current liabilities** at a specific moment in time (typically at close). The core concept is simple: every operating business needs a certain amount of "fuel in the tank", cash, accounts receivable being collected, and other liquid assets — to function normally. When a buyer acquires that business, they expect to receive it with the normal amount of fuel included. The **working capital peg** (also called the target) is the agreed-upon level of working capital that the seller must deliver at close. If working capital at close is above the peg, the purchase price increases dollar-for-dollar. If it is below the peg, the purchase price decreases. --- ## Why Home Care Has Complex Working Capital Issues Home care agency working capital is more complex than most industries because of: **Accounts receivable:** Home care agencies have large A/R balances because Medicare, Medicaid, and commercial insurance payers typically pay 30–90 days after services are rendered. But not all A/R is worth face value. Old receivables (90+ days) are frequently uncollectible. A/R reserves must be estimated correctly, and both parties need to agree on which receivables count toward working capital. **Unbilled revenue:** Home care agencies often have services rendered but not yet billed, because documentation is incomplete, authorization is pending, or billing has a backlog. This "unbilled" balance may or may not count toward working capital depending on how the purchase agreement defines it. **Payroll accruals:** Home care payroll is processed weekly or bi-weekly. At any closing date, there will be wages earned but not yet paid. These are current liabilities that reduce working capital. Buyers expect these to be included. **PTO accruals:** Accrued paid time off is a liability on your balance sheet. Depending on your state's law and your PTO policy, you may have meaningful PTO accrual that reduces working capital at close. **Medicare cost report settlements:** For Medicare-certified home health and hospice agencies, open Medicare cost reports represent contingent liabilities that must be addressed in the deal structure. These are typically excluded from working capital and handled via indemnification. **Deferred revenue:** If you received a Medicaid advance or capitated payment for services not yet rendered, this is a current liability that reduces working capital. --- ## How the Working Capital Peg Is Set The peg is typically set as the **average monthly working capital over the trailing 12 months**, excluding cash (which typically stays with the seller unless specifically included). The logic is that the average represents "normal" operating working capital. However: - If your business has been growing rapidly, the trailing 12-month average may understate your current working capital requirements (and disadvantage the seller in the true-up) - If you have been drawing down receivables or deferring payables in anticipation of a sale, the average may misrepresent the steady-state working capital level - Seasonal businesses will have very different working capital at different points in the year, the close date matters Negotiations about the peg methodology, the reference period, and the close date can have significant dollar impact. --- ## The Working Capital True-Up Process Because working capital cannot be precisely calculated until close — A/R continues to be collected, payroll continues to be processed, most deals use a **post-close true-up mechanism**: 1. At close, a **preliminary working capital estimate** is used as the basis for the initial payment 2. Within 60–90 days post-close, the buyer (using access to the books) calculates actual working capital at close 3. If actual working capital is above the peg, buyer pays seller the difference 4. If actual working capital is below the peg, seller pays buyer the difference (typically funded from an escrow) 5. Disputed items go to an **independent accounting firm arbiter** (not litigation, this is important) The true-up can create post-close payments in either direction. The amount can be substantial, we have seen true-up payments of $300,000–$700,000 in both directions on commercial home care transactions. --- ## What Sellers Should Negotiate ### Definition of Accounts Receivable Specify exactly: - Which aging buckets count toward working capital A/R (typically all A/R under 180 days from Medicare/Medicaid, with agreed-upon reserve percentages) - What reserve methodology applies (% of each aging bucket, or specific write-offs) - Whether unbilled or work-in-progress revenue is included ### Exclusion of Cost Report Liabilities Open Medicare cost reports should be explicitly excluded from working capital and placed in a separate indemnification framework with a defined liability estimate and reserve. ### PTO Accrual Treatment Whether accrued PTO is included as a working capital liability (reducing the peg, and therefore reducing your exposure to shortfall scenarios) is negotiable. Get explicit agreement in the LOI. ### Cash Inclusion Most deals exclude cash from working capital (seller keeps operating cash). The agreement should specify exactly what counts as "cash" vs. restricted cash vs. deposits. ### Peg Reference Period Negotiate for a reference period that represents normal working capital — not a period distorted by rapid growth, one-time events, or seasonal anomalies. ### Collar (Floor and Ceiling) Many deals include a "collar", a range within which working capital can vary before any true-up payment is required. For example, the first $150,000 in shortfall or surplus may be ignored, with true-up only applying to amounts outside the collar. This reduces the significance of minor variations. ### Dispute Resolution Timeline and Arbiter If the buyer's and seller's post-close working capital calculations differ, the dispute goes to an agreed-upon independent accounting firm. Specify: - Acceptable arbiters (typically Big 4 or large regional firms with no conflicts) - Timeline for submission and decision (30–60 days) - Binding nature of the arbiter's decision --- ## Common Post-Close Working Capital Disputes The most frequent sources of dispute: **A/R collection performance after close:** If receivables the seller counted as valuable are not collected by the buyer, the buyer argues they should have been reserved. The seller argues they were collectible. This dispute is very common in Medicaid-heavy agencies where payment delays can extend 90–120 days. **Pre-close billing accuracy:** If the seller had unbilled services that were included as working capital value but turn out to be uncollectible after close (due to documentation issues), the buyer seeks a working capital adjustment. **Undisclosed liabilities:** If liabilities not included in the seller's working capital calculation surface post-close, deferred payroll taxes, unrecorded vendor invoices, accrued vacation above what was represented, these create true-up claims. **Accounting methodology changes:** Post-close, the buyer may use a different accounting platform or methodology, classifying items differently than the seller did. Well-drafted agreements should specify that the close-date working capital is calculated using the seller's historical accounting policies, not the buyer's platform's default methods. --- ## Practical Recommendations for Sellers **1. Have your CPA calculate working capital before the LOI.** Understand your own working capital position before a buyer proposes a peg. Sellers who don't know their number are at a significant negotiating disadvantage. **2. Monitor working capital in the period leading up to close.** Don't let receivables age out or payables build up in the 90 days before close. Unusual working capital movements create true-up exposure. **3. Agree on A/R reserve methodology explicitly.** Don't leave A/R reserve calculation vague in the purchase agreement. A difference of 10% in the reserve rate on $2M of A/R is $200,000. **4. Understand the close date's seasonal implications.** If your business naturally has low working capital in January and high working capital in October, closing in January requires a careful look at whether the peg appropriately reflects close-date seasonality. **5. Use an experienced M&A attorney.** Working capital mechanics are technical and require specialized drafting. General business attorneys miss these nuances regularly. --- **[Contact Hendon Partners to discuss your home care transaction structure →](/contact-us)** --- *Hendon Partners specializes in home care M&A advisory. We have navigated complex working capital negotiations on dozens of transactions.* --- ### Behavioral Health M&A in 2026: Valuations, Buyers, and Market Outlook URL: https://www.hendonpartners.com/insights/behavioral-health-ma-2026 Published: 2025-11-21 09:00 Category: Market Intelligence > Behavioral health is experiencing the most active M&A market in its history. Mental health practices, SUD treatment programs, and outpatient behavioral services are attracting intense PE interest. Here's what your business is worth and who is buying. Behavioral health M&A has emerged as one of the most dynamic sectors in all of healthcare dealmaking. Private equity investment in mental health, substance use disorder (SUD) treatment, autism, and outpatient behavioral services reached record levels in 2024–2025, and early 2026 shows no signs of deceleration. For owners of behavioral health practices and organizations, this market environment represents a generational opportunity — but one that requires specialized knowledge of valuations, buyer motivations, and process to capture maximum value. --- ## Why Behavioral Health Is the Most Active Healthcare M&A Sector The behavioral health investment thesis is unusually strong across multiple dimensions: **1. Demand has structurally outpaced supply for years.** Mental health conditions affect 1 in 5 Americans annually. Wait times for psychiatric care in most major markets exceed 4–6 weeks. The provider shortage is severe, and no market signal indicates it will close. This creates stable, growing demand for every behavioral health provider. **2. Parity enforcement has expanded coverage.** The Mental Health Parity and Addiction Equity Act (MHPAEA) has been more aggressively enforced since 2022, requiring commercial insurance and Medicare Advantage plans to cover behavioral health on the same terms as medical-surgical care. This has unlocked commercial reimbursement in previously underfunded service lines. **3. Federal and state investment has increased.** SAMHSA grants, Medicaid expansion, and specific programs like the 988 Lifeline and COCM (Collaborative Care Model) reimbursement have expanded the financial infrastructure for behavioral health services. **4. Extreme fragmentation.** Behavioral health is extraordinarily fragmented, the majority of practitioners are solo or small-group practices without institutional infrastructure. PE sees the same consolidation opportunity that made home health and physician practices highly attractive sectors 5–10 years earlier. --- ## Behavioral Health Valuation by Service Line (2026) | Service Type | Typical EBITDA Multiple | |---|---| | Outpatient mental health (group practice) | 4.0 – 7.0× | | SUD/addiction treatment (outpatient/IOP) | 4.5 – 7.5× | | Residential behavioral health | 3.5 – 6.0× | | Applied Behavior Analysis (ABA / autism) | 6.0 – 10×+ | | Psychiatric practice (owned or contracted) | 5.0 – 9.0× | | Integrated behavioral health (primary care + BH) | 6.0 – 10×+ | | Crisis services (CSU, crisis centers) | 5.0 – 8.0× | *ABA commands the highest multiples in behavioral health due to strong commercial insurance revenue, evidence-based outcomes, and exceptionally strong demand.* --- ## High-Demand Service Lines in 2026 ### Applied Behavior Analysis (ABA) ABA therapy for autism spectrum disorder remains the most actively acquired behavioral health service. Demand is structurally robust, autism diagnoses have increased dramatically, commercial insurance coverage is mandated in nearly all states, and there are far more children who need ABA than centers that can serve them. ABA organizations with commercial insurance revenue (vs. Medicaid-only), strong BCBA retention, and growth trajectories regularly achieve 8–11× EBITDA in competitive processes. The buyer universe for premium ABA agencies includes both large national platforms and PE firms making first-time behavioral health investments. ### Outpatient Mental Health Group Practices Large DSM-5-diagnosis group practices — psychologists, licensed clinical social workers, counselors, and prescribers, are actively sought by PE-backed mental health platforms building regional and national networks. The consolidation logic: individual practices have minimal back-office infrastructure, which creates immediate PE value creation through centralized billing, credentialing, and HR. Premium multiples go to practices with: - A mix of prescribers (psychiatrists, NPs, PAs) and therapists on the same platform - Commercial insurance dominance (60%+ commercial) - Telehealth capability enabling geographic reach - Documentation and outcome measurement systems ### CCBHC (Certified Community Behavioral Health Clinic) CCBHC certification is an increasingly powerful revenue driver. Certified organizations receive enhanced Medicaid payments well above standard rates, draw federal grant support, and operate under a comprehensive care model. Buyers with CCBHC knowledge are actively acquiring because CCBHC organizations are both financially attractive and expansion-ready. ### Integrated Behavioral Health Organizations that integrate behavioral health with primary care, through co-location, telehealth collaborative care, or care management programs — represent the future of value-based behavioral health delivery. The Collaborative Care Model (CoCM) in particular has strong evidence and growing payer support. Buyers pay premium multiples for true integration. --- ## Key Valuation Drivers in Behavioral Health ### Payer Mix The most influential single variable. The valuation hierarchy: 1. **Commercial insurance (highest value):** Federal parity requirements have driven commercial rates up, and MA plans are increasingly covering behavioral health extensively. 2. **Medicare:** Growing coverage through Medicare Advantage, and through value-based care arrangements. 3. **Medicaid:** Dominant payer for most behavioral health but subject to state budget risk and rate variability. Medicaid-dominant practices receive meaningful multiple discounts relative to commercially-dominant peers. 4. **Out-of-pocket private pay:** Only relevant for premium practices not accepting insurance; valued differently (revenue multiple methodology rather than EBITDA multiple). ### Provider Retention (Specifically Clinical Staff) In behavioral health, the therapist or clinician *is* the product. A practice that has invested in provider retention, competitive compensation, strong culture, low administrative burden, appropriate caseloads, is worth dramatically more than one with chronic therapist turnover. PE buyers will specifically examine: - Annual clinician turnover rate - BCBA turnover (for ABA organizations) - Prescriber turnover (for organizations with psychiatrists or NPs) - Clinical vacancy rate (positions open vs. needed) - Average caseload per clinician (a proxy for burnout risk) ### Organizational Dependency on a Single Provider If your practice depends significantly on a single psychiatrist, clinical director, or founder-therapist's referrals, patient relationships, or credentials, buyers will discount or require earnout protections. Distributing clinical capability across multiple providers is an essential pre-sale preparation step. ### Documentation, Credentialing, and Compliance Behavioral health practices are frequent subjects of Medicaid and commercial insurance audits, particularly in high-growth service lines. Buyers scrutinize: - Clinical documentation completeness and timeliness - Provider credentialing status with all payers - Any past or pending payer audits or overpayment demands - HIPAA compliance program - Any state licensing board investigations --- ## The Current Buyer Landscape **National behavioral health platforms (PE-backed):** Optum Behavioral Health, Mindpath Health, LifeStance Health, Elara Caring Behavioral, and dozens of newer platforms building regional chains. **ABA-specific platforms:** Learn Behavioral, Verbal Beginnings, Centria Autism, and many smaller regional platforms backed by PE. **Health systems:** Major health systems increasingly acquiring or affiliating with behavioral health organizations to manage population health and close care gaps. **Payer-owned providers:** Commercial insurance companies such as UnitedHealth (Optum), Cigna (Evernorth), and Humana are actively building behavioral health delivery capacity, either through acquisition or joint venture. **PE first-time platform builders:** Dozens of PE firms are entering behavioral health for the first time in 2025–2026, making their initial platform investment in the sector. --- ## Regulatory Considerations Specific to Behavioral Health **State licensure complexity:** Behavioral health organizations often hold multiple licenses (outpatient behavioral health license, SUD license, group home license, etc.). Change-of-ownership requires notification or approval of each, which varies by state and license type. **CON requirements:** Some states require Certificate of Need for residential behavioral health or detox facilities. **Federal 42 CFR Part 2:** Substance use disorder treatment records are subject to more stringent federal confidentiality requirements than standard HIPAA. Buyers must navigate this in due diligence data room access. **State-specific SUD licensing:** Multi-site SUD providers face complex multi-state licensing situations, particularly for residential levels of care. --- ## Preparing Your Behavioral Health Organization for a Sale The preparation steps for behavioral health M&A mirror those for other healthcare businesses, with some specifics: 1. **Diversify payer mix toward commercial insurance** — credential with additional commercial plans 12–18 months before going to market. 2. **Reduce provider dependency**, hire and develop clinical leaders who have their own patient panels and referral relationships. 3. **Document everything**, clinical notes, credentialing files, compliance policies. 4. **Resolve any payer audits or licensing findings** before going to market. 5. **Build management depth**, a COO, clinical director, or director of operations who can run the business without you. --- **[Contact Hendon Partners to discuss your behavioral health organization →](/contact-us)** --- *Hendon Partners advises behavioral health and home-based care organizations. Our team has experience in ABA, mental health, SUD, and integrated care M&A transactions.* --- ### Private Duty Nursing Agency Valuation: What Buyers Pay and Why URL: https://www.hendonpartners.com/insights/private-duty-nursing-agency-valuation Published: 2025-11-14 09:00 Category: Valuation Insights > Private duty nursing agencies serving medically complex patients are among the highest-value home care businesses per dollar of revenue. Here's what drives PDN valuations in 2026 and what buyers look for in this specialized market. Private duty nursing (PDN) is one of the most specialized and highest-value niches within home-based care. Agencies serving medically complex patients — children and adults requiring skilled nursing many hours per day, often funded through Medicaid Technology-Dependent Children waivers, TEFRA programs, or Long-Term Care waivers, occupy a distinctive position in the M&A market. High barriers to entry. Strong payer relationships. Medically essential care that is difficult to replace. These characteristics make quality PDN agencies attractive acquisition targets, when they are prepared and positioned correctly. This guide covers what PDN agencies are worth in 2026, what drives valuations, who the buyers are, and how to position your agency for a premium transaction. --- ## What Is Private Duty Nursing (For Valuation Purposes)? For M&A purposes, "private duty nursing" typically refers to agencies providing: - **State waiver-funded skilled nursing** for technology-dependent children (trach/vent, TPN, complex medical needs) - **Long-term care Medicaid waiver nursing** for medically complex adults - **Private pay skilled nursing** at high hourly rates for affluent families - **Pediatric home health** with significant skilled nursing component This is distinct from: - Medicare-certified home health (episodic, condition-driven) - Non-skilled personal care or companion services - Intermittent skilled therapy (PT/OT/ST) PDN patients typically receive 8–24 hours of nursing per day. The revenue per patient is extraordinarily high, often $150,000–$300,000+ per patient per year. And once a PDN relationship is established with a medically complex pediatric or adult patient, churn is extremely rare. --- ## PDN Valuation Benchmarks (2026) | Agency Profile | EBITDA Multiple Range | |---|---| | Small PDN operator (<$500K EBITDA, single state) | 3.5 – 5.5× | | Mid-size PDN operator ($500K – $2M EBITDA) | 5.0 – 7.0× | | Large multi-state PDN platform ($2M+ EBITDA) | 6.5 – 9.0× | | Specialized pediatric vent/trach programs | 7.0 – 10×+ | *Note: Valuations reflect engaged, competitive M&A process; individual unsolicited offers run 20–40% below these ranges.* PDN multiples are generally higher than non-skilled personal care (EBITDA multiples of 2.5–4.5×) for the structural reasons discussed below. --- ## Why Private Duty Nursing Commands Premium Value ### Critical Medical Necessity PDN services are not discretionary. A vent-dependent child requires 16 hours of nursing per day to survive at home. This is not care that can be paused, reduced, or switched to a different provider without profound disruption. Once an agency is established as that family's provider, the relationship is effectively permanent barring significant quality failure. This characteristic — essential, high-stakes, relationships that typically last years, creates the kind of predictable, low-churn revenue that PE investors pay premium multiples to acquire. ### High Revenue Per Patient A PDN patient generating $250,000 per year in revenue is worth dramatically more to a buyer than 20 personal care clients generating $10,000–$15,000 each. The revenue concentration in individual patients is high, but so is the stickiness, and the per-patient economics are far superior. ### Licensing Barriers to Entry In many states, PDN providers must hold specific licenses, pediatric nursing, ventilator care certifications, clinical program accreditations — that take meaningful time and capital to acquire. States with strong waiver programs (Texas, Ohio, New York, Georgia, Illinois, Florida) have established provider ecosystems where starting a new PDN agency from scratch is exceptionally difficult. Buyers pay for licensed, operating PDN agencies in part because they cannot easily build the equivalent. ### Skilled Clinical Staff as Moat A PDN agency's nursing staff, particularly those with pediatric, vent, or trach experience, are scarce and highly specialized. An agency that has recruited, trained, and retained a clinical nursing staff of 20–50 skilled nurses has built something that is genuinely hard to replicate. Buyers recognize and value this. --- ## The Critical Value Drivers for PDN Agencies ### Patient Census Stability Because individual PDN patients generate very high revenue, census stability at the patient level is the primary risk buyers underwrite. They examine: - Average length of service per patient (ideally years, not months) - Discharge patterns, are patients aging out, transitioning to residential care, or experiencing care failures? - Concentration — if 10 patients generate 50% of revenue, what is the sensitivity to losing one? For pediatric PDN specifically, buyers model the likelihood that patients will age into adult waiver programs rather than discharge. In states with robust adult Medicaid waiver programs, this transition typically sustains revenue, patients don't "graduate" from needing care. ### Nursing Retention and Wages PDN agencies face the same nursing shortage as the rest of healthcare, amplified by the specialized skillset required. An agency with high nursing turnover faces referral source dissatisfaction, incident rate increases, and census instability. Buyers ask: - What is annual licensed nurse turnover (as distinct from aide turnover)? - Are nurses W-2 employees or 1099 independent contractors? (1099 nurses carry misclassification risk that buyers discount for) - What is your average nurse-to-patient continuity ratio? (Higher continuity = better outcomes = more stable census) **The 1099 nurse risk:** Many PDN agencies staff using independent contractors to reduce employment overhead. Buyers are increasingly cautious about agencies with predominantly 1099 nurse workforces, because IRS and state labor enforcement has increased scrutiny of nurse classification. Agencies that convert to W-2 prior to sale reduce this risk and typically see improved valuation. ### State Waiver Program Quality Not all Medicaid waiver programs are equal. States like Texas (STAR PLUS, STAR Kids), Ohio (PASSPORT), and Florida (iBudget) have large, well-funded programs with established referral ecosystems. States with underfunded or highly bureaucratic waiver programs create revenue risk. Buyers will assess: - Current Medicaid rate levels and recent trend - Pending rate changes or budget risk - Prior authorization complexity and denial rate - Case manager relationship quality ### Referral Source Diversification In PDN, primary referral sources are typically: - NICU and PICU discharge planners at children's hospitals - Pediatric pulmonology and neurology practices - Adult hospital discharge planning departments - Medicaid case management agencies Agencies heavily dependent on a single hospital system for referrals are at risk if that hospital changes its preferred PDN provider list or hires a competitor. Buyers discount for hospital concentration above 30–40% of referrals. --- ## The PDN Buyer Universe **Large home care platforms** that serve medically complex populations (e.g., BrightSpring Health Services, Sevita's home nursing programs, LHC Group, Bayada Home Health Care) are strategic acquirers in this market. **PE-backed PDN-focused platforms** are the most active buyers. Several PE firms have specifically entered the PDN space because of its premium characteristics. **Regional hospital system acquisition** is a meaningful but sporadic buyer type, health systems that want to keep complex pediatric patients in-home as part of a broader care management strategy. --- ## Common Issues That Reduce PDN Agency Value **High 1099 nurse concentration.** Regulatory risk from IRS and state labor boards is a material valuation discount factor. **Single hospital referral concentration.** >40% of referrals from one source is a significant risk. **Open Medicaid audits or overpayment notices.** PDN agencies often have large revenue per day of service, which makes Medicaid auditors attentive. Open audits create contingent liability. **Poor documentation practices.** PDN care requires detailed nursing notes, physician orders, and prior authorization compliance. Agencies with documentation deficiencies face billing hold risk and compliance liability. **Lack of accreditation.** CHAP or ACHC accreditation is increasingly expected by institutional buyers and by state programs. --- ## Getting a Real Valuation PDN agency valuation is genuinely specialized. Advisors without specific PDN deal experience frequently misvalue these agencies, because they apply non-skilled personal care multiples to businesses with fundamentally different characteristics. If you own a PDN agency and are considering a sale or explorer, request a preliminary valuation from advisors with demonstrated PDN transaction experience. **[Contact Hendon Partners for a confidential PDN valuation →](/contact-us)** --- *Hendon Partners advises owners of home health, hospice, private duty nursing, personal care, and IDD agencies. Our team has experience in pediatric, geriatric, and medically complex care M&A.* --- ### How to Find a Buyer for Your Home Care Agency (The Right Way) URL: https://www.hendonpartners.com/insights/how-to-find-buyer-home-care-agency Published: 2025-11-07 09:00 Category: Seller Guides > Finding the right buyer for your home care agency is not about listing on BizBuySell or waiting for a cold call. The buyers who pay the highest prices are rarely the ones who find you first. Here's how the process actually works. "How do I find a buyer for my home care agency?" It's one of the most common questions owners ask when they start thinking seriously about an exit. The assumption behind the question is often wrong — most sellers assume finding a buyer is the hard part. It isn't. The real challenge is not finding *a* buyer. It's finding the *right* buyers, the 5–15 highly qualified, financially credible acquirers who will compete for your business and drive the price to its genuine market value. This guide explains how buyers find home care agencies, how agencies find buyers, and, most importantly, how a professional process produces dramatically better outcomes than both. --- ## How Buyers Are Currently Finding Home Care Agencies Understanding how the buyer side works helps you recognize why reactive selling puts sellers at a disadvantage. **Direct outreach from PE-backed platforms.** Private equity-backed home care companies have dedicated M&A teams, sometimes called Corporate Development — whose full-time job is identifying and approaching potential acquisition targets. They monitor state licensee lists, attend industry conferences, and review LinkedIn actively. When they call you, they have already researched your agency. They know your approximate revenue, your payer mix (from public data), and your geography. They have a price they are willing to pay, and it is calibrated to assume you are not working with an advisor and have no competing offers. **Investment bankers and brokers calling on behalf of buyers.** Some firms represent buyers (rather than sellers). They are paid to source deals for their clients. When they contact you, they are working for the buyer, not for you. **Business listing sites (BizBuySell, BusinessForSale.com).** Posting your agency on a business listing site is equivalent to putting a "for sale" sign in your window with the price attached. The buyers who browse these sites are typically: - Small regional operators who can't access institutional capital - Individual buyers with financing contingencies - Intermediaries scouting for clients These are rarely the buyers who pay premium multiples. And listing publicly announces to employees, competitors, referral sources, and payers that your business is for sale, which can destabilize operations before any deal closes. **Your accountant, attorney, or banker.** Well-meaning but typically poorly positioned. General professional advisors do not have relationships with the 80+ PE-backed home care platforms, national strategic acquirers, and regional operators who are most likely to pay premium prices for your specific business. --- ## Why Waiting for the Right Buyer to Find You Is a Mistake The buyers who approach you proactively have already decided what they are willing to pay. More precisely: they have modeled your business at the lowest price they believe you will accept, without competition. This is not cynical — it is rational. Every buyer is negotiating. A sophisticated acquirer knows that: 1. If they are the only buyer at the table, there is no market clearing mechanism 2. Without market clearing, the seller has no way to know whether the offer is fair 3. The absence of competition is worth millions of dollars to the buyer This dynamic consistently produces below-market outcomes for sellers who "find a buyer" on their own. The research is clear: sellers who run competitive processes with multiple qualified buyers receive **24–40% more** in transaction value than sellers who negotiate with a single buyer. On a $10M transaction, that is $2.4M–$4M in additional proceeds. --- ## What a Real Buyer Identification Process Looks Like A professional M&A process for a home care agency involves systematically identifying and contacting every credible potential buyer, not waiting for them to find you. ### Step 1: Build a Comprehensive Buy-Side Universe A specialized home care M&A advisor maintains active relationships with: - 80–120 PE-backed home care platforms nationally and regionally - National strategic acquirers (Addus, Amedisys/UnitedHealth, Enhabit, etc.) - Regional operators in adjacent geographies - Health systems with home care ambitions - Private equity firms making first-time home care investments For any given agency, the appropriate buyer list is typically 50–150 organizations, filtered by geography, service line, size requirements, and current acquisition activity. ### Step 2: Blind Teasers to the Full List A one-to-two page summary called a "blind teaser" is distributed to the full buyer list. It describes the business without identifying it, markets served (e.g., "northwest metropolitan market"), service line, scale (revenue range), and key financial characteristics. Interested buyers execute an NDA before receiving the Confidential Information Memorandum (CIM) with full details. ### Step 3: The CIM Creates the Market The CIM is a professional, detailed presentation of your business, financials, operations, growth strategy, market position, and management team. It is the document that buyers use to build their initial financial model and decide whether to bid. A well-crafted CIM does not just inform — it **positions**. It frames the business in its most compelling accurate light, emphasizes the opportunities that matter most to each buyer type, and anticipates and addresses concerns before they become objections. ### Step 4: Management Presentations Create Relationships Qualified buyers are invited to meet you and your management team. This is a 60–90 minute presentation and Q&A. It is your opportunity to convey what the numbers can't, the culture, the growth vision, the team quality, and the reasons buyers should want to own this business. ### Step 5: Competitive Bid Process Buyers submit competing offers (Letters of Intent or Indications of Interest). With multiple credible offers on the table, your advisor negotiates from position of strength, using each offer as leverage against the others and systematically improving terms across all bidders. ### Step 6: Select the Best Overall Offer "Best offer" is not just the highest price. It includes deal certainty (has the buyer closed similar transactions?), speed (do they have capital committed?), structure (cash at close vs. earnout), post-close terms (non-compete scope, employment agreement), and fit (PE firm quality, operator reputation). A well-run process produces 5–15 competitive offers and a clear answer on which buyer combination of price, terms, and fit is optimal for your situation. --- ## The Types of Buyers and What They Pay | Buyer Type | Typical Multiple | Speed | Earnout Likelihood | |---|---|---|---| | PE-backed platform (add-on) | 4.5 – 7× EBITDA | Fast | Low | | PE firm (platform investment) | 5.5 – 9× EBITDA | Moderate | Moderate | | National strategic acquirer | 3.5 – 6× EBITDA | Slow | Low | | Regional strategic acquirer | 3.0 – 5.5× EBITDA | Moderate | Moderate | | Individual/lifestyle buyer | 2.5 – 4× EBITDA | Variable | High | *Ranges reflect market conditions as of early 2026. Actual multiples depend on agency-specific characteristics.* The highest multiples consistently come from PE-backed platforms and PE firms making platform investments, the buyers who are least likely to approach you directly on your own. --- ## Do I Really Need a Broker or M&A Advisor? Every seller asks this question. The calculation is straightforward: A specialized M&A advisor typically charges a transaction fee of 3–6% for home care agency sales (lower on larger transactions). On a $10M sale, that is $300K–$600K. Research consistently shows that represented sellers receive 24–40% more than unrepresented sellers. On a $10M sale, that is $2.4M–$4M in additional value. The question is not whether an advisor costs money. The question is whether the net benefit, additional proceeds minus advisory fee, is positive. For virtually every home care seller in the $2M–$50M+ enterprise value range, the answer is overwhelmingly yes. What varies is **advisor quality**. A generalist business broker who lists your agency on BizBuySell and sends blind emails will not produce the competitive tension that drives premium pricing. A specialized home care M&A advisor with active relationships across the entire buyer universe will. --- ## Questions to Ask Before Engaging an Advisor Not all advisors are equal. When evaluating M&A representation: 1. **How many home care agencies have you closed in the past 3 years?** (Minimum: 10+) 2. **Can you provide a list of all buyers you have contacted on the last 3–5 comparable transactions?** (The answer tells you how broad their buyer coverage is.) 3. **What are your last 10 closed transactions' enterprise values and EBITDA multiples?** (Verified against public records or reference calls) 4. **Do you represent buyers as well as sellers?** (Conflict of interest if yes) 5. **What is your average days-to-close from engagement to funded close?** --- **[Contact Hendon Partners to discuss finding the right buyers for your home care agency →](/contact-us)** --- *Hendon Partners is a sell-side-only M&A advisory firm. We represent sellers. We do not represent buyers, which means there is no conflict of interest in our advocacy.* --- ### Tax Planning Before You Sell Your Home Care Agency: What to Do 12–24 Months in Advance URL: https://www.hendonpartners.com/insights/tax-planning-selling-home-care-agency Published: 2025-10-31 09:00 Category: Seller Guides > The tax structure of your home care sale can reduce your net proceeds by 10–20% — or protect them. The strategies that matter most must be implemented 12–24 months before close. Here's what every owner needs to know. A profound number of home care owners who sell their businesses pay far more in taxes than they had to — not because the tax laws were different, but because they didn't plan. Tax planning before a home care agency sale is not about loopholes or aggressive strategies. It is about understanding the structure of your transaction, implementing legitimate tax-reduction strategies that take time to put in place, and working with qualified advisors who have done this before. The window for most of the high-impact strategies is **12–24 months before closing**. Not three months. Not 30 days. If you wait until you're in due diligence, most of the planning opportunities are gone. This guide outlines the most important pre-sale tax planning considerations for home care agency owners. --- ## The Fundamental Tax Question: How Is the Deal Structured? Your tax bill starts with the deal structure. In home care M&A, transactions are structured as either: - **Asset purchase:** Buyer purchases specific assets (licenses, contracts, patient records, goodwill, equipment). You retain the corporate entity and receive the sale proceeds inside the corporation or directly. - **Stock/equity purchase:** Buyer purchases your equity in the business. LLC membership interests, S-corp shares, or C-corp stock. The corporate entity changes hands. **Why it matters:** Asset sales and stock/equity sales are taxed very differently, and the difference can be millions of dollars. In a **stock sale**, if your business qualifies, the entire gain can potentially be taxed at **long-term capital gains rates** (20% federal + 3.8% NIIT for high earners + state). This is the most favorable outcome. In an **asset sale**, the gain is allocated across different asset classes, some taxed at ordinary income rates (up to 37% federal for recaptured depreciation or compensation-classified goodwill), some at capital gains rates. The blended effective rate is often higher than a pure stock sale. Buyers almost always prefer asset purchases (cleaner, step-up in tax basis). Sellers almost always prefer stock sales (lower tax rates). This tension is negotiated in every transaction. --- ## Key Tax Planning Strategies (And the Timeline That Matters) ### 1. Qualify for Qualified Small Business Stock (QSBS) — Section 1202 **What it is:** If you hold equity (C-corporation stock) that qualifies under IRC Section 1202 as Qualified Small Business Stock, you can exclude up to $10M (or 10× your cost basis, whichever is greater) of capital gain from federal income tax entirely. **The catch:** The stock must have been issued originally to you as a C-corporation with assets under $50M at the time of original issuance, and you must hold it for more than 5 years before sale. **Why it matters:** For qualifying founders, Section 1202 can eliminate millions in federal capital gains taxes. **The 12–24 month planning action:** If your business is structured as an S-corp or LLC and you are considering a sale in the next 3–7 years, evaluate whether converting to a C-corp and issuing fresh QSBS makes sense. The 5-year holding clock starts at conversion/issuance. *Note: S-corps and LLCs do not qualify for QSBS. Most home care agencies are organized as LLCs or S-corps, which means this strategy requires restructuring and a planning horizon.* ### 2. Installment Sale Treatment **What it is:** If any portion of your purchase price is paid over time (seller note, earnout), you can elect installment sale treatment, paying capital gains taxes only as you receive each installment, rather than the entire gain in the year of sale. **Why it matters:** If your sale price is large enough to push you into the highest tax bracket, deferring recognition can reduce your effective tax rate in high-income years and allow you to spread recognition across potentially lower-rate future years. **The planning action:** Work with your tax advisor to model whether installment sale treatment produces net tax savings, factoring in the time value of payments, rates assumptions, and state tax treatment. Not all states follow federal installment sale rules. ### 3. Charitable Giving Strategies Before Sale **What it is:** Donating appreciated equity (LLC interests, S-corp shares) to a Donor Advised Fund (DAF) or charitable remainder trust (CRT) before a transaction closes eliminates capital gains tax on the donated portion and generates a charitable deduction. **Why it matters:** If you plan to make charitable gifts and you do so after the sale (when you have cash), you are giving post-tax dollars. If you give the appreciated equity before sale, the appreciation escapes capital gains taxation, and you receive a charitable deduction based on fair market value. **Example:** Your agency will sell for $10M. You plan to donate $1M to charity anyway. If you donate $1M in equity before close, you avoid paying approximately $238,000 in capital gains taxes on that $1M + receive a $1M charitable deduction (saving an additional ~$370K in income taxes, subject to limitations). **The 12-month action:** Establish a DAF well before the sale process begins. Donate the equity to the DAF after LOI execution but before close, the value must be determined, which can require a 409A valuation. ### 4. Structure the Deal as a Stock Sale **What it is:** Negotiating for stock/equity deal structure rather than asset purchase structure. **Why it matters:** A stock sale eliminates ordinary income treatment on portions of the purchase price (specifically non-personal goodwill and covenant-not-to-compete allocations, which in asset deals are taxed at ordinary income rates). **The reality:** Buyers strongly prefer asset deals and will often resist stock sales. However, in competitive processes where multiple buyers are bidding, sellers gain leverage to negotiate structure. Some buyers will accept stock sales in return for slightly lower headline pricing. **The planning action:** Before going to market, your M&A attorney and tax advisor should model the post-tax proceeds under both asset and stock structures at various headline prices. In many cases, a stock sale at a 5% lower headline price produces more in net after-tax proceeds than an asset sale at full price. ### 5. State Tax Residency Planning **What it is:** If you reside in a high-tax state (California, New York, New Jersey — with marginal state income tax rates up to 13.3%), the state tax cost on a home care sale can be substantial. **Why it matters:** California taxes capital gains as ordinary income at the full state rate. A $10M gain in California bears up to 13.3% in state taxes, or approximately $1.3M, compared to a Florida or Texas resident who pays $0 in state taxes. **The planning action:** Changing your domicile to a no-income-tax state (Florida, Texas, Nevada, Washington, Tennessee) is a legitimate tax planning strategy, but it must be done 12–24 months before the sale, properly executed (genuine change of residency, not just a mailbox), and with evidence of intent to permanently reside there. States like California aggressively audit supposed domicile changes, particularly in connection with large income events. *This requires careful legal advice — not a simplistic move.* ### 6. Entity Structure Review and Optimization **What it is:** Reviewing whether your current entity structure (LLC, S-corp, C-corp) is optimal for a sale transaction. **Why it matters:** - S-corporations have restrictions on buyer entities (no corporate shareholders) that can complicate deal structure - LLCs have maximum flexibility but may have different A/P treatment - C-corporations work best for QSBS strategies but come with double-taxation risk absent careful planning **The planning action:** At least 12 months before a planned sale, have your M&A tax advisor review your entity structure in the context of your likely buyer universe and transaction structure. Restructuring after a letter of intent is signed is extremely difficult. --- ## The Advisors You Need Tax planning for a significant home care sale requires: **1. CPA or tax attorney with M&A transaction experience** (not just a general CPA who files your annual returns). You need someone who has structured dozens of business sales and understands deal structure, asset allocation, installment sales, and QSBS. **2. M&A attorney with healthcare experience** who can advocate for stock vs. asset deal structure and understands the regulatory implications of each. **3. Financial advisor** for post-sale wealth management planning, reinvestment, estate planning, and tax-efficient investment structure for your proceeds. **4. M&A advisor** who understands the buyer universe and can structure a process that maximizes both gross price and deal structure flexibility. --- ## What Happens If You Wait Too Long? The most common scenario we see: an owner receives an unsolicited offer, gets excited about the price, signs an LOI, and then engages a CPA for the first time to help with taxes. By that point: - QSBS eligibility has not been established (requires years of holding qualified stock) - Charitable giving strategies are difficult to execute in a live deal (timing and valuation issues) - Domicile change is too recent to withstand scrutiny - Entity structure is locked in by the LOI terms The result is a transaction that produces the expected gross proceeds but 15–20% less in net after-tax proceeds than the same transaction, properly planned. --- ## Start the Planning Conversation Now If a sale is on your 2-to-5 year horizon, the planning conversation should start today. Most strategies require lead time, and doing this right is worth several hundred thousand dollars or more in additional take-home proceeds. **[Contact Hendon Partners, we work with M&A tax advisors and can connect you with specialized resources →](/contact-us)** --- *This article is for informational purposes and does not constitute legal or tax advice. Consult a qualified tax advisor for guidance specific to your situation.* --- ### Earnout Agreements in Home Care M&A: When to Accept and When to Walk Away URL: https://www.hendonpartners.com/insights/earnout-agreements-home-care-ma Published: 2025-10-24 09:00 Category: Seller Guides > An earnout looks like more money. It often isn't. Understanding when earnouts protect sellers — and when they are a trap that transfers risk without reward — is essential before signing any home care acquisition agreement. The earnout is one of the most commonly misunderstood — and most commonly misused, tools in M&A deal structures. Buyers love them. Sellers often accept them without fully understanding the risks. Disputes over earnout payments are among the most common forms of post-close litigation in healthcare M&A. This guide explains exactly what earnouts are, when they make sense for home care sellers, the terms to negotiate, and the situations where you should push back hard or decline entirely. --- ## What Is an Earnout? An earnout is a **contingent purchase price mechanism** that provides additional compensation to the seller if the business achieves certain performance benchmarks after the transaction closes. Basic example: > Buyer pays $8M at close, with an additional "earnout" of up to $2M if the agency's EBITDA exceeds $2M in the 12 months following close. From the headline perspective, this looks like a $10M deal. In reality, it is an $8M deal with a conditional option to receive $2M, one the seller may or may not ever collect. --- ## Why Buyers Use Earnouts Buyers propose earnouts for a reason, usually one of three: **1. Valuation gap.** The buyer and seller agree the business is worth somewhere between $7.5M and $10M, but they can't agree on a precise number. The earnout bridges the gap by saying: "You'll get $10M if you're right; $7.5M if we're right." **2. Revenue concentration risk.** If your agency depends heavily on a few key referral sources or clients, the buyer may structure an earnout to protect against the risk that those relationships don't transfer post-close. **3. Founder dependency.** If the business depends heavily on the owner's relationships or clinical leadership, the buyer uses an earnout to align the seller's incentive to stay engaged and transition effectively. In each case, the earnout transfers risk from buyer to seller. The key question for every seller is: **is that risk-transfer fair and is it priced fairly?** --- ## When Earnouts Are Legitimate and Appropriate Earnouts are not inherently bad. There are situations where they are appropriate and can genuinely benefit sellers: ### Bridging a Genuine Valuation Gap If your agency had an exceptional year that you believe is repeatable but the buyer is skeptical of, an earnout lets you "prove it" and get paid accordingly. If you're right, you get more. If the buyer is right and performance reverts, the earnout compensates for the risk they took. **Seller requirement:** You must have **operational control** over the business post-close for this to be fair. If you have no control over staffing decisions, marketing spend, or operational policy, you can't be responsible for hitting a revenue target. ### Transition Period in a Founder-Dependent Business If the business genuinely depends on you — your clinical license, your referral relationships, your community reputation, it is not unreasonable for a buyer to require some portion of the purchase price to be contingent on a successful transition. This aligns your incentives with the buyer's. **Seller requirement:** The transition period should be defined, the earnout tied specifically to metrics within your control during that period, and the duration should be short (12 months is reasonable; 36 months is not). ### Portfolio Add-On With Specific Growth Mandate If you are rolling equity and staying on as a division CEO with a specific growth mandate, new geography, new service line, an earnout tied to that growth can make sense because it compensates you for the incremental work you're agreeing to do. --- ## When Earnouts Are Problematic ### Loss of Operational Control This is the most common earnout problem in home care. After close, the buyer controls: - Staffing decisions (your caregivers may be reassigned, pay rates changed) - Billing and coding (revenue cycle changes may reduce revenue) - Referral development spend (cutting marketing affects census) - Technology systems (billing system migration typically causes revenue disruption) - Management (your key clinical staff may be redirected or let go) Yet the earnout requires you to hit a revenue or EBITDA target that depends on all of these variables. The target is effectively in the buyer's hands. You are being asked to accept risk you can no longer control. **Standard clause to negotiate:** Any earnout agreement should include explicit language that the buyer will not take actions that "materially and adversely affect the seller's ability to achieve the earnout" — and specific examples of prohibited actions (staff reductions, billing system migrations, referral source changes). ### Metrics You Can't Monitor If the earnout is based on EBITDA, and the buyer controls the accounting, how do you verify you've hit the target? EBITDA can be influenced by cost allocations, intercompany charges, or simply management decisions about how to classify expenses. **Requirement:** Earnout metric should be as close to gross revenue as possible (harder to manipulate) rather than EBITDA. Or, if EBITDA-based, the agreement should specify the exact accounting method, chart of accounts, and cost allocation methodology that will apply, and give the seller audit rights. ### Extremely Long Earnout Periods A 3-year earnout is a long time to be emotionally and financially tethered to an outcome you may not control. The first year post-close, you may still have operational influence. Three years post-close, you are likely a consultant or an observer. **Requirement:** Push for 12-month earnouts. Accept 18 months in compelling circumstances. Resist 24+ month earnouts, which primarily serve buyers. ### Cumulative vs. Annual Targets A cumulative earnout (total revenue or EBITDA over 24 months must hit $X) is almost always worse for sellers than annual targets. A missed year cannot be caught up. **Requirement:** If multiple years are involved, ensure each year has its own independent target — and that a good year carries forward if the annual target is exceeded. --- ## Negotiating Earnout Terms: The Key Provisions If an earnout is part of your deal, here is what to negotiate: **1. Earnout metric:** Revenue is better than EBITDA (less manipulable). EBITDA is better if cost allocations are explicitly defined. **2. Accounting methodology:** Specify the exact method for calculating the earnout metric. Any changes to accounting method require mutual written consent. **3. Buyer conduct restrictions:** Buyer may not make material operational changes without seller consent during the earnout period if those changes are reasonably likely to reduce performance below the target. **4. Monthly reporting:** Seller receives monthly financial reports against the earnout metric. **5. Audit rights:** Seller (or seller's accountant) has the right to audit earnout calculations within 60 days of each earnout payment notice. **6. Dispute resolution:** Disputes referred to an independent accounting firm, not litigation. This is faster and cheaper. **7. Acceleration clause:** If the buyer sells the business during the earnout period, the earnout accelerates and is paid in full. Otherwise, buyers can sell the platform (capturing value you helped create) while you are still waiting for your earnout. **8. Anti-assignment provision:** The earnout obligation cannot be assigned to a shell entity or subsidiary with limited assets. The obligation stays with the entity that has the financial resources to pay. --- ## The Bitter Truth About Earnout Disputes Studies of M&A earnout disputes consistently show that a large percentage of earnouts are never paid in full, and a significant proportion generate litigation. In healthcare specifically, the combination of regulatory complexity, billing system migrations, and management changes creates ample opportunity for disputes. Buyers who structure deals with earnouts often have more experience managing earnout disputes than sellers do. The best protection is not better dispute resolution language, it is **minimizing the earnout in the first place** through a competitive process that produces clean, upfront pricing. A well-run competitive M&A process with multiple qualified buyers removes the buyer's ability to use an earnout as a valuation gap bridge. If five buyers are competing for your agency, none of them can get away with a large deferred payment, because their competitors will offer more cash upfront. --- ## The Bottom Line Earnouts are a tool that buyers use to transfer risk to sellers, and they are often proposed when buyers are uncertain about some element of your business. Accepting an earnout without carefully negotiating its terms is one of the most common ways home care sellers leave money on the table. Our recommendation: work with an advisor whose goal is to structure a process that minimizes the need for earnouts by creating genuine competition. When they are necessary, negotiate every term with experienced M&A counsel. **[Talk to Hendon Partners about structuring your deal to minimize earnout risk →](/contact-us)** --- *Hendon Partners is a sell-side M&A advisor for home-based care. We have structured dozens of home care transactions and negotiated earnout terms extensively.* --- ### Home Care M&A Due Diligence: The Complete Seller's Checklist URL: https://www.hendonpartners.com/insights/home-care-ma-due-diligence-checklist Published: 2025-10-17 09:00 Category: Seller Guides > Due diligence is where deals die — or get repriced by millions. This complete checklist covers every document, record, and disclosure a home care agency seller needs to prepare before going to market. Due diligence is the phase of a home care agency sale where the buyer's team — accountants, lawyers, and operational consultants, systematically examines every aspect of your business. It typically runs 45–90 days after LOI execution. Most sellers experience due diligence as stressful and reactive, fielding requests for documents they can't find, explaining items they don't understand, and watching buyers use discovered issues to reprice the transaction downward. It does not have to be this way. Sellers who prepare a complete, organized data room before due diligence begins: - Close transactions faster (30–45 days less diligence time) - Receive fewer late-stage price reduction requests - Build buyer confidence that reduces the cost-of-uncertainty premium buyers apply to messy deals - Are perceived as more sophisticated and trustworthy counterparties This checklist covers every major category of due diligence a home care seller should prepare for. Not every item will apply to every agency, the relevant checklist depends on your license type, payer mix, state of operation, and transaction structure. Use this as a starting point. --- ## Section 1: Corporate and Organizational Documents - [ ] Certificate of Incorporation or Organization for each legal entity - [ ] Articles of Incorporation / Operating Agreement / Partnership Agreement - [ ] List of all current shareholders/members/partners and ownership percentages - [ ] Capitalization table - [ ] All amendments to operating documents - [ ] Board or manager meeting minutes (last 3 years) - [ ] All prior acquisition agreements, seller notes, or prior equity transactions - [ ] List of all subsidiaries and related entities - [ ] State qualification documents (foreign qualification for multi-state operators) - [ ] Any applicable buy-sell agreements between owners - [ ] Pending or threatened litigation involving the company or its owners --- ## Section 2: Financial Statements and Accounting - [ ] Full P&L and balance sheets, 3 years, plus trailing 12 months monthly detail - [ ] Federal and state tax returns — 3 years - [ ] Accounts receivable aging by payer, current plus trailing 12 months - [ ] Accounts payable aging, current - [ ] Working capital calculation workup (assets and liabilities) - [ ] Bank statements, 12–24 months - [ ] Chart of accounts and accounting system description - [ ] EBITDA bridge from reported to adjusted (normalized add-back schedule with documentation for each) - [ ] Revenue by service line and payer, monthly for 24 months - [ ] Payroll records and summary — 24 months - [ ] Workers' compensation and general liability insurance history including claims --- ## Section 3: Revenue Cycle and Payer Documentation - [ ] List of all payer contracts with current executed copies - [ ] Explanation of benefits (EOB) samples by payer type - [ ] Revenue cycle management SOP or process documentation - [ ] Claims denial rate by payer, monthly for 12 months - [ ] Days sales outstanding (DSO) by payer, trailing 12 months - [ ] Outstanding credit balances by payer - [ ] Any payer termination notices or contract non-renewals (last 3 years) - [ ] Any CMS audit letters, request for information (RFI), or ADR (Additional Documentation Request) for home health - [ ] Any Medicare or Medicaid Targeted Probe and Educate (TPE) results - [ ] Explanation of any open cost report settlements (Medicare-certified agencies) - [ ] Recovery Audit Contractor (RAC) activity, if any --- ## Section 4: Licensing and Regulatory Compliance - [ ] All current state and local operating licenses with expiration dates - [ ] Medicare provider number(s) and certification documentation (CMS 855A or 855B) - [ ] Medicaid provider enrollment records by state - [ ] CHAP, ACHC, or Joint Commission accreditation (if applicable) - [ ] Certificate of Need (CON) documentation (if applicable in your state) - [ ] All survey/inspection reports (last 5 years) - [ ] Plan of correction responses for any cited deficiencies - [ ] State licensing complaint history and resolution documentation - [ ] OIG exclusion list check history - [ ] OSHA inspection history (if any) - [ ] Workers' compensation audit history - [ ] Wage and hour compliance documentation (FLSA, state rules) - [ ] Anti-kickback and Stark Law compliance program documentation --- ## Section 5: Clinical Operations and Quality Metrics - [ ] CMS STARS ratings history (home health agencies) - [ ] OASIS/CAHPS outcome data and trends (Medicare home health) - [ ] Rehospitalization rate by payer and diagnosis type - [ ] Average length of stay and ADC trends (hospice) - [ ] Episode management and certification data (home health) - [ ] Clinical policy and procedure manual (current version) - [ ] Physician order management and authorization process documentation - [ ] Incident reporting history and resolution (last 3 years) - [ ] Infection control protocols and COVID-19 compliance documentation - [ ] Medical director/supervising physician agreement(s) - [ ] Quality assurance and performance improvement (QAPI) program documentation - [ ] Any SIR (serious incident reporting) history (for IDD or residential providers) --- ## Section 6: Human Resources and Workforce - [ ] Complete employee roster with tenure, title, FTE/PTE status, and compensation - [ ] Job descriptions for all key positions - [ ] Caregiver/DSP headcount and turnover data by month, 24 months - [ ] I-9 file compliance audit results - [ ] Background check policy and log of checks conducted - [ ] Employee handbook (current version) - [ ] Any employment claims, EEOC complaints, or investigations (last 5 years) - [ ] Key employee agreements (non-competes, non-solicitations, confidentiality) - [ ] PTO accrual balance report - [ ] Benefit plan documents and current enrollment - [ ] Independent contractor (1099) agreements and classification compliance documentation - [ ] Workers' compensation loss run, 3 years --- ## Section 7: Client and Census Data - [ ] Client census by service line — monthly for 24 months - [ ] Client roster by payer type (anonymized for initial review) - [ ] Top 10 referral sources and estimated referral percentage - [ ] Client satisfaction survey data (if collected) - [ ] Average hours per client per week and trends - [ ] Client disenrollment/discharge rates and reasons (last 12 months) - [ ] Waiting list or unfilled demand, if any - [ ] Geographic service area maps --- ## Section 8: Technology Systems and Infrastructure - [ ] List of all technology platforms and licenses (EHR, billing, scheduling, payroll) - [ ] Technology vendor contracts with term and renewal dates - [ ] Data security and HIPAA compliance policy documentation - [ ] Any data breach history (including incidents not rising to reportable threshold) - [ ] IT infrastructure description (cloud-based vs. on-premise) - [ ] Electronic visit verification (EVV) system and compliance status --- ## Section 9: Facilities and Equipment - [ ] List of all office and facility locations with lease agreements - [ ] Lease expiration dates and renewal options - [ ] Security deposits and any landlord relationships disclosure - [ ] Fixed asset schedule with depreciation schedule - [ ] Vehicle inventory and related insurance - [ ] Capital expenditure history (last 3 years) and planned capex --- ## Section 10: Material Contracts and Third-Party Relationships - [ ] All material vendor contracts (clinical supplies, staffing agencies, billing vendors) - [ ] Real property leases and any related-party arrangements - [ ] Any management agreements, marketing agreements, or referral agreements - [ ] Any non-compete or non-solicitation agreements with prior owners or employees - [ ] Accountant/CPA engagement letters - [ ] Legal counsel engagement letters - [ ] Insurance policies, D&O, E&O, general liability, professional liability, with coverage limits --- ## Organizing Your Data Room A well-organized virtual data room is the difference between a smooth due diligence and a chaotic one. Best practices: 1. **Use a professional VDR platform.** Box, Datasite, or DealRoom provide appropriate security, user access controls, and activity tracking. 2. **Mirror the sections.** Organize your data room folders to match the due diligence request list your buyer sends. Makes cross-referencing easy. 3. **Audit readiness before upload.** Review every document before loading it. Missing pages, documents that refer to unnamed exhibits, or conflicting information will generate follow-up questions. 4. **Name files clearly.** "2024 Federal Tax Return.pdf" is better than "Doc_147_final_v3.pdf." 5. **Manage access levels.** Start with a limited document set for initial diligence; unlock sensitive items (employee names, client details) only after appropriate NDA protections are in place. --- ## Pre-Sale Preparation Is Your Highest-ROI Activity For most home care owners, the investment of time in building this data room before receiving an LOI pays for itself manyfold, in faster closing, higher price, and fewer post-LOI surprises. Our experience: sellers who prepare their data room before an offer consistently close 30–45 days faster than those who collect documents reactively. At a 10-12x EBITDA multiple, that time is worth hundreds of thousands of dollars in operational income during the close period, and the cleaner process builds confidence that translates to price. **[Work with Hendon Partners to prepare your sale, start with a confidential consultation →](/contact-us)** --- *Hendon Partners is a specialized M&A advisor for home-based care. We guide sellers from preparation through funded close.* --- ### Caregiver Turnover and Your Home Care Agency's Value: What Buyers Really Think URL: https://www.hendonpartners.com/insights/caregiver-turnover-home-care-valuation Published: 2025-10-10 09:00 Category: Valuation Insights > Caregiver turnover is the #1 operational risk buyers underwrite in every home care acquisition. High turnover can reduce your multiple by 1–2× EBITDA. Here's exactly how buyers assess your workforce and what you can do about it before going to market. Ask any private equity analyst who has underwritten a home care acquisition what keeps them up at night, and most will give you the same answer: **caregiver turnover**. The home care industry's DSP and caregiver workforce turnover rate has averaged 60–80% annually for more than a decade — and in some markets and service lines, it exceeds 100%. This is not a new problem. But its effect on agency valuation is something most owners seriously underestimate. High caregiver turnover is not just an operational headache. It is a **valuation discount** that buyers systematically apply, a **due diligence disqualifier** in extreme cases, and a signal about business quality that sophisticated investors know matters more than any single financial metric. Here is how buyers think about your workforce, and what you can do about it. --- ## Why Caregiver Turnover Matters So Much to Buyers Buyers pay for cash flow they can sustain and grow. Caregiver turnover directly threatens both. **Revenue risk.** When a caregiver leaves, the client it serves is either reassigned (with service disruption risk) or temporarily uncovered. Uncovered shifts represent unbilled hours, lost revenue that does not show up on your P&L but represents economic leakage. The higher your turnover, the more leakage exists in the system. **Cost risk.** Replacing a caregiver costs an estimated **$2,500–$5,000** in recruiting, background checks, onboarding, training, and initial productivity loss. An agency with 150 caregivers and 70% annual turnover replaces more than 100 caregivers per year, a $250,000–$500,000 per year labor overhead that is partially hidden in your overhead costs. **Client retention risk.** Clients who experience chronic caregiver reassignment are more likely to disenroll, complain, or switch providers. In personal care especially, the caregiver relationship is deeply personal, and disrupting it drives client churn. **Growth limitation.** Agencies with staffing gaps cannot accept new referrals. A business that is consistently turning away business because it can't staff it is fundamentally limited in its growth potential, and buyers model that limitation into their forward projections. **Management distraction.** If your management team spends 40% of its time on caregiver recruitment and replacement rather than on clinical quality, business development, and operational improvement, that is an internal cost that buyers price in. --- ## How Buyers Measure Caregiver Retention During due diligence, buyers will request detailed workforce data. Expect requests for: - **Monthly headcount by employment type** (W-2, 1099) for the trailing 24 months - **Monthly hire and termination counts** - **Reason for termination** (voluntary vs. involuntary, if tracked) - **Average tenure by cohort** - **Overtime percentage by month** - **Benefit enrollment rates** (health insurance, 401k) — a proxy for workforce stability From this data, they will calculate: **Annual attrition rate:** Total separations ÷ Average headcount × 100. Industry average is approximately 65–80%. Best-in-class agencies are below 40%. Rates above 90% are disqualifying for premium buyers. **Median caregiver tenure:** How long does the average caregiver stay? Under 6 months is very concerning. Over 18 months is premium. **New hire 90-day retention:** What percentage of new hires are still employed after 90 days? Industry average is approximately 60%. Premium agencies achieve 75%+. **Open shift/unfilled shift rate:** How many scheduled client hours go unstaffed each month? This measures operational leakage. Buyers for home health or personal care specifically ask for this. --- ## The Valuation Impact of High Turnover The quantitative impact on your EBITDA multiple depends on how your turnover compares to benchmarks, and whether buyers believe turnover will improve, persist, or worsen under new ownership. Consider two functionally identical home care agencies, same revenue, same markets, same EBITDA: **Agency A:** 35% annual caregiver turnover, 78% 90-day retention, median tenure 22 months. Growing census, no chronic open shifts. **Agency B:** 85% annual caregiver turnover, 54% 90-day retention, median tenure 8 months. Flat census, 12% open shift rate. Agency A will receive a multiple in the high end of the applicable range, or above it. Agency B will receive a 1–2× EBITDA discount relative to the range, earnout conditions tied to improving retention, or declining offers in late diligence as buyers model operational risk. At $2M EBITDA and a 5.5× market multiple, the difference between 4.5× (Agency B) and 6.5× (Agency A) is **$4M in purchase price**. --- ## The Root Causes of High Turnover: and What Buyers Believe About Them Buyers don't just look at your turnover rate. They form a view about **why** your turnover is high and whether it can be fixed. Turnover causes that buyers consider **manageable (lower discount):** - Market-rate pay below competitors (a capital investment that a well-resourced buyer can address) - Lack of benefits (PE-backed platforms typically offer better benefits packages than small independents) - Inadequate scheduling technology leading to inefficient schedules (solvable with technology investment) Turnover causes that buyers consider **structural (higher discount or disqualifying):** - Toxic culture or poor management that affects caregiver satisfaction - Chronic understaffing at the client level (caregivers burning out faster) - Market dynamics, competitors paying significantly higher rates in a tight labor market with no margin to respond - High-acuity or undesirable client mix that makes the work harder than alternatives Buyers who believe your turnover is manageable will underwrite a post-close improvement plan and pay closer to full price. Buyers who believe your turnover is structural will either pass or discount heavily. --- ## What to Do Before Going to Market If your caregiver retention is below benchmark, the highest-ROI investment you can make before a sale is fixing it. Here's where to focus: ### Compensation Benchmarking Determine whether your base pay is competitive in every market you serve. In 2026, competitive personal care aide wages range from $14/hour in rural low-cost markets to $20+/hour in urban California, New York, and Washington state. If you are 10–15% below market, incremental revenue from improved retention will typically exceed the wage investment. ### Benefits Access Providing access to health insurance — even if you don't pay the full premium, meaningfully improves retention for a subset of your workforce. An increasing number of home care agencies offer health insurance through group plans, and part-time caregivers are often eligible under ACA marketplace plans that don't require full employer contribution. ### Scheduling Consistency Inconsistent schedules, where caregivers don't know their hours week-to-week, are among the most commonly cited sources of caregiver dissatisfaction. Investing in predictive scheduling technology and offering consistent weekly hours to reliable caregivers reduces turnover materially. ### Onboarding Quality The first 90 days determine whether a caregiver stays. Agencies with structured onboarding, orientation, shadow shifts, regular check-ins, a named mentor, retain a higher percentage of new hires. This is one of the lowest-cost, highest-impact retention investments available. ### Caregiver Recognition Programs Simple, consistent recognition — a monthly "Caregiver of the Month" with a small financial award, birthday acknowledgments, and tenure milestones, costs almost nothing and improves caregiver loyalty meaningfully, particularly when combined with a management culture of genuine appreciation. --- ## Presenting Turnover to Buyers If your turnover is above benchmark but declining, the narrative matters. Buyers want to see: - **A measured trend:** "Our annual turnover was 85% in 2023, 72% in 2024, and 58% in 2025 following implementation of our scheduled consistency initiative." - **Root cause understanding:** "Our turnover was concentrated in the first 60 days among new hires. We added a structured onboarding process in early 2024, and new hire 90-day retention improved from 51% to 70%." - **Investments in place:** "We implemented a next-day direct deposit program and caregiver check-in app in Q1 2025, and we are seeing continued improvement." A declining trend with a credible explanation and measurable improvement is dramatically better than a flat high number, or, worst of all, a high number with no explanation or improvement plan. --- ## The Bottom Line Caregiver retention is the single most controllable variable that determines where within the EBITDA multiple range your agency will price. It is also the most visible operational metric to experienced buyers. Owners who invest in workforce retention 12–24 months before going to market consistently achieve better multiples than those who don't, often by $2M–$5M in purchase price on transactions in the $5–20M range. **[Talk to Hendon Partners about how workforce metrics affect your agency's value →](/contact-us)** --- *Hendon Partners specializes in the sale of home-based care agencies. Our advisors help owners prepare, operationally and financially, for the best possible market outcome.* --- ### How to Sell an IDD Agency in 2026: Valuations, Buyers, and What Makes a Premium Deal URL: https://www.hendonpartners.com/insights/idd-agency-valuation-sale-2026 Published: 2025-10-03 09:00 Category: Valuation Insights > Intellectual and developmental disability (IDD) agencies are among the most actively acquired healthcare businesses in the country right now. Here's what your IDD agency is worth, who is buying, and how to run a process that captures maximum value. The market for intellectual and developmental disability (IDD) and autism services businesses has never been more active. In 2025 and 2026, private equity — attracted by Medicaid-funded revenues, demographic demand, and extreme fragmentation, made IDD one of the most transacted sub-sectors in all of healthcare. If you own an agency providing residential support, day programs, supported living, community-based services, or behavioral support for individuals with IDD or autism, there is a large and motivated buyer universe for your business right now. This guide covers what IDD agencies are worth in 2026, who the buyers are, and how to navigate a sale that captures real premium value. --- ## What Makes IDD Businesses Attractive to Buyers Before discussing valuation, it's worth understanding why buyers are so active in IDD. The investment thesis is strong: **Medicaid waiver funding.** IDD services are primarily funded through Home and Community-Based Services (HCBS) Medicaid waivers, the fastest-growing component of Medicaid spending. Federal policy under both HCBS Final Rule and the ADA integration mandate has consistently pushed states toward expanding community-based IDD services. **Mission-driven, low churn.** Individuals with IDD have lifelong service needs. Once an agency establishes a relationship with a participant and their family, retention is extremely high. This creates the kind of predictable, recurring revenue that PE investors value above almost anything else. **Extreme fragmentation.** The IDD industry is dominated by small nonprofits and family-owned operators. Less than 10% of IDD services are provided by companies with more than 500 employees. This fragmentation creates significant consolidation opportunity. **Critical shortage of providers.** In virtually every state, IDD waitlists exceed available provider capacity. Being a licensed, established provider creates meaningful entry barriers for new competitors. --- ## IDD Agency Valuation Benchmarks (2026) IDD valuations are EBITDA multiple-based, like most healthcare M&A. The relevant multiples in 2026: | Agency Type and Scale | Typical EBITDA Multiple | |---|---| | Small residential operator (<$500K EBITDA) | 3.5 – 5.5× | | Mid-size community services operator ($500K – $2M EBITDA) | 5.0 – 7.0× | | ABA/behavioral therapy provider ($1M+ EBITDA) | 6.0 – 9.0× | | Large IDD platform ($2M+ EBITDA, multiple services) | 7.0 – 10×+ | *Note: ABA therapy providers focused on autism may qualify for higher multiples, particularly when school-district contracting or commercial insurance revenues add payer diversification.* The wide ranges reflect variability in key drivers discussed below. --- ## Value Drivers in IDD ### Service Line Mix Not all IDD services are equal from a valuation perspective: - **Residential (group homes, host homes, supported living):** Highest-value, most recurring. Once a participant is placed in residential supports, the relationship is typically years long. Buyers pay premium multiples for residential programs. - **Day habilitation/adult day programs:** Strong recurring revenue, community-based, lower capital intensity. Good multiples, but investors care about facility lease terms and whether participants have alternatives. - **Employment supports (supported employment, job coaching):** Solid but more variable — employment placements can be discontinued. Good add-on within a platform but less valued as a standalone. - **ABA therapy:** High demand, but reimbursement environment is evolving. Commercial insurance payers increasingly dominating over Medicaid-only. Buyers value ABA with payer diversification (Medicaid + commercial) over Medicaid-only ABA. - **Crisis/behavioral support:** Specialized skill set, high need, meaningful Medicaid rates in many states. Attractive niche, especially for platforms building comprehensive service arrays. ### State and Waiver Quality Medicaid waiver rates vary enormously by state, sometimes by a factor of 2–3×. High-rate states (Colorado, Massachusetts, Connecticut, Washington) support higher EBITDA margins and therefore higher enterprise values than lower-rate states (many Southern states, Mississippi, Alabama). Buyers actively track state policies, pending rate increases, and HCBS expansion plans. Being in a state with a favorable rate environment is itself a valuation multiplier. ### Staffing Quality and Retention Direct Support Professionals (DSPs) are the business. An IDD agency with a stable, well-trained DSP workforce is categorically different from one with chronic turnover. Buyers look at: - Annual DSP turnover rate (national average is approximately 40–50%; agencies below 30% command premium multiples) - Wage competitiveness relative to local market - Training certification levels (nationally certified DSPs) - Any DSP unionization risk ### Regulatory Compliance IDD providers are among the most heavily regulated in healthcare. State developmental disability agencies conduct licensing inspections, plan reviews, and incident investigations. Buyers will thoroughly review your licensing history. Critical flags that reduce value or disqualify transactions: - Recent state findings of abuse, neglect, or exploitation (ANE) - Medicaid overpayment or fraud findings - Active licensing probation or moratorium - Recurring deficiencies in the same area (documentation, medication administration, etc.) A clean regulatory record, by contrast, is a material positive. Buyers pay for compliance certainty when acquiring IDD businesses. ### Residential Real Estate IDD group home programs often involve residential properties, owned or leased. Buyers care about: - Lease structure and length (long-term leases reduce transition risk) - Whether leases are with related parties (common problem in family-owned businesses) - ADA and Fair Housing Act compliance of residential properties - Whether CARF or other accreditation is in place --- ## Who Is Buying IDD Agencies in 2026? The buyer landscape includes: **Large national IDD platforms** — companies like Sevita (formerly ResCare), Pathways, Redwood Family Care Network, and others that operate in multiple states and are actively building scale. These buyers pay competitive multiples but expect you to join their operating infrastructure. **PE-backed regional platforms**, sponsor-backed companies that may operate in 3–10 states and are actively acquiring to expand geographic footprint. These buyers often offer better price, more operational autonomy, and rollover equity. **State-level consolidators**, operators that dominate one or two states and are building density within their geography before considering geographic expansion. **Nonprofit acquirers** — in IDD specifically, nonprofit buyers are an active part of the market. They typically pay lower multiples than PE-backed buyers, but they may offer better cultural fit for mission-driven sellers. In a competitive process, having PE-backed platform buyers competing against strategic operators typically produces the highest multiples. --- ## Nonprofit vs. For-Profit: Tax and Mission Considerations Many IDD owner-operators started as nonprofits or converted at some point. If you are a nonprofit considering strategic options, the sale analysis is different: - Nonprofit assets must be used for charitable purposes; a sale must be structured as an **asset purchase** with proceeds applied to mission-aligned uses or reinvested - Board fiduciary duties require demonstrating fair market value, which typically means a formal valuation and competitive process - Attorney General review is often required for nonprofit healthcare transactions in many states - Tax treatment for founding donors or embedded restricted endowments may complicate or delay close Nonprofit IDD owners should involve specialized healthcare transactional counsel early in the process. --- ## The Pre-Sale Preparation Checklist for IDD Agencies The quality of your preparation directly determines the price you receive. Prioritize: **12+ months before sale:** - Begin building or formalizing your management team - Address any open regulatory findings or licensing conditions - Diversify participant base across waiver categories and geographies if possible - Ensure all direct support staff have documentation, certifications, and training records up to date **6 months before sale:** - Engage a specialized M&A advisor with IDD experience - Prepare 3 years of clean financial statements - Conduct preliminary EBITDA normalization exercise - Review all residential property leases for market terms and length **At launch:** - Organize virtual data room with all due diligence materials - Brief key management on the process and confidentiality obligations - Prepare for management presentations with buyer groups --- ## Getting Your IDD Agency Valuation The IDD market is active enough that knowing your range before speaking to any buyer is not optional, it's essential. Buyers who approach you directly have already priced in the absence of competition. Hendon Partners provides confidential preliminary valuations for IDD and IDD-adjacent agencies at no cost. We combine publicly available benchmark data with our own closed-transaction experience to give you a realistic picture of what your business would achieve in a competitive process. **[Request your IDD valuation, confidentially and at no cost →](/contact-us)** --- *Hendon Partners covers all sub-sectors of home-based and community-based care including IDD, autism services, home health, hospice, and private duty.* --- ### What Private Equity Looks for in a Home Care Acquisition URL: https://www.hendonpartners.com/insights/what-private-equity-looks-for-home-care-acquisition Published: 2025-09-26 09:00 Category: Market Intelligence > Private equity firms have acquired hundreds of home care agencies in the past decade. Here's exactly what they screen for, what disqualifies an agency immediately, and how to position your business to attract the most competitive PE offers. Private equity has transformed the home-based care industry. Over the past decade, PE firms have deployed tens of billions of dollars acquiring home health, hospice, personal care, and IDD agencies — and the pace of investment has only accelerated in 2025–2026. For agency owners considering a sale, understanding what PE buyers actually look for, and what immediately disqualifies a business, is not just interesting context. It is actionable intelligence that can significantly affect your preparation, timing, and ultimate outcome. This guide is written from the buyer's perspective: what does a PE firm's investment committee need to see to approve an acquisition thesis for a home care agency? --- ## The PE Investment Thesis for Home Care Before getting into specific criteria, it helps to understand *why* private equity is attracted to home care in the first place. PE investors typically underwrite to three core theses: **1. Demographic inevitability.** With 11,000 Americans turning 65 daily and a preference for aging in place that spans all demographics, demand for home-based care has structural, multi-decade tailwinds that are essentially recession-proof. **2. Fragmentation creates consolidation opportunity.** The U.S. home care industry is dominated by small, independent operators. The top 10 companies controlled less than 15% of total market revenue as of 2024. This fragmentation means PE firms can acquire at moderate multiples, build scale, and eventually sell the larger platform at a meaningful multiple expansion. **3. Reimbursement predictability.** Medicare home health and hospice operate under known, federally-set rates. Compared to hospital or specialist physician physician practice M&A, home care revenue is highly predictable. Given these theses, a PE buyer evaluating your agency is asking a single core question: **"Does this business fit the platform we are building, and can we grow it?"** --- ## What PE Firms Require (The Must-Haves) ### Minimum Scale Most institutional PE buyers have a minimum EBITDA threshold. The market in 2026 breaks down roughly as follows: | EBITDA Level | Realistic PE Buyer Type | |---|---| | <$500K | Smaller sponsorless buyers; some PE searches | | $500K – $1.5M | Lower-middle-market PE, PE-backed platforms as add-ons | | $1.5M – $5M | Core lower-middle-market PE; most home care platforms | | $5M+ | Larger PE platforms; institutional firm primary investments | Agencies below $500K in EBITDA may still receive PE interest, particularly as add-on acquisitions for existing platforms — but they rarely attract competitive interest from multiple buyers. ### Revenue Diversification PE buyers stress-test every business against the question: "What happens if I lose my most important relationship?" They require: - No single payer representing more than 25–30% of revenue (ideally under 20%) - No single referral source representing more than 20% of census - No single client exceeding 10–15% of revenue Agencies with significant concentration are not automatically disqualified, but they receive lower valuations and often face earnout provisions tied to the concentration risk. ### Operational Transferability A business that depends entirely on the founder is a PE firm's nightmare. They are buying a going concern, not a personal services business. The minimum they need to see: - A functional management team (clinical director, operations manager, billing) - Documented operational processes - Technology systems that don't rely on founder knowledge - Referral relationships that are institution-to-institution, not purely personal If you are the only person who knows how to run the business, the business is not saleable to PE at a premium multiple. ### Clean Compliance History PE firms with existing home care platforms are registered Medicare and Medicaid providers. Acquiring an agency with compliance problems can contaminate their entire portfolio. They screen aggressively for: - Any OIG or DOJ matters, current or recent - Open Medicare overpayment demands - Pending or recent accreditation issues - Any pattern of billing irregularities - OSHA, wage-and-hour, or employment litigation history Minor historical issues can sometimes be addressed with an indemnification structure. Active investigations or ongoing regulatory exposure will disqualify most transactions. ### Quality Financial Records Three years of clean, accountant-prepared financial statements, ideally reviewed or audited, are the minimum threshold for any institutional buyer. Many PE firms require: - Monthly P&L and balance sheet for trailing 24 months - Revenue by service line and payer - Payroll records and employee census - A/R aging by payer - Documentation supporting all EBITDA add-backs Agencies with cash-based or informal "shoebox" financials rarely attract PE interest, and when they do, they receive deep valuation discounts. --- ## What PE Firms Prefer (The Value Premium Drivers) Beyond the must-haves above, these attributes push acquisitions from "approved" to "aggressively priced": ### EBITDA Growth Trend A business growing at 15%+ per year gets a different underwriting treatment than a flat business, even with the same trailing EBITDA. PE firms model forward years — and a growing business compounds their return. They are buying trajectory, not just current earnings. ### Medicare Certification For home care agencies serving elderly or chronically ill populations, Medicare certification is a premium signal. Medicare revenue is federal, predictable, and demand is growing. Agencies certified for Medicare home health or hospice command meaningfully higher multiples than non-certified operators. ### High Caregiver Retention Caregiver turnover is the operational problem that ruins PE returns in home care. Agencies with 70%+ annual retention rates, and documented practices for achieving it, are perceived as lower-risk and more scalable. ### Proprietary Technology or Processes An agency that has built a differentiated care delivery model, proprietary training program, or specialized population management capability has an identifiable moat. PE buyers value differentiation because it is hard for competitors to replicate. ### Multi-County or Multi-State Presence Geographic reach reduces single-market risk and signals operational scalability. A two-county operator is more attractive than a single-county operator at the same revenue level. ### Alignment on Rollover PE firms strongly prefer sellers who are willing to roll equity into the platform. An owner who rolls 20–30% of their equity signals confidence in the business and alignment with the buyer's growth thesis. It also reduces the cash required at close, which PE firms appreciate especially in add-on transactions. --- ## Immediate Disqualifiers Some attributes will cause PE buyers to pass — regardless of price: - **Founder-controlled referral relationships with no management layer:** If the doctor referrals come because of you personally, they leave when you leave. - **Medicaid as the only payer:** Medicaid rates, reimbursement policies, and program structures vary by state and are politically vulnerable. A Medicaid-only agency is difficult to underwrite at high multiples. - **Active legal or regulatory investigation:** Does not close at any price until resolved. - **Undocumented workforce:** Agencies with H-2A/temporary workers or informal employment arrangements face immigration and wage-hour risk that institutional buyers cannot accept. - **Poor clinical outcomes:** Agencies with CMS star ratings below 2.5 or significant recent survey deficiencies will struggle to attract institutional buyers. --- ## How to Position Your Agency for PE Interest Given everything above, the strategic implication for owners is clear: the best time to begin positioning for PE demand is **12–24 months before you want to sell**, not 30 days before. Specific actions that increase PE attractiveness: 1. **Build your management layer.** Hire or promote a clinical director and operations manager. Document their roles, responsibilities, and decision-making authority. 2. **Diversify your referral base.** Actively cultivate new referral relationships to reduce concentration. Track referral source diversification as a metric. 3. **Invest in your documentation.** Clean financial records, compliant HR practices, and documented clinical processes are not just operational good practice, they are directly monetizable in a sale. 4. **Achieve or maintain Medicare certification.** If you're a personal care agency without Medicare certification, explore whether a Medicare home health certification makes business sense for your market. 5. **Address compliance issues now.** Anything pending, a cost report, an audit finding, a wage complaint, should be resolved before going to market. Deals die or get repriced because of issues the seller "assumed would resolve themselves." --- ## The PE Buyer Landscape in 2026 The number of PE-backed home care platforms has grown significantly. Key platform types active in 2026: - **National consolidators** building scale across multiple states and service lines - **Regional platforms** seeking density within specific geographies - **Payer-owned platforms** (large insurers building care-delivery capabilities) - **First-time investor platforms**. PE firms making their initial home care investment through your agency Each type has different acquisition criteria, offers different multiples, and requires a different pitch. A skilled advisor knows which buyers are most active, what their current portfolio looks like, and where your agency creates the most strategic value. **[Talk to us about the PE buyer universe for your specific business →](/contact-us)** --- *Hendon Partners is a sell-side M&A advisory firm for home-based care owners. We never represent buyers.* --- ### The Quality of Earnings Report: What It Is and Why It Determines Your Final Home Care Sale Price URL: https://www.hendonpartners.com/insights/quality-of-earnings-home-care-ma Published: 2025-09-19 09:00 Category: Seller Guides > The Quality of Earnings (QoE) report is the buyer's most powerful tool for repricing your home care agency after you sign the LOI. Understanding how QoE works — and preparing for it — can protect millions in proceeds. You've signed the Letter of Intent. The buyer has agreed to a $9M enterprise value based on your $1.8M EBITDA at a 5× multiple. You feel good. Then — 45 days into due diligence, the buyer comes back with a revised offer of $7.5M. What happened? In most cases, the answer is the **Quality of Earnings (QoE) report**, a detailed financial analysis conducted by the buyer's accounting firm during due diligence. If the QoE produces a lower EBITDA than the one in your CIM, the buyer will reprice. And sellers who don't understand how QoE works are consistently blindsided by it. This guide explains exactly what a QoE report is, how it works in home care transactions, what analysts look for, and, most importantly — how to prepare for it so the findings support rather than undermine your price. --- ## What Is a Quality of Earnings Report? A Quality of Earnings analysis is a forensic review of a company's financial performance conducted by an independent accounting firm engaged by the buyer. Unlike a standard audit, which verifies that financial statements comply with GAAP, a QoE is specifically designed to answer the question: **"Is the EBITDA in this CIM real, repeatable, and sustainable?"** The output is a report that includes: - A restated EBITDA figure (often different from what was represented in the CIM) - A breakdown of every add-back and whether the QoE analysts agree with it - Analysis of revenue quality (is it recurring? concentrated? at risk?) - Working capital analysis and normalized working capital recommendation - Balance sheet observations - Key risk observations QoE reports cost buyers $25,000–$75,000 for a typical home care transaction. Buyers do not pay that amount to affirm the CIM, they pay it to find every dollar of EBITDA that doesn't hold up under scrutiny. --- ## How QoE Affects Your Purchase Price The relationship is straightforward: **if the QoE produces a lower EBITDA than the CIM, the buyer adjusts the price downward at the same multiple.** Example: - CIM EBITDA: $1.8M - LOI price: $9M at 5× multiple - QoE restated EBITDA: $1.5M - Revised buyer offer: $7.5M A $300K EBITDA reduction at 5× = $1.5M purchase price reduction. This is not unusual in poorly prepared processes. It is extremely common in transactions where the seller's CIM was prepared by a non-specialized advisor or by the seller directly. --- ## What QoE Analysts Look for in Home Care Home care has several sector-specific areas that QoE analysts scrutinize heavily: ### Add-Back Validity Your CIM EBITDA reflects "normalized" earnings, raw EBITDA plus add-backs for owner-benefit items and one-time expenses. QoE analysts challenge every add-back: - **Owner compensation add-back:** Are you really paying yourself above market? They will benchmark your role against comparable market comp data. If you claim a $250K owner add-back but the market rate for your function is $180K, only $70K holds. - **Personal expenses:** Every expense categorized as a personal charge through the business must have documentation. If you expensed a vacation as a "conference," that is not a legitimate add-back. - **"One-time" items:** Analysts are skeptical of one-time expense claims. If you had a "one-time" legal expense last year and another one the year before, they will argue these are recurring. - **Consulting fees to related parties:** Payment to a family member or related entity will be scrutinized for market-rate validity. ### Revenue Sustainability and Concentration QoE analysts examine whether your revenue is truly repeatable: - **Client concentration:** If 30% of your revenue comes from three clients, they will assess what happens if those clients leave. - **Episodic vs. recurring:** For home health, they review whether census is building or declining, and whether any large Medicare episodes are truly repeatable. - **Rate risk:** For Medicaid-heavy agencies, they will assess recent rate changes and exposure to state budget cuts. - **Contract expiration:** Any payer contract or facility agreement expiring within 12 months is flagged as a revenue risk. ### Revenue Cycle and Billing Quality Home care has complex revenue cycles. QoE analysts will review: - **Days Sales Outstanding (DSO):** How long does it take to collect from payers? High DSO signals billing problems. - **Denial rates:** What percentage of your claims are initially denied? High denial rates indicate coding or documentation issues and suggest revenue at risk. - **Unbilled revenue:** A large unbilled balance can signal either a backlog problem or, worse, revenue that will never be collected. - **Accounts receivable aging:** Any receivables over 180 days from Medicare or Medicaid are essentially uncollectible and will be written down. - **Cost report liability:** For Medicare-certified agencies, open cost reports represent potential liabilities that reduce working capital or generate indemnification claims. ### Caregiver and Employee Costs Labor is home care's largest expense — typically 60–75% of revenue. QoE analysts look at: - **Hours billed vs. hours paid:** Billing leakage (hours paid but not billed) reduces EBITDA and signals operational problems. - **Overtime percentage:** High overtime is both a current cost and a future risk. - **Turnover-related costs:** Recruiting, onboarding, and training costs for high-turnover businesses are normalized into EBITDA. - **Workers' compensation and general liability claims:** Outstanding claims or a poor loss history will be reflected in reserve adjustments. ### Working Capital Normalization The QoE will produce a recommended working capital target, often the most consequential number in the report. If their recommended peg is higher than what was implicitly understood at LOI, the effective purchase price decreases dollar-for-dollar. The QoE working capital analysis includes: - Average monthly working capital over the trailing 12 months - Adjustments for seasonality - Exclusion of cash (typically) - Treatment of AR reserves and payroll accruals --- ## How to Prepare for a QoE Review The best protection against a QoE that damages your price is preparation, not manipulation, but honest, proactive review of your own financials before the buyer's accountants arrive. **1. Commission a sell-side QoE or financial review.** Many experienced M&A advisors will recommend, and some will facilitate, a preliminary financial review before launch so you see what the buyer's accountants will see. This allows you to resolve issues before they become surprises. **2. Document every add-back.** Every EBITDA add-back in your CIM should be supported by documentation: bank statements, invoices, payroll records, or written explanation. An add-back without documentation will be rejected. **3. Clean up your AR before going to market.** Write off clearly uncollectible old receivables. Address high-denial payers. Close open cost reports where possible. Buyers pay for clean AR — not for the chance that you might collect it someday. **4. Normalize the business before going to market.** If you have been running excessive personal expenses through the business, cleaning them up a year before going to market will produce a cleaner income statement that's less likely to generate add-back disputes. **5. Understand your revenue concentration risks and address them.** Diversify referral sources before going to market. A business with evident concentration will face QoE discounts, and post-close earnout conditions designed to protect the buyer from that concentration risk. --- ## Should Sellers Ever Commission Their Own QoE? Yes, increasingly, sophisticated home care sellers commission a **sell-side Quality of Earnings analysis** conducted by their own accounting firm before launching a process. Benefits: - You see what buyers will see before they see it - You can resolve or explain issues proactively - You gain credibility with buyers, a sell-side QoE signals transparency - You reduce the risk of price reductions in late-stage due diligence Cost: $15,000–$40,000, depending on the scope and complexity of the business. Return: For a transaction in the $8–15M range, a sell-side QoE that prevents even a $300K EBITDA haircut at 5× multiple saves $1.5M in purchase price. The ROI is compelling. --- ## Final Thought: The QoE Is Not the Enemy Sellers who understand QoE see it as a tool, not an adversarial process. Buyers need to trust that the EBITDA they're paying for is real. A QoE that confirms (or comes close to confirming) your CIM EBITDA builds that trust, accelerates closing, and reduces the chances of price re-trades in late due diligence. The sellers who get hurt are those who don't understand QoE, or who presented inflated EBITDA in their CIM without supporting documentation. Work with an advisor who helps you build a defensible EBITDA narrative, and then defend it. **[Talk to Hendon Partners about preparing your financials for a competitive sale →](/contact-us)** --- *Hendon Partners advises home care agency owners exclusively. We do not represent buyers.* --- ### The Letter of Intent in Home Care M&A: What to Accept, Negotiate, and Reject URL: https://www.hendonpartners.com/insights/letter-of-intent-home-care-ma Published: 2025-09-12 09:00 Category: Seller Guides > The Letter of Intent is the most important document you will sign in your home care agency sale — and the most negotiated. Most sellers don't realize how many critical terms are set at the LOI stage. Here's what every clause means and how to protect yourself. The **Letter of Intent (LOI)** is arguably the most critical document in a home care agency transaction — more important at a practical level than the purchase agreement itself. Counterintuitively, the LOI is largely non-binding. It describes the buyer's intent, not a legal obligation. But make no mistake: the terms you agree to in the LOI set the expectations, the negotiating baseline, and the psychological anchors that govern every conversation that follows. Sellers who give up ground at the LOI stage almost never recover it. This guide walks through every major LOI term, what buyers typically request, what is negotiable, and where you should hold firm. --- ## What Is a Letter of Intent? An LOI is a written document, typically 5–15 pages, that outlines the proposed terms of a transaction. It is submitted by the buyer after completing initial diligence (management presentations, CIM review) and before full due diligence begins. **What the LOI is:** A statement of intent with non-binding economic terms and several binding provisions (exclusivity, confidentiality, no-shop). **What the LOI is not:** A binding commitment to purchase. The buyer retains the right to renegotiate or walk away based on due diligence findings. The LOI formally begins the relationship between buyer and seller on specific terms. Once signed, you enter an exclusivity period, often 45–90 days, during which you cannot solicit or accept competing offers. This is why the LOI **requires expert review** before signature. Once you are exclusive, your leverage for major term changes drops significantly. --- ## Key LOI Terms: What Each Means ### 1. Purchase Price and Structure The most visible term. But headline price is only part of the story. **Enterprise value** is the total value of the business. **Equity value** is what you actually receive — enterprise value minus assumed debt and plus (or minus) working capital settlement. Two LOIs with the same headline price can produce dramatically different proceeds depending on: - How "working capital" is defined and targeted - Whether any debt or liabilities are assumed by the buyer - Whether there is an earnout attached *What to watch:* Buyers sometimes quote enterprise value in their headline while intending to apply a working capital peg that reduces your actual cash proceeds. Always model the full waterfall from enterprise value to net proceeds before comparing offers. ### 2. Transaction Structure: Asset Sale vs. Stock Sale **Asset purchase:** Buyer acquires specific assets (contracts, licenses, equipment) and assumes specific liabilities. The legal entity remains yours. Generally **favored by buyers**, they get a clean slate, step-up in tax basis, and limited liability exposure. **Stock purchase:** Buyer acquires the entire legal entity, including all historical liabilities. Generally **favored by sellers**, simpler for license transfers, potentially more favorable tax treatment, and no complex asset allocation discussions. *What to negotiate:* Sellers should push for stock sale treatment, particularly for Medicare/Medicaid certified agencies where license transfer is complex. Buyers typically push back because stock purchases expose them to pre-close liabilities. The compromise often involves a stock purchase with specific indemnification carve-outs for pre-close regulatory matters. *Important tax note:* For C-corporations, a stock sale vs. asset sale difference can be significant. For S-corporations, LLCs, and partnerships, the difference is often less material. Discuss with your tax advisor before signing. ### 3. Exclusivity and No-Shop Period Almost all LOIs include a **no-shop clause**, you agree not to solicit or enter discussions with other buyers for a specified period (typically 45–90 days). This is binding regardless of the non-binding nature of everything else. *What to negotiate:* - Keep the exclusivity period as short as possible. 45 days is reasonable; 90 days is long. 120 days is too much. - Include a "good faith progress" requirement, if the buyer goes dark or stops responding, you should have a right to terminate exclusivity. - Request a **right to accept superior proposals** — if you receive an unsolicited, materially higher offer during exclusivity, you should have some ability to respond to it. *Why this matters:* Exclusivity turns off the market for your business. If the exclusive buyer eventually walks away or dramatically reduces price in late diligence, you have lost weeks or months of market presence. Protecting your right to terminate exclusivity for cause is critical. ### 4. Working Capital Target and Mechanism Working capital in M&A is often described as the amount of "fuel in the tank", the net current assets required to operate the business normally. The **working capital target** (the "peg") is the amount that must be in the business at close. If working capital at close exceeds the peg, you receive a dollar-for-dollar upward adjustment to your purchase price. If it falls short, you owe the buyer a dollar-for-dollar reduction. This sounds simple. It is not. **Issues to negotiate:** - **How is working capital defined?** Accounts receivable (at what age?), cash (excluded?), accrued vacation (included?), Medicare/Medicaid payables (excluded?), deferred revenue? - **What is the reference period for the peg?** Trailing 12 months, trailing 6 months, or a specific date? - **Who holds the disputed amounts?** Often the first $200–500K of dispute goes to escrow while resolved via accounting firm arbitration. *Real-world impact:* We have seen working capital disputes reduce seller proceeds by $300K–$1.5M on transactions that appeared to be at full price. A rigorous working capital negotiation at the LOI stage, or at minimum a clear definition of terms, is essential. ### 5. Due Diligence Period The LOI specifies how long the buyer has to conduct due diligence, usually 45–75 days from LOI execution (for home care, excluding states with long CHOW timelines). *What to watch:* - Is the due diligence period tied to a hard drop-dead date? - What happens if the buyer needs more time? Do they have an automatic extension right? - Is there a mechanism to terminate if due diligence stalls with no progress? ### 6. Conditions to Closing Conditions that must be satisfied before closing include standard items (regulatory approvals, no material adverse change) and potentially deal-specific conditions. *Watch for:* Overly broad "material adverse change" (MAC) conditions. A well-drafted MAC clause is narrow — limited to events that would materially impair the business specifically, not general market or industry conditions. Buyers with broadly defined MAC provisions can theoretically use them to walk away or reprice based on events unrelated to your specific business. ### 7. Indemnification Terms Even in a non-binding LOI, the expected indemnification framework is often sketched out. The key parameters: **Indemnification cap:** The maximum amount you can be required to pay for post-close claims. Typically 10–20% of purchase price for general representations, 100% for fraud. **Deductible/basket:** You only pay indemnification claims that exceed a minimum threshold (basket). Typically 0.5–1.5% of enterprise value. **Survival period:** How long after close can the buyer file claims? Typically 18–24 months for general representations; longer for tax, environmental, and fundamental representations. **R&W insurance availability:** If the deal uses Representations and Warranties insurance, the indemnification structure changes significantly, and typically in the seller's favor. *What to negotiate:* Push for lower caps, smaller survival periods, and explicit escrow limitations. If R&W insurance is available (most transactions $5M+ enterprise value), insist on it, it dramatically reduces your post-close exposure. ### 8. Rollover Equity Terms (If Applicable) If the LOI includes a rollover equity component, the basic terms should be sketched here: - What percentage of equity do you retain? - Is the rollover on common shares or preferred? - What are the basic drag/tag rights? - What is the expected hold period before next liquidity? *What to negotiate:* Ensure common stock treatment, tag-along rights, and reasonable governance protections. If the LOI says "approximately 20% rollover on terms to be negotiated," push the buyer to specify equity class and basic rights. These become very hard to negotiate after exclusivity starts. --- ## Red Flags in Any LOI ### Excessively Broad MAC Provisions If the buyer can terminate or reprice based on "any adverse development in the healthcare industry" or "changes in reimbursement rates generally," this is not a serious LOI, it is an option to buy at the buyer's discretion. ### Unlimited Indemnification No indemnification cap, combined with a long survival period and broad representations, can expose you to claims that exceed your sale proceeds. Require a cap. ### Vague Working Capital Definition An LOI that says "working capital will be settled at close per the purchase agreement" without defining key terms is a trap. You are agreeing to a mechanism you haven't reviewed. ### 90+ Day Exclusivity with No Good-Faith Obligation Locking up the business for three months with a buyer who has no defined obligation to proceed in good faith is a gift to the buyer and a risk to you. ### Unsigned "Subject To" Clauses Phrases like "subject to financing," "subject to board approval," or "subject to partner review" in an LOI from a late-stage buyer signal that the offer is not real. Only accept LOIs from decision-makers with authority. --- ## The Right Approach to LOI Negotiation The LOI is not a document to review on your own over a weekend. The terms set here, exclusivity, price, structure, working capital mechanics, indemnification framework, are the foundation of a $5M–$20M+ transaction. An experienced M&A advisor who has signed hundreds of home care LOIs will recognize every non-standard clause, know what the market terms are, and know which battles are worth fighting. Combined with an M&A attorney who specializes in healthcare transactions, you have the expertise to negotiate from strength. **[Contact Hendon Partners about your pending or upcoming LOI →](/contact-us)** --- *Hendon Partners represents home care owners exclusively. Our advisors have guided sellers through the LOI process on dozens of transactions across all home-based care verticals.* --- ### The Majority Recapitalization: A Smarter Exit for Home Care Owners Who Aren't Ready to Fully Walk Away URL: https://www.hendonpartners.com/insights/majority-recapitalization-home-care-agency Published: 2025-09-05 09:00 Category: Exit Strategy > A majority recapitalization lets you sell 60–80% of your home care agency now — taking a large liquidity event — while retaining equity to capture the upside of the next phase of growth. Here's how it works and when it makes sense. Most home care owners think of selling their business as a binary decision: sell 100% now, or keep running it. But there is a third path that has quietly become one of the most popular exit structures for home care owners who have built valuable businesses and aren't quite ready to fully step away: **the majority recapitalization**. In a majority recap, you sell a controlling interest — typically 60–80%, to a private equity partner, while retaining 20–40% of the equity. You receive a large cash payment at close (your "first bite of the apple"), continue operating the business with the support of an institutional partner, and position yourself for a potentially larger "second bite" when the PE firm exits in 3–7 years. For the right seller, it is one of the highest-return exit structures available. --- ## How a Majority Recapitalization Works Here is a simplified example: Your home care agency generates $2M in EBITDA. A PE firm values it at 6× EBITDA = **$12M enterprise value**. In a majority recap structure: - PE firm acquires 75% of the company for $9M in cash - You retain 25% equity stake - You continue as CEO with an employment agreement - The company is recapitalized with PE growth capital Three years later, the company has grown to $5M EBITDA. The PE firm sells the platform at 8× = **$40M enterprise value**. Your 25% stake = **$10M**. **Total proceeds: $9M (at close) + $10M (at exit) = $19M**, compared to $12M in a clean 100% sale. Of course, the $10M second check is not guaranteed. But for an operator who continues running and growing the business, recaps have historically produced extraordinary total returns. --- ## Why Private Equity Loves Recapitalizations PE firms favor recap structures for several reasons: **Seller-operators stay motivated.** When you retain 20–40% of the equity, you are financially aligned with the PE firm. You are not a hired employee counting down to a vesting cliff, you are an owner with real upside. This alignment reduces the "walking dead" risk that haunts acquisitions where the seller fully cashes out and then coasts. **Your relationships and knowledge stay in place.** In home care, the founder's relationships, with referral sources, key employees, and community partners, are often irreplaceable. A recap keeps those relationships intact and fully invested. **Platform building requires operating partners.** PE firms building home care platforms through acquisition need operators who understand the business. Recapping the founding operator creates an instant, experienced management team. --- ## When a Majority Recap Makes Sense for You A majority recapitalization is the right structure when several conditions align: **You still have growth ahead.** If your agency is at $1.5M EBITDA and you believe it can reach $4–5M with capital and resources, the recap captures the value of that growth upside. The best time to sell 100% is when you've maximized the business; the best time to recap is when real growth is still in front of you. **You want to keep running the business.** If you enjoy what you do and would find a clean exit disorienting or unfulfilling, a recap gives you liquidity without forcing you to stop. You continue as CEO, typically with meaningful autonomy over day-to-day operations. **You want a partner, not a boss.** The best PE partners provide resources — acquisition capital, technology, back-office infrastructure, management resources, without micromanaging operations. They add value; they don't extract it. **You have been approached by buyers.** If you have received unsolicited acquisition interest, it may mean the market recognizes growth potential in your business. A properly run process can convert that surface-level interest into a competitive recap transaction. **You want diversification without full exit.** Having 100% of your net worth tied to one home care business is concentrated risk. A recap converts the majority to cash, diversified across your portfolio, while preserving upside on the retained position. --- ## When a Full Sale Is Better Than a Recap A majority recap is not always the right structure. Consider a full 100% sale if: - **You are truly ready to stop.** If your goal is to close the chapter and retire, a recap, which requires you to remain engaged for 3–7 years, is the wrong structure. You will be miserable, and so will your PE partner. - **The business is at or near peak.** If you have maximized the business and have no realistic growth path remaining, the time to sell is now at peak multiple, not to roll equity into a business with flat trajectory. - **Health or family circumstances require certainty.** A recap creates structured obligations. If your personal circumstances require flexibility and complete capital access, take the clean exit. - **You don't want a PE partner making decisions.** Recaps require governance. PE firms take board seats and have meaningful rights. If you are not comfortable with an institutional partner reviewing financials, approving major hires, and participating in strategic decisions, a recap will be frustrating. --- ## Evaluating the PE Partner: This Is Everything The quality of your PE partner is the single most important variable in a recap transaction. The upside of your retained equity depends entirely on: 1. **Their track record**, How many home care or healthcare platforms have they built? What were the exit multiples? What happened to the management teams they partnered with? 2. **Their capital availability**. Can they fund acquisitions to grow the platform? A PE firm without dry powder is a passive investor, not a growth partner. 3. **Their operational support model** — What resources do they actually provide? Technology? Billing? Clinical infrastructure? Ask for specifics and contact references. 4. **Their timeline and exit thesis**. What is their target hold period? Are they aligned with your timeline for liquidity? 5. **The governance terms**, How much autonomy do you retain? What decisions require board approval? What are the drag-along provisions if they want to sell and you don't? A good M&A advisor will not just find you the highest valuation, they will help you evaluate the quality and fit of each PE partner and negotiate governance terms that protect your interests. --- ## Structuring the Retained Equity Not all equity is equal. In a recap, the terms of your retained equity stake matter enormously: **Common vs. Preferred stock:** Ideally, your retained equity is common stock, pari passu with the PE firm. If the PE firm has preferred equity with liquidation preferences or IRR hurdles, your common equity may receive nothing unless the exit exceeds certain thresholds. **Anti-dilution provisions:** If the company raises additional capital in add-on acquisitions, your 25% can dilute to 15% or less unless you have anti-dilution protections. **Tag-along rights:** You need the right to sell your equity alongside the PE firm when they exit, not be left behind as a minority shareholder in a company you no longer control. **Information rights:** You are entitled to regular financial reporting and board meeting attendance as a minority owner. Your M&A attorney needs to review all equity terms carefully. These provisions can mean the difference between $10M and $3M on your second check. --- ## The Tax Implications of a Majority Recap A majority recapitalization has different tax treatment than a full sale, and the implications can be significant: - The **cash received at close** is typically taxed as a capital gain (assuming a stock structure), at current long-term capital gains rates (20% federal + state). - The **retained equity** is not a taxable event at close, it is carried forward at your adjusted basis. - The **second exit** will be taxed as a capital gain at that future date's rates. In some structures, sellers are able to use **installment sale treatment** or **Section 1202 QSBS exclusions** (for qualifying small business stock) to reduce effective tax rates. These strategies require advance planning with a qualified M&A tax advisor — ideally 12+ months before close. --- ## Is a Recap Right for You? The best way to answer this question is with a candid conversation about your goals, financial, personal, and professional. Not every owner is right for a recap. Not every business is at the right stage. At Hendon Partners, we advise home care owners on the full range of exit structures, full sale, majority recap, minority recapitalization, and phased exit strategies, and we help each client understand the trade-offs before any process begins. **[Talk to us, confidentially, about your exit options →](/contact-us)** --- *Hendon Partners is a sell-side-only M&A advisory firm. We represent home care owners, not buyers. Every engagement is confidential.* --- ### How Long Does It Take to Sell a Home Care Agency? The Realistic Timeline URL: https://www.hendonpartners.com/insights/how-long-to-sell-home-care-agency Published: 2025-08-29 09:00 Category: Seller Guides > From first conversation to funded close, selling a home care agency typically takes 6 to 12 months. Here's exactly what happens at each stage, what causes delays, and how to move faster without leaving money on the table. One of the most common questions from home care agency owners considering a sale is deceptively simple: **"How long will this take?"** The honest answer: from the moment you engage an M&A advisor to the moment funds clear your bank account, a home care agency sale typically takes **6 to 12 months**. Some transactions close faster — particularly smaller agencies with clean financials and motivated buyers. Others take longer, especially if due diligence uncovers issues, regulatory approvals are required, or buyer financing is complex. Understanding the timeline is critical for planning purposes. If you are planning to sell in 2026, you need to start the process now. Decisions made in the next 30 days will determine whether you close in Q4 2026 or push into 2027. This guide walks you through every stage, how long each takes, and what you can do to accelerate without sacrificing outcome. --- ## The Complete Home Care M&A Timeline ### Phase 1: Advisory Engagement and Preparation (4–8 Weeks) The process begins when you sign an engagement letter with your M&A advisor. This phase is not visible to buyers, it is entirely internal — but it is the foundation of everything that follows. **What happens:** - Financial analysis and EBITDA normalization (identifying legitimate add-backs) - Preparation of the Confidential Information Memorandum (CIM), the primary document buyers use to evaluate your business - Development of a financial model and management presentation - Creation of a target buyer list (typically 50–150 qualified buyers for home care) - Preparation of the Non-Disclosure Agreement (NDA) template - Development of the process timeline and bid instructions **Why it takes this long:** The CIM is a 40–80 page document that tells your agency's story in the most compelling, accurate way possible. A week's work on the CIM often translates to hundreds of thousands of dollars in additional offer price, because it shapes how buyers model your business before they ever speak to you. *Common issue at this stage:* Disorganized financials. If your last three years of P&Ls and tax returns are not clean and readily available, your advisor will need additional time to reconstruct them. This is the #1 cause of delayed launch. --- ### Phase 2: Market Launch and Buyer Outreach (2–4 Weeks) Once materials are finalized, your advisor contacts all pre-qualified buyers, simultaneously and confidentially. Buyers sign NDAs to receive the CIM. **What happens:** - Blind teasers sent to target buyer list (1–2 page summary without identifying your agency) - NDAs executed by interested parties - CIM distributed to credentialed buyers - Preliminary buyer questions answered **Typical response rates:** In a well-run process with a relevant buyer list, 30–50% of contacted buyers will execute an NDA and review the CIM. Of those, 10–25 will express meaningful interest and advance to the next stage. --- ### Phase 3: Management Presentations (3–5 Weeks) Buyers who reviewed the CIM and want to learn more are invited to a management presentation, typically a 60–90 minute video call where you and your leadership team present the business and answer buyer questions directly. **What happens:** - Six to twelve management presentations with qualified buyers - Buyer follow-up questions answered - Site visits in some cases (more common for larger transactions) **Seller preparation:** This is your most important performance in the process. An experienced advisor will help you prepare, anticipate tough questions about census trends, compliance history, and key dependencies, and coach you on how to present the business in its strongest possible light — accurately. --- ### Phase 4: Indication of Interest and Letter of Intent (3–6 Weeks) After management presentations, buyers submit **Indications of Interest (IOIs)**, non-binding written offers that specify a valuation range, deal structure, and key assumptions. Your advisor reviews all IOIs and selects the best candidates to advance to a final bid round. Final bids come in as **Letters of Intent (LOIs)**, more specific, binding-in-intent offers that specify price, structure, earnout terms (if any), due diligence requirements, and exclusivity period. **What happens:** - IOI review and analysis - Negotiations and clarifying questions with top bidders - Final LOI submitted by preferred buyer - LOI negotiation and execution **Key decision point:** Signing an LOI typically initiates an exclusivity period, usually 45–90 days — during which you cannot negotiate with other buyers. Your advisor should ensure the LOI is as complete and precise as possible before you grant exclusivity, because it becomes the baseline for the purchase agreement. --- ### Phase 5: Due Diligence (45–90 Days) Due diligence is the buyer's thorough investigation of every aspect of your business. It is the longest single phase of the transaction and the most intensive for sellers. **What buyers examine:** *Financial due diligence:* - Three to five years of financial statements and tax returns - Accounts receivable aging by payer - Revenue cycle process and denial rates - EBITDA normalization verification - Working capital analysis *Operational due diligence:* - Scheduling, staffing, and HR records - Caregiver turnover data (typically last 24 months) - Technology systems (EHR, billing, payroll) - Office leases and equipment *Clinical and regulatory due diligence:* - Medicare/Medicaid certification status - Survey history and any deficiencies - CMS star ratings (for home health) - Outcome measures - Billing and coding audit (often a sample-based review) *Legal due diligence:* - Corporate formation documents - Material contracts (payer agreements, facility agreements, technology licenses) - Employee agreements and non-competes - Any pending or threatened litigation Most buyers hire outside accountants (Quality of Earnings firm), a healthcare regulatory attorney, and sometimes an operational consultant to conduct parallel workstreams. **Virtual Data Room:** All due diligence documents are organized in a secure online portal (data room) that your advisor manages. A well-organized data room significantly accelerates due diligence. *What delays due diligence:* - Missing or disorganized documents - Unresolved compliance issues discovered during review - Significant EBITDA restatement (QoE findings that differ materially from the CIM) - High caregiver turnover or client concentration issues requiring explanation --- ### Phase 6: Purchase Agreement Negotiation (3–6 Weeks) While due diligence is underway, the buyer's attorneys draft the **Asset Purchase Agreement (APA)** or **Stock Purchase Agreement (SPA)**. This is the legally binding document that governs the transaction. Major negotiated terms include: - Purchase price and payment structure - Working capital target and mechanism - Representations and warranties (and survival period) - Indemnification caps and baskets - Non-compete scope, geography, and duration - Conditions to closing **R&W Insurance:** Most transactions above $5M now use Representations and Warranties (R&W) insurance, a policy that covers claims arising from seller breaches rather than requiring large escrow holdbacks. This significantly reduces the risk that post-close claims will claw back your sale proceeds. --- ### Phase 7: Licensing and Regulatory Approvals (Running Concurrently) Medicare and Medicaid certified agencies require CMS notification and/or approval for ownership changes. In many states, your state Medicaid license and home care operating license also require change-of-ownership (CHOW) approval. The CHOW process runs concurrently with due diligence and APA negotiation, but it can be the rate-limiting step for close, particularly in states with slow licensing processes. **States with notoriously long CHOW timelines:** California, New York, Illinois, and Pennsylvania can take 4–6 months for Medicaid CHOW approval. In these states, experienced buyers and advisors will file CHOW applications immediately after LOI execution. --- ### Phase 8: Closing (1–2 Weeks) Once due diligence is complete, the APA is signed, and all regulatory approvals are received, closing can proceed. **At close:** - Wire transfer of purchase price to your designated accounts - Proration of operating accounts, receivables, and payables - Working capital settlement (adjusted against the purchase price) - Execution of non-compete, employment/consulting agreement, and other ancillary documents - Transfer of licenses, contracts, and certifications The wire typically clears within 24–48 hours of the closing call. --- ## Full Timeline Summary | Phase | Typical Duration | |---|---| | Preparation and CIM | 4–8 weeks | | Market launch and buyer outreach | 2–4 weeks | | Management presentations | 3–5 weeks | | IOIs and LOI negotiation | 3–6 weeks | | Due diligence | 6–12 weeks | | APA negotiation | 3–6 weeks | | Regulatory approvals | Running concurrently (can take 4–6 months in some states) | | Closing | 1–2 weeks | | **Total** | **6–12 months** | --- ## How to Move Faster **Start preparation early.** The fastest transactions we close are for sellers who spent 6–12 months before engaging us getting their financials, compliance, and operations in order. Clean businesses close faster. **Use an experienced advisor.** An advisor who has closed 50+ home care transactions knows every potential snag in advance and proactively resolves issues before they become delays. **Organize your data room before launch.** Buyers stall when documents are missing. Have your data room 80% complete before signing an LOI. **Choose a buyer who knows home care regulatory requirements.** A strategic buyer or experienced PE platform knows how to navigate CHOW. A first-time buyer in your state will slow you down. **Don't over-negotiate.** Late-stage deal fatigue is real. Know which battles are worth fighting in the APA and which concessions can be made without meaningful financial impact. --- ## The Right Time to Start If you are considering a sale in the next 12–24 months, the right time to begin the conversation with an advisor is now, not when you have "everything in order." Part of an advisor's value is identifying exactly what needs to be improved before going to market. **[Schedule a confidential conversation with Hendon Partners →](/contact-us)** --- *Hendon Partners is a specialized M&A advisory firm for home-based care. All conversations are strictly confidential.* --- ### Strategic Buyer vs. Private Equity: Which Is the Right Home Care Exit for You? URL: https://www.hendonpartners.com/insights/strategic-buyer-vs-private-equity-home-care Published: 2025-08-22 09:00 Category: Seller Guides > Should you sell your home care agency to a strategic acquirer or a private equity-backed platform? The answer depends on price, culture, your post-close role, and what you want your legacy to look like. Here's the complete comparison. One of the most consequential decisions in any home care agency sale is also one of the least understood: **should you sell to a strategic acquirer or a private equity-backed platform?** The answer isn't obvious. Strategic buyers and PE firms have fundamentally different motivations, price differently, operate differently post-close, and will treat your employees and culture differently. Getting this decision right can mean millions of dollars in outcome — and months or years of post-close satisfaction or regret. This guide breaks down both buyer types, when each makes sense, and how to structure your process to get the best outcome regardless of which path you choose. --- ## Who Are Strategic Buyers? A **strategic buyer** is an operating company that acquires to expand its existing business. In home-based care, strategic acquirers include: - **National home health or hospice companies** (Amedisys, Addus, LHC Group/UnitedHealth, Enhabit) - **Regional home care operators** seeking geographic expansion - **Hospital systems and health networks** building a post-acute continuum - **Insurance companies and managed care organizations** seeking care-delivery capabilities Strategic buyers pay for **operational synergies**, they expect to reduce costs, expand revenue, and leverage your accounts, licenses, and geography within their existing infrastructure. Their model assumes you become part of them. ## Who Are Private Equity Buyers? A **private equity buyer** is a financial sponsor, typically a PE firm or PE-backed platform, that acquires to grow and eventually resell the business, usually within 3–7 years. In home care, PE buyers include: - **PE-backed home care platforms** (Elara Caring, Help at Home, AccordantHealth, and many others) - **PE firms making a home care "platform" investment:** their first acquisition in the space, which they then grow via add-ons - **Growth equity firms** seeking minority positions in larger agencies PE buyers do not plan to operate your business forever. They are building for a future sale or recapitalization. Their model assumes the agency continues to operate relatively independently, at least initially, while they inject capital, infrastructure, and management support to accelerate growth. --- ## Head-to-Head Comparison | Factor | Strategic Buyer | Private Equity | |---|---|---| | **Typical multiple** | Moderate — pays on synergies | Higher, pays on standalone cash flow | | **Process speed** | Slower, requires board approval | Faster, partners have more authority | | **Post-close independence** | Low, expect integration | Higher, often retain brand and operations | | **Your role post-close** | Typically 6–24 months transition | 2–5 year earnout/run-role common | | **Employee retention risk** | High, redundant roles eliminated | Lower — culture often preserved | | **Rollover equity opportunity** | Rare | Common, often expected | | **Cultural fit** | Absorbed into corporate culture | More entrepreneurial, growth-focused | | **Brand retention** | Usually eliminated | Often retained, especially early | --- ## When Strategic Buyers Pay More The conventional wisdom is that "PE pays more." This is often true, but not always. Strategic buyers can and do pay premium prices in specific circumstances: **Geography is a key unlock.** If your agency operates in a market where a strategic buyer has zero presence, your licenses, referral relationships, and accreditations represent the fastest (and cheapest) path to market entry. In this scenario, the strategic buyer may pay above-market multiples because the alternative, starting from scratch, is far more expensive. **Your payer mix complements theirs.** A Medicare-certified home health agency being acquired by a hospice company seeking to add home health services may command a premium because the buyer values the complement to its existing revenue base. **Scale creates negotiating leverage.** Large agencies ($3M+ EBITDA) attract multiple strategic buyers, which creates competitive tension. Competition, not buyer type, is the primary driver of price. ## When PE Buyers Pay More PE buyers typically lead on price for several reasons: **They value standalone cash flow, not synergies.** PE firms price based on your normalized EBITDA multiplied by a market multiple. They are not assuming cost cuts or revenue tricks — they are buying the cash flow as-is. This is often more favorable to sellers than synergy-based pricing. **They have flexible capital structures.** PE firms can structure deals with seller rollover equity, earnouts, and creative deal structures that increase total potential value. A deal that looks smaller on day one can produce significantly more total proceeds if the platform is eventually sold at a higher multiple. **Rollover equity is a real asset.** Many PE-backed platforms offer sellers the opportunity to roll 10–30% of their sale proceeds into equity in the platform. If the platform exits in 5 years at a higher multiple, that rolled equity can produce a second liquidity event that exceeds the initial sale proceeds. --- ## The Rollover Equity Decision: Worth It? The most financially sophisticated home care exits of the past decade have involved **rollover equity**, selling 70–80% of the business now and keeping 20–30% equity in the PE-backed platform. Here is a simplified example: > You sell your agency for $10M in total enterprise value. You take $7.5M in cash at close and roll $2.5M into the platform. > > The PE firm grows the platform from $5M EBITDA to $12M EBITDA over 5 years and sells it at 8× EBITDA = $96M. > > Your 5% equity stake (representing your $2.5M roll on a $50M platform) is worth $4.8M at exit. > > **Total proceeds: $7.5M + $4.8M = $12.3M**, 23% more than a clean cash sale. Of course, rollover equity carries real risk. The platform may fail to grow. The next buyer may offer lower multiples. Management may change. Every rollover decision requires careful legal review and realistic assessment of the sponsoring PE firm's track record. --- ## The Earnout: Promise or Trap? Both strategic and PE buyers sometimes offer **earnouts**, additional purchase price paid if the business hits certain performance targets post-close. Earnouts are often presented as a way to bridge a valuation gap. But sellers should approach them with extreme caution: - **Integration risk:** In a strategic acquisition, you no longer control the variables that determine your earnout. If the buyer changes billing systems, reassigns your staff, or cuts referral-development spending, your earnout may miss through no fault of your own. - **Definition disputes:** Even well-drafted earnout language can lead to disagreements about what counts as revenue, EBITDA, or census. - **The psychology trap:** An earnout keeps you working toward a number that may already be baked into the buyer's model for your business. A strong M&A process typically minimizes the need for earnouts by creating enough competition that buyers offer clean, full-value upfront pricing. --- ## The Decision Framework: Which Buyer Should You Pursue? Ask yourself these five questions: **1. How important is your brand and legacy?** If you've built a 20-year business and the name means something to your community and employees, a PE buyer who retains your brand and management team will feel very different from a strategic buyer who repaints your vehicles and re-badges your staff within 90 days. **2. Do you want to keep working, and in what capacity?** Strategic buyers often want you gone in 12–24 months. PE buyers frequently want you to keep running the business and accelerate growth. If you love what you do and want to stay involved, PE is often a better fit. **3. How much risk are you willing to take on rollover equity?** Rollover equity can double your total outcome, or disappear. It requires a thesis about the PE firm, the platform, and the market. If you need certainty, take more cash upfront. **4. What's your timeline?** If you need to close in 6 months for personal reasons, a PE buyer's faster process may be preferable. Strategic buyers' boards move slowly. **5. What do your key employees need?** In a strategic acquisition, overlapping back-office functions are typically eliminated. In PE, growth-mode acquisitions often expand the team. Consider the people who've built the business with you. --- ## The Answer: Run a Process That Includes Both The most reliable way to maximize your outcome is not to pre-select a buyer type, it's to **run a competitive process that includes all qualified buyer types** and let the market tell you who values your business most and under what terms. This is precisely what a specialized M&A advisor does: they know every active buyer in home-based care, understand each buyer's current acquisition criteria, and can position your agency to five, ten, or twenty buyers simultaneously, creating genuine competition. Competition is what produces premium pricing. Without it, you are negotiating alone against a buyer who has done this hundreds of times. **[Contact Hendon Partners to discuss your exit options →](/contact-us)** --- *Hendon Partners is a sell-side M&A advisory firm exclusively focused on home-based care. We do not represent buyers. Every engagement is structured to maximize seller outcomes.* --- ### Hospice Agency Valuation in 2026: What Your Business Is Really Worth URL: https://www.hendonpartners.com/insights/hospice-agency-valuation-2026 Published: 2025-08-15 09:00 Category: Valuation Insights > Hospice agencies are commanding the highest EBITDA multiples in all of home-based care — 5× to 9× or more for quality operators. Here's exactly how buyers value hospice businesses in 2026 and what separates an average outcome from a premium one. Of all the home-based care verticals, hospice consistently commands the highest EBITDA multiples at acquisition. In 2026, quality hospice agencies are transacting at **5.0× to 9.0× EBITDA** — and exceptional platforms with strong payor mix, low churn, and geographic density regularly exceed that range. Yet the vast majority of hospice owners we speak with significantly underestimate what their business is worth. This guide explains exactly how hospice agency valuations are determined, what drives multiples to the high end of the range, and where the market stands today. --- ## Why Hospice Commands Premium Multiples Hospice is one of the most attractive acquisition targets in healthcare M&A for several converging reasons: **1. Medicare as the dominant payer.** Roughly 87% of hospice days are paid by Medicare, federal, reliable, and not subject to the Medicaid rate risk that weighs on non-skilled home care. Institutional buyers model Medicare revenue as highly predictable, which reduces their discount rate and supports higher multiples. **2. Recurring, non-episodic revenue.** Unlike home health, which is episodic by nature (START → CERT → discharge), hospice patients remain enrolled for months or years. Average length of stay in a well-run hospice is 90–180 days, with a meaningful percentage of patients enrolled for over 6 months. This creates predictable census, predictable revenue, and predictable cash flow. **3. Demographic tailwinds.** The U.S. has approximately 11,000 Baby Boomers turning 65 every day. Hospice utilization rates have grown every consecutive year for the past decade. Buyers are not just paying for today's cash flow, they are buying into a secular growth trend. **4. High barriers to entry.** Starting a new Medicare-certified hospice from scratch requires a Certificate of Need (CON) in many states, a complex enrollment process, 12–18 months of operating history before meaningful census, and significant working capital. Acquiring an established agency is far cheaper and faster than building one, which creates structural premium for existing operators. --- ## 2026 Hospice Valuation Benchmarks | Hospice Agency Profile | EBITDA Multiple Range | |---|---| | Small (<$500K EBITDA), single market | 4.5 – 6.0× | | Mid-size ($500K – $2M EBITDA), established census | 5.5 – 7.5× | | Large ($2M+ EBITDA), multi-county presence | 7.0 – 9.0× | | Platform / multi-site ($5M+ EBITDA) | 8.0 – 11×+ | *Source: Irving Levin Associates 2025, Scope Research Q4 2025, Hendon Partners deal data* The wide range within each tier reflects the quality variables discussed below. Two hospice agencies with identical EBITDA can achieve materially different multiples depending on how they score on the drivers that matter most to buyers. --- ## The Key Drivers of Hospice Valuation ### Average Daily Census (ADC) and Growth Trend Average Daily Census is the single most scrutinized metric in any hospice acquisition. Buyers look at: - **Current ADC** and whether it's growing, flat, or declining - **Trailing 12-month ADC trend** — is the business gaining or losing patients? - **Seasonality patterns:** hospice census typically declines in Q1 (post-holiday discharge spike) and builds through Q3/Q4 An ADC growing at 10%+ year-over-year commands a meaningful premium over a flat or declining census, even if the EBITDA is identical in the trailing twelve months. Buyers underwrite to future performance, and a growing census signals momentum. ### Average Length of Stay (ALOS) ALOS in hospice is a proxy for clinical quality, referral relationships, and community trust. The national average ALOS is approximately 90 days. Agencies with ALOS above 90 days, particularly above 120 days, signal: - Strong relationships with families and facilities that are referring appropriate (longer-stay) diagnoses - Clinical teams that enroll patients proactively rather than in the final days of life - Less revenue concentration in the high-acuity, short-stay patients (who are more expensive to serve) One important nuance: **very high ALOS (180+ days)** can trigger buyer concern about compliance risk, particularly around diagnosis appropriateness and recertification practices. Buyers will scrutinize your medical review processes. ### Geographic Concentration and CON Position In CON states, your geographic authorization to operate is a direct asset. Buyers are paying not just for your census and cash flow but for your right to serve specific counties. Multiple-county or multi-state operations with CON protection are worth materially more than a single-county license. Even in non-CON states, your referral relationships, with physicians, hospitals, skilled nursing facilities, and assisted living communities, are geographically specific. Buyers assess whether those relationships can survive ownership transition. ### Referral Concentration Risk The most common risk factor buyers identify in hospice due diligence is **referral concentration**. If more than 20–25% of your ADC comes from a single facility, physician group, or referral source, buyers will apply a discount. The concern is straightforward: if that relationship doesn't transfer, the census, and therefore the value — evaporates. Agencies with diversified referral networks across multiple facility types (SNF, ALF, hospital, community/home) consistently achieve better multiples. ### Payor Mix and Acuity While Medicare is the primary payer, buyers also look at: - **Medicare Advantage (MA) penetration:** Growing but typically lower rates than traditional Medicare. Agencies with high MA exposure face more rate uncertainty. - **Medicaid hospice:** Available in all states, usually at lower rates. A high Medicaid mix compresses multiples. - **Level of care (LOC) mix:** Routine Home Care is the baseline. Continuous Home Care (CHC) and General Inpatient Care (GIP) days indicate clinical capacity for complex patients, buyers view this as a quality signal. ### Cost Report History and Compliance A clean Medicare cost report history is non-negotiable for institutional buyers. Buyers will request 3–5 years of cost reports and will specifically look for: - Overpayment demands or RAC/MAC audit findings - Hospice cap liability (aggregate cap or inpatient cap exposure) - Enrollment gaps or location additions If you have unresolved compliance issues, address them before going to market. Even allegations, not just findings, can derail a transaction or reduce pricing significantly. --- ## EBITDA Normalization for Hospice "EBITDA" as reported on your tax return or P&L is rarely the number a buyer will use to value your business. A skilled M&A advisor will work through **EBITDA normalization** — adding back legitimate owner-benefit items and one-time expenses to arrive at the true recurring cash flow. Common hospice add-backs: | Item | Description | |---|---| | Owner compensation above market | If you pay yourself $400K but a replacement clinical director costs $150K, the $250K difference is an add-back | | Personal expenses run through the business | Vehicle, travel, home office, personal insurance | | One-time expenses | Legal fees for a resolved matter, a facility buildout not recurring, one-time IT migration | | Startup costs | If you opened a new location in the past 12 months, its startup losses may be partially added back | | Non-recurring revenue | If you received a one-time Medicare bonus or settlement, buyers may exclude it | The difference between raw reported EBITDA and normalized EBITDA can be $200K–$500K for a well-run hospice, which translates to $1M–$4M in additional enterprise value at current multiples. --- ## The Hospice M&A Buyer Universe in 2026 Understanding who will buy your agency is as important as understanding what it's worth. The buyer landscape for hospice in 2026 includes: **Private Equity-Backed Platforms** The most active buyers. These are PE-funded hospice companies using acquisition as their primary growth engine. They move quickly, pay competitive multiples, and often offer sellers rollover equity in the platform. Examples include Traditions Health, Compassus, VITAS, and dozens of regional platforms. **National Home-Based Care Companies** Companies like Amedisys, LHC Group (now part of UnitedHealth), and Enhabit/Encompass are strategic acquirers when they want geographic fill-in. They tend to pay lower multiples than PE but offer more operational stability. **Regional Health Systems** Hospital systems seeking to complete their continuum of care are sporadic but meaningful buyers. They typically pay more than financial buyers because they value the referral relationships strategically (not just financially). **Independent Hospice Operators** Smaller operators seeking to scale within a specific geography. Typically pay the lowest multiples but can move faster and offer more cultural continuity. In a well-run competitive M&A process, having all four buyer types at the table creates genuine competition, which is where premium multiples come from. --- ## Common Mistakes Hospice Owners Make When Selling **1. Selling to the first buyer who calls.** Unsolicited buyers have already priced in the absence of competition. The first call is almost never the best offer. **2. Not having three years of clean financials.** Missing or unorganized financials delay due diligence, increase buyer skepticism, and give sophisticated buyers leverage to renegotiate price downward. **3. Ignoring the hospice cap.** If your agency is approaching the Medicare aggregate cap, buyers will discount heavily, or walk away. Monitor your cap position and manage census mix accordingly. **4. Waiting too long.** Owners in their 60s who want to sell "in a few years" frequently encounter health challenges, key employee departures, or market shifts that reduce value. The best time to sell is when the business is strong. **5. Using a generalist broker.** Hospice M&A is highly specialized. A generalist broker does not know the hospice-specific regulatory framework, the buyer universe, or how to present your census and compliance profile to maximize value. --- ## Getting Your Hospice Valuation The first step in any intelligent exit is getting an accurate picture of your baseline value, before you engage any buyer. At Hendon Partners, our preliminary valuations for hospice agencies are free, confidential, and based on real deal data from closed transactions in the market. We'll review your EBITDA, census profile, payor mix, and geography and give you a realistic range of what your agency would achieve in a competitive process. **[Request your confidential hospice valuation →](/contact-us)** --- *Hendon Partners is a specialized M&A advisory firm exclusively focused on home-based care. Our team has represented owners of hospice, home health, private pay, and IDD agencies across the country. We do not represent buyers.* ---